Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. by Weston, Jennifer et al.
Cochrane Database of Systematic Reviews
Monotherapy treatment of epilepsy in pregnancy: congenital
malformation outcomes in the child (Review)
Weston J, Bromley R, Jackson CF, Adab N, Clayton-Smith J, Greenhalgh J, Hounsome J, McKay
AJ, Tudur Smith C, Marson AG
Weston J, Bromley R, Jackson CF, Adab N, Clayton-Smith J, Greenhalgh J, Hounsome J, McKay AJ, Tudur Smith C, Marson AG.
Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.
Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No.: CD010224.
DOI: 10.1002/14651858.CD010224.pub2.
www.cochranelibrary.com
Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
53DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
60AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
61ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
61REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
69CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
125DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 CBZ vs Controls, Outcome 1 All Major Malformations. . . . . . . . . . . . 151
Analysis 1.2. Comparison 1 CBZ vs Controls, Outcome 2 Neural Tube Malformations. . . . . . . . . . . 152
Analysis 1.3. Comparison 1 CBZ vs Controls, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 154
Analysis 1.4. Comparison 1 CBZ vs Controls, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . 155
Analysis 1.5. Comparison 1 CBZ vs Controls, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . 156
Analysis 2.1. Comparison 2 GBP vs Controls, Outcome 1 All Major Malformations. . . . . . . . . . . . 157
Analysis 3.1. Comparison 3 LEV vs Controls, Outcome 1 All Major Malformations. . . . . . . . . . . . 158
Analysis 4.1. Comparison 4 LTG vs Controls, Outcome 1 All Major Malformations. . . . . . . . . . . . 159
Analysis 4.2. Comparison 4 LTG vs Controls, Outcome 2 Neural Tube Malformations. . . . . . . . . . . 160
Analysis 4.3. Comparison 4 LTG vs Controls, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 161
Analysis 4.4. Comparison 4 LTG vs Controls, Outcome 4 Oro-Facial Cleft / Crainofacial Malformations. . . . . 162
Analysis 4.5. Comparison 4 LTG vs Controls, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . 163
Analysis 5.1. Comparison 5 OXC vs Controls, Outcome 1 All Major Malformations. . . . . . . . . . . . 164
Analysis 6.1. Comparison 6 PB vs Controls, Outcome 1 All Major Malformations. . . . . . . . . . . . . 165
Analysis 6.2. Comparison 6 PB vs Controls, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 166
Analysis 6.3. Comparison 6 PB vs Controls, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . . 167
Analysis 6.4. Comparison 6 PB vs Controls, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 168
Analysis 6.5. Comparison 6 PB vs Controls, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 169
Analysis 7.1. Comparison 7 PHT vs Controls, Outcome 1 All Major Malformations. . . . . . . . . . . . 170
Analysis 7.2. Comparison 7 PHT vs Controls, Outcome 2 Neural Tube Malformations. . . . . . . . . . . 171
Analysis 7.3. Comparison 7 PHT vs Controls, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 172
Analysis 7.4. Comparison 7 PHT vs Controls, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . 173
Analysis 7.5. Comparison 7 PHT vs Controls, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . 174
Analysis 8.1. Comparison 8 PRM vs Controls, Outcome 1 All Major Malformations. . . . . . . . . . . . 175
Analysis 9.1. Comparison 9 TPM vs Controls, Outcome 1 All Major Malformations. . . . . . . . . . . . 176
Analysis 9.2. Comparison 9 TPM vs Controls, Outcome 2 Neural Tube Malformations. . . . . . . . . . . 177
Analysis 9.3. Comparison 9 TPM vs Controls, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 178
Analysis 9.4. Comparison 9 TPM vs Controls, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . 179
Analysis 9.5. Comparison 9 TPM vs Controls, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . 180
Analysis 10.1. Comparison 10 VPA vs Controls, Outcome 1 All Major Malformations. . . . . . . . . . . 181
Analysis 10.2. Comparison 10 VPA vs Controls, Outcome 2 Neural Tube Malformations. . . . . . . . . . . 182
Analysis 10.3. Comparison 10 VPA vs Controls, Outcome 3 Cardiac Malformations. . . . . . . . . . . . 183
Analysis 10.4. Comparison 10 VPA vs Controls, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . 184
Analysis 10.5. Comparison 10 VPA vs Controls, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . 185
Analysis 11.1. Comparison 11 ZNS vs Controls, Outcome 1 All Major Malformations. . . . . . . . . . . 186
Analysis 12.1. Comparison 12 CBZ vs GBP, Outcome 1 All Major Malformations. . . . . . . . . . . . . 187
iMonotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 12.2. Comparison 12 CBZ vs GBP, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 187
Analysis 12.3. Comparison 12 CBZ vs GBP, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . . 188
Analysis 12.4. Comparison 12 CBZ vs GBP, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 188
Analysis 12.5. Comparison 12 CBZ vs GBP, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 189
Analysis 13.1. Comparison 13 CBZ vs LEV, Outcome 1 All Major Malformations. . . . . . . . . . . . . 189
Analysis 13.2. Comparison 13 CBZ vs LEV, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 190
Analysis 13.3. Comparison 13 CBZ vs LEV, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . . 190
Analysis 13.4. Comparison 13 CBZ vs LEV, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 191
Analysis 13.5. Comparison 13 CBZ vs LEV, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 192
Analysis 14.1. Comparison 14 CBZ vs LTG, Outcome 1 All Major Malformations. . . . . . . . . . . . . 193
Analysis 14.2. Comparison 14 CBZ vs LTG, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 194
Analysis 14.3. Comparison 14 CBZ vs LTG, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 195
Analysis 14.4. Comparison 14 CBZ vs LTG, Outcome 4 Oro-Facial Cleft / Crainofacial Malformations. . . . . 196
Analysis 14.5. Comparison 14 CBZ vs LTG, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 197
Analysis 15.1. Comparison 15 CBZ vs OXC, Outcome 1 All Major Malformations. . . . . . . . . . . . . 198
Analysis 15.2. Comparison 15 CBZ vs OXC, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 199
Analysis 15.3. Comparison 15 CBZ vs OXC, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 200
Analysis 15.4. Comparison 15 CBZ vs OXC, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . 201
Analysis 15.5. Comparison 15 CBZ vs OXC, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 202
Analysis 16.1. Comparison 16 CBZ vs PB, Outcome 1 All Major Malformations. . . . . . . . . . . . . 203
Analysis 16.2. Comparison 16 CBZ vs PB, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 204
Analysis 16.3. Comparison 16 CBZ vs PB, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . . 205
Analysis 16.4. Comparison 16 CBZ vs PB, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 206
Analysis 16.5. Comparison 16 CBZ vs PB, Outcome 5 Skeletal / Limb Malformation. . . . . . . . . . . . 207
Analysis 17.1. Comparison 17 CBZ vs PHT, Outcome 1 All Major Malformations. . . . . . . . . . . . . 208
Analysis 17.2. Comparison 17 CBZ vs PHT, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 209
Analysis 17.3. Comparison 17 CBZ vs PHT, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 210
Analysis 17.4. Comparison 17 CBZ vs PHT, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . 211
Analysis 17.5. Comparison 17 CBZ vs PHT, Outcome 5 Skeletal / Limb Malformation. . . . . . . . . . . 212
Analysis 18.1. Comparison 18 CBZ vs PRM, Outcome 1 All Major Malformations. . . . . . . . . . . . . 213
Analysis 18.2. Comparison 18 CBZ vs PRM, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 214
Analysis 18.3. Comparison 18 CBZ vs PRM, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 214
Analysis 18.4. Comparison 18 CBZ vs PRM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . 215
Analysis 18.5. Comparison 18 CBZ vs PRM, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 215
Analysis 19.1. Comparison 19 CBZ vs TPM, Outcome 1 All Major Malformations. . . . . . . . . . . . . 216
Analysis 19.2. Comparison 19 CBZ vs TPM, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 216
Analysis 19.3. Comparison 19 CBZ vs TPM, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 217
Analysis 19.4. Comparison 19 CBZ vs TPM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . 218
Analysis 19.5. Comparison 19 CBZ vs TPM, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 218
Analysis 20.1. Comparison 20 CBZ vs VPA, Outcome 1 All Major Malformations. . . . . . . . . . . . . 219
Analysis 20.2. Comparison 20 CBZ vs VPA, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 220
Analysis 20.3. Comparison 20 CBZ vs VPA, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 222
Analysis 20.4. Comparison 20 CBZ vs VPA, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 223
Analysis 20.5. Comparison 20 CBZ vs VPA, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 224
Analysis 21.1. Comparison 21 CBZ vs ZNS, Outcome 1 All Major Malformations. . . . . . . . . . . . . 225
Analysis 22.1. Comparison 22 GBP vs LTG, Outcome 1 All Major Malformations. . . . . . . . . . . . . 225
Analysis 22.2. Comparison 22 GBP vs LTG, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 226
Analysis 22.3. Comparison 22 GBP vs LTG, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 226
Analysis 22.4. Comparison 22 GBP vs LTG, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 227
Analysis 22.5. Comparison 22 GBP vs LTG, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 227
Analysis 23.1. Comparison 23 GBP vs OXC, Outcome 1 All Major Malformations. . . . . . . . . . . . . 228
Analysis 23.2. Comparison 23 GBP vs OXC, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 228
Analysis 23.3. Comparison 23 GBP vs OXC, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 229
iiMonotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 23.4. Comparison 23 GBP vs OXC, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . 229
Analysis 23.5. Comparison 23 GBP vs OXC, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 230
Analysis 24.1. Comparison 24 GBP vs PB, Outcome 1 All Major Malformations. . . . . . . . . . . . . 230
Analysis 24.2. Comparison 24 GBP vs PB, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 231
Analysis 24.3. Comparison 24 GBP vs PB, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . . 231
Analysis 24.4. Comparison 24 GBP vs PB, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 232
Analysis 24.5. Comparison 24 GBP vs PB, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 232
Analysis 26.1. Comparison 26 GBP vs TPM, Outcome 1 All Major Malformations. . . . . . . . . . . . . 233
Analysis 26.2. Comparison 26 GBP vs TPM, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 233
Analysis 26.3. Comparison 26 GBP vs TPM, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 234
Analysis 26.4. Comparison 26 GBP vs TPM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . 234
Analysis 26.5. Comparison 26 GBP vs TPM, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 235
Analysis 27.1. Comparison 27 GBP vs ZNS, Outcome 1 All Major Malformations. . . . . . . . . . . . . 235
Analysis 28.1. Comparison 28 LEV vs GBP, Outcome 1 All Major Malformations. . . . . . . . . . . . . 236
Analysis 28.2. Comparison 28 LEV vs GBP, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 236
Analysis 28.3. Comparison 28 LEV vs GBP, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . . 237
Analysis 28.4. Comparison 28 LEV vs GBP, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 237
Analysis 28.5. Comparison 28 LEV vs GBP, Outcome 5 Skeletal / Limb Malformation. . . . . . . . . . . 238
Analysis 29.1. Comparison 29 LEV vs LTG, Outcome 1 All Major Malformations. . . . . . . . . . . . . 238
Analysis 29.2. Comparison 29 LEV vs LTG, Outcome 2 Neural Tude Malformations. . . . . . . . . . . . 239
Analysis 29.3. Comparison 29 LEV vs LTG, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . . 239
Analysis 29.4. Comparison 29 LEV vs LTG, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 240
Analysis 29.5. Comparison 29 LEV vs LTG, Outcome 5 Skeletal / Limb Malformation. . . . . . . . . . . 241
Analysis 30.1. Comparison 30 LEV vs OXC, Outcome 1 All Major Malformations. . . . . . . . . . . . . 241
Analysis 30.2. Comparison 30 LEV vs OXC, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 242
Analysis 30.3. Comparison 30 LEV vs OXC, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 243
Analysis 30.4. Comparison 30 LEV vs OXC, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . 243
Analysis 30.5. Comparison 30 LEV vs OXC, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 244
Analysis 31.1. Comparison 31 LEV vs PB, Outcome 1 All Major Malformations. . . . . . . . . . . . . . 244
Analysis 31.2. Comparison 31 LEV vs PB, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . . 245
Analysis 31.3. Comparison 31 LEV vs PB, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . . 245
Analysis 31.4. Comparison 31 LEV vs PB, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 246
Analysis 31.5. Comparison 31 LEV vs PB, Outcome 5 Skeletal / Limb Malformation. . . . . . . . . . . . 246
Analysis 32.1. Comparison 32 LEV vs PHT, Outcome 1 All Major Malformations. . . . . . . . . . . . . 247
Analysis 32.2. Comparison 32 LEV vs PHT, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 247
Analysis 32.3. Comparison 32 LEV vs PHT, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . . 248
Analysis 32.4. Comparison 32 LEV vs PHT, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 249
Analysis 32.5. Comparison 32 LEV vs PHT, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 249
Analysis 34.1. Comparison 34 LEV vs TPM, Outcome 1 All Major Malformations. . . . . . . . . . . . . 250
Analysis 34.2. Comparison 34 LEV vs TPM, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 251
Analysis 34.3. Comparison 34 LEV vs TPM, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 251
Analysis 34.4. Comparison 34 LEV vs TPM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . 252
Analysis 34.5. Comparison 34 LEV vs TPM, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 253
Analysis 35.1. Comparison 35 LEV vs ZNS, Outcome 1 All Major Malformations. . . . . . . . . . . . . 253
Analysis 36.1. Comparison 36 LTG vs OXC, Outcome 1 All Major Malformations. . . . . . . . . . . . . 254
Analysis 36.2. Comparison 36 LTG vs OXC, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 254
Analysis 36.3. Comparison 36 LTG vs OXC, Outcome 3 Cardiac Malformation. . . . . . . . . . . . . . 255
Analysis 36.4. Comparison 36 LTG vs OXC, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . 255
Analysis 36.5. Comparison 36 LTG vs OXC, Outcome 5 Skeletal / Limb Malformation. . . . . . . . . . . 256
Analysis 37.1. Comparison 37 LTG vs PB, Outcome 1 All Major Malformations. . . . . . . . . . . . . 256
Analysis 37.2. Comparison 37 LTG vs PB, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 257
Analysis 37.3. Comparison 37 LTG vs PB, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . . 258
Analysis 37.4. Comparison 37 LTG vs PB, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 258
iiiMonotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 37.5. Comparison 37 LTG vs PB, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . . 259
Analysis 38.1. Comparison 38 LTG vs PHT, Outcome 1 All Major Malformations. . . . . . . . . . . . . 260
Analysis 38.2. Comparison 38 LTG vs PHT, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 261
Analysis 38.3. Comparison 38 LTG vs PHT, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . . 262
Analysis 38.4. Comparison 38 LTG vs PHT, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 263
Analysis 38.5. Comparison 38 LTG vs PHT, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 264
Analysis 39.1. Comparison 39 LTG vs TPM, Outcome 1 All Major Malformations. . . . . . . . . . . . . 265
Analysis 39.2. Comparison 39 LTG vs TPM, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 265
Analysis 39.3. Comparison 39 LTG vs TPM, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 266
Analysis 39.4. Comparison 39 LTG vs TPM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . 267
Analysis 39.5. Comparison 39 LTG vs TPM, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 268
Analysis 40.1. Comparison 40 PHT vs GBP, Outcome 1 All Major Malformations. . . . . . . . . . . . . 268
Analysis 40.2. Comparison 40 PHT vs GBP, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 269
Analysis 40.3. Comparison 40 PHT vs GBP, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 270
Analysis 40.4. Comparison 40 PHT vs GBP, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 270
Analysis 40.5. Comparison 40 PHT vs GBP, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 271
Analysis 41.1. Comparison 41 PHT vs OXC, Outcome 1 All Major Malformations. . . . . . . . . . . . 271
Analysis 41.2. Comparison 41 PHT vs OXC, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 272
Analysis 41.3. Comparison 41 PHT vs OXC, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 272
Analysis 41.4. Comparison 41 PHT vs OXC, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . 273
Analysis 41.5. Comparison 41 PHT vs OXC, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 274
Analysis 42.1. Comparison 42 PHT vs PB, Outcome 1 All Major Malformations. . . . . . . . . . . . . 275
Analysis 42.2. Comparison 42 PHT vs PB, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 276
Analysis 42.3. Comparison 42 PHT vs PB, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . . 277
Analysis 42.4. Comparison 42 PHT vs PB, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 278
Analysis 42.5. Comparison 42 PHT vs PB, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 279
Analysis 43.1. Comparison 43 PHT vs TPM, Outcome 1 All Major Malformations. . . . . . . . . . . . 280
Analysis 43.2. Comparison 43 PHT vs TPM, Outcome 2 Neural Tube Malformations. . . . . . . . . . . 280
Analysis 43.3. Comparison 43 PHT vs TPM, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 281
Analysis 43.4. Comparison 43 PHT vs TPM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . 282
Analysis 43.5. Comparison 43 PHT vs TPM, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 282
Analysis 44.1. Comparison 44 PB vs OXC, Outcome 1 All Major Malformations. . . . . . . . . . . . . 283
Analysis 44.2. Comparison 44 PB vs OXC, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 284
Analysis 44.3. Comparison 44 PB vs OXC, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . . 284
Analysis 44.4. Comparison 44 PB vs OXC, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 285
Analysis 44.5. Comparison 44 PB vs OXC, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 286
Analysis 45.1. Comparison 45 PB vs TPM, Outcome 1 All Major Malformations. . . . . . . . . . . . . 286
Analysis 45.2. Comparison 45 PB vs TPM, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 287
Analysis 45.3. Comparison 45 PB vs TPM, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . . 288
Analysis 45.4. Comparison 45 PB vs TPM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 288
Analysis 45.5. Comparison 45 PB vs TPM, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 289
Analysis 46.1. Comparison 46 VPA vs GBP, Outcome 1 All Major Malformations. . . . . . . . . . . . . 289
Analysis 46.2. Comparison 46 VPA vs GBP, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 290
Analysis 46.3. Comparison 46 VPA vs GBP, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . . 291
Analysis 46.4. Comparison 46 VPA vs GBP, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 291
Analysis 46.5. Comparison 46 VPA vs GBP, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 292
Analysis 47.1. Comparison 47 VPA vs LEV, Outcome 1 All Major Malformations. . . . . . . . . . . . . 292
Analysis 47.2. Comparison 47 VPA vs LEV, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 293
Analysis 47.3. Comparison 47 VPA vs LEV, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . . 293
Analysis 47.4. Comparison 47 VPA vs LEV, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 294
Analysis 47.5. Comparison 47 VPA vs LEV, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 295
Analysis 48.1. Comparison 48 VPA vs LTG, Outcome 1 All Major Malformations. . . . . . . . . . . . . 296
Analysis 48.2. Comparison 48 VPA vs LTG, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 297
ivMonotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 48.3. Comparison 48 VPA vs LTG, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . . 298
Analysis 48.4. Comparison 48 VPA vs LTG, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 299
Analysis 48.5. Comparison 48 VPA vs LTG, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 300
Analysis 49.1. Comparison 49 VPA vs TPM, Outcome 1 All Major Malformations. . . . . . . . . . . . . 301
Analysis 49.2. Comparison 49 VPA vs TPM, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 301
Analysis 49.3. Comparison 49 VPA vs TPM, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 302
Analysis 49.4. Comparison 49 VPA vs TPM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . 303
Analysis 49.5. Comparison 49 VPA vs TPM, Outcome 5 Skeletal / Limb Malformation. . . . . . . . . . . 303
Analysis 50.1. Comparison 50 VPA vs OXC, Outcome 1 All Major Malformations. . . . . . . . . . . . . 304
Analysis 50.2. Comparison 50 VPA vs OXC, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 305
Analysis 50.3. Comparison 50 VPA vs OXC, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 306
Analysis 50.4. Comparison 50 VPA vs OXC, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . 307
Analysis 50.5. Comparison 50 VPA vs OXC, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 308
Analysis 51.1. Comparison 51 VPA vs PB, Outcome 1 All Major Malformations. . . . . . . . . . . . . . 309
Analysis 51.2. Comparison 51 VPA vs PB, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . . 310
Analysis 51.3. Comparison 51 VPA vs PB, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . . 311
Analysis 51.4. Comparison 51 VPA vs PB, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 312
Analysis 51.5. Comparison 51 VPA vs PB, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . . 313
Analysis 52.1. Comparison 52 VPA vs PHT, Outcome 1 All Major Malformations. . . . . . . . . . . . . 314
Analysis 52.2. Comparison 52 VPA vs PHT, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 315
Analysis 52.3. Comparison 52 VPA vs PHT, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . . 316
Analysis 52.4. Comparison 52 VPA vs PHT, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 317
Analysis 52.5. Comparison 52 VPA vs PHT, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 318
Analysis 54.1. Comparison 54 PHT vs PRM, Outcome 1 All Major Malformations. . . . . . . . . . . . 319
Analysis 54.2. Comparison 54 PHT vs PRM, Outcome 2 Neural Tube Malformations. . . . . . . . . . . 320
Analysis 54.3. Comparison 54 PHT vs PRM, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 320
Analysis 54.4. Comparison 54 PHT vs PRM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . 321
Analysis 54.5. Comparison 54 PHT vs PRM, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 321
Analysis 55.1. Comparison 55 PB vs PRM, Outcome 1 All Major Malformations. . . . . . . . . . . . . 322
Analysis 55.2. Comparison 55 PB vs PRM, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 323
Analysis 55.3. Comparison 55 PB vs PRM, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . . 323
Analysis 55.4. Comparison 55 PB vs PRM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . . 324
Analysis 55.5. Comparison 55 PB vs PRM, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 324
Analysis 56.1. Comparison 56 LTG vs ZNS, Outcome 1 All Major Malformations. . . . . . . . . . . . . 325
Analysis 57.1. Comparison 57 OXC vs PRM, Outcome 1 All Major Malformations. . . . . . . . . . . . 325
Analysis 58.1. Comparison 58 OXC vs TPM, Outcome 1 All Major Malformations. . . . . . . . . . . . 326
Analysis 58.2. Comparison 58 OXC vs TPM, Outcome 2 Neural Tube Malformations. . . . . . . . . . . 326
Analysis 58.3. Comparison 58 OXC vs TPM, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 327
Analysis 58.4. Comparison 58 OXC vs TPM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . 327
Analysis 58.5. Comparison 58 OXC vs TPM, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . 328
Analysis 59.1. Comparison 59 OXC vs ZNS, Outcome 1 All Major Malformations. . . . . . . . . . . . . 328
Analysis 60.1. Comparison 60 PB vs ZNS, Outcome 1 All Major Malformations. . . . . . . . . . . . . 329
Analysis 61.1. Comparison 61 PHT vs ZNS, Outcome 1 All Major Malformations. . . . . . . . . . . . . 329
Analysis 63.1. Comparison 63 PRM vs VPA, Outcome 1 All Major Malformations. . . . . . . . . . . . . 330
Analysis 63.2. Comparison 63 PRM vs VPA, Outcome 2 Neural Tube Malformations. . . . . . . . . . . . 331
Analysis 63.3. Comparison 63 PRM vs VPA, Outcome 3 Cardiac Malformations. . . . . . . . . . . . . 331
Analysis 63.4. Comparison 63 PRM vs VPA, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations. . . . . 332
Analysis 63.5. Comparison 63 PRM vs VPA, Outcome 5 Skeletal / Limb Malformations. . . . . . . . . . . 332
Analysis 65.1. Comparison 65 TPM vs ZNS, Outcome 1 All Major Malformations. . . . . . . . . . . . . 333
Analysis 66.1. Comparison 66 VPA vs ZNS, Outcome 1 All Major Malformations. . . . . . . . . . . . . 333
333ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
339APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
346CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
vMonotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
346DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
346SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
347DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
347INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
viMonotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Monotherapy treatment of epilepsy in pregnancy: congenital
malformation outcomes in the child
Jennifer Weston1, Rebecca Bromley2, Cerian F Jackson1, Naghme Adab3, Jill Clayton-Smith2, Janette Greenhalgh4, Juliet Hounsome
4, Andrew J McKay5, Catrin Tudur Smith6, Anthony G Marson1
1Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
2Institute of Human Development, University of Manchester, Manchester, UK. 3Department of Neurology, A5 Corridor, Walsgrave
Hospital, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK. 4Liverpool Reviews and Implementation
Group, University of Liverpool, Liverpool, UK. 5Clinical Trials Unit, Institute of Child Health, Alder Hey Hospital, Liverpool, UK.
6Department of Biostatistics, University of Liverpool, Liverpool, UK
Contact address: Rebecca Bromley, Institute of HumanDevelopment, University ofManchester, 6th Floor, GeneticMedicine, StMary’s
Hospital, Oxford Road, Manchester, M13 9WL, UK. rebecca.bromley@manchester.ac.uk, rebeccalbromley@googlemail.com.
Editorial group: Cochrane Epilepsy Group.
Publication status and date: New, published in Issue 11, 2016.
Review content assessed as up-to-date: 14 September 2015.
Citation: Weston J, Bromley R, Jackson CF, Adab N, Clayton-Smith J, Greenhalgh J, Hounsome J, McKay AJ, Tudur Smith C,
Marson AG. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database of
Systematic Reviews 2016, Issue 11. Art. No.: CD010224. DOI: 10.1002/14651858.CD010224.pub2.
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
There is evidence that certain antiepileptic drugs (AEDs) are teratogenic and are associated with an increased risk of congenital
malformation. The majority of women with epilepsy continue taking AEDs throughout pregnancy; therefore it is important that
comprehensive information on the potential risks associated with AED treatment is available.
Objectives
To assess the effects of prenatal exposure to AEDs on the prevalence of congenital malformations in the child.
Search methods
We searched the Cochrane Epilepsy Group Specialized Register (September 2015), Cochrane Central Register of Controlled Trials
(CENTRAL) (2015, Issue 11), MEDLINE (via Ovid) (1946 to September 2015), EMBASE (1974 to September 2015), Pharmline
(1978 to September 2015), Reprotox (1983 to September 2015) and conference abstracts (2010-2015) without language restriction.
Selection criteria
We included prospective cohort controlled studies, cohort studies set within pregnancy registries and randomised controlled trials.
Participants were women with epilepsy taking AEDs; the two control groups were women without epilepsy and women with epilepsy
who were not taking AEDs during pregnancy.
Data collection and analysis
Three authors independently selected studies for inclusion. Five authors completed data extraction and risk of bias assessments. The
primary outcome was the presence of a major congenital malformation. Secondary outcomes included specific types of major congenital
malformations. Where meta-analysis was not possible, we reviewed included studies narratively.
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Main results
We included 50 studies, with 31 contributing to meta-analysis. Study quality varied, and given the observational design, all were at
high risk of certain biases. However, biases were balanced across the AEDs investigated and we believe that the results are not explained
by these biases.
Children exposed to carbamazepine (CBZ) were at a higher risk of malformation than children born to women without epilepsy (N
= 1367 vs 2146, risk ratio (RR) 2.01, 95% confidence interval (CI) 1.20 to 3.36) and women with untreated epilepsy (N = 3058 vs
1287, RR 1.50, 95% CI 1.03 to 2.19). Children exposed to phenobarbital (PB) were at a higher risk of malformation than children
born to women without epilepsy (N = 345 vs 1591, RR 2.84, 95% CI 1.57 to 5.13). Children exposed to phenytoin (PHT) were at
an increased risk of malformation compared with children born to women without epilepsy (N = 477 vs 987, RR 2.38, 95% CI 1.12
to 5.03) and to women with untreated epilepsy (N = 640 vs 1256, RR 2.40, 95% CI 1.42 to 4.08). Children exposed to topiramate
(TPM) were at an increased risk of malformation compared with children born to women without epilepsy (N = 359 vs 442, RR 3.69,
95% CI 1.36 to 10.07). The children exposed to valproate (VPA) were at a higher risk of malformation compared with children born
to women without epilepsy (N = 467 vs 1936, RR 5.69, 95% CI 3.33 to 9.73) and to women with untreated epilepsy (N = 1923
vs 1259, RR 3.13, 95% CI 2.16 to 4.54). There was no increased risk for major malformation for lamotrigine (LTG). Gabapentin
(GBP), levetiracetam (LEV), oxcarbazepine (OXC), primidone (PRM) or zonisamide (ZNS) were not associated with an increased
risk, however, there were substantially fewer data for these medications.
For AED comparisons, children exposed to VPA had the greatest risk of malformation (10.93%, 95% CI 8.91 to 13.13). Children
exposed to VPA were at an increased risk of malformation compared with children exposed to CBZ (N = 2529 vs 4549, RR 2.44, 95%
CI 2.00 to 2.94), GBP (N = 1814 vs 190, RR 6.21, 95% CI 1.91 to 20.23), LEV (N = 1814 vs 817, RR 5.82, 95% CI 3.13 to 10.81),
LTG (N = 2021 vs 4164, RR 3.56, 95% CI 2.77 to 4.58), TPM (N = 1814 vs 473, RR 2.35, 95% CI 1.40 to 3.95), OXC (N = 676
vs 238, RR 3.71, 95% CI 1.65 to 8.33), PB (N = 1137 vs 626, RR 1.59, 95% CI 1.11 to 2.29, PHT (N = 2319 vs 1137, RR 2.00,
95% CI 1.48 to 2.71) or ZNS (N = 323 vs 90, RR 17.13, 95% CI 1.06 to 277.48). Children exposed to CBZ were at a higher risk
of malformation than those exposed to LEV (N = 3051 vs 817, RR 1.84, 95% CI 1.03 to 3.29) and children exposed to LTG (N =
3385 vs 4164, RR 1.34, 95% CI 1.01 to 1.76). Children exposed to PB were at a higher risk of malformation compared with children
exposed to GBP (N = 204 vs 159, RR 8.33, 95% CI 1.04 to 50.00), LEV (N = 204 vs 513, RR 2.33, 95% CI 1.04 to 5.00) or LTG (N
= 282 vs 1959, RR 3.13, 95% CI 1.64 to 5.88). Children exposed to PHT had a higher risk of malformation than children exposed
to LTG (N = 624 vs 4082, RR 1.89, 95% CI 1.19 to 2.94) or to LEV (N = 566 vs 817, RR 2.04, 95% CI 1.09 to 3.85); however, the
comparison to LEV was not significant in the random-effects model. Children exposed to TPM were at a higher risk of malformation
than children exposed to LEV (N = 473 vs 817, RR 2.00, 95% CI 1.03 to 3.85) or LTG (N = 473 vs 3975, RR 1.79, 95% CI 1.06 to
2.94). There were no other significant differences, or comparisons were limited to a single study.
We found significantly higher rates of specific malformations associating PB exposure with cardiac malformations and VPA exposure
with neural tube, cardiac, oro-facial/craniofacial, and skeletal and limb malformations in comparison to other AEDs. Dose of exposure
mediated the risk of malformation following VPA exposure; a potential dose-response association for the other AEDs remained less
clear.
Authors’ conclusions
Exposure in the womb to certain AEDs carried an increased risk of malformation in the foetus and may be associated with specific
patterns of malformation. Based on current evidence, LEV and LTG exposure carried the lowest risk of overall malformation; however,
data pertaining to specific malformations are lacking. Physicians should discuss both the risks and treatment efficacy with the patient
prior to commencing treatment.
P L A I N L A N G U A G E S U M M A R Y
Treatment for epilepsy in pregnant women and the physical health of the child
Background
For most women who have epilepsy, continuing their medication during pregnancy is important for their health. Over the last 25 years,
research has shown that children exposed to these medications in the womb can be at a higher risk of having a malformation or birth
defect.
Research question
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This review aimed to understand whether exposure to antiepileptic drugs (AEDs) during pregnancy is linked to an increased risk of
having a child with a malformation.
Characteristics of the studies
The review included 50 published studies. We compared the children of women with epilepsy who were taking a single AED to the
children of women without epilepsy or women who had epilepsy but who were not treating it with AEDs. We also made comparisons
between children exposed to different AEDs in the womb. The evidence presented in this review was up to date in September 2015.
Results
The amount of data available from the studies reviewed varied greatly by the AED under investigation, and this could account for some
of the findings.
- Children exposed to valproate compared to other AEDs had the highest level of risk of a malformation at 10.93%. The children
exposed to valproate had a higher level of risk than both groups of control children and than children exposed to carbamazepine,
gabapentin, levetiracetam, lamotrigine, oxcarbazepine, phenobarbital, phenytoin, topiramate and zonisamide. The level of risk of having
a malformation was linked to the amount or dose of valproate the child was exposed to in the womb.
- Children exposed to carbamazepine were at a higher risk of malformations than both groups of control children and children exposed
to levetiracetam and lamotrigine.
- Children exposed to phenobarbital were at a higher risk of malformations than children born to women without epilepsy but not
those born to women with untreated epilepsy. They were also at a higher risk of malformation than children exposed to gabapentin,
levetiracetam or lamotrigine.
- Children exposed to phenytoin were at an increased risk of malformation compared with both groups of control children and children
exposed to levetiracetam and lamotrigine.; although the result of the comparison to levetriacetam is less clear.
- Children exposed to topiramate were at a higher risk ofmalformation than children born towomenwithout epilepsy but not those born
to women with untreated epilepsy. They were at a higher risk of malformation in comparison to the children exposed to levetiracetam
or lamotrigine.
- There were no other significant differences between AEDs, or comparisons were limited to a single study.
-We also found higher rates of specific types of malformations, particularly associating phenobarbital exposure with heartmalformations
and valproate exposure with a range of specific types of malformation affecting a number of different areas of the body.
Quality of the studies
The quality of how studies were designed varied, but we do not consider that this accounts for the results of the review.
Conclusions
This review found that children exposed to valproate in the womb were at an increased risk of having a malformation at birth and that
the level of risk is determined by the dose of valproate the child is exposed to. Based on current evidence, levetiracetam and lamotrigine
appear to be the AEDs associated with the lowest level of risk, but more data are needed, particularly concerning individual types of
malformation.
B A C K G R O U N D
Description of the condition
Epilepsy is a common disorder affecting up to 1% of the popula-
tion (Hauser 1990). Approximately one third of people receiving
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antiepileptic drugs (AEDs) are of reproductive age (Yerby 1994),
and between 0.5% to 0.6% of all pregnancies are reportedly ex-
posed to an AED (Man 2012). There is a large body of research
that demonstrates an association between children born to women
with epilepsy treated with AEDs and an increased risk of congeni-
tal malformations, including cardiac, neural tube and craniofacial
defects (Jentink 2010; Meador 2008; Tomson 2011).
Description of the intervention
AEDs are the most common treatment for epilepsy, and most
women with epilepsy require treatment continuation during preg-
nancy. AEDs readily cross the placenta from the mother into the
foetus (Bossi 1982).
How the intervention might work
Prospective observational studies (e.g. Canger 1999), registry-
based studies (e.g. Tomson 2011), large case control studies
(Jentink 2010), and meta-analysis studies (Meador 2008) provide
evidence of an associationbetween treatmentwith particular AEDs
and an increased prevalence of malformations. There have been re-
ports of differential outcomes for the AEDswith sodium valproate
(VPA), which are associated with the largest increase in prevalence
(Canger 1999; EURAP; Meador 2006; North American Register;
UK Register).
The mechanisms through which prenatal exposure to AEDs is as-
sociated with an increased prevalence of major and minor con-
genital malformations remain unknown, and they may differ by
treatment type. Therefore, this review investigates the outcomes
for each monotherapy separately so as to provide the most reliable
evidence available.
Why it is important to do this review
The decision to continue AED treatment during pregnancy re-
quires taking a risk-benefit decision. On the one hand, there is
the potential risk exposure in utero that AEDs pose to the physi-
cal and neurodevelopment of the child, with lifelong implications
when the medication in question is a teratogen (Bromley 2014).
On the other hand lies the health and well-being of the mother,
who requires treatment for epilepsy throughout her pregnancy to
minimise the risk of seizures, with varying efficacy against seizure
activity depending on treatment type (EURAP STUDY GROUP
2006).
While a number of studies indicate a teratogenic risk from AEDs,
there are conflicting results regarding the degree of risk and the type
of malformations associated with specific AEDs, and the strength
of the evidence is often limited by cohort size. This makes it diffi-
cult to counsel women about treatment choices before or during
pregnancy. There is, therefore, a clear need for a systematic re-
view and meta-analysis of existing data to inform these decisions.
Although randomised controlled trials (RCTs) would provide the
most reliable evidence about the effects of AEDs taken in preg-
nancy, they have been considered unethical in this area, and even
if undertaken would pose considerable difficulties in terms of de-
sign, recruitment and interpretation.
In view of this, we have decided to proceed with a systematic re-
view of all available evidence including registry-based, prospec-
tive cohort studies and RCTs. At the protocol stage we decided
not to include malformation case-control studies (e.g. Jentink
2010; Jentink 2010b) and studies using electronic health care re-
sources (e.g. Wide 2004) due to the lack of understanding of how
these methods compare to prospective observational cohort stud-
ies. This decision is discussed further in Overall completeness and
applicability of evidence.
Evidence from this review along with the related review by the
same Cochrane team will aid the decisions clinicians and women
with epilepsy have to make about the treatment of epilepsy dur-
ing the potential childbearing years (Bromley 2014). This review
and its linked review, Bromley 2014 replace the previously pub-
lished review entitled ’Common antiepileptic drugs in pregnancy
in women with epilepsy’ (Adab 2004).
O B J E C T I V E S
To assess the effects of prenatal exposure to commonly prescribed
AEDs on the prevalence of congenital malformations in the child.
This review examines the association between AED exposure and
the prevalence of congenital malformations compared to the gen-
eral population or unexposed pregnancies in women with epilepsy.
It also compares the prevalence of congenital malformations in
children exposed to different monotherapy AEDs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered the following types of studies.
1. Randomised controlled trials (RCTs). These are studies that
included women with epilepsy requiring treatment and
randomised them to a particular AED prior to conception. The
intervention group(s) comprised women with epilepsy taking an
AED of interest as monotherapy.
2. Prospective observational cohort studies. These included
consecutive participants from single or multicentre participating
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sites, where investigators collected information regarding the
pregnancy and history prior to the birth of the child. The
intervention group(s) comprised women with epilepsy taking an
AED of interest as monotherapy.
3. Registry studies. Registry studies involve the collection of
data from a wide region, country or number of countries, and
recruitment is often based on self referral or clinician referral
leading to non-sequential case ascertainment. We considered
both independent and industry-sponsored registry datasets to be
eligible. These included recruited pregnant women ascertained
prospectively prior the birth of the child. The intervention
group(s) comprised women with epilepsy taking an AED of
interest as monotherapy.
Types of participants
Pregnant women with epilepsy taking a single AED of interest
were eligible for the intervention group.
Participants eligible for the comparator groups were:
• pregnant women with epilepsy taking an AED;
• pregnant women with epilepsy taking no AED; or
• pregnant women who do not have epilepsy.
We excluded studies reporting AED use solely in pregnant women
with other conditions (e.g. mood disorders, pain, etc). We in-
cluded studies involving women taking AEDs for epilepsy and
other conditions, but we only included their results in meta-anal-
ysis if the rate of other conditions was lower than 10% of the total
treatment group.
Types of interventions
Intervention group
Women with epilepsy who received any of the following AEDs in
monotherapy: phenobarbitone, phenytoin, carbamazepine, oxcar-
bazepine, sodium valproate, lamotrigine, topiramate, gabapentin,
vigabatrin, tiagabine, zonisamide, levetiracetam, ethosuximide,
clobazam, clonazepam, zonisamide, pregabalin, lacosamide, reti-
gabine, rufinamide or sulthiame.
Comparator groups
We used two separate types of comparator groups in this review,
as currently there is no clear evidence regarding the reliability of
combining data from these two different groups. The two com-
parator groups are:
• controls: women with a diagnosis of epilepsy who were not
taking AEDs and women without epilepsy.
• comparator treatment: women with epilepsy taking
monotherapy treatment, evaluated in subgroup analyses to
enable treatment comparisons.
Types of outcome measures
Primary outcomes
Major congenital malformations
The proportion of children who present with any type of major
congenital malformation (as defined by original study authors).
Major congenital malformations are structural abnormalities of
the body or organs present from birth that impair viability and
require significant intervention (EUROCAT).
Secondary outcomes
Specific major congenital malformations
The proportion of childrenwho present with the following specific
major congenital malformations by area of the body.
• Neural tube malformations.
• Cardiac malformations.
• Orofacial cleft/craniofacial malformation.
• Skeletal or limb malformations.
We chose the above disorders because they are important major
malformations associated with exposure to AEDs in utero and be-
cause of the availability of data within the included studies (Brent
2004). When extracting data from included studies, we compiled
a list of all the specified malformations. JCS, a clinical geneticist,
then reviewed the list and classified the items into one of the four
specific malformation categories.
Minor congenital malformations
Minor congenital malformations are a structural anomaly or dys-
morphic feature present from birth which does not impair viabil-
ity or require intervention or treatment (EUROCAT).
The proportion of children who present with the following minor
congenital malformations.
1. All minor congenital malformations.
2. Eyes (e.g. epicanthal folds, hypertelorism).
3. Ears (e.g. low set ears).
4. Nose (e.g. flat and or broad nasal bridge, long/short/shallow
philtrum, anteverted nostrils).
5. Mouth (e.g. microstomia, prominent lower lip, thin upper
lip).
6. Digits (e.g. distal phalangeal, finger or nail hypoplasia,
arachnodactyly, toe or toenail hypoplasia).
7. Limb (not inducing significant life impacting difficulty, e.g.
mild talipes correctable by physiotherapy, and not requiring
surgical correction, e.g. limb reduction, congenital dislocation of
hip, joint laxity).
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8. Other (e.g. hernia, sacral dimples).
Search methods for identification of studies
Electronic searches
We searched the following databases.
1. Cochrane Epilepsy Review Group Specialized Register,
using the search strategy set out in Appendix 1 (14 September
2015).
2. The Cochrane Central Register of Controlled trials
(CENTRAL, The Cochrane Library, 2015 Issue 9), using the
search strategy set out in Appendix 2.
3. MEDLINE (Ovid) using the search strategy set out in
Appendix 3 (1946 to September 2015).
4. EMBASE (1974 to September 2015).
5. Pharmline (1978 to September 2015).
6. Reprotox (1983 to September 2015).
7. ClinicalTrials.gov, using the search terms: “congenital
malformation” AND epilepsy (14 September 2015).
8. WHO International Clinical Trials Registry Platform
(ICTRP) using the search terms: congenital malformation AND
epilepsy (15 September 2015).
We adapted the MEDLINE search strategy to meet requirements
of the EMBASE, Pharmline and Reprotox databases.
We did not impose any language restrictions in the search, and
when necessary we obtained translations of articles written in lan-
guages other than English.
Searching other resources
We reviewed conference abstracts from neurology meetings pub-
lished from 2010 to 2015 , including abstracts from the Inter-
national League Against Epilepsy meetings (American Epilepsy
Society, International Epilepsy Congress, European Congress on
Epileptology, Asian and Oceanian Epilepsy Congress and Latin
American Congress on Epilepsy) and Teratology meetings (The
Teratology Society and European Teratology Society). Where pos-
sible, we linked abstracts to published datasets or categorised them
as awaiting classification.
We handsearched the Epilepsia Journal supplements from 2010
to 2015 for conference proceedings.
We cross matched reference lists of original research and review
articles to the studies generated from the electronic searches. We
handsearched reference lists of recent review articles and contacted
lead and corresponding authors in the area for any relevant un-
published material.
Data collection and analysis
Selection of studies
Three authors (RB, JW, JG) reviewed the titles and abstracts of
articles highlighted by the searches and removed studies that ob-
viously did not meet the inclusion criteria. Two authors (RB, JW)
used full-text reports to determine study eligibility. We discussed
disagreements and sought the opinion of a third author (JG) when
necessary. Multiple reports from single studies are common in
this field, so if it was unclear if study populations overlapped, we
linked them together by date of recruitment and tried to contact
authors to determine whether different reports referred to single
study populations..
Data extraction and management
Five authors (RB, JW, NA, JG, AM) undertook data extraction on
the included studies by splitting the number of studies into equal
parts. We used pre-standardised electronic data extraction forms
that members of the review team piloted and then amended where
necessary. We then cross-checked data extraction.
Assessment of risk of bias in included studies
Due to the observational design of some of the studies, we decided
to utilise a draft version of the extendedCochrane tool for assessing
risk of bias, which the Cochrane Non-Randomised Studies Meth-
ods Group was developing. This has now been superseded by the
ROBINS-I tool that will be used in future updates of this review.
The extended version of the Cochrane tool for assessing risk of
bias examines selection bias (sequence generation, allocation con-
cealment), performance bias (blinding), attrition bias (incomplete
outcome data, blinding), detection bias (blinding, other potential
threats to validity), reporting bias (selective outcome reporting)
and the influence of confounding variables. We used a five-point
scale to rate the domains of blinding, incomplete outcome data,
selective outcome reporting, confounding variables and other bias
according to the risk of bias on the outcome. See Appendix 4 and
Appendix 5 for extended risk of bias tools. The review authors
determined the parameters of this scale; see Table 1 for scale pa-
rameters.
For RCTs, we assessed all domains of the current Cochrane tool
for assessing risk of bias (Higgins 2011).
We intended, where applicable, to create ’Summary of findings’
tables for outcomes and to grade each outcome accordingly using
the GRADE (Grading of Recommendations Assessment, Devel-
opment and Evaluation) approach (Guyatt 2008). However, we
did not create ’Summary of findings’ tables due to the complex-
ity and vast amount of comparisons this review investigates (see
Differences between protocol and review).
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Measures of treatment effect
Both the primary and secondary outcomes are presented as risk
ratios (RRs). We also computed risk differences (RDs) using Re-
view Manager (RevMan) to take into account studies with no re-
ported events. We calculated these effect estimates in accordance
with theCochrane Handbook for Systematic Reviews of Interventions
and reported them in the results section (Higgins 2011).
In some cases the reporting of the analyses were required to be
presented the opposite way around to themeta-analyses (i.e. Table
2). These were calculated as follows: A risk ratio for A vs. B is
presented as RR [Lower Limit (LL), Upper Limit (UL)]. A risk ratio
for B vs. A can be calculated as the reciprocal by (1/RR) [1/UL, 1/
LL]. A risk difference for A vs. B is presented as RD [LL, UL]. A risk
difference for B vs. A can be calculated by RD*(-1) [UL*(-1), LL*(-
1)].
Unit of analysis issues
Data published in studies are often duplicated with updated data
over time, particularly in the case of the prospective pregnancy reg-
istries, which update their publications as the numbers of enrolled
pregnancies increases. In such cases, we considered the latest time
point as themain study. In some cohorts, thismeant that investiga-
tors used different publications for different AEDs. Further, there
are studies that report on data from a number of registers (e.g.
EURAP; Samren 1997); we could not confirm the independence
of this data and therefore only reviewed these studies narratively.
We carefully examined data to ensure that we did not include
them more than once in the analysis and that we did not omit
any non-duplicated data. Where appropriate, we intended to use
subgroup analysis to account for the likelihood of omitting non-
duplicated data. We expected studies to use different definitions
of major and minor congenital malformations, and we examined
these variations thoroughly in order to inform the combination of
data for analysis.
Dealing with missing data
We contacted study authors to obtain missing statistics from stud-
ies. We also investigated reasons for missing data to determine if
they were missing at random or not.
Assessment of heterogeneity
We assessed clinical heterogeneity by examining the differences
in study characteristics in order to inform decisions regarding the
combination of study data in meta-analysis. A priori hypotheses
of sources of clinical heterogeneity included: type of population
(regional, national or international, single or multicentre), loss to
follow-up, maternal factors including age, duration of AED treat-
ment, family history of congenital malformation, lifestyle factors,
monotherapy, socioeconomic status, type of epilepsy, use of other
medications and years of education. Child factors included: age
of assessment, gestational age at birth, sex, seizure exposure, time
of follow-up and outcome measurement. Where applicable, we
also assessed statistical heterogeneity by examining the I2 statistic
and a Chi2 test, using the guidelines outlined in Higgins 2011
for interpreting the results. According to these guidelines, an I
2 statistic of 0% to 40% may not be important, 30% to 60%
may indicate moderate heterogeneity, 50% to 90% may indicate
substantial heterogeneity and 75% to 100% indicated consider-
able heterogeneity. Therefore for this review, we considered an I
2 statistic of more than 50% to indicate significant heterogeneity.
The I2 statistic was not applicable in comparisons where there was
only a single study or when only one study contributed data to the
analysis. When interpreting the Chi2 test, a P value of less than
0.01 was considered to indicate significant heterogeneity. When
we found statistical heterogeneity, we presented both fixed-effect
and random-effects analyses to enable exploration of differences.
Assessment of reporting biases
We investigated included studies using the ORBIT classification
system if we suspected selective outcome reporting bias. We re-
quested all protocols from included study authors to enable com-
parison of outcomes of interest; however, we received very little
response from them, complicating our performance of this com-
parison.
Our comprehensive search of multiple sources, together with our
requests for unpublished data from authors, minimised the risk of
publication bias. We looked for small-study effects to establish the
likelihood of publication bias and examined funnel plots when we
could combine an appropriate number of studies. Cochrane rec-
ommends combining a minimum of 10 studies when examining
funnel plots (Higgins 2011). We found no evidence of reporting
bias in the funnel plot inspection.
Data synthesis
We employed both fixed-effect and random-effects meta-analyses
to synthesise the data. We presented the primary outcome (major
congenital malformations) and the secondary outcome of specific
malformations as a risk ratio (RR). We intended to present the
secondary outcome (minor congenital malformations) as an RR;
however, meta-analysis was not possible due to extremely limited
data.
Due to the small number of events within certain comparisons, we
have also presented the risk differences (RD) for both the primary
outcome and the secondary outcome of specific malformation
type. In the event that we deemedmeta-analysing appropriate (e.g.
presence of clinical heterogeneity), we applied a narrative form to
the review, discussing all comparisons according to the findings
presented within the studies.
Comparisons carried out included:
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1. specific intervention monotherapy group versus controls on
major congenital malformations;
2. specific intervention monotherapy group versus controls on
specific major congential malformation types;
3. specific intervention monotherapy group versus specific
intervention monotherapy group on major congential
malformations;
4. specific intervention monotherapy group versus specific
intervention monotherapy group on specific major congential
malformations.
We stratified each comparison by control group and comparator
group to ensure appropriate combination of study data.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis was stratified by AED and type of control or
comparator group. When heterogeneity was present across out-
comes, we carried out a random-effects analysis. We examined dif-
ferences between analyses and reported the appropriate analysis.
Sensitivity analysis
We intended to carry out sensitivity analysis if we found peculiar-
ities in study quality, but this step was not required.
R E S U L T S
Description of studies
Results of the search
The search identified 11,695 records from the databases outlined
in Electronic searches, and we found 48 records through hand-
searching. Following the removal of duplicates, 11,348 records re-
mained; these were screened for inclusion in the review. We ex-
cluded 11,215 records due to irrelevance, leaving 133 full texts
(80 unique studies) to be assessed for eligibility. We excluded
21 and categorised 9 as ’awaiting classification’ (Babic 2014;
Idriz-Oglu 2014; Jones 1992; Kaabi 2013; Kutlu 2013; Lazzaroni
Fossati 1986; Midi 2014; Shvartzman 1986; Vlasov 2014). See
Characteristics of excluded studies and Characteristics of studies
awaiting classification for available details of these studies and
Figure 1 for the study flow diagram. We ultimately included 50
studies in the review, from 103 reports; we included 31 of these in
the meta-analyses, with the remainder contributing to the review
narratively.
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Figure 1. Study flow diagram.
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Included studies
A total of 103 included full texts reported on 50 independent
studies included in this review, of which all but one were non-
randomised studies. There were 53 linked papers pertaining to 23
studies. These full texts were related to an included study, as they
presented information on the same cohort of children but either at
a different time point or on a related, but not included, outcome
(i.e. obstetric or neurodevelopmental outcome).
Excluded studies
We excluded 21 studies from the review (Annegers 1974;
Artama 2013; Arteaga-Vazques 2012; Baermig 1973; Canun-
Serrano 1986; Castilla-Puentes 2014; Dobos 1985; Elshove
1971; Holmes 1994; Jacobsen 2014; Knight 1975; Lamotrigine
Pregnancy Register; Miskov 2009; Monson 1973; Montouris
2003; Mostacci 2014; Nakane 1980; Pearse 1992; Robert 1983;
Starveld-Zimmerman 1975; Veiby 2014). Several of these papers
were not written in the English language and therefore were sent
for translation and data extraction in order to determine the study
design and methodology used. Sixteen of the excluded studies em-
ployed a retrospective design or they were classed as a record link-
age study or case series, and were therefore not eligible for inclu-
sion within this review.
Risk of bias in included studies
We rated all domains of bias except sequence generation and allo-
cation concealment on a scale of 1 (low risk of bias) to 5 (high risk
of bias). We describe the scale parameters for each domain in Table
1. We rated sequence generation and allocation concealment as
having low, high or unclear risk of bias.
Allocation
For the domains of sequence generation and allocation conceal-
ment, we rated all included studies as being at high risk of bias.
Whether carried out prospectively or as a registry study, the in-
cluded studies did not employ rigorous methods (that is, randomi-
sation to treatment), as the research questions were not conducive
to the features of these types of study design. However, the non-
randomised risk of bias tool used in this review required the as-
sessment of these two domains. See Figure 2 for a summary of
risk of bias judgements. There was one RCT; however, it provided
no information regarding randomisation to the treatment group
(controls were not randomised), and therefore we still considered
this study to be at high risk of bias (Barqawi 2005).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Blinding
We did not rate any studies as ’1’, which would have meant
that assessors and participants were blinded to drug regimen.
Eight studies employed full assessor blinding (D’Souza 1990;
Gaily 1988; Hill 1974; Jones 1989; Mawer 2010; Meador 2006;
Wide 2000; Yerby 1992). Motherisk Registry employed par-
tial blinding with a possible impact on outcome, whilst Kerala
Pregnancy Registry employed partial blinding with a likely ef-
fect on outcome. Ten studies did not employ any blinding of as-
sessors, and usually their judgements regarding the presence or
absence of a malformation were made in routine healthcare sit-
uations (Al Bunyan 1999; Australian; Cassina 2013; EURAP;
Israeli Teratogen Service; Koch 1992; North American Register;
Omtzigt 1992; Samren 1997; UK Register). Unfortunately, 30
studies failed to provide information as to whether the outcome as-
sessorswere blinded or not, and thereforewe had to rate themas be-
ing at an unclear risk (Arulmozhi 2006; Bag 1989; Barqawi 2005;
Bozhinova 2009; Canger 1999;Delmiš 1991;Diaz-Romero 1990;
Dravet 1992; Eroglu 2008; Fairgrieve 2000; Froscher 1991; Fujji
2013; Garza-Morales 1996; Goujard 1974; Kaaja 2003; Kaneko
1999; Kelly 1984; Laskowska 2002; Lindhout 1992; Martinez
Ferri 2009; Meischenguiser 2004; Montreal Series; Pardi 1982;
Richmond 2004; Sabers 2004; Shapiro 1976; Steegers-Theunissen
1994; Tanganelli 1992; Torres 1995; Waters 1994) leaving open
the possibility that the outcomes were affected by knowledge of
the AED treatment.
Incomplete outcome data
We assigned a rating of ’1’ to only five studies, as there were no
missing data (Al Bunyan 1999; Barqawi 2005; D’Souza 1990;
Delmiš 1991; Richmond 2004). We gave the majority of studies
a ’2’, as there was only a small amount of missing data from the
reports (< 25%), and study authors gave appropriate reasons (i.e.
foetal loss or loss to follow-up) (Arulmozhi 2006; Australian;
Bag 1989; Canger 1999; Cassina 2013; Dravet 1992; Eroglu
2008; EURAP; Fairgrieve 2000; Froscher 1991; Gaily 1988; Hill
1974; Kaaja 2003; Kaneko 1999; Kelly 1984; Kerala Pregnancy
Registry; Lindhout 1992; Martinez Ferri 2009; Mawer 2010;
Meador 2006; Meischenguiser 2004; Montreal Series; Motherisk
Registry; North American Register; Omtzigt 1992; Pardi 1982;
Sabers 2004; Torres 1995; UK Register; Waters 1994;Wide 2000;
Yerby 1992). We assigned a rating of ’3’ to Israeli Teratogen
Service, as there was a possible impact from missing data on the
assessment of outcomes due to a larger amount of missing data,
and to six other studies where the number of participants recruited
or analysed was unclear, introducing a possible impact of missing
data on study outcomes (Fujji 2013; Goujard 1974; Koch 1992;
Samren 1997; Steegers-Theunissen 1994; Tanganelli 1992). We
rated Jones 1989 as ’4’, as there was a large amount of missing data
that was imbalanced across the groups, suggesting a likely effect on
the outcomes. Finally, we rated five studies a ’5’, suggesting a high
risk of bias, due to the lack of information pertaining to missing
data (Bozhinova 2009; Diaz-Romero 1990; Garza-Morales 1996;
Laskowska 2002; Shapiro 1976).
Selective reporting
We rated selective outcome reporting on a scale of 1 to 5, where ’1’
denotes a low risk of bias and ’5’ a high risk of bias. We requested
study protocols from authors with contact details available on
the Internet. We received only 14 responses and eight protocols
(Australian; Cassina 2013; Fujji 2013; Israeli Teratogen Service;
Mawer 2010; Meador 2006; UK Register; Wide 2000). For the
eight studies with an available protocol, we assigned a rating of ’1’
for low risk of bias, as there was no evidence of selective outcome
reporting following protocol review.
We assigned a ’2’ to the majority of studies, as there was no
evidence of selective outcome reporting within the publications
(Al Bunyan 1999; Canger 1999; D’Souza 1990; Diaz-Romero
1990; Dravet 1992; Eroglu 2008; EURAP; Gaily 1988; Hill
1974; Jones 1989; Kaaja 2003; Kaneko 1999; Kelly 1984; Kerala
Pregnancy Registry; Koch 1992; Lindhout 1992; Martinez Ferri
2009;Meischenguiser 2004;Montreal Series; Motherisk Registry;
North American Register; Omtzigt 1992; Richmond 2004; Sabers
2004; Samren 1997; Steegers-Theunissen 1994; Yerby 1992);
however, we could not test the studies against their protocols, as
they were not available. We rated 15 studies as ’3’, as the risk
of bias was unclear due to limited information regarding a priori
outcomes in the text (Arulmozhi 2006; Bag 1989; Barqawi 2005;
Bozhinova 2009; Delmiš 1991; Fairgrieve 2000; Froscher 1991;
Garza-Morales 1996;Goujard 1974; Laskowska 2002; Pardi 1982;
Shapiro 1976; Tanganelli 1992; Torres 1995; Waters 1994). We
didn’t give any studies a rating of ’4’ or ’5’.
Other potential sources of bias
We examined any other potential sources of bias and rated the
risk on a scale of 1 to 5. The main other sources of bias that
we identified included grouped analysis of AEDs, or analysis of
monotherapy and polytherapy data for a specific drug together,
recruitment of pregnancies at any time in gestation (or a failure to
report upper limit of pregnancy enrolment) and failure to exclude
malformations that occurred with genetic conditions. We rated
only three studies as ’1’, indicating that they were at low risk for
other sources of bias (Canger 1999; EURAP; Omtzigt 1992). We
assigned a ’5’ to all other studies, indicating that they were at high
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risk of one or more of the other biases listed above. See the ’Risk
of bias’ tables for the individual studies in the Characteristics of
included studies.
Confounding variables
We compiled a pre-specified list of confounding variables prior
to carrying out the review as described in Assessment of risk of
bias in included studies. We did not rate any studies as a ’1’,
as no studies had considered and adjusted for all possible con-
founders. We rated six studies as ’2’ to indicate that they had con-
sidered and adjusted for all important confounders (Australian;
EURAP; Mawer 2010; Meador 2006; North American Register;
Steegers-Theunissen 1994). Fourteen studies considered and ad-
justed for some important confounders, so we assigned a rating
of ’3’ (Cassina 2013; D’Souza 1990; Delmiš 1991; Diaz-Romero
1990; Dravet 1992; Israeli Teratogen Service; Jones 1989; Kaaja
2003; Koch 1992; Martinez Ferri 2009; Montreal Series; Samren
1997;UKRegister;Waters 1994). Fourteen studies had considered
but not adjusted for confounders, sowe gave them a ’4’ (Al Bunyan
1999; Arulmozhi 2006; Bag 1989; Canger 1999; Gaily 1988; Hill
1974; Kerala Pregnancy Registry; Lindhout 1992;Meischenguiser
2004;Motherisk Registry; Omtzigt 1992; Richmond 2004; Wide
2000; Yerby 1992). Finally, a further 14 studies failed to undertake
any considerationor adjustment for confounders, sowe rated them
as ’5’ (Bozhinova 2009; Eroglu 2008; Fairgrieve 2000; Froscher
1991; Garza-Morales 1996; Goujard 1974; Kaneko 1999; Kelly
1984; Laskowska 2002; Pardi 1982; Sabers 2004; Shapiro 1976;
Tanganelli 1992; Torres 1995).
Effects of interventions
We computed pooled prevalences of malformations within AED
groups (using fixed-effect models, unless otherwise stated) and
report them at the beginning of each drug section. Table 3 displays
a matrix of comparisons and their results for quick reference.
The reported results are fromfixed-effectmeta-analyses unless oth-
erwise stated. Outcomes are reported as both RR and RDs. The
RR is a measure of relative effect expressed as the ratio of the risk
of an event in the two groups. If the 95% confidence interval in-
cludes the value of 1.00, this implies there is no difference between
the groups (i.e. a non-significant result). If the value of 1.00 lies
outside the 95% confidence interval, this implies there is a dif-
ference between the groups (i.e. a significant result). The RD is a
measure of absolute effect expressed as the difference of the risk of
an event in the two groups. If the 95% confidence interval con-
tains the value of 0.00, this implies there is no difference between
the groups (i.e. both groups have the same risk). If the value of
0.00 lies outside the 95% confidence interval, this implies there is
a difference between the groups (i.e. a significant result). We ex-
plicitly state whether all of the results shown in the Results section
are significant or not. The significance of the RR and RD may be
different, as the RD takes into account comparisons where there
were no events in either arm, whilst the other does not. Where the
lower or upper CIs were on the line of no effect for both RR and
RD calculations, we added an asterisk to draw readers’ attention
to a remote possibility of no effect.
Although the RR estimates are large in many comparisons, the
corresponding risk difference estimates are fairly small (see Table
2), but even a small increase in risk for a specific major malforma-
tion is clinically meaningful. In these cases it would be up to the
patient/clinician to interpret these risk estimates in the context of
the adverse outcome and in relation to the potential benefits of
treatment (e.g. treatment efficacy).
Finally, we did not carry out any formal analysis of a dose-response
relationship. We have taken any dose-response results reported
directly from the study papers.
We provide the results of the meta-analyses and narrative report
below by AED type, with comparisons to the controls presented
first and comparisons between different AEDs following.
Carbamazepine
The prevalence of major malformations (any type) for children
exposed to carbamazepine (CBZ) (N = 4666), based on data from
30 studies, was 3.71% (95%CI 3.19 to 4.27; I2 = 45.5%, P value =
0.004). Due to significant variance, we undertook random-effects
modelling, giving a prevalence of 4.93% (95% CI 3.84 to 6.16; I
2 = 45.5%, P value = 0.004).
1 CBZ versus controls
1.1 All major malformations
1.1.1 CBZ versus no medication (in women without epilepsy)
Pooled results from eight studies reported a significant outcome
(RR 2.01, 95% CI 1.20 to 3.36; I2 = 0%), with children ex-
posed to CBZ (N = 1367) experiencing more major malforma-
tions than control children (N = 2146) (Arulmozhi 2006; Cassina
2013; Israeli Teratogen Service; Koch 1992; Mawer 2010; North
American Register; Steegers-Theunissen 1994; Tanganelli 1992;
see Analysis 1.1). This gave a significant RD (RD 0.02, 95% CI
0.00* to 0.03; I2 = 0%).
We did not combine data from Motherisk Registry, which in-
cluded women treated with CBZ for epilepsy and other condi-
tions, within the meta-analysis. This study reported prevalence
of major congenital malformations to be 2/35 (5.7%) for those
exposed to CBZ and 2/36 (5.6%) for the control children. The
multicentre study Samren 1997 reported 22 (8%) cases of major
malformation from 280 infants exposed to CBZ. However, the
numbers from centres with a control group were smaller, with four
cases of malformation out of just 14 exposed infants. This gave a
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significantly higher risk estimate than the control children born
to women without epilepsy (RR 4.9, 95% CI 1.3 to 18.0).
1.1.2 CBZ versus no medication (in women with epilepsy)
Pooled findings from17 studies showed a significant outcome (RR
1.50, 95% CI 1.03 to 2.19; I2 = 0%), with children exposed to
CBZ (N = 3058) experiencing more major malformations than
control children (N =1287) (Al Bunyan 1999; Australian; Barqawi
2005; Canger 1999;Delmiš 1991;D’Souza 1990;Fairgrieve 2000;
Garza-Morales 1996;Kaaja 2003;Kaneko1999;KeralaPregnancy
Registry; Koch 1992; Lindhout 1992; Mawer 2010; Montreal
Series; UK Register; Waters 1994; see Analysis 1.1). This gave a
significant RD (RD 0.01, 95% CI 0.00* to 0.03; I2 = 4%).
1.2 Neural tube malformations
1.2.1 CBZ versus no medication (in women without epilepsy)
Pooled results from three studies showed a non-significant out-
come (RR 1.40, 95% CI 0.06 to 34.14; I2 = 0%), with no dif-
ference in the number of neural tube malformations in children
exposed to CBZ (N = 191) and compared to control children (N
= 641) (Israeli Teratogen Service; Mawer 2010; Koch 1992; see
Analysis 1.2). This gave a non-significant RD (RD −0.00, 95%
CI −0.01 to 0.01, I2 = 0%).
1.2.2 CBZ versus no medication (in women with epilepsy)
Pooled results from seven studies showed a non-significant out-
come (RR 0.91, 95%CI 0.15 to 5.61; I2 = 0%), with no difference
in the number of neural tube malformations in children exposed
to CBZ (N = 713) and in control children (N = 313) (Al Bunyan
1999; Australian; Barqawi 2005; Canger 1999; Fairgrieve 2000;
Koch 1992; Mawer 2010; see Analysis 1.2). This gave a non-sig-
nificant RD (RD 0.00, 95% CI −0.01 to 0.02; I2 = 0%).
1.3 Cardiac malformations
1.3.1 CBZ versus no medication (in women without epilepsy)
Pooled results from three studies showed a non-significant out-
come (RR 1.41, 95% CI 0.28 to 7.02; I2 = 0%), with no dif-
ference in the number of cardiac malformations in children ex-
posed to CBZ (N = 191) and in control children (N = 641) (Israeli
Teratogen Service; Koch 1992; Mawer 2010; see Analysis 1.3).
This gave a non-significant RD (RD −0.00, 95% CI −0.02 to
0.01; I2 = 0%).
1.3.2 CBZ versus no medication (in women with epilepsy)
Pooled results from seven studies showed a non-significant out-
come (RR 1.84, 95% CI 0.32 to 10.71; I2 = 0%), with no differ-
ence in the number of cardiac malformations in children exposed
toCBZ (N = 713) Cardiac malformation sand control children (N
= 313) (Al Bunyan 1999; Australian; Barqawi 2005; Canger 1999;
Fairgrieve 2000; Koch 1992; Mawer 2010; see Analysis 1.3). This
gave a non-significant RD (RD 0.01, 95% CI −0.01 to 0.02; I2
= 0%).
1.4 Oro-facial cleft/craniofacial malformations
1.4.1 CBZ versus no medication (in women without epilepsy)
Pooled results from three studies showed a significant outcome
(RR 6.13, 95% CI 1.19 to 31.49; I2 = 0%), with children exposed
to CBZ (N = 191) experiencing more oro-facial cleft/craniofacial
malformations than control children (N = 641) (Israeli Teratogen
Service; Koch 1992; Mawer 2010; see Analysis 1.4). This gave a
non-significant RD (RD 0.01, 95% CI −0.01 to 0.04; I2 = 0%).
1.4.2 CBZ versus no medication (in women with epilepsy)
Pooled results from seven studies showed a non-significant out-
come (RR 1.16, 95% CI 0.27 to 5.00; I2 = 11%), with no differ-
ence in the number of oro-facial cleft/craniofacial malformations
in children exposed to CBZ (N = 713) and control children (N =
313) (Al Bunyan 1999; Australian; Barqawi 2005; Canger 1999;
Fairgrieve 2000; Koch 1992; Mawer 2010; see Analysis 1.4). This
gave a non-significant RD (RD 0.00, 95% CI −0.01 to 0.02; I2
= 0%).
1.5 Skeletal/limb malformations
1.5.1 CBZ versus no medication (in women with epilepsy)
Pooled results from three studies showed a non-significant out-
come (RR 3.90, 95% CI 0.17 to 89.64, I2 = NA), with no differ-
ence in skeletal/limb malformations in children exposed to CBZ
(N = 191) and control children (N = 641) (Israeli Teratogen
Service; Koch 1992; Mawer 2010; see Analysis 1.5). This gave
a non-significant RD (RD −0.00, 95% CI −0.01 to 0.01, I2 =
0%).
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1.5.2 CBZ versus no medication (in women with epilepsy)
Pooled results from seven studies showed a non-significant out-
come (RR 0.73, 95% CI 0.18 to 3.01; I2 = 0%), with no differ-
ence in the number of skeletal and limbmalformations in children
exposed to CBZ (N = 713) and control children (N = 313) (Al
Bunyan 1999; Australian; Barqawi 2005; Canger 1999;Fairgrieve
2000; Koch 1992; Mawer 2010; see Analysis 1.5). This gave a
non-significant RD (RD−0.00, 95%CI−0.02 to 0.02; I2 = 0%).
Carbamazepine dose
Most included studies did not investigate the effect ofCBZdose on
malformation prevalence, and themajority of data comes from the
pregnancy registries. The EURAP collaboration reported higher
malformation rates with higher doses of CBZ (N = 1402). When
compared to children exposed to < 300 mg/d of LTG, CBZ <
400 mg/d was not significantly different (OR 1.6 95% CI 0.56
to 4.53, P = 0.380), whilst there was a significantly higher risk
with higher doses of CBZ: 400 to 1000 mg/d: OR 2.5 (95% CI
1.45 to 4.48, P = 0.0012) and > 1000 mg/d: OR 4.6 (95% CI
2.28 to 9.31, P < 0.0001). UK Register (N = 1657) found a non-
significant association in malformation outcome between doses of
CBZ < 500 mg/d and doses of CBZ 500 to 1000 mg/d (P = 0.33)
but a significant increase in risk from CBZ doses of < 500 mg/d,
at 1.9%, in comparison to doses of > 1000 mg/d, at 5.3% (OR
2.82 95% CI 1.20 to 6.64, P = 0.01) was reported. In contrast,
the North American Register (N = 1033) failed to document an
association (P value not reported). A number of smaller studies
did not identify a dose effect (Canger 1999; Kaaja 2003; Kaneko
1999; Motherisk Registry; Samren 1997).
Gabapentin
The prevalence of major malformations (any type) for children
exposed to gabapentin (GBP) (N = 190) based on data from three
studies was 1.47% (95%CI 0.26 to 3.64; I2 = 0%, P value = 0.50).
2 GBP versus controls
2.1 All major malformations
2.1.1 GBP versus no medication (in women without epilepsy)
The results from North American Register showed a non-signif-
icant outcome (RR 0.61, 95% CI 0.07 to 5.18; I2 = NA), with
children exposed toGBP (N = 145) experiencing comparable rates
of major malformations to control children (N = 442) (Analysis
2.1). This gave a non-significant RD (RD−0.00, 95% CI−0.02
to 0.01; I2 = NA).
Fujji 2013 reported sevenmajor malformations out of 223 (4.1%)
GBP-exposed infants (only 71 were in cases where the indication
for maternal treatment was epilepsy). Caution is required, how-
ever, as the levels of concomitant medications were high in this
study.
2.1.2 GBP versus no medication (in women with epilepsy)
Pooled results from two studies showed a non-significant outcome
(RR 1.16, 95% CI 0.23 to 5.93; I2 = 0%), with children exposed
to GBP (N = 45) experiencing comparable rates of major malfor-
mations to control children (N = 688) (Australian; UK Register;
see Analysis 2.1). This gave a non-significant RD (RD −0.00,
95% CI −0.06 to 0.05; I2 = 0%).
2.2 Neural tube malformations
2.2.1 GBP versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
2.2.2 GBP versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
2.3 Cardiac malformations
2.3.1 GBP versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
2.3.2 GBP versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
2.4 Oro-facial cleft/craniofacial malformations
2.4.1 GBP versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
2.4.2 GBP versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
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2.5 Skeletal/limb malformations
2.5.1 GBP versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
2.5.2 GBP versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
Gabapentin dose
The investigation of GBP dose and its potential association with
an increased rate ofmalformations is limited due to the numbers of
pregnancies where data is currently available. The largest cohort of
GBP-exposed pregnancies (N = 145) failed to find an association
with increasing dose and increased malformation risk (P value
not reported) (North American Register). Included numbers in
Australian and UK Register were too small to investigate dose (N
= 14 and 31, respectively) and Fujji 2013 did not investigate dose.
Levetiracetam
The prevalence of major malformations (any type) for children
exposed to levetiracetam (LEV) (N = 817) based on data from
three studies was 1.77% (95% CI 0.98%-2.79; I2 = 45.5%, P
value = 0.16).
3 LEV versus controls
3.1 All major malformations
3.1.1 LEV versus no medication (in women without epilepsy)
North American Register reported a non-significant outcome (RR
2.16, 95% CI 0.76 to 6.17; I2 = NA), with children exposed to
LEV (N = 450) experiencing comparable rates of major malfor-
mations to control children (N = 442) (Analysis 3.1). This gave a
non-significant RD (RD 0.01, 95% CI −0.00 to 0.03; I2 = NA).
3.1.2 LEV versus no medication (in women with epilepsy)
Pooled results from two studies showed a non-significant outcome
(RR 0.32, 95% CI 0.10 to 1.07; I2 = NA), with children exposed
to LEV (N = 367) experiencing comparable rates of major malfor-
mations to control children (N = 688) (Australian; UK Register;
see Analysis 3.1). This gave a significant RD (RD−0.02, 95% CI
−0.03 to −0.00; I2 = NA).
3.2 Neural tube malformations
3.2.1 LEV versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
3.2.2 LEV versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
3.3 Cardiac malformations
3.3.1 LEV versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
3.3.2 LEV versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
3.4 Oro-facial cleft/craniofacial malformations
3.4.1 LEV versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
3.4.2 LEV versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
3.5 Skeletal/limb malformations
3.5.1 LEV versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
3.5.2 LEV versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
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Levetiracetam dose
In 450 LEV-exposed cases, no dose-response association was ap-
parent (P value not reported) (North American Register). Consis-
tently, the UK Register also failed to find an association between
increasing dose of LEV (N = 304) and malformation risk (P =
0.09). Australian did not investigate dose of LEV.
Lamotrigine
The prevalence of major malformations (any type) for children
exposed to lamotrigine (LTG) (N = 4195) based on data from
seven studies was 2.31% (95% CI 1.87 to 2.78; I2 = 29.2%, P
value = 0.21).
4 LTG versus controls
4.1 All major malformations
4.1.1 LTG versus no medication (in women without epilepsy)
Pooled results from three studies showed a non-significant out-
come (RR 1.68, 95% CI 0.78 to 3.65; I2 = 0%), with children
exposed to LTG (N = 1628) experiencing comparable rates of ma-
jor malformations to control children (N = 1560) (Cassina 2013;
Mawer 2010; North American Register; see Analysis 4.1). This
gave a non-significant RD (RD 0.01, 95% CI −0.00 to 0.02; I2
= 23%).
4.1.2 LTG versus no medication (in women with epilepsy)
Pooled results from three studies showed a non-significant out-
come (RR 1.07, 95% CI 0.64 to 1.77; I2 = 0%), with children ex-
posed to LTG (N = 2453) experiencing comparable rates of major
malformations to control children (N = 728) (Australian; Mawer
2010; UK Register; see Analysis 4.1). This gave a non-significant
RD (RD 0.00, 95% CI −0.01 to 0.02; I2 = 0%).
4.2 Neural tube malformations
4.2.1 LTG versus no medication (in women without epilepsy)
Mawer 2010 reported a non-significant outcome (RR 2.57, 95%
CI 0.11 to 62.03; I2 = NA), with no difference in the number of
neural tube malformations in children exposed to LTG (N = 40)
and control children (N = 315) (Analysis 4.2). This gave a non-
significant RD (RD −0.00, 95% CI −0.04 to 0.03; I2 = NA).
4.2.2 LTG versus no medication (in women with epilepsy)
We could not estimate pooled results from two studies on LTG, as
there were no reported neural tube malformations in children ex-
posed to LTG (N = 355) or control children (N = 187) (Australian;
Mawer 2010; see Analysis 4.2). The RD was calculable, and it
gave a non-significant result (RD 0.00, 95% CI −0.01 to 0.01; I
2 = 0%).
4.3 Cardiac malformations
4.3.1 LTG versus no medication (in women without epilepsy)
Mawer 2010 reported a non-significant outcome (RR 2.57, 95%
CI 0.11 to 62.03; I2 = NA), with no difference in the number
of cardiac malformations in children exposed to LTG (N = 40)
and control children (N = 315) (Analysis 4.3). This gave a non-
significant RD (RD −0.00, 95% CI −0.04 to 0.03; I2 = NA).
4.3.2 LTG versus no medication (in women with epilepsy)
Pooled results from two studies showed a non-significant outcome
(RR 1.40, 95% CI 0.15 to 13.35; I2 = NA), with no difference in
the number of cardiac malformations in children exposed to LTG
(N = 355) and control children (N = 187) (Australian; Mawer
2010; see Analysis 4.3). This gave a non-significant RD (RD 0.00,
95% CI −0.01 to 0.02; I2 = NA).
4.4 Oro-facial cleft/craniofacial malformations
4.4.1 LTG versus no medication (in women without epilepsy)
We were unable to estimate RR inMawer 2010 due to there being
no reported oro-facial cleft/craniofacial malformations in children
exposed to LTG (N = 40) or control children (N = 315) (Analysis
4.4). RDwas calculable, and this gave a non-significant result (RD
0.00, 95% CI −0.03 to 0.03; I2 = NA).
4.4.2 LTG versus no medication (in women with epilepsy)
Pooled results from two studies reported a non-significant out-
come (RR 5.15, 95% CI 0.29 to 92.56; I2 = NA), with no differ-
ence in the number of oro-facial cleft/craniofacial malformations
in children exposed to LTG (N = 355) and control children (N =
187) (Australian; Mawer 2010; see Analysis 4.4). This gave a non-
significant RD (RD 0.01, 95% CI −0.00 to 0.03; I2 = NA).
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4.5 Skeletal/limb malformations
4.5.1 LTG versus no medication (in women without epilepsy)
Mawer 2010 reported a non-significant outcome (RR 23.12, 95%
CI 0.96 to 558.25; I2 = NA), with no difference in the number of
skeletal/limbmalformations in children exposed to LTG (N = 40)
and control children (N = 315) (Analysis 4.5). This gave a non-
significant RD (RD 0.03, 95% CI −0.03 to 0.08; I2 = NA).
4.5.2 LTG versus no medication (in women with epilepsy)
Pooled results from two studies reported a non-significant out-
come (RR 0.72, 95% CI 0.12 to 4.12; I2 = 40%), with no dif-
ference in the number of skeletal/limb malformations in chil-
dren exposed to LTG (N = 355) and control children (N = 187)
(Australian; Mawer 2010; see Analysis 4.5). This gave a non-sig-
nificant RD (RD −0.00, 95% CI −0.02 to 0.02; I2 = 0%).
Lamotrigine dose
North American Register did not find any association between
dose of LTG and malformation prevalence (N = 1562; P value not
reported). The UK Register (N = 2198) found no significant risk
with increasing dose (0 to 200 mg/d vs 200 to 400 mg/d, P = 0.67;
0 to 200 mg/d vs > 400 mg/d, P = 0.22). Australian also failed to
find a significant dose association (N = 315; P value not reported).
The frequency of malformations was too low in Cassina 2013 and
Mawer 2010 to allow investigation of dose. In EURAP, exposure
to higher doses of LTG (based on 1420 cases) was associated with
a significantly increased rate of malformation (< 300 mg/d 2.0%
vs > 300 mg/d 4.5%, OR 2.2 95% CI 1.12 to 4.35, P = 0.0221).
Oxcarbazepine
The prevalence of major malformations (any type) for children
exposed to oxcarbazepine (OXC) (N = 238), based on data from
four studies, was 2.39% (95% CI 0.85% to 4.68%; I2 = 0.2%, P
value = 0.39).
5 OXC versus controls
5.1 All major malformations
5.1.1 OXC versus no medication (in women without epilepsy)
North American Register reported a non-significant outcome (RR
1.94, 95% CI 0.53 to 7.15; I2 = NA), with children exposed to
OXC (N = 182) experiencing comparable rates of major malfor-
mations to control children (N = 442) (Analysis 5.1). This gave a
non-significant RD (RD 0.01, 95% CI −0.01 to 0.03; I2 = NA).
5.1.2 OXC versus no medication (in women with epilepsy)
Pooled results from two studies showed a non-significant outcome
(RR 2.75, 95% CI 0.53 to 14.43; I2 = 55%), with children ex-
posed to OXC (N = 21) experiencing comparable rates of major
malformations to control children (N = 386) (Australian; Kaaja
2003; see Analysis 5.1). This gave a non-significant RD (RD 0.03,
95% CI −0.09 to 0.14; I2 = 41%).
5.2 Neural tube malformations
5.2.1 OXC versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
5.2.2 OXC versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
5.3 Cardiac malformations
5.3.1 OXC versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
5.3.2 OXC versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
5.4 Oro-facial cleft/craniofacial malformations
5.4.1 OXC versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
5.4.2 OXC versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
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5.5 Skeletal/limb malformations
5.5.1 OXC versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
5.5.2 OXC versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
Oxcarbazpine dose
No included studies reported on the relationship between OXC
dose and malformation rates.
Phenobarbital
The prevalence of major malformations (any type) for children
exposed to phenobarbital (PB) (N = 709), based on data from 23
studies, was 7.10% (95% CI 5.36 to 9.08; I2 = 0%, P value =
0.74).
6 PB versus controls
6.1 All major malformations
6.1.1 PB versus no medication (in women without epilepsy)
Pooled results from five studies showed a significant outcome (RR
2.84, 95% CI 1.57 to 5.13; I2 = 0%), with children exposed to PB
(N = 345) experiencing more major malformations than control
children (N = 1591) (Cassina 2013; Koch 1992; North American
Register; Steegers-Theunissen 1994; Tanganelli 1992; see Analysis
6.1). This gave a significant RD (RD 0.04, 95% CI 0.01 to 0.06;
I2 = 0%).
Samren 1997 reported five cases of major malformation out of
48 exposed infants (10%). Numbers were more limited in the
comparison to control children (as not all centres in the study
included control children), with just one malformation case out
of six PB-exposed children; analysis produced a non-significant
difference between the groups (RR 2.4, 95% CI 0.3 to 23.0).
6.1.2 PB versus no medication (in women with epilepsy)
Pooled results from 13 studies showed a non-significant outcome
(RR 1.95, 95% CI 0.97 to 3.93; I2 = 0%), with no difference
in the number of major malformations in children exposed to
PB (N = 385) and control children (N = 645) (Al Bunyan 1999;
Australian; Canger 1999; Delmiš 1991; D’Souza 1990; Kaaja
2003; Kaneko 1999; Kelly 1984; Kerala Pregnancy Registry; Koch
1992; Lindhout 1992; Montreal Series; Waters 1994; see Analysis
6.1). This gave a non-significant RD (RD 0.03, 95% CI −0.01
to 0.07; I2 = 0%).
6.2 Neural tube malformations
6.2.1 PB versus no medication (in women without epilepsy)
We could not estimate data from Koch 1992 due to there being
no reported neural tube malformations in children exposed to PB
(N = 4) or control children (N = 116) (Analysis 6.2). RD was
calculable and this gave a non-significant result (RD 0.00, 95%
CI −0.26 to 0.26; I2 = NA).
6.2.2 PB versus no medication (in women with epilepsy)
Pooled results from two studies showed a non-significant outcome
(RR 1.73, 95% CI 0.08 to 36.75, I2 = 0%), with no difference in
the number of neural tube malformations in children exposed to
PB (N=5) and control children (N=147) (Australian;Koch 1992;
see Analysis 6.2). This gave a non-significant RD (RD −0.02,
95% CI −0.23 to 0.19; I2 = 0%).
6.3 Cardiac malformations
6.3.1 PB versus no medication (in women without epilepsy)
Koch 1992 reported a non-significant outcome (RR 7.80, 95%
CI 0.36 to 168.52; I2 = NA), with children exposed to PB (N = 4)
no more likely to experience cardiac malformations than control
children (N = 116) (Analysis 6.3). This gave a non-significant RD
(RD −0.01, 95% CI −0.27 to 0.26; I2 = NA).
6.3.2 PB versus no medication (in women with epilepsy)
Pooled results from two studies reported a non-significant out-
come (RR 8.22, 95% CI 0.37 to 181.57, I2 = NA), with no dif-
ference in the number of cardiac malformations in children ex-
posed to PB (N = 9) and control children (N = 172) (Australian;
Koch 1992; see Analysis 6.3). This gave a non-significant RD (RD
−0.00, 95% CI −0.21 to 0.20; I2 = NA).
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6.4 Oro-facial cleft/craniofacial malformations
6.4.1 PB versus no medication (in women without epilepsy)
Koch 1992 reported a non-significant outcome (RR 3.34, 95%
CI 0.20 to 56.35; I2 = NA), with no difference in the number of
oro-facial cleft/craniofacial malformations in children exposed to
PB (N = 4) and control children (N = 116) (Analysis 6.4). This
gave a non-significant RD (RD −0.03, 95% CI −0.29 to 0.24; I
2 = NA).
6.4.2 PB versus no medication (in women with epilepsy)
We could not estimate the pooled results from two studies due to
there being no reported oro-facial cleft/craniofacial malformations
in children exposed to PB (N = 9) or control children (N = 172)
(Australian; Koch 1992; see Analysis 6.4). RD was calculable, and
this gave a non-significant result (RD 0.00, 95% CI −0.21 to
0.21, I2 = 0%).
6.5 Skeletal/limb malformations
6.5.1 PB versus no medication (in women without epilepsy)
Koch 1992 reported a non-significant outcome (RR 7.80, 95%
CI 0.36 to 168.52; I2 = NA), with no difference in number of
skeletal/limb malformations in children exposed to PB (N = 4)
and control children (N = 116) (Analysis 6.5). This gave a non-
significant RD (RD −0.01, 95% CI −0.27 to 0.26; I2 = NA).
6.5.2 PB versus no medication (in women with epilepsy)
Pooled results from two studies showed a non-significant outcome
(RR 8.22, 95%CI 0.37 to 181.57; I2 =NA), with no difference in
number of skeletal/limbmalformations in children exposed to PB
(N = 9) and control children (N = 172) (Australian; Koch 1992;
see Analysis 6.5). This gave a non-significant RD (RD −0.00,
95% CI −0.21 to 0.20; I2 = 0%).
Phenobarbital dose
Most studies did not investigate dose or report the results of anal-
yses of PB dose with regards to malformation risk (Al Bunyan
1999; Australian; Canger 1999; Cassina 2013; D’Souza 1990;
Kaaja 2003; Kerala Pregnancy Registry; Koch 1992; Lindhout
1992; Montreal Series; Steegers-Theunissen 1994; Tanganelli
1992; Waters 1994), and many were too limited in terms of num-
bers of included pregnancies to be able to do this. North American
Register included 199 PB-exposed pregnancies and did not find
an association with dose (P value not reported). Samren 1997
found a non-significant trend for an association with dose (N =
48, P value not reported). Kaneko 1999 did find a an association
between PB exposure (N = 79) or increased malformation rate;
however, the study did not report the statistical analysis. Finally,
EURAP reported a significant increase in malformation rate with
increasing doses of PB (N = 217), with the prevalence of malfor-
mation increasing from 5.4% for doses < 150 mg/d to 13.7% for
doses > 150 mg/d (OR 3.2 95% CI 1.11 to 9.45, P = 0.0316).
Phenytoin
The prevalence of major malformations (any type) for children
exposed to phenytoin (PHT) (N = 1279), based on data from 25
studies, was 5.38% (95% CI 4.22 to 6.67; I2 = 41.1%, P value =
0.02). Due to significant variance, we undertook random-effects
modelling, generating a prevalence of 6.26% (95% CI 4.37 to
8.47; I2 =41.1 %, P value = 0.02).
7 PHT versus controls
7.1 All major malformations
7.1.1 PHT versus no medication (in women without epilepsy)
Pooled results from five studies showed a significant outcome (RR
2.38, 95% CI 1.12 to 5.03; I2 = 0%), with children exposed to
PHT (N = 477) experiencing more major malformations than
control children (N = 987) (D’Souza 1990; Koch 1992; Mawer
2010; North American Register; Steegers-Theunissen 1994; see
Analysis 7.1). However, this gave a non-significant RD (RD 0.02,
95% CI −0.00 to 0.04; I2 = 0%).
In our meta-analysis, we did not include data from the Motherisk
Registry, which included women treated with PHT for epilepsy
and other conditions. Investigators reported the prevalence of
MCM to be 3/34 (8.8%) for those exposed to PHT and 2/34 (6%)
for control children. Samren 1997 reported nine cases of major
malformation in 141 (6%) PHT-exposed children. Outcomes at
centres with a control group in this study were limited to five cases
from 33 exposed children, which gave a non-significant difference
(RR 2.2, 95% CI 0.7 to 6.7).
7.1.2 PHT versus no medication (in women with epilepsy)
Pooled results from 15 studies showed a significant outcome
(RR 2.40, 95% CI 1.42 to 4.08; I2 = 0%), with children ex-
posed to PHT (N = 640) experiencing more major malformations
than control children (N = 1256) (Al Bunyan 1999; Arulmozhi
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2006; Australian; Canger 1999; Garza-Morales 1996; Kaaja 2003;
Kaneko 1999; Kelly 1984; Kerala Pregnancy Registry; Koch 1992;
Lindhout 1992; Mawer 2010; Montreal Series; UK Register;
Waters 1994; see Analysis 7.1). This gave a significant RD (RD
0.03, 95% CI 0.01 to 0.06; I2 = 0%).
7.2 Neural tube malformations
7.2.1 PHT versus no medication (in women without epilepsy)
Pooled results from two studies showed a non-significant outcome
(RR 13.17, 95% CI 0.58 to 299.00, I2 = NA), with children ex-
posed to PHT (N = 31) experiencing no more neural tube mal-
formations than control children (N = 431) (Koch 1992; Mawer
2010; see Analysis 7.2). This gave a non-significant RD (RD
−0.00, 95% CI −0.07 to 0.06, I2 = 0%).
7.2.2 PHT versus no medication (in women with epilepsy)
Pooled results from five studies showed a non-significant outcome
(RR 1.65, 95% CI 0.32 to 8.51; I2 = 54%), with no difference
in the number of neural tube malformations in children exposed
to PHT (N = 133) and control children (N = 255) (Australian;
Canger 1999; Garza-Morales 1996; Koch 1992; Mawer 2010; see
Analysis 7.2). This gave a non-significant RD (RD 0.00, 95% CI
−0.03 to 0.04; I2 = 0%).
7.3 Cardiac malformations
7.3.1 PHT versus no medication (in women without epilepsy)
Pooled results from two studies reported a non-significant out-
come (RR 6.31, 95% CI 0.75 to 52.91, I2 = 0%), with no differ-
ence in the number of cardiac malformations in children exposed
to PHT (N = 31) and control children (N = 431) (Koch 1992;
Mawer 2010; see Analysis 7.3). This gave a non-significant RD
(RD 0.02, 95% CI −0.05 to 0.10; I2 = 0%).
7.3.2 PHT versus no medication (in women with epilepsy)
Pooled results from five studies showed a non-significant outcome
(RR 3.23, 95% CI 0.40 to 26.25; I2 = 0%), with no difference in
the number of cardiac malformations in children exposed to PHT
(N = 133) and control children (N = 255) (Australian; Canger
1999;Garza-Morales 1996; Koch 1992;Mawer 2010; see Analysis
7.3). This gave a non-significant RD (RD 0.01, 95% CI −0.02
to 0.05; I2 = 0%).
7.4 Oro-facial cleft/craniofacial malformations
7.4.1 PHT versus no medication (in women without epilepsy)
Pooled results from two studies showed a non-significant outcome
(RR 0.67, 95% CI 0.04 to 12.54, I2 = NA), with no difference in
the number of oro-facial cleft/craniofacial malformations between
children exposed to PHT (N = 31) and control children (N = 431)
(Koch 1992; Mawer 2010; see Analysis 7.4). This gave a non-
significant RD (RD −0.02, 95% CI −0.09 to 0.05; I2 = 0%).
7.4.2 PHT versus no medication (in women with epilepsy)
We could not estimate the pooled results from five studies due to
the lack of reported oro-facial cleft/craniofacial malformations in
children exposed to PHT (N = 133) and control children (N =
530) (Australian; Canger 1999; Garza-Morales 1996; Koch 1992;
Mawer 2010; see Analysis 7.4). RD was calculable, and this gave
a non-significant result (RD 0.00, 95% CI −0.03 to 0.03; I2 =
0%).
7.5 Skeletal/limb malformations
7.5.1 PHT versus no medication (in women without epilepsy)
Pooled results from two studies showed a non-significant outcome
(RR 1.56, 95% CI 0.07 to 37.19; I2 = NA), with no difference
in the number of skeletal and limb malformations in children
exposed to PHT (N = 31) and control children (N = 431) (Koch
1992; Mawer 2010; see Analysis 7.4). This gave a non-significant
RD (RD −0.01, 95% CI −0.07 to 0.06; I2 = 0%).
7.5.2 PHT versus no medication (in women with epilepsy)
Pooled results from five studies showed a non-significant outcome
(RR 1.69, 95% CI 0.19 to 15.30; I2 = 0%), with no difference
in the number of skeletal/limbmalformations in children exposed
to PHT (N = 133) and control children (N = 255) (Australian;
Canger 1999; Garza-Morales 1996; Koch 1992; Mawer 2010; see
Analysis 7.5). This gave a non-significant RD (RD 0.00, 95% CI
−0.03 to 0.04; I2 = 0%).
Phenytoin dose
The majority of included studies did not investigate or formally
report on the relationship between dose of PHTandmalformation
outcome (Al Bunyan 1999; Arulmozhi 2006, Australian, Koch
1992, Canger 1999, Garza-Morales 1996, Steegers-Theunissen
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1994, Mawer 2010,D’Souza 1990, Kelly 1984, UK Register,
Waters 1994), with many being limited by included numbers of
PHT-exposed pregnancies. Kaaja 2003 reported no association
with dose of PHT and increased malformation rate based on 124
monotherapy exposed children (P value not reported). Similarly,
Motherisk Registry also failed to find an association (N = 36; P
value not reported) as did North American Register, based on 416
exposed children (P value not reported). In contrast, Kaneko 1999
reported a significant association between PHT dose and malfor-
mation prevalence (P = 0.015), based on 132 children exposed to
monotherapy PHT (no further details given). Samren 1997 also
found an increase in malformation risk from 2.0% to 4.1% for
doses < 200 mg/d and doses > 300 to 500 mg/d (N = 33; P value
not reported).
Primidone
The prevalence of major malformations (any type) for children
exposed to PRM (N = 110) based on data from six studies was
8.49% (95% CI 4.13 to 14.22; I2 = 23.1%, P value = 0.26).
8 PRM versus controls
8.1 All major malformations
8.1.1 PRM versus no medication (in women without epilepsy)
Koch 1992 reported a non-significant outcome (RR 0.48, 95%
CI 0.03 to 8.43; I2 = NA) for major malformations in children
exposed to PRM (N = 21) in comparison to control children (N =
116) (Analysis 8.1). This gave a significant RD (RD−0.04, 95%
CI −0.12 to 0.03; I2 = NA).
Samren 1997 reported four cases of major malformations out of
43 PRM-exposed children (9%). When limited to centres with
control children, there were three cases out of 39 exposed children,
which was not significantly different from control children (RR
1.0, 95% CI 0.3 to 3.8).
8.1.2 PRM versus no medication (in women with epilepsy)
Pooled results from four studies showed a significant outcome (RR
2.81, 95% CI 1.13 to 7.02; I2 = 52%), with children exposed
to PRM (N = 106) experiencing more major malformations than
control children (N = 397) (Canger 1999; Kaaja 2003; Kaneko
1999; Koch 1992; see Analysis 8.1). Due to high heterogeneity,
we undertook a random-effects (RE) analysis, which changed the
result to non-significant (RR (RE) 3.92, 95% CI 0.76 to 20.14;
I2 = 52%). This gave a non-significant RD (RD 0.07, 95% CI
−0.00 to 0.14; I2 = 38%).
8.2 Neural tube malformations
8.2.1 PRM versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
8.2.2 PRM versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
8.3 Cardiac malformations
8.3.1 PRM versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
8.3.2 PRM versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
8.4 Oro-facial cleft/craniofacial malformations
8.4.1 PRM versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
8.4.2 PRM versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
8.5 Skeletal/limb malformations
8.5.1 PRM versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
8.5.2 PRM versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
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Primidone dose
No included studies investigated dose of PRM and malformation
risk.
Topiramate
The prevalence of major malformations (any type) for children
exposed to TPM (N = 473) based on data from three studies was
4.28% (95% CI 2.65 to 6.29; I2 = 0%, P value = 0.91).
9 TPM versus controls
9.1 All major malformations
9.1.1 TPM versus no medication (in women without epilepsy)
NorthAmericanRegister reported a significant outcome (RR3.69,
95% CI 1.36 to 10.07; I2 = NA), with children exposed to TPM
(N = 359) experiencing more major malformations than control
children (N = 442) (Analysis 9.1). This gave a significant RD (RD
0.03, 95% CI 0.01 to 0.05; I2 = NA).
In 41 cases described by Israeli Teratogen Service, there were two
non-genetic linked malformations, which gave a prevalence of
4.9%, which was not significantly higher than control children
(3.4%, P value not reported).
9.1.2 TPM versus no medication (in women with epilepsy)
Pooled results from two studies showed a non-significant outcome
(RR1.99, 95%CI 0.65 to 6.08; I2 = 0%), with no difference in the
number of major malformations in children exposed to TPM (N
= 114) and control children (N = 688) (Australian; UK Register;
see Analysis 9.1). This gave a non-significant RD (RD 0.02, 95%
CI −0.02 to 0.05; I2 = 0%).
9.2 Neural tube malformations
9.2.1 TPM versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
9.2.2 TPM versus no medication (in women with epilepsy)
We could not estimate data from one study due to the lack of
reported neural tube malformations in children exposed to TPM
(N = 44) and control children (N = 147) (Australian; see Analysis
9.2). RDwas calculable, and this gave a non-significant result (RD
0.00, 95% CI −0.03 to 0.03; I2 = NA).
9.3 Cardiac malformations
9.3.1 TPM versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
9.3.2 TPM versus no medication (in women with epilepsy)
Data fromAustralian showed anon-significant outcome (RR1.10,
95%CI 0.05 to 26.45; I2 =NA), with no difference in the number
of cardiac malformations in children exposed to TPM (N = 44)
and control children (N = 147) (Analysis 9.3). This gave a non-
significant RD (RD −0.01, 95% CI −0.04 to 0.03; I2 = NA).
9.4 Oro-facial cleft/craniofacial malformations
9.4.1 TPM versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
9.4.2 TPM versus no medication (in women with epilepsy)
We could not estimate data from one study due to the lack of
reported oro-facial cleft/craniofacial malformations in children
exposed to TPM (N = 44) and control children (N = 147)
(Australian; see Analysis 9.4). RD was calculable, and this gave
a non-significant result (RD 0.00, 95% CI −0.03 to 0.03; I2 =
NA).
9.5 Skeletal/limb malformations
9.5.1 TPM versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
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9.5.2 TPM versus no medication (in women with epilepsy)
Australian reported a non-significant outcome (RR 1.10, 95% CI
0.05 to 26.45; I2 = NA), with no difference in the number of
skeletal/limbmalformations in children exposed to TPM (N = 44)
and control children (N = 147) (Analysis 9.5). This gave a non-
significant RD (RD −0.01, 95% CI −0.04 to 0.03; I2 = NA).
Topiramate dose
North American Register found no significant difference in me-
dian doses between TPM-exposed children (N = 359) who had
malformations versus those who did not (P value not reported).
Consistently, but with smaller numbers, Australian (N = 44; P
value not reported) and UK Register cohorts (N = 70; P value not
reported) also failed to find an association between dose of TPM
and risk of overall malformations.
Valproate
The prevalence of major malformations (any type) for children
exposed to valproate (VPA) (N = 2565), based on data from 26
studies, was 9.09% (95% CI 8.02 to 10.23; I2 = 37.8%, P value =
0.03). Due to significant variance, we undertook random-effects
modelling, giving a prevalence of 10.93% (95% CI 8.91 to 13.13;
I2 = 37.8%, P value = 0.03).
10 VPA versus controls
10.1. All major malformations
10.1.1 VPA versus no medication (in women without epilepsy)
Pooled results from seven studies showed a significant outcome
(RR 5.69, 95% CI 3.33 to 9.73; I2 = 0%), with children ex-
posed to VPA (N = 467) experiencing more major malforma-
tions than control children (N = 1936) (Arulmozhi 2006; Cassina
2013; Koch 1992; Mawer 2010; North American Register;
Steegers-Theunissen 1994; Tanganelli 1992; see Analysis 10.1).
This gave a significant RD (RD 0.08, 95% CI 0.05 to 0.11; I2 =
0%).
Data from the Israeli Teratogen Service study, including women
treated with VPA for epilepsy and other indications (restricted to
monotherapy), reported major congenital malformations (MCM)
in 3/89 (3.4%) VPA-treated cases compared with 31/1236 (2.5%)
of control children. Samren 1997 reported 16 cases of major mal-
formations out of 184 (9%) VPA-exposed children.When limited
to the two sites with control children, investigators reported six
cases withmalformation out of 21 children exposed toVPA, which
was significantly higher than control children (RR 4.9, 95% CI
1.6 to 15.0).
10.1.2 VPA versus no medication (in women with epilepsy)
Pooled results from 14 studies showed a significant outcome (RR
3.13, 95%CI2.16 to 4.54; I2 =0%),with children exposed toVPA
(N = 1923) experiencing more major malformations than control
children (N = 1259) (Al Bunyan 1999; Australian; Canger 1999;
Fairgrieve 2000; Garza-Morales 1996; Kaaja 2003; Kaneko 1999;
Kelly 1984; Kerala Pregnancy Registry; Koch 1992; Lindhout
1992; Mawer 2010; Montreal Series; UK Register; see Analysis
10.1). This gave a significant RD (RD 0.06, 95% CI 0.04 to 0.08;
I2 = 33%). Due to high heterogeneity, we undertook a random-
effects analysis (RD (RE) 0.07, 95% CI 0.03 to 0.10; I2 = 33%),
but this did not change the significance of the result.
10.2 Neural tube malformations
10.2.1 VPA versus no medication (in women without epilepsy)
Pooled results from two studies showed a non-significant outcome
(RR 6.05, 95% CI 0.94 to 38.81; I2 = 20%), with no difference
in the number of neural tube malformations in children exposed
to VPA (N = 71, 1.4%) and control children (N = 431, 0.2%)
(Koch 1992; Mawer 2010; see Analysis 10.2). This gave a non-
significant RD (RD 0.01, 95% CI −0.03 to 0.05; I2 = 51%).
10.2.2 VPA versus no medication (in women with epilepsy)
Pooled results from six studies showed a significant outcome (RR
5.30, 95%CI 1.05 to 26.70; I2 = 0%), withmore children exposed
to VPA (N = 465) experiencing neural tube malformations than
control children (N = 303) (Australian; Canger 1999; Fairgrieve
2000;Garza-Morales 1996; Koch 1992; Mawer 2010; see Analysis
10.2). This gave a significant RD (RD 0.03, 95% CI 0.01 to 0.05;
I2 = 21%).
10.3 Cardiac malformations
10.3.1 VPA versus no medication (in women without epilepsy)
Pooled results from two studies showed a significant outcome (RR
16.40, 95% CI 3.05 to 88.19; I2 = 0%), with children exposed
to VPA (N = 71) experiencing more cardiac malformations than
control children (N = 431) (Koch 1992;Mawer 2010; see Analysis
10.3). This gave a significant RD (RD 0.07, 95% CI 0.01 to 0.13;
I2 = 0%).
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10.3.2 VPA versus no medication (in women with epilepsy)
Pooled results from six studies showed a significant outcome (RR
4.85, 95% CI 1.28 to 18.47; I2 = 0%), with no difference in the
number of cardiac malformations in children exposed to VPA (N
= 465) and control children (N = 303) (Australian; Canger 1999;
Fairgrieve 2000; Garza-Morales 1996; Koch 1992; Mawer 2010;
see Analysis 10.3). This gave a significant RD (RD 0.03, 95% CI
0.01 to 0.05; I2 = 0%).
10.4 Oro-facial cleft/craniofacial malformations
10.4.1 VPA versus no medication (in women without epilepsy)
Pooled results from two studies showed a non-significant outcome
(RR 2.76, 95% CI 0.31 to 24.78; I2 = NA), with no difference
in the number of oro-facial cleft/craniofacial malformations in
children exposed to VPA (N = 71) and control children (N = 431)
(Koch 1992; Mawer 2010; see Analysis 10.3). This gave a non-
significant RD (RD 0.01, 95% CI −0.03 to 0.04; I2 = 0%).
10.4.2 VPA versus no medication (in women with epilepsy)
Pooled results from six studies showed a significant outcome (RR
5.16, 95% CI 1.13 to 23.69; I2 = 24%), with more children ex-
posed to VPA (N = 465) experiencing oro-facial cleft/craniofa-
cial malformations than control children (N = 303) (Australian;
Canger 1999; Fairgrieve 2000; Garza-Morales 1996; Koch 1992;
Mawer 2010; see Analysis 10.4). This gave a significant RD (RD
0.03, 95% CI 0.01 to 0.05; I2 = 20%).
10.5 Skeletal/limb malformations
10.5.1 VPA versus no medication (in women without epilepsy)
Pooled results from two studies showed a significant outcome (RR
16.48, 95% CI 2.46 to 110.49; I2 = 0%), with children exposed
to VPA (N = 71) experiencing more skeletal/limb malformations
than control children (N = 431) (Koch 1992; Mawer 2010; see
Analysis 10.5). This gave a non-significant RD (RD 0.04, 95%
CI −0.01 to 0.09; I2 = 56%).
10.5.2 VPA versus no medication (in women with epilepsy)
Pooled results from six studies showed a non-significant outcome
(RR 2.57, 95% CI 0.82 to 8.04; I2 = 0), with no difference in
the number of skeletal/limb malformations in children exposed
to VPA (N = 465) and control children (N = 303) (Australian;
Canger 1999; Fairgrieve 2000; Garza-Morales 1996; Koch 1992;
Mawer 2010; see Analysis 10.5). This gave a non-significant RD
(RD 0.02, 95% CI −0.00 to 0.04; I2 = 0%).
Valproate dose
In contrast to the results on dosage for the other AEDs, for VPA
there appears to be a consistently documented association between
increased dose and the risk for malformation in the exposed child.
In the largest group of children exposed to VPA included (N =
1220),UKRegister documented an increase inmalformation from
5.0% at doses < 600 mg/d to 10.4% for doses > 1000 mg/d (OR
2.20 95% CI 1.26 to 3.82, P = 0.0045). Consistently, the large
cohort followed by the EURAP collaboration (N = 1010) notes a
significantly lower malformation rate (6.7%) at doses < 600 mg/
d compared with doses of > 700 mg/d to 1500 mg/d (10.4%, OR
3.8, 95% CI 3.27 to 10.13, P < 0.0001) and doses of > 1500 mg/
d (24.2%, OR 16.1, 95% CI 8.22 to 31.54, P < 0.0001). The
Australian cohort also demonstrated an association with VPA (N
= 271) (P value not reported) as did the North American Register
(N = 323; P value not reported), where investigators reported the
median daily dose in VPA-exposed children with a malformation
to be 1000 mg/d compared with children exposed to VPA with-
out a malformation (750 mg/d). Studies with smaller numbers of
VPA-exposed children also reported data showing an association
betweenVPAdose or serum levels and increasedmalformation rate
(Canger 1999; Israeli Teratogen Service; Kaneko 1999; Lindhout
1992; Mawer 2010; Meador 2006; Samren 1997).
A number of studies did not investigate the dose of VPA
and malformation outcome (Al Bunyan 1999; Arulmozhi 2006;
Cassina 2013; Fairgrieve 2000; Garza-Morales 1996; Koch 1992;
Montreal Series; Steegers-Theunissen 1994; Tanganelli 1992).
Kaaja 2003 was the only study that investigated a dose-response
association without finding a positive correlation (N = 61 VPA
exposed pregnancies).
Zonisamide
The prevalence of major malformations (any type) for children
exposed to zonisamide (ZNS) (N = 90), based on data from one
study, was 0.28% (95% CI 0.25 to 2.39; I2 = NA, P value = NA).
11 ZNS versus controls
11.1. All major malformations
11.1.1 ZNS versus no medication (in women without epilepsy)
North American Register reported a non-significant outcome (RR
0.44, 95% CI 0.02 to 7.93; I2 = NA), with no difference in the
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number of major malformations in children exposed to ZNS (N
= 90) and control children (N = 442) (Analysis 11.1). This gave
a non-significant RD (RD −0.01, 95% CI −0.03 to 0.01; I2 =
NA).
11.1.2 ZNS versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
11.2. Neural tube malformations
11.2.1 ZNS versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
11.2.2 ZNS versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
11.3 Cardiac malformations
11.3.1 ZNS versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
11.3.2 ZNS versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
11.4 Oro-facial cleft/craniofacial malformations
11.4.1 ZNS versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
11.4.2 ZNS versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
11.5 Skeletal/limb malformations
11.5.1 ZNS versus no medication (in women without epilepsy)
No included studies reported data on this outcome.
11.5.2 ZNS versus no medication (in women with epilepsy)
No included studies reported data on this outcome.
Zonisamide dose
No included study investigated a potential association between
ZNS and malformation risk.
AED versus AED comparisons
12 CBZ versus GBP
12.1. All major malformations
Pooled results from three studies showed a non-significant out-
come (RR 2.28, 95% CI 0.67 to 7.79; I2 = 0%), with no differ-
ence in the number of major malformations in children exposed
to CBZ (N = 3051) and children exposed to GBP (N = 190)
(Australian; North American Register; UK Register; see Analysis
12.1). This gave a significant RD (RD 0.02, 95% CI 0.00* to
0.04; I2 = 0%).
12.2 Neural tube malformations
Data fromAustralian showed anon-significant outcome (RR0.12,
95% CI 0.01 to 2.93; I2 = NA), with no difference in the number
of neural tube malformations in children exposed to CBZ (N =
361) and children exposed to GBP (N = 14) (Analysis 12.2). This
gave a non-significant RD (RD 0.00, 95% CI −0.09 to 0.09; I2
= NA).
12.3 Cardiac malformations
Data fromAustralian showed anon-significant outcome (RR0.29,
95% CI 0.02 to 5.37; I2 = NA), with no difference in the number
of cardiac malformations in children exposed to CBZ (N = 361)
and children exposed to GBP (N = 14) (Analysis 12.3). This gave
a non-significant RD (RD 0.01, 95%CI−0.08 to 0.10; I2 =NA).
12.4 Oro-facial cleft/craniofacial malformations
Data fromAustralian showed anon-significant outcome (RR0.37,
95% CI 0.02 to 6.62; I2 = NA), with no difference in the number
of oro-facial cleft/craniofacial malformations in children exposed
toCBZ (N=361) and children exposed toGBP (N=14) (Analysis
12.4). This gave a non-significant RD (RD 0.01, 95% CI −0.08
to 0.10; I2 = NA).
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12.5 Skeletal/limb malformations
Data fromAustralian showed anon-significant outcome (RR0.21,
95% CI 0.01 to 4.13; I2 = NA), with no difference in the number
of skeletal/limb malformations in children exposed to CBZ (N =
361) and children exposed to GBP (N = 14) (Analysis 12.5). This
gave a non-significant RD (RD 0.01, 95% CI −0.09 to 0.10; I2
= NA).
13 CBZ versus LEV
13.1. All major malformations
Pooled results from three studies showed a significant outcome
(RR 1.84, 95%CI 1.03 to 3.29; I2 = 27%), with more children ex-
posed to CBZ (N = 3051) experiencing major malformations than
children exposed to LEV (N = 817) (Australian; North American
Register; UK Register; see Analysis 13.1). This gave a significant
RD (RD 0.01, 95% CI 0.00* to 0.02; I2 = 28%).
13.2 Neural tube malformations
Pooled results from three studies showed a non-significant out-
come (RR 1.19, 95% CI 0.25 to 5.55; I2 = 0%), with no differ-
ence in the number of neural tube malformations in children ex-
posed to CBZ (N = 3051) and children exposed to LEV (N = 817)
(Australian; North American Register; UK Register; see Analysis
13.2). This gave a non-significant RD (RD 0.00, 95% CI −0.00
to 0.01; I2 = 0%).
13.3 Cardiac malformations
Pooled results from three studies showed a non-significant out-
come (RR 1.83, 95% CI 0.48 to 6.97; I2 = 0%), with no dif-
ference in the number of cardiac malformations in children ex-
posed to CBZ (N = 3051) and children exposed to LEV (N = 817)
(Australian; North American Register; UK Register; see Analysis
13.3). This gave a non-significant RD (RD 0.00, 95% CI −0.00
to 0.01; I2 = 48%).
13.4 Oro-facial cleft/craniofacial malformations
Pooled results from three studies showed a non-significant out-
come (RR 1.83, 95% CI 0.44 to 7.61; I2 = 0%), with no dif-
ference in the number of oro-facial cleft/craniofacial malforma-
tions in children exposed to CBZ (N = 3051) and children ex-
posed to LEV (N = 817) (Australian; North American Register;
UK Register; see Analysis 13.4). This gave a non-significant RD
(RD 0.00, 95% CI −0.00 to 0.01; I2 = 0%).
13.5 Skeletal/limb malformations
Pooled results from three studies showed a non-significant out-
come (RR 2.30, 95% CI 0.44 to 11.86; I2 = 0%), with no dif-
ference in the number of skeletal/limb malformations in children
exposed to CBZ (N = 3051) and children exposed to LEV (N
= 817) (Australian; North American Register; UK Register; see
Analysis 13.5). This gave a non-significant RD (RD 0.00, 95%
CI −0.00 to 0.01; I2 = 0%).
14 CBZ versus LTG
14.1. All major malformations
Pooled results from seven studies showed a significant outcome
(RR 1.34, 95% CI 1.01 to 1.76; I2 = 0%), with children ex-
posed toCBZ (N=3385) experiencingmoremajormalformations
than children exposed to LTG (N = 4164) (Australian; Cassina
2013; Martinez Ferri 2009; Mawer 2010; Meador 2006; North
American Register; UK Register; see Analysis 14.1). This gave a
significant RD (RD 0.01, 95% CI 0.00* to 0.02; I2 = 10%).
In the EURAP data, rates of malformation in children exposed
to CBZ were: 5/148 (3.4%) for exposures < 400 mg/d, 56/1047
(5.3%) for exposures > 400 to 1000 mg/d and 18/207 (8.7%) for
exposures > 1000 mg/d. In comparison, the rates of MCM for
children exposed to LTG were: 17/836 (2.0%) for exposures < 300
mg/d and 20/444 (4.5%) for exposures > 300 mg/d. We did not
find a significant difference between children exposed to CBZ <
400 mg/d compared with children exposed to LTG < 300 mg/d.
However, children exposed to > 400 to 1000 mg/d of CBZ were
significantly more likely to have a MCM than children exposed
to < 300 mg of LTG (P = 0.0012), as were children exposed to >
1000 mg/d of CBZ (< 0.0001). We did not compare higher levels
of CBZ versus higher levels of LTG.
14.2. Neural tube malformations
Pooled results from six studies showed a non-significant outcome
(RR 2.32, 95% CI 0.79 to 6.82; I2 = 0%), with no difference
in the number of neural tube malformations in children exposed
to CBZ (N = 3354) and children exposed to LTG (N = 4155)
(Australian; Cassina 2013; Martinez Ferri 2009; Meador 2006;
North American Register; UK Register; see Analysis 14.2). This
gave a non-significant RD (RD 0.00, 95% CI −0.00 to 0.00; I2
= 0%).
In the EURAP data, the prevalence of neural tube malformations
in those exposed to CBZ and LTG was: CBZ < 400 mg/d, 0/148
(0%); CBZ > 400 to 1000 mg/d, 1/1047 (0%); CBZ > 1000 mg/
d, 4/207 (2%); LTG < 300 mg/d, 0/836 (0%); LTG > 300 mg/d,
0/444 (0%).
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14.3 Cardiac malformations
Pooled results from six studies showed a non-significant outcome
(RR 1.57, 95% CI 0.85 to 2.89; I2 = 0%), with no difference
in the number of cardiac malformations in children exposed to
CBZ (N = 3354) and children exposed to LTG (N = 4155) (
Australian; Cassina 2013; Martinez Ferri 2009; Meador 2006;
North American Register; UK Register; see Analysis 14.3). This
gave a non-significant RD (RD 0.00, 95% CI −0.00 to 0.01; I2
= 0%).
In the EURAP data, the prevalence of cardiac malformations in
those exposed to CBZ and LTG was: CBZ < 400 mg/d, 2/148
(1%); CBZ > 400 to 1000 mg/d, 16/1047 (2%); CBZ > 1000
mg/d, 4/207 (2%); LTG < 300, 3/836 (0%); LTG > 300 mg/d,
5/444 (1%).
14.4 Oro-facial cleft/craniofacial malformations
Pooled results from six studies showed a non-significant outcome
(RR1.12, 95%CI 0.53 to 2.37; I2 = 0%), with no difference in the
number of oro-facial cleft/craniofacial malformations in children
exposed to CBZ (N = 3354) and children exposed to LTG (N =
4155) (Australian; Cassina 2013; Martinez Ferri 2009; Meador
2006; North American Register; UK Register; see Analysis 14.4).
This gave a non-significant RD (RD 0.00, 95%CI−0.00 to 0.00;
I2 = 0%).
In the EURAP data, the prevalence of oro-facial cleft malforma-
tions in those exposed to CBZ and LTG was: CBZ < 400 mg/d, 0/
148 (0%); CBZ > 400 to 1000 mg/d, 2/1047 (0%); CBZ > 1000
mg/d, 0/207 (0%); LTG < 300, 0/836 (0%); LTG > 300 mg/d,
2/444 (1%).
14.5 Skeletal/limb malformations
Pooled results from six studies showed a non-significant outcome
(RR 2.56, 95% CI 0.97 to 6.73; I2 = 0%), with no difference in
the number of skeletal/limb malformations in children exposed
to CBZ (N = 3354) and children exposed to LTG (N = 4155)
(Australian; Cassina 2013; Martinez Ferri 2009; Meador 2006;
North American Register; UK Register; see Analysis 14.5). This
gave a non-significant RD (RD 0.00, 95% CI −0.00 to 0.00; I2
= 0%).
15 CBZ versus OXC
15.1. All major malformations
Pooled results from four studies showed a non-significant outcome
(RR 1.44, 95% CI 0.66 to 3.16; I2 = 38%), with no difference in
the number of major malformations in children exposed to CBZ
(N = 1773) and children exposed to OXC (N = 238) (Australian;
Kaaja 2003; Meischenguiser 2004; North American Register; see
Analysis 15.1). This gave a non-significant RD (RD 0.01, 95%
CI −0.01 to 0.04; I2 = 3%).
15.2 Neural tube malformations
Pooled results from four studies showed a non-significant outcome
(RR 0.48, 95% CI 0.09 to 2.54; I2 = 0%), with no difference
in the number of neural tube malformations in children exposed
to CBZ (N = 1773) and children exposed to OXC (N = 238)
(Australian; Kaaja 2003; Meischenguiser 2004; North American
Register; see Analysis 15.2). This gave a non-significant RD (RD
0.00, 95% CI −0.01 to 0.02; I2 = 0%).
15.3 Cardiac malformations
Pooled results from four studies showed a non-significant outcome
(RR 0.51, 95% CI 0.10 to 2.69; I2 = 0%), with no difference in
the number of cardiac malformations in children exposed to CBZ
(N = 1773) and children exposed to OXC (N = 238) (Australian;
Kaaja 2003; Meischenguiser 2004; North American Register; see
Analysis 15.3). This gave a non-significant RD (RD 0.00, 95%
CI −0.01 to 0.02; I2 = 0%)
15.4 Oro-facial cleft/craniofacial malformations
Pooled results from four studies showed a non-significant outcome
(RR 0.53, 95% CI 0.12 to 2.33; I2 = 0%), with no difference
in the number of oro-facial cleft/craniofacial malformations in
children exposed to CBZ (N = 1773) and children exposed to
OXC (N = 238) (Australian; Kaaja 2003; Meischenguiser 2004;
North American Register; see Analysis 15.4). This gave a non-
significant RD (RD 0.00, 95% CI −0.01 to 0.02; I2 = 0%).
15.5 Skeletal/limb malformations
Pooled results from four studies showed a non-significant outcome
(RR 0.48, 95% CI 0.11 to 2.11; I2 = 0%), with no difference in
the number of skeletal/limb malformations in children exposed
to CBZ (N = 1773) and children exposed to OXC (N = 238)
(Australian; Kaaja 2003; Meischenguiser 2004; North American
Register; see Analysis 15.5). This gave a non-significant RD (RD
−0.00, 95% CI −0.01 to 0.01; I2 = 0%).
16 CBZ versus PB
16.1 All major malformations
Pooled results from 22 studies showed a non-significant outcome
(RR 0.84, 95% CI 0.60 to 1.16; I2 = 0%), with no difference
in the number of major malformations in children exposed to
CBZ (N = 2665) and children exposed to PB (N = 703) (Al
Bunyan 1999; Australian; Canger 1999; Cassina 2013; Delmiš
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1991; D’Souza 1990; Eroglu 2008;Martinez Ferri 2009; Froscher
1991; Kaaja 2003; Kaneko 1999; KeralaPregnancy Registry; Koch
1992; Lindhout 1992; Meischenguiser 2004; Montreal Series;
North American Register; Omtzigt 1992; Pardi 1982; Steegers-
Theunissen 1994; Tanganelli 1992; Waters 1994; see Analysis
16.1). This gave a non-significant RD (RD−0.01, 95%CI−0.03
to 0.02; I2 = 0%).
In the EURAP, data the prevalence of MCM between these two
groups for children exposed to CBZ was: 5/148 (3.4%) for ex-
posures < 400 mg/d, 56/1047 (5.3%) for exposures 400 to 1000
mg/d and 18/207 (8.7%) for exposures > 1000 mg/d. In compar-
ison, the rates of MCM for children exposed to PB were: 9/166
(5.4%) for exposures < 150 mg/d and 7/51 (13.7%) for exposures
> 150 mg/d. Samren 1997 reported 22 major malformation cases
in 280 (8%) CBZ-exposed children and five cases from 48 (10%)
PB exposed children.
16.2 Neural tube malformations
Pooled results from 12 studies showed a non-significant outcome
(RR 1.02, 95% CI 0.19 to 5.39; I2 = 49%), with no difference
in the number of neural tube malformations in children exposed
to CBZ (N = 1830) and children exposed to PB (N = 416) (
Australian; Canger 1999; Cassina 2013; D’Souza 1990; Eroglu
2008; Froscher 1991; Kerala Pregnancy Registry; Koch 1992;
Meischenguiser 2004; North American Register; Omtzigt 1992;
Pardi 1982; see Analysis 16.2). This gave a non-significant RD
(RD 0.00, 95% CI −0.01 to 0.02; I2 = 0%).
In the EURAP data, the prevalence of neural tube malformations
in those exposed to CBZ and PB was: CBZ < 400 mg/d, 0/148
(0%); CBZ 400 to 1000 mg/d, 1/1047 (0%); CBZ > 1000 mg/
d, 4/207 (2%); PB < 150 mg/d, 1/166 (1%); PB > 150 mg/d, 0/
51 (0%).
16.3 Cardiac malformations
Pooled results from 12 studies showed a significant outcome (RR
0.34, 95% CI 0.18 to 0.62; I2 = 19%), with children exposed
to CBZ (N = 1935) experiencing fewer cardiac malformations
than children exposed to PB (N = 450) (Australian; Canger 1999;
Cassina 2013; D’Souza 1990; Eroglu 2008; Froscher 1991; Kerala
Pregnancy Registry; Koch 1992; Meischenguiser 2004; North
American Register; Omtzigt 1992; Pardi 1982; see Analysis 16.5).
This gave a significant RD (RD−0.02, 95% CI−0.05 to−0.00;
I2 = 0%).
In the EURAP data, the prevalence of cardiac malformations in
those exposed to CBZ and PBwas: CBZ < 400mg/d, 2/148 (1%);
CBZ 400 to 1000 mg/d, 16/1047 (2%); CBZ > 1000 mg/d, 4/
207 (2%); PB < 150 mg/d, 2/166 (1%); PB > 150 mg/d, 4/51
(8%).
16.4 Oro-facial cleft/craniofacial malformations
Pooled results from 12 studies showed a significant outcome (RR
0.18, 95% CI 0.07 to 0.48; I2 = 0%), with children exposed to
CBZ (N = 1830) experiencing fewer oro-facial cleft/craniofacial
malformations than children exposed to PB (N = 416) (Australian;
Canger 1999;Cassina 2013;D’Souza 1990; Eroglu2008; Froscher
1991; Kerala Pregnancy Registry; Koch 1992; Meischenguiser
2004; North American Register; Omtzigt 1992; Pardi 1982; see
Analysis 16.4). However, this gave a non-significant RD (RD
−0.01, 95% CI −0.03 to 0.00; I2 = 0%).
In the EURAP data, the prevalence of oro-facial cleft malforma-
tions in those exposed to CBZ and PB was: CBZ < 400 mg/d, 0/
148 (0%); CBZ 400 to 1000 mg/d, 2/1047 (0%); CBZ > 1000
mg/d, 0/207 (0%); PB < 150 mg/d, 0/166 (0%); PB > 150 mg/
d, 1/51 (2%).
16.5 Skeletal/limb malformations
Pooled results from 12 studies showed a non-significant outcome
(RR 1.20, 95% CI 0.45 to 3.21; I2 = 5%), with no difference in
the number of skeletal/limb malformations in children exposed
to CBZ (N = 1830) and children exposed to PB (N = 416) (
Australian; Canger 1999; Cassina 2013; D’Souza 1990; Eroglu
2008; Froscher 1991; Kerala Pregnancy Registry; Koch 1992;
Meischenguiser 2004; North American Register; Omtzigt 1992;
Pardi 1982; see Analysis 16.5). This gave a non-significant RD
(RD 0.00, 95% CI −0.01 to 0.02; I2 = 0%).
17 CBZ versus PHT
17.1 All major malformations
Pooled results from 23 studies showed a non-significant outcome
(RR 0.82, 95% CI 0.61 to 1.11; I2 = 0%), with no difference
in the number of major malformations in children exposed to
CBZ (N = 4262) and children exposed to PHT (N = 1183) (Al
Bunyan 1999; Arulmozhi 2006; Australian; Bag 1989; Canger
1999; D’Souza 1990; Eroglu 2008; Froscher 1991;Garza-Morales
1996; Kaaja 2003; Kaneko 1999; KeralaPregnancy Registry; Koch
1992; Lindhout 1992; Mawer 2010; Meador 2006; Montreal
Series; North American Register; Omtzigt 1992; Pardi 1982;
Steegers-Theunissen 1994;UKRegister;Waters 1994; seeAnalysis
17.1). This gave a non-significant RD (RD−0.01, 95%CI−0.02
to 0.01; I2 = 0%).
Data from the Motherisk Registry, including women treated with
CBZ for epilepsy and other conditions, showed a prevalence of
MCM to be 3/34 (8.8%) for children exposed to PHT and 2/35
(5.7%) for those exposed to CBZ. Samren 1997 reported 22 cases
of major malformation out of 280 (8%) CBZ-exposed children
and 9 cases from 141 PHT exposed children (9%).
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17.2 Neural tube malformations
Pooled results from 14 studies showed a non-significant outcome
(RR1.03, 95%CI 0.31 to 3.37; I2 = 0%), with no difference in the
number of neural tube malformations in children exposed to CBZ
(N = 3860) and children exposed to PHT (N = 874) (Australian;
Bag 1989; Canger 1999; D’Souza 1990; Eroglu 2008; Froscher
1991;Kaaja 2003;KeralaPregnancyRegistry; Koch1992;Meador
2006; North American Register; Omtzigt 1992; Pardi 1982; UK
Register; see Analysis 17.2). This gave a non-significant RD (RD
0.00, 95% CI −0.01 to 0.01; I2 = 0%).
17.3 Cardiac malformations
Pooled results from 14 studies showed a non-significant outcome
(RR 0.92, 95% CI 0.47 to 1.78; I2 = 8%), with no difference in
the number of cardiac malformations in children exposed to CBZ
(N = 3965) and children exposed to PHT (N = 969) (Australian;
Bag 1989; Canger 1999; D’Souza 1990; Eroglu 2008; Froscher
1991;Kaaja 2003;KeralaPregnancyRegistry; Koch1992;Meador
2006; North American Register; Omtzigt 1992; Pardi 1982; UK
Register; see Analysis 17.3). This gave a non-significant RD (RD
−0.00, 95% CI −0.01 to 0.01; I2 = 0%).
17.4 Oro-facial cleft/craniofacial malformations
Pooled results from 14 studies showed a non-significant outcome
(RR 0.80, 95% CI 0.31 to 2.05; I2 = 0%), with no difference
in the number of oro-facial cleft/craniofacial malformations in
children exposed to CBZ (N = 3860) and children exposed to
PHT (N = 874) (Australian; Bag 1989; Canger 1999; D’Souza
1990; Eroglu 2008; Froscher 1991; Kaaja 2003; Kerala Pregnancy
Registry; Koch 1992; Meador 2006; North American Register;
Omtzigt 1992; Pardi 1982; UK Register; see Analysis 17.4). This
gave a non-significant RD (RD −0.00, 95% CI −0.01 to 0.01; I
2 = 0%).
17.5 Skeletal/limb malformations
Pooled results from 14 studies showed a non-significant outcome
(RR 0.78, 95% CI 0.35 to 1.75; I2 = 0%), with no difference in
the number of skeletal/limb malformations in children exposed
to CBZ (N = 3860) and children exposed to PHT (N = 874)
(Australian; Bag 1989; Canger 1999; D’Souza 1990; Eroglu 2008;
Froscher 1991; Kaaja 2003; Kerala Pregnancy Registry; Koch
1992; Meador 2006; North American Register; Omtzigt 1992;
Pardi 1982; UK Register; see Analysis 17.5). This gave a non-
significant RD (RD 0.00, 95% CI −0.01 to 0.01; I2 = 0%).
18 CBZ versus PRM
18.1 All major malformations
Pooled results from six studies showed a non-significant outcome
(RR 0.80, 95% CI 0.41 to 1.57; I2 = 54%), with no difference
in the number of major malformations in children exposed to
CBZ (N = 667) and children with PRM (N = 110) (Canger 1999;
Delmiš 1991; Kaaja 2003; Kaneko 1999; Koch 1992; Pardi 1982;
see Analysis 18.1). Due to high heterogeneity, we undertook a
random-effects analysis (RR (RE) 0.64, 95% CI 0.21 to 2.01; I2
= 54%), but this did not change the significance of the result. The
RD was also non-significant (RD−0.02, 95% CI−0.09 to 0.05;
I2 = 22%).
Samren 1997 reported 22 cases of major malformation out of 280
(8%) CBZ-exposed children and 4 cases out of 43 (9%) PRM-
exposed children.
18.2 Neural tube malformations
Pooled results from two studies showed a non-significant outcome
(RR 0.95, 95% CI 0.04 to 22.75; I2 = NA), with no difference in
the number of neural tube malformations in children exposed to
CBZ (N = 119) and children exposed to PRM (N = 39) (Canger
1999; Pardi 1982; see Analysis 18.2). This gave a non-significant
RD (RD 0.01, 95% CI −0.04 to 0.06; I2 = 0%).
18.3 Cardiac malformations
Pooled results from two studies showed a non-significant outcome
(RR 0.11, 95% CI 0.00* to 2.53; I2 = 0%), with no difference
in the number of cardiac malformations in children exposed to
CBZ (N = 119) and children exposed to PRM (N = 39) (Canger
1999; Pardi 1982; see Analysis 18.3). This gave a non-significant
RD (RD −0.03, 95% CI −0.10 to 0.04; I2 = 0%).
18.4 Oro-facial cleft/craniofacial malformations
We were unable to estimate pooled results from two studies due to
there being no reported oro-facial cleft/craniofacial malformations
in children exposed to CBZ (N = 119) and children exposed to
PRM (N = 39) (Canger 1999; Pardi 1982; see Analysis 18.4). RD
was calculable, and this gave a non-significant RD (RD 0.00, 95%
CI −0.05 to 0.05; I2 = 0%).
18.5 Skeletal/limb malformations
Pooled results from two studies showed a non-significant outcome
(RR 2.84, 95% CI 0.16 to 51.53; I2 = NA), with no difference in
the number of skeletal/limbmalformations in children exposed to
CBZ (N = 119) and children exposed to PRM (N = 39) (Canger
1999; Pardi 1982; see Analysis 18.5). This gave a non-significant
RD (RD 0.03, 95% CI −0.03 to 0.09; I2 = 0%).
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19 CBZ versus TPM
19.1 All major malformations
Pooled results from three studies showed a non-significant result
(RR 0.78, 95% CI 0.47 to 1.31; I2 = 0%), with no difference in
the number of major malformations in children exposed to CBZ
(N = 3051) and children exposed to TPM (N = 473) (Australian;
North American Register; UK Register; see Analysis 19.1). This
gave a non-significant RD (RD −0.01, 95% CI −0.03 to 0.01; I
2 = 9%).
19.2 Neural tube malformations
Pooled results from three studies showed a non-significant result
(RR 0.97, 95% CI 0.19 to 5.06; I2 = 0%), with no difference
in the number of neural tube malformations in children exposed
to CBZ (N = 3051) and children exposed to TPM (N = 473)
(Australian; North American Register; UK Register; see Analysis
19.2). This gave a non-significant RD (RD 0.00, 95% CI −0.00
to 0.01; I2 = 0%).
19.3 Cardiac malformations
Pooled results from three studies showed a non-significant result
(RR 1.05, 95% CI 0.23 to 4.78; I2 = 0%), with no difference in
the number of cardiac malformations in children exposed to CBZ
(N = 3051) and children exposed to TPM (N = 473) (Australian;
North American Register; UK Register; see Analysis 19.3). This
gave a non-significant RD (RD 0.00, 95% CI −0.00 to 0.01; I2
= 0%).
19.4 Oro-facial cleft/craniofacial malformations
Pooled results from three studies showed a significant result (RR
0.32, 95% CI 0.13 to 0.81; I2 = 36%), with children exposed
to CBZ (N = 3051) experiencing fewer oro-facial cleft/cranio-
facial malformations than children exposed to TPM (N = 473)
(Australian; North American Register; UK Register; see Analysis
19.4). This gave a non-significant RD (RD−0.01, 95%CI−0.02
to 0.00; I2 = 12%)
19.5 Skeletal/limb malformations
Pooled results from three studies showed a non-significant result
(RR 0.38, 95% CI 0.13 to 1.09; I2 = 0%), with no difference in
the number of skeletal/limb malformations in children exposed
to CBZ (N = 3051) and children exposed to TPM (N = 473)
(Australian; North American Register; UK Register; see Analysis
19.5). This gave a non-significant RD (RD−0.01, 95%CI−0.02
to 0.00; I2 = 0%).
20 CBZ versus VPA
20.1. All major malformations
Pooled results from 25 studies showed a significant outcome (RR
0.41, 95% CI 0.34 to 0.50; I2 = 0%), with children exposed
to CBZ (N = 4549) experiencing fewer major malformations
than children exposed to VPA (N = 2529) (Al Bunyan 1999;
Arulmozhi 2006; Australian; Canger 1999; Cassina 2013; Eroglu
2008; Fairgrieve 2000; Martinez Ferri 2009; Froscher 1991;
Garza-Morales 1996;Kaaja 2003;Kaneko1999;KeralaPregnancy
Registry; Koch1992; Lindhout 1992;Mawer 2010;Meador 2006;
Meischenguiser 2004; Montreal Series; North American Register;
Omtzigt 1992; Pardi 1982; Steegers-Theunissen 1994; Tanganelli
1992; UK Register; see Analysis 20.1). This gave a significant RD
(RD −0.05, 95% CI −0.07 to −0.04; I2 = 0%).
In the EURAP data, the prevalence of MCM between these two
groups for children exposed to CBZ were: 5/148 (3.4%) for expo-
sures < 400 mg/d, 56/1047 (5.3%) for exposures of 400 to 1000
mg/d and 18/207 (8.7%) for exposures > 1000 mg/d. In compari-
son, the rates of MCM for children exposed to VPA were: 24/431
(5.6%) for exposures < 700 mg/d, 50/480 (10.4%) for exposures
> 700 and < 1500 mg/d, and 24/99 (24.2%) for exposures > 1500
mg/d. Samren 1997 reported 22 cases of major malformation out
of 280 (8%) CBZ-exposed children and six cases out of 184 (9%)
VPA-exposed children.
20.2 Neural tube malformations
Pooled results from 16 studies showed a significant outcome (RR
0.17, 95% CI 0.09 to 0.31; I2 = 0%), with children exposed to
CBZ (N = 4171) experiencing fewer neural tube malformations
than children exposed to VPA (N = 2305) (Australian; Canger
1999; Cassina 2013; Eroglu 2008; Fairgrieve 2000;Martinez Ferri
2009; Froscher 1991; Kaaja 2003; Kerala Pregnancy Registry;
Koch 1992;Meador 2006;Meischenguiser 2004;NorthAmerican
Register; Omtzigt 1992; Pardi 1982; UK Register; Analysis 20.2).
This gave a significant RD (RD−0.02, 95% CI−0.02 to−0.01;
I2 = 35%).
In the EURAP data, the prevalence of neural tube malformations
in those exposed to CBZ and VPA was: CBZ < 400 mg/d, 0/148
(0%); CBZ 400 to 1000 mg/d, 1/1047 (0%); CBZ > 1000 mg/d,
4/207 (2%); VPA < 700 mg/d, 2/431 (1%); VPA 700 to < 1500
mg/d, 7/480 (2%) and VPA > 1500 mg/d, 2/99 (2%).
20.3 Cardiac malformations
Pooled results from 16 studies showed a significant outcome (RR
0.45, 95% CI 0.31 to 0.68; I2 = 12%), with children exposed
to CBZ (N = 4276) experiencing fewer cardiac malformations
than children exposed to VPA (N = 2370) (Australian; Canger
1999; Cassina 2013; Eroglu 2008; Fairgrieve 2000;Martinez Ferri
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2009; Froscher 1991; Kaaja 2003; Kerala Pregnancy Registry;
Koch 1992;Meador 2006;Meischenguiser 2004;NorthAmerican
Register; Omtzigt 1992; Pardi 1982; UK Register; see Analysis
20.3). This gave a significant RD (RD −0.01, 95% CI −0.02 to
−0.01; I2 = 7%).
In the EURAP data, the prevalence of cardiac malformations in
those exposed to CBZ and VPA was: CBZ < 400 mg/d, 2/148
(1%); CBZ > 400 to 1000 mg/d, 16/1047 (2%); CBZ > 1000
mg/d, 4/207 (2%); VPA < 700 mg/d, 5/431 (1%); VPA 700 to <
1500 mg/d, 10/480 (2%) and VPA > 1500 mg/d, 7/99 (7%).
20.4 Oro-facial cleft/craniofacial malformations
Pooled results from 16 studies (Australian; Canger 1999; Cassina
2013; Eroglu 2008; Fairgrieve 2000; Martinez Ferri 2009;
Froscher 1991; Kaaja 2003; Kerala Pregnancy Registry; Koch
1992; Meador 2006; Meischenguiser 2004; North American
Register; Omtzigt 1992; Pardi 1982; UK Register) reported a sig-
nificant outcome (RR 0.28, 95% CI 0.16 to 0.49; I2 = 0%), with
children exposed to CBZ (N= 4171) experiencing fewer oro-facial
cleft/craniofacial malformations than children exposed to VPA (N
= 2305) (Analysis 20.4). This gave a significant RD (RD −0.01,
95% CI −0.02 to −0.01; I2 = 0%).
In the EURAP data the prevalence of oro-facial cleft malforma-
tions in those exposed to CBZ and VPA were: CBZ < 400 mg/d
0/148, 0%; CBZ > 400 to 1000 mg/d 2/1047, 0%; CBZ > 1000
mg/d 0/207, 0%; VPA < 700 mg/d 3/431, 1%; VPA > 700 to <
1500 mg/d 1/480, 0% and VPA > 1500 mg/d 0/99, 0%.
20.5 Skeletal/limb malformations
Pooled results from 16 studies showed a significant outcome (RR
0.33, 95% CI 0.19 to 0.57; I2 = 0%), with children exposed to
CBZ (N = 4171) experiencing fewer skeletal/limb malformations
than children exposed to VPA (N = 2305) (Australian; Canger
1999; Cassina 2013; Eroglu 2008; Fairgrieve 2000;Martinez Ferri
2009; Froscher 1991; Kaaja 2003; Kerala Pregnancy Registry;
Koch 1992;Meador 2006;Meischenguiser 2004;NorthAmerican
Register; Omtzigt 1992; Pardi 1982; UK Register; see Analysis
20.5). This gave a significant RD (RD −0.01, 95% CI −0.02 to
−0.00; I2 = 0%).
21 CBZ versus ZNS
21.1 All major malformations
North American Register reported a non-significant outcome (RR
5.54, 95% CI 0.34 to 89.86; I2 = NA), with no difference in the
number of major malformations in children exposed to CBZ (N
= 1033) and children exposed to ZNS (N = 90) (Analysis 21.1).
This gave a non-significant RD (RD 0.03, 95% CI 0.01 to 0.05;
I2 = NA).
21.2 Neural tube malformations
No included studies reported data on this outcome.
21.3 Cardiac malformations
No included studies reported data on this outcome.
21.4 Oro-facial cleft/craniofacial malformations
No included studies reported data on this outcome.
21.5 Skeletal/limb malformations
No included studies reported data on this outcome.
22 GBP versus LTG
22.1 All major malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.60, 95%CI 0.17 to 2.07; I2 = 0%), with no difference
in the number ofmajormalformations in children exposed toGBP
(N = 190) and children exposed to LTG (N = 3975) (Australian;
North American Register; UK Register; see Analysis 22.1). This
gave a non-significant RD (RD −0.01, 95% CI −0.03 to 0.01; I
2 = 0%).
22.2 Neural tube malformations
We could not estimate data from Australiandue to there being no
neural tube malformations in children exposed to GBP (N = 14)
or children exposed to LTG (N = 315) (see Analysis 22.2). RD
was calculable, and this gave a non-significant result (RD 0.00,
95% CI −0.09 to 0.09; I2 = NA).
22.3 Cardiac malformations
Data fromAustralianshowed a non-significant outcome (RR 3.01,
95%CI 0.16 to 55.67; I2 =NA), with no difference in the number
of cardiac malformations in children exposed to GBP (N = 14)
and children exposed to LTG (N = 315) (Analysis 22.3). This gave
a non-significant RD (RD −0.01, 95% CI −0.10 to 0.08; I2 =
NA).
22.4 Oro-facial cleft/craniofacial malformations
Data fromAustralianshowed a non-significant outcome (RR 1.92,
95%CI 0.11 to 33.05; I2 =NA), with no difference in the number
of oro-facial/craniofacial malformations in children exposed to
GBP (N = 14) and children exposed to LTG (N = 315) (Analysis
22.4). This gave a non-significant RD (RD−0.02, 95%CI−0.11
to 0.08; I2 = NA).
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22.5 Skeletal/limb malformations
We could not estimate data from one study due to there being no
skeletal/limbmalformations in children exposed to GBP (N = 14)
or children exposed to LTG (N = 315) (Australian; see Analysis
22.5). RD was calculable, and this gave a non-significant result
(RD 0.00, 95% CI −0.09 to 0.09; I2 = NA).
23 GBP versus OXC
23.1 All major malformations
Pooled results from two studies showed a non-significant outcome
(RR 0.31, 95% CI 0.04 to 2.78; I2 = NA), with no difference in
the number of major malformations in children exposed to GBP
(N = 159) and children exposed to OXC (N = 194) (Australian;
North American Register; see Analysis 23.1). This gave a non-
significant RD (RD −0.01, 95% CI −0.04 to 0.01; I2 = 0%).
23.2 Neural tube malformations
We could not estimate data from one study due to there being
no neural tube malformations in children exposed to GBP (N =
14) or children exposed to OXC (N = 12) (Australian; se Analysis
23.2). RD was calculable, and this gave a non-significant result
(RD 0.00, 95% CI −0.14 to 0.14; I2 = NA).
23.3 Cardiac malformations
We could not estimate data from one study due to there being
no cardiac malformations in children exposed to GBP (N = 14)
or children exposed to OXC (N = 12) (Australian; see Analysis
23.3). RD was calculable, and this gave a non-significant result
(RD 0.00, 95% CI −0.14 to 0.14; I2 = NA).
23.4 Oro-facial cleft/craniofacial malformations
We could not estimate data from one study due to there being no
oro-facial cleft/craniofacial malformations in children exposed to
GBP (N = 14) or children exposed to OXC (N = 12) (Australian;
see Analysis 23.4). RD was calculable, and this gave a non-signif-
icant RD (RD 0.00, 95% CI −0.14 to 0.14; I2 = NA).
23.5 Skeletal/limb malformations
We could not estimate data from one study due to there being no
skeletal/limbmalformations in children exposed to GBP (N = 14)
or children exposed to OXC (N = 12) (Australian; see Analysis
23.5). RD was calculable, and this gave a non-significant result
(RD 0.00, 95% CI −0.14 to 0.14; I2 = NA).
24 GBP versus PB
24.1 All major malformations
Pooled results from two studies showed a significant outcome
(RR 0.12, 95% CI 0.02 to 0.96; I2 = 0%), with children ex-
posed to GBP (N = 159) experiencing fewer major malforma-
tions than children exposed to PB (N = 204) (Australian; North
American Register; see Analysis 24.1). This gave a significant RD
(RD −0.05, 95% CI −0.08 to −0.01; I2 = 0%).
24.2 Neural tube malformations
We could not estimate data from one study due to there being
no neural tube malformations in children exposed to GBP (N =
14) or children exposed to PB (N = 5) (Australian; see Analysis
24.2). RD was calculable, and this gave a non-significant result
(RD 0.00, 95% CI −0.24 to 0.24; I2 = NA).
24.3 Cardiac malformations
We could not estimate data from one study due to there being no
cardiac malformations in children exposed to GBP (N = 14) or
children exposed to PB (N = 5) (Australian; see Analysis 24.3). RD
was calculable, and this gave a non-significant result (RD 0.00,
95% CI −0.24 to 0.24; I2 = NA).
24.4 Oro-facial cleft/craniofacial malformations
We could not estimate data from one study due to there being no
oro-facial cleft/craniofacial malformations in children exposed to
GBP (N = 14) or children exposed to PB (N = 5) (Australian; see
Analysis 24.4). RD was calculable, and this gave a non-significant
result (RD 0.00, 95% CI −0.24 to 0.24; I2 = NA).
24.5 Skeletal/limb malformations
Wewere unable to estimate data from one study due to there being
no skeletal/limb malformations in children exposed to GBP (N =
14) or children exposed to PB (N = 5) (Australian; see Analysis
24.5). RD was calculable, and this gave a non-significant result
(RD 0.00, 95% CI −0.24 to 0.24; I2 = NA).
25 GBP versus PRM
25.1 All major malformations
No included studies reported data on this outcome.
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25.2 Neural tube malformations
No included studies reported data on this outcome.
25.3 Cardiac malformations
No included studies reported data on this outcome.
25.4 Oro-facial cleft/craniofacial malformations
No included studies reported data on this outcome.
25.5 Skeletal/limb malformations
No included studies reported data on this outcome.
26 GBP versus TPM
26.1 All major malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.32, 95%CI 0.09 to 1.17; I2 = 0%), with no difference
in the number ofmajormalformations in children exposed toGBP
(N = 190) and children exposed to TPM (N = 473) (Australian;
North American Register; UK Register; see Analysis 26.1). How-
ever, this gave a significant RD (RD −0.03, 95% CI −0.05 to
−0.01; I2 = 0%).
26.2 Neural tube malformations
Wewere unable to estimate data from one study due to there being
no neural tube malformations in children exposed to GBP (N =
14) or children exposed to TPM (N = 44) (Australian; see Analysis
26.2). RD was calculable, and this gave a non-significant result
(RD 0.00, 95% CI −0.10 to 0.10; I2 = NA).
26.3 Cardiac malformations
Wewere unable to estimate data from one study due to there being
no cardiac malformations in children exposed to GBP (N = 14)
or children exposed to TPM (N = 44) (Australian; see Analysis
26.3). RD was calculable, and this gave a non-significant result
(RD 0.00, 95% CI −0.10 to 0.10; I2 = NA).
26.4 Oro-facial cleft/craniofacial malformations
We were unable to estimate data from one study due to there
being no oro-facial cleft/craniofacial malformations in children
exposed to GBP (N = 14) or children exposed to TPM (N = 44)
(Australian; see Analysis 26.4). RD was calculable, and this gave
a non-significant result (RD 0.00, 95% CI −0.10 to 0.10; I2 =
NA).
26.5 Skeletal/limb malformations
Wewere unable to estimate data from one study due to there being
no skeletal/limb malformations in children exposed to GBP (N =
14) or children exposed to TPM (N = 44) (Australian; see Analysis
26.5). RD was calculable, and this gave a non-significant result
(RD 0.00, 95% CI −0.10 to 0.10; I2 = NA).
27 GBP versus ZNS
27.1 All major malformations
Data from one study showed a non-significant outcome (RR 1.87,
95%CI 0.08 to 45.41; I2 =NA), with no difference in the number
of major malformations in children exposed to GBP (N = 145)
and children exposed to ZNS (N = 90) (North American Register;
see Analysis 27.1). This gave a non-significant RD (RD 0.01, 95%
CI −0.02 to 0.03; I2 = NA).
27.2 Neural tube malformations
No included studies reported data on this outcome.
27.3 Cardiac malformations
No included studies reported data on this outcome.
27.4 Oro-facial cleft/craniofacial malformations
No included studies reported data on this outcome.
27.5 Skeletal/limb malformations
No included studies reported data on this outcome.
28 LEV versus GBP
28.1 All major malformations
Pooled results from three studies showed a non-significant out-
come (RR 1.52, 95% CI 0.43 to 5.42; I2 = 45%), with no dif-
ference in the number of major malformations in children ex-
posed to LEV (N = 817) and children exposed to GBP (N = 190)
(Australian; North American Register; UK Register; see Analysis
28.1). This gave a non-significant RD (RD 0.01, 95% CI −0.01
to 0.03; I2 = 0%).
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28.2 Neural tube malformations
Wewere unable to estimate data from one study due to there being
no reportedneural tubemalformations in children exposed to LEV
(N = 63) or children exposed to GBP (N = 14) (Australian; see
Analysis 28.2). RD was calculable, and this gave a non-significant
result (RD 0.00, 95% CI −0.09 to 0.09; I2 = NA).
28.3 Cardiac malformations
Data from one study showed a non-significant outcome (RR 0.70,
95%CI 0.03 to 16.42; I2 =NA), with no difference in the number
of cardiac malformations in children exposed to LEV (N = 63)
and children exposed to GBP (N = 14) (Australian; see Analysis
28.3). This gave a non-significant RD (RD 0.02, 95% CI −0.08
to 0.11; I2 = NA).
28.4 Oro-facial cleft/craniofacial malformations
Data from one study showed a non-significant outcome (RR 0.70,
95% CI 0.03 to 16.42; I2 = NA), with no difference in the num-
ber of oro-facial cleft/craniofacial malformations in children ex-
posed to LEV (N = 63) and children exposed to GBP (N = 14)
(Australian; see Analysis 28.4). This gave a non-significant RD
(RD 0.02, 95% CI −0.08 to 0.11; I2 = NA).
28.5 Skeletal/limb malformations
Wewere unable to estimate data from one study due to there being
no reported skeletal/limb malformations in children exposed to
LEV (N = 63) and children exposed to GBP (N = 14) (Australian;
see Analysis 28.3). RD was calculable, and this gave a non-signif-
icant result (RD 0.00, 95% CI −0.09 to 0.09; I2 = NA).
29 LEV versus LTG
29.1. All major malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.73, 95% CI 0.41 to 1.29; I2 = 55%), with no dif-
ference in the number of major malformations in children ex-
posed to LEV (N = 817) and children exposed to LTG (N = 3975)
(Australian; North American Register; UK Register; see Analysis
29.1). Due to high heterogeneity, we undertook a random-effects
analysis was undertaken, which upheld the non-significant result
(RR (RE) 0.62, 95%CI 0.20 to 1.88; I2 = 55%). The RDwas also
non-significant (RD −0.01, 95% CI −0.02 to 0.00; I2 = 68%).
29.2 Neural tube malformations
Pooled results from three studies showed a non-significant out-
come (RR 1.59, 95% CI 0.24 to 10.38; I2 = 0%), with no differ-
ence in the number of neural tube malformations in children ex-
posed to LEV (N = 817) and children exposed to LTG (N = 3975)
(Australian; North American Register; UK Register; see Analysis
29.2). This gave a non-significant RD (RD 0.00, 95% CI −0.00
to 0.00; I2 = 0%).
29.3 Cardiac malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.86, 95% CI 0.22 to 3.36; I2 = 0%), with no dif-
ference in the number of cardiac malformations in children ex-
posed to LEV (N = 817) and children exposed to LTG (N = 3975)
(Australian; North American Register; UK Register; see Analysis
29.3). This gave a non-significant RD (RD−0.00, 95%CI−0.01
to 0.00; I2 = 0%).
29.4 Oro-facial cleft/craniofacial malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.59, 95% CI 0.14 to 2.48; I2 = 0%), with no dif-
ference in the number of oro-facial cleft/craniofacial malforma-
tions in children exposed to LEV (N = 817) and children exposed
to LTG (N = 3975) (Australian; North American Register; UK
Register; see Analysis 29.4). This gave a non-significant RD (RD
−0.00, 95% CI −0.01 to 0.00; I2 = 0%).
29.5 Skeletal/limb malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.82, 95% CI 0.10 to 6.80; I2 = 0%), with no differ-
ence in the number of skeletal/limbmalformations in children ex-
posed to LEV (N = 817) and children exposed to LTG (N = 3975)
(Australian; North American Register; UK Register; see Analysis
29.5). This gave a non-significant RD (RD−0.00, 95%CI−0.00
to 0.00; I2 = 0%).
30 LEV versus OXC
30.1 All major malformations
Pooled results from two studies showed a non-significant outcome
(RR 1.05, 95% CI 0.36 to 3.03; I2 = 0%), with no difference in
the number of major malformations in children exposed to LEV
(N = 513) and children exposed to OXC (N = 194) (Australian;
North American Register; see Analysis 30.1). This gave a non-
significant RD (RD 0.00, 95% CI −0.02 to 0.03; I2 = 0%).
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30.2 Neural tube malformations
Pooled results from two studies showed a non-significant outcome
(RR 1.22, 95% CI 0.05 to 29.74; I2 = NA), with no difference
in the number of neural tube malformations in children exposed
to LEV (N = 513) and children exposed to OXC (N = 194) (
Australian;North American Register; see Analysis 30.2). This gave
a non-significant RD (RD 0.00, 95%CI−0.01 to 0.01; I2 = 0%).
30.3 Cardiac malformations
Pooled results from two studies showed a non-significant outcome
(RR 0.89, 95% CI 0.10 to 8.21; I2 = 0%), with no difference in
the number of cardiac malformations in children exposed to LEV
(N = 513) and children exposed to OXC (N = 194) (Australian;
North American Register; see ). This gave a non-significant RD
(RD 0.00, 95% CI −0.01 to 0.02; I2 = 0%).
30.4 Oro-facial cleft/craniofacial malformations
Pooled results from two studies showed a non-significant outcome
(RR0.27, 95%CI 0.03 to 2.20; I2 = 0%), with no difference in the
number of oro-facial cleft/craniofacial malformations in children
exposed to LEV (N = 513) and children exposed to OXC (N =
194) (Australian; North American Register; see Analysis 30.4).
This gave a non-significant RD (RD −0.00, 95% CI −0.02 to
0.01; I2 = 0%).
30.5 Skeletal/limb malformations
Pooled results from two studies showed a non-significant outcome
(RR 0.14, 95% CI 0.01 to 3.30; I2 = 0%), with no difference in
the number of skeletal/limbmalformations in children exposed to
LEV (N = 513) children exposed to OXC (N = 194) (Australian;
North American Register; see Analysis 30.5). This gave a non-
significant RD (RD −0.01, 95% CI −0.02 to 0.01; I2 = 0%).
31 LEV versus PB
31.1 All major malformations
Results from two studies showed a significant outcome (RR 0.43,
95% CI 0.20 to 0.96; I2 = 0%), with children exposed to LEV
(N = 513) experiencing fewer major malformations than children
exposed to PB (N = 204) (Australian; North American Register;
see Analysis 31.1). This gave a non-significant RD (RD −0.03,
95% CI −0.06 to 0.01; I2 = 0%).
31.2 Neural tube malformations
Results from two studies showed a non-significant outcome (RR
1.33, 95% CI 0.05 to 32.52; I2 = NA), with no difference in the
number of neural tube malformations in children exposed to LEV
(N = 513) and children exposed to PB (N = 204) (Australian;
North American Register; see Analysis 31.2). This gave a non-
significant RD (RD 0.00, 95% CI −0.01 to 0.01; I2 = 0%).
31.3 Cardiac malformations
Results from two studies showed a significant outcome (RR 0.11,
95% CI 0.02 to 0.66; I2 = 0%), with children exposed to LEV (N
= 513) experiencing fewer cardiac malformations than children
exposed to PB (N = 204) (Australian; North American Register;
see Analysis 31.3). However, this gave a non-significant RD (RD
−0.02, 95% CI −0.04 to 0.00; I2 = 0%).
31.4 Oro-facial cleft/craniofacial malformations
Results from two studies showed a significant outcome (RR 0.08,
95% CI 0.01 to 0.67; I2 = 0%), with children exposed to LEV (N
= 513) experiencing fewer oro-facial cleft/craniofacial malforma-
tions than children exposed to PB (N = 204) (Australian; North
American Register; see Analysis 31.4). However, this gave a non-
significant RD (RD −0.02, 95% CI −0.04 to 0.00; I2 = 0%).
31.5 Skeletal/limb malformations
Results from two studies showed a non-significant outcome (RR
0.15, 95% CI 0.01 to 3.61; I2 = NA), with no difference in the
number of skeletal/limb malformations in children exposed to
LEV (N = 513) and children exposed to PB (N = 204) (Australian;
North American Register; see Analysis 31.5). This gave a non-
significant RD (RD −0.00, 95% CI −0.02 to 0.01; I2 = 0%).
32 LEV versus PHT
32.1 All major malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.49, 95% CI 0.26 to 0.92; I2 = 66%), with no dif-
ference in the number of major malformations in children ex-
posed to LEV (N = 817) and children exposed to PHT (N = 566)
(Australian; North American Register; UK Register; see Analysis
32.1). Due to high heterogeneity, we undertook a random-effects
analysis, which changed the significance of the result (RR (RE)
0.34, 95% CI 0.08 to 1.50; I2 = 66%). The RD however was
significant (RD−0.02, 95% CI−0.04 to−0.00; I2 = 57%). Due
to high heterogeneity, we undertook a random-effects analysis,
which upheld the non-significant result (RD (RE) −0.03, 95%
CI −0.06 to 0.01; I2 = 57%).
36Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
32.2 Neural tube malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.81, 95% CI 0.12 to 5.34; I2 = 13%), with no differ-
ence in the number of neural tube malformations in children ex-
posed to LEV (N = 817) and children exposed to PHT (N = 542)
(Australian; North American Register; UK Register; see Analysis
32.2). This gave a non-significant RD (RD−0.00, 95%CI−0.01
to 0.01; I2 = 0%).
32.3 Cardiac malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.26, 95% CI 0.06 to 1.09; I2 = 0%), with no dif-
ference in the number of cardiac malformations in children ex-
posed to LEV (N = 817) and children exposed to PHT (N = 542)
(Australian; North American Register; UK Register; see Analysis
32.3). This gave a non-significant RD (RD−0.01, 95%CI−0.02
to 0.00; I2 = 0%).
32.4 Oro-facial cleft/craniofacial malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.35, 95%CI 0.08 to 1.56; I2 = 4%), with no difference
in the number of oro-facial cleft/craniofacial malformations in
children exposed to LEV (N = 817) and children exposed to PHT
(N = 542) (Australian; North American Register; UK Register; see
Analysis 32.4). This gave a non-significant RD (RD −0.00, 95%
CI −0.01 to 0.00; I2 = 0%).
32.5 Skeletal/limb malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.10, 95% CI 0.01 to 1.90; I2 = NA), with no differ-
ence in the number of skeletal/limbmalformations in children ex-
posed to LEV (N = 817) and children exposed to PHT (N = 542)
(Australian; North American Register; UK Register; see Analysis
32.5). This gave a non-significant RD (RD−0.01, 95%CI−0.02
to 0.00; I2 = 0%).
33 LEV versus PRM
33.1 All major malformations
No included studies reported data on this outcome.
33.2 Neural tube malformations
No included studies reported data on this outcome.
33.3 Cardiac malformations
No included studies reported data on this outcome.
33.4 Oro-facial cleft/craniofacial malformations
No included studies reported data on this outcome.
33.5 Skeletal/limb malformations
No included studies reported data on this outcome.
34 LEV versus TPM
34.1 All major malformations
Pooled results from three studies showed a significant outcome
(RR 0.50, 95% CI 0.26 to 0.97; I2 = 0%), with children exposed
to LEV (N = 817) experiencing fewer major malformations than
children exposed to TPM (N = 473) (Australian; North American
Register; UK Register; see Analysis 34.1). However, this gave a
non-significant RD (RD−0.02, 95%CI−0.04 to 0.00; I2 = 0%).
34.2 Neural tube malformations
Pooled results from three studies showed a non-significant out-
come (RR 2.39, 95% CI 0.10 to 58.61; I2 = NA), with no differ-
ence in the number of neural tube malformations in children ex-
posed to LEV (N = 817) and children exposed to TPM (N = 473)
(Australian; North American Register; UK Register; see Analysis
34.2). This gave a non-significant RD (RD 0.00, 95% CI −0.01
to 0.01; I2 = 0%).
34.3 Cardiac malformations
Pooled results from three studies showed a non-significant out-
come (RR 1.25, 95% CI 0.16 to 9.54; I2 = 0%), with no dif-
ference in the number of cardiac malformations in children ex-
posed to LEV (N = 817) and children exposed to TPM (N = 473)
(Australian; North American Register; UK Register; see Analysis
34.2). This gave a non-significant RD (RD 0.00, 95% CI −0.01
to 0.01; I2 = 0%).
34.4 Oro-facial cleft/craniofacial malformations
Pooled results from three studies showed a significant outcome
(RR 0.17, 95% CI 0.04 to 0.68; I2 = 42%), with children exposed
to LEV (N = 817) experiencing fewer oro-facial/craniofacial mal-
formations than children exposed to TPM (N = 473) (Australian;
North American Register; UK Register; see Analysis 34.4). This
gave a significant RD (RD −0.01, 95% CI −0.03 to−0.00; I2 =
0%).
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34.5 Skeletal/limb malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.07, 95% CI 0.00* to 1.31; I2 = NA), with no differ-
ence in the number of skeletal/limbmalformations in children ex-
posed to LEV (N = 817) and children exposed to TPM (N = 473)
(Australian; North American Register; UK Register; see Analysis
34.5). This gave a non-significant RD (RD−0.01, 95%CI−0.02
to 0.00; I2 = 0%).
35 LEV versus ZNS
35.1 All major malformations
One study reported a non-significant outcome (RR 4.64, 95%
CI 0.28 to 78.05; I2 = NA), with no difference in the number
of major malformations in children exposed to LEV (N = 450)
and children exposed to ZNS (N = 90) (North American Register;
see Analysis 35.1). However, this gave a significant RD (RD 0.02,
95% CI 0.00* to 0.05; I2 = NA).
35.2 Neural tube malformations
No included studies reported data on this outcome.
35.3 Cardiac malformations
No included studies reported data on this outcome.
35.4 Oro-facial cleft/craniofacial malformations
No included studies reported data on this outcome.
35.5 Skeletal/limb malformations
No included studies reported data on this outcome.
36 LTG versus OXC
36.1 All major malformations
Pooled results from two studies showed a non-significant outcome
(RR 0.93, 95% CI 0.35 to 2.43; I2 = 0%), with no difference in
the number of major malformations in children exposed to LTG
(N = 1877) and children exposed to OXC (N = 194) (Australian;
North American Register; see Analysis 36.1). This gave a non-
significant RD (RD 0.00, 95% CI −0.02 to 0.02; I2 = 0%).
36.2 Neural tube malformations
Pooled results from two studies showed a non-significant outcome
(RR 0.59, 95% CI 0.03 to 12.15; I2 = NA), with no difference
in the number of neural tube malformations in children exposed
to LTG (N = 1877) and children exposed to OXC (N = 194)
(Australian; North American Register; see Analysis 36.2). This
gave a non-significant RD (RD 0.00, 95% CI −0.01 to 0.01; I2
= 0%).
36.3 Cardiac malformations
Pooled results from two studies showed a non-significant outcome
(RR 0.54, 95% CI 0.07 to 4.30; I2 = 0%), with no difference in
the number of cardiac malformations in children exposed to LTG
(N = 1877) and children exposed to OXC (N = 194) (Australian;
North American Register; see Analysis 36.3). This gave a non-
significant RD (RD 0.00, 95% CI −0.01 to 0.01; I2 = 0%).
36.4 Oro-facial cleft/craniofacial malformations
Pooled results from two studies showed a non-significant outcome
(RR0.69, 95%CI 0.13 to 3.71; I2 = 0%), with no difference in the
number of oro-facial cleft/craniofacial malformations in children
exposed to LTG (N = 1877) and children exposed to OXC (N
= 194) (Australian; North American Register; see Analysis 36.4).
This gave a non-significant RD (RD 0.00, 95%CI−0.01 to 0.01;
I2 = 0%).
36.5 Skeletal/limb malformations
Pooled results from two studies showed a non-significant outcome
(RR 0.23, 95% CI 0.02 to 2.56; I2 = NA), with no difference in
the number of skeletal/limb malformations in children exposed
to LTG (N = 1877) and children exposed to OXC (N = 194)
(Australian; North American Register; see Analysis 36.5). This
gave a non-significant RD (RD −0.00, 95% CI −0.02 to 0.01; I
2 = 0%).
37 LTG versus PB
37.1 All major malformations
Pooled results from four studies showed a significant outcome (RR
0.32, 95%CI0.17 to 0.61; I2 =0%),with children exposed toLTG
(N=1959) experiencing fewermajormalformations than children
exposed to PB (N=282) (Australian; Cassina 2013;Martinez Ferri
2009; North American Register; see Analysis 37.1). This gave a
significant RD (RD −0.04, 95% CI −0.07 to −0.01; I2 = 0%).
In the EURAP data, rates of MCM for children exposed to LTG
were: 17/836 (2.0%) for exposures < 300mg/d and 20/444 (4.5%)
for exposures > 300 mg/d. In comparison, the rates of MCM
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for children exposed to PB were: 9/166 (5.4%) for exposures <
150 mg/d and 7/51 (13.7%) for exposures > 150 mg/d. Children
exposed to < 150 mg/d of PB were not at an increased risk for
MCM (P = 0.0275); however, we did find a significant increase
in risk for PB exposures > 150 mg/d (P < 0.0001). There was no
comparison to higher doses of LTG.
37.2 Neural tube malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.64, 95% CI 0.03 to 13.28; I2 = NA), with no dif-
ference in the number of neural tube malformations in children
exposed to LTG (N = 1903) and children exposed to PB (N = 271)
(Australian; Cassina 2013; North American Register; see Analysis
37.2). This gave a non-significant RD (RD 0.00, 95% CI −0.01
to 0.01; I2 = 0%).
In the EURAP data, there was no direct statistical comparison
between the prevalence of neural tube malformations in those
exposed to LTG and PB; however, the rates were: LTG < 300 mg/
d, 0/836 (0%); LTG > 300 mg/d, 0/444 (0%) and PB < 150 mg/
d, 1/166 (0.6%); PB > 150 mg/d, 0/51 (0%).
37.3 Cardiac malformations
Pooled results from three studies showed a significant outcome
(RR 0.14, 95% CI 0.04 to 0.42; I2 = 0%), with children exposed
to LTG (N = 1903) experiencing fewer cardiac malformations
than children exposed to PB (N = 271) (Australian; Cassina 2013;
North American Register; see Analysis 37.3). This gave a signifi-
cant RD (RD −0.02, 95% CI −0.04 to −0.00; I2 = 0%).
In the EURAP data the prevalence of cardiac malformations in
those exposed to LTG and PB was: LTG < 300, 3/836 (0%); LTG
> 300 mg/d, 5/444 (1%) and PB < 150 mg/d, 2/166 (1.2%); PB
> 150 mg/d, 4/51 (7.8%).
37.4 Oro-facial cleft/craniofacial malformations
Pooled results from three studies showed a significant outcome
(RR 0.22, 95% CI 0.07 to 0.68; I2 = 0%), with children exposed
to LTG (N = 1903) experiencing fewer oro-facial cleft/craniofacial
malformations than children exposed to PB (N = 271) (Australian;
Cassina 2013; North American Register; see Analysis 37.4). How-
ever, this gave a non-significant RD (RD −0.01, 95% CI −0.03
to 0.01; I2 = 0%).
In the EURAP data, the prevalence of oro-facial cleft malforma-
tions in those exposed to VPA and PB was: LTG < 300 mg/d, 0/
836 (0%); LTG > 300 mg/d, 2/444 (1%) and PB < 150 mg/d, 0/
166 (0%); PB > 150 mg/d, 1/51 (2%).
37.5 Skeletal/limb malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.25, 95% CI 0.02 to 2.80; I2 = 0%), with no dif-
ference in the number of skeletal/limb malformations in children
exposed to LTG (N = 1903) and children exposed to PB (N = 271)
(Australian; Cassina 2013; North American Register; see Analysis
37.5). This gave a non-significant RD (RD−0.00, 95%CI−0.02
to 0.01; I2 = 0%).
38 LTG versus PHT
38.1 All major malformations
Pooled results from five studies showed a significant outcome (RR
0.53, 95% CI 0.34 to 0.84; I2 = 17%), with children exposed to
LTG (N = 4082) experiencing fewer major malformations than
children exposed to PHT (N = 624) (Australian; Mawer 2010;
Meador 2006;NorthAmericanRegister; UKRegister; see Analysis
38.1). This gave a significant RD (RD −0.02, 95% CI −0.04 to
−0.00; I2 = 0%).
38.2 Neural tube malformations
Pooled results from four studies showed a non-significant outcome
(RR 0.31, 95% CI 0.07 to 1.34; I2 = 13%), with no difference
in the number of neural tube malformations in children exposed
to LTG (N = 4073) and children exposed to PHT (N = 598)
(Australian;Meador 2006;NorthAmericanRegister;UKRegister;
see Analysis 38.2). This gave a non-significant RD (RD −0.00,
95% CI −0.01 to 0.01; I2 = 0%).
38.3 Cardiac malformations
Pooled results from four studies showed a significant outcome (RR
0.35, 95% CI 0.14 to 0.92; I2 = 0%), with children exposed to
LTG (N = 4073) experiencing fewer cardiac malformations than
children exposed to PHT (N = 598) (Australian; Meador 2006;
North American Register; UK Register; see Analysis 38.3). This
gave a non-significant RD (RD −0.01, 95% CI −0.02 to 0.00; I
2 = 0%).
38.4 Oro-facial cleft/craniofacial malformations
Pooled results from four studies showed a non-significant outcome
(RR 0.75, 95% CI 0.24 to 2.34; I2 = 47%), with no difference
in the number of oro-facial cleft/craniofacial malformations in
children exposed to LTG (N=4073) and children exposed to PHT
(N = 598) (Australian; Meador 2006; North American Register;
UK Register; see Analysis 38.4). This gave a non-significant RD
(RD −0.00, 95% CI −0.01 to 0.01; I2 = 0%).
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38.5 Skeletal/limb malformations
Pooled results from four studies showed a significant outcome (RR
0.15, 95% CI 0.03 to 0.66; I2 = 0%), with children exposed to
LTG (N = 4073) experiencing fewer skeletal/limb malformations
than children exposed to PHT (N = 598) (Australian; Meador
2006; North American Register; UK Register; see Analysis 38.5).
This gave a non-significant RD (RD −0.01, 95% CI −0.01 to
0.00; I2 = 0%).
39 LTG versus TPM
39.1 All major malformations
Pooled results from three studies showed a significant outcome
(RR 0.56, 95% CI 0.34 to 0.94; I2 = 0%), with children exposed
to LTG (N = 3975) experiencing fewer major malformations than
children exposed to TPM (N = 473) (Australian; North American
Register; UK Register; see Analysis 39.1). However, this gave a
non-significant RD (RD −0.02, 95% CI −0.04 to 0.00; I2 =
10%).
39.2 Neural tube malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.62, 95%CI 0.08 to 4.94; I2 = 0%), with no difference
in the number of neural tube malformations in children exposed
to LTG (N = 3975) and children exposed to TPM (N = 473)
(Australian; North American Register; UK Register; see Analysis
39.2). This gave a non-significant RD (RD 0.00, 95% CI −0.00
to 0.01; I2 = 0%).
39.3 Cardiac malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.75, 95% CI 0.17 to 3.42; I2 = 0%), with no differ-
ence in the number of cardiac malformations in children exposed
to LTG (N = 3975) and children exposed to TPM (N = 473)
(Australian; North American Register; UK Register; see Analysis
39.3). This gave a non-significant RD (RD 0.00, 95% CI −0.01
to 0.01; I2 = 0%).
39.4 Oro-facial cleft/craniofacial malformations
Pooled results from three studies showed a significant outcome
(RR 0.32, 95% CI 0.13 to 0.76; I2 = 69%), with children exposed
to LTG (N = 3975) experiencing fewer of oro-facial cleft/cranio-
facial malformations than children exposed to TPM (N = 473)
(Australian; North American Register; UK Register; see Analysis
39.4). Due to high heterogeneity, we undertook a random-effects
analysis, which changed the result to non-significant (RR (RE)
0.22, 95% CI 0.03 to 1.56; I2 = 69%). The RD was also non-
significant (RD −0.01, 95% CI −0.02 to 0.00; I2 = 34%).
39.5 Skeletal/limb malformations
Pooled results from three studies showed a significant outcome
(RR0.11, 95%CI 0.03 to 0.45; I2 = 0%), with children exposed to
LTG (N = 3975) experiencing fewer skeletal/limb malformations
than children exposed to TPM (N = 473) (Australian; North
American Register; UK Register; see Analysis 39.5). This gave a
non-significant RD (RD−0.01, 95%CI−0.02 to 0.00; I2 = 0%).
40 PHT versus GBP
40.1 All major malformations
Pooled results from three studies showed a non-significant out-
come (RR 2.81, 95% CI 0.77 to 10.23; I2 = 0%), with no dif-
ference in the number of major malformations in children ex-
posed to PHT (N = 566) and children exposed to GBP (N = 190)
(Australian; North American Register; UK Register; see Analysis
40.1). This gave a significant RD (RD 0.03, 95% CI 0.00* to
0.05; I2 = 0%).
40.2 Neural tube malformations
Data from one study showed a non-significant outcome (RR 1.00,
95%CI 0.04 to 23.26; I2 =NA), with no difference in the number
of neural tubemalformations in children exposed to PHT (N=44)
and children exposed to GBP (N = 14) (Australian; see Analysis
40.2). This gave a non-significant RD (RD 0.02, 95% CI −0.08
to 0.13; I2 = NA).
40.3 Cardiac malformations
Data from one study showed a non-significant outcome (RR 1.00,
95% CI 0.04 to 23.26), with no difference in the number of
cardiac malformations in children exposed to PHT (N = 44) and
children exposed to GBP (N = 14) (Australian; see Analysis 40.3).
This gave a non-significant RD (RD 0.02, 95%CI−0.08 to 0.13;
I2 = NA).
40.4 Oro-facial cleft/craniofacial malformations
We could not estimate data from one study due to there being
no reported oro-facial cleft/craniofacial malformations in children
exposed to PHT (N = 44) or children exposed to GBP (N = 14)
(Analysis 40.4). RDwas calculable, and this gave a non-significant
result (RD 0.00, 95% CI −0.10 to 0.10; I2 = NA).
40.5 Skeletal/limb malformations
We could not estimate data from one study due to there being no
reported skeletal/limbmalformations in children exposed to PHT
(N = 44) or children exposed to GBP (N = 14) (Australian; see
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Analysis 40.5). RD was calculable, and this gave a non-significant
result (RD 0.00, 95% CI −0.10 to 0.10; I2 = NA).
41 PHT versus OXC
41.1 All major malformations
Pooled results from three studies showed a non-significant out-
come (RR 1.08, 95% CI 0.43 to 2.71; I2 = 12%), with no dif-
ference in the number of major malformations in children ex-
posed to PHT (N = 584) and children exposed to OXC (N = 203)
(Australian; Kaaja 2003; North American Register; see Analysis
41.1). This gave a non-significant RD (RD 0.00, 95% CI −0.02
to 0.03; I2 = 0%).
41.2 Neural tube malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.87, 95% CI 0.04 to 20.03; I2 = NA), with no differ-
ence in the number of neural tube malformations in children ex-
posed to PHT (N = 584) and children exposed to OXC (N = 203)
(Australian; Kaaja 2003; North American Register; see Analysis
41.2). This gave a non-significant RD (RD 0.00, 95% CI −0.01
to 0.02; I2 = 0%).
41.3 Cardiac malformations
Pooled results from three studies showed a non-significant out-
come (RR 2.32, 95% CI 0.30 to 18.27; I2 = 0%), with no dif-
ference in the number of cardiac malformations in children ex-
posed to PHT (N = 584) and children exposed to OXC (N = 203)
(Australian; Kaaja 2003; North American Register; see Analysis
41.3). This gave a non-significant RD (RD 0.01, 95% CI −0.01
to 0.03; I2 = 0%).
41.4 Oro-facial cleft/craniofacial malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.62, 95%CI 0.10 to 4.05; I2 = 0%), with no difference
in the number of oro-facial cleft/craniofacial malformations in
children exposed to PHT (N = 584) and children exposed toOXC
(N = 203) (Australian; Kaaja 2003; North American Register; see
Analysis 41.4). This gave a non-significant RD (RD −0.00, 95%
CI −0.02 to 0.02; I2 = 0%).
41.5 Skeletal/limb malformations
Pooled results from three studies showed a non-significant out-
come (RR 1.75, 95% CI 0.20 to 15.55; I2 = NA), with no differ-
ence in the number of skeletal/limbmalformations in children ex-
posed to PHT (N = 584) and children exposed to OXC (N = 203)
(Australian; Kaaja 2003; North American Register; see Analysis
41.5). This gave a non-significant RD (RD 0.00, 95% CI −0.01
to 0.02; I2 = 0%).
42 PHT versus PB
42.1 All major malformations
Pooled results from 19 studies showed a non-significant outcome
(RR 0.80, 95% CI 0.53 to 1.21; I2 = 0%), with no difference in
the number of major malformations in children exposed to PHT
(N = 978) and children exposed to PB (N = 505) (Al Bunyan
1999; Australian; Canger 1999; D’Souza 1990; Eroglu 2008;
Fairgrieve 2000; Froscher 1991; Kaaja 2003; Kaneko 1999; Kelly
1984; Kerala Pregnancy Registry; Koch 1992; Lindhout 1992;
Montreal Series; North American Register; Omtzigt 1992; Pardi
1982; Steegers-Theunissen 1994;Waters 1994; see Analysis 42.1).
This gave a non-significant RD (RD −0.01, 95% CI −0.04 to
0.02; I2 = 0%).
Samren 1997 reported nine case of major malformation in 141
(6%) PHT cases and five cases in 48 (10%) PB-exposed children.
42.2 Neural tube malformations
Pooled results from 10 studies showed a non-significant out-
come (RR 0.40, 95% CI 0.02 to 8.75; I2 = NA), with no dif-
ference in the number of neural tube malformations in children
exposed to PHT (N = 592) and children exposed to PB (N = 344)
(Australian; Canger 1999; D’Souza 1990; Eroglu 2008; Froscher
1991; Kerala Pregnancy Registry; Koch 1992; North American
Register; Omtzigt 1992; Pardi 1982; see Analysis 42.2). This gave
a non-significant RD (RD 0.00, 95% CI−0.02 to 0.02; I2 = 0%).
42.3 Cardiac malformations
Pooled results from 10 studies showed a significant outcome (RR
0.33, 95% CI 0.16 to 0.71; I2 = 0%), with children exposed to
PHT (N = 687) experiencing fewer cardiac malformations than
children exposed to PB (N = 378) (Australian; Canger 1999;
D’Souza 1990; Eroglu 2008; Froscher 1991; Kerala Pregnancy
Registry; Koch 1992; North American Register; Omtzigt 1992;
Pardi 1982; see Analysis 42.3). This gave a significant RD (RD
−0.03, 95% CI −0.05 to −0.00; I2 = 0%).
42.4 Oro-facial cleft/craniofacial malformations
Pooled results from 10 studies showed a significant outcome (RR
0.25, 95% CI 0.07 to 0.82; I2 = 0%), with children exposed
to PHT (N = 592) experiencing fewer oro-facial cleft/cranio-
facial malformations than children exposed to PB (N = 344)
(Australian; Canger 1999; D’Souza 1990; Eroglu 2008; Froscher
1991; Kerala Pregnancy Registry; Koch 1992; North American
Register; Omtzigt 1992; Pardi 1982; see Analysis 42.4). This gave
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a non-significant RD (RD −0.02, 95% CI −0.04 to 0.01; I2 =
0%).
42.5 Skeletal/limb malformations
Pooled results from 10 studies showed a non-significant outcome
(RR 1.45, 95% CI 0.40 to 5.22; I2 = 0%), with no difference
in the number of skeletal/limb malformations in children ex-
posed to PHT (N = 592) and children exposed to PB (N = 344)
(Australian; Canger 1999; D’Souza 1990; Eroglu 2008; Froscher
1991; Kerala Pregnancy Registry; Koch 1992; North American
Register; Omtzigt 1992; Pardi 1982; see Analysis 42.5). This gave
a non-significant RD (RD 0.01, 95%CI−0.01 to 0.03; I2 = 0%).
43 PHT versus TPM
43.1 All major malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.90, 95%CI 0.49 to 1.67; I2 = 0%), with no difference
in the number ofmajormalformations in children exposed toPHT
(N = 566) and children exposed to TPM (N = 473) (Australian;
North American Register; UK Register; see Analysis 43.1). This
gave a non-significant RD (RD −0.00, 95% CI −0.03 to 0.02; I
2 = 0%).
43.2 Neural tube malformations
Pooled results from three studies showed a non-significant out-
come (RR 3.00, 95% CI 0.13 to 71.70; I2 = NA), with no differ-
ence in the number of neural tube malformations in children ex-
posed to PHT (N = 542) and children exposed to TPM (N = 473)
(Australian; North American Register; UK Register; see Analysis
43.2). This gave a non-significant RD (RD 0.00, 95% CI −0.01
to 0.01; I2 = 0%).
43.3 Cardiac malformations
Pooled results from three studies showed a non-significant out-
come (RR 3.12, 95% CI 0.65 to 14.93; I2 = 0%), with no dif-
ference in the number of cardiac malformations in children ex-
posed to PHT (N = 542) and children exposed to TPM (N = 473)
(Australian; North American Register; UK Register; see Analysis
43.3). This gave a non-significant RD (RD 0.01, 95% CI −0.00
to 0.02; I2 = 0%).
43.4 Oro-facial cleft/craniofacial malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.37, 95% CI 0.10 to 1.42; I2 = 0%), with no dif-
ference in the number of oro-facial cleft/craniofacial malforma-
tions in children exposed to PHT (N = 542) and children exposed
to TPM (N = 473) (Australian; North American Register; UK
Register; see Analysis 43.4). This gave a non-significant RD (RD
−0.01, 95% CI −0.02 to 0.00; I2 = 0%).
43.5 Skeletal/limb malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.69, 95% CI 0.19 to 2.55; I2 = NA), with no dif-
ference in the number of skeletal/limb malformations in children
exposed to PHT (N = 542) and children exposed to TPM (N
= 473) (Australian; North American Register; UK Register; see
Analysis 43.5). This gave a non-significant RD (RD −0.00, 95%
CI −0.02 to 0.01; I2 = 0%).
44 PB versus OXC
44.1 All major malformations
Pooled results from four studies showed a non-significant outcome
(RR 2.52, 95% CI 0.98 to 6.43; I2 = 21%), with no difference
in the number of major malformations in children exposed to PB
(N = 214) and children exposed to OXC (N = 238) (Australian;
Kaaja 2003; Meischenguiser 2004; North American Register; see
Analysis 44.1). This gave a non-significant RD (RD 0.03, 95%
CI −0.01 to 0.08; I2 = 0%).
44.2 Neural tube malformations
We we unable to estimate pooled results from three studies due
to there being no reported neural tube malformations in children
exposed to PB (N = 209) or children exposed to OXC (N = 229)
(Australian; Meischenguiser 2004; North American Register; see
Analysis 44.2). RD was calculable, and this gave a non-significant
result (RD 0.00, 95% CI −0.02 to 0.02; I2 = 0%).
44.3 Cardiac malformations
Pooled results from three studies showed a significant outcome (RR
11.77, 95% CI 1.24 to 111.80; I2 = 0%), with children exposed
to PB (N = 209) experiencing more cardiac malformations than
children exposed to OXC (N = 229) (Australian; Meischenguiser
2004; North American Register; see Analysis 44.3). This gave a
significant RD (RD 0.03, 95% CI 0.00* to 0.06; I2 = 0%).
44.4 Oro-facial cleft/craniofacial malformations
Pooled results from three studies showed a non-significant out-
come (RR 3.66, 95% CI 0.41 to 32.43; I2 = NA), with no differ-
ence in the number of oro-facial cleft/craniofacial malformations
in children exposed to PB (N= 209) and children exposed toOXC
(N = 229) (Australian; Meischenguiser 2004; North American
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Register; see Analysis 44.4). This gave a non-significant RD (RD
0.01, 95% CI −0.01 to 0.04; I2 = 0%).
44.5 Skeletal/limb malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.91, 95% CI 0.06 to 14.52; I2 = NA), with no dif-
ference in the number of skeletal/limb malformations in children
exposed to PB (N = 209) and children exposed to OXC (N = 229)
(Australian; Meischenguiser 2004; North American Register; see
Analysis 44.5). This gave a non-significant RD (RD −0.00, 95%
CI −0.02 to 0.02; I2 = 0%).
45 PB versus TPM
45.1 All major malformations
Pooled results from two studies showed a non-significant outcome
(RR 1.36, 95% CI 0.65 to 2.84; I2 = 0%), with no difference in
the number of major malformations in children exposed to PB
(N = 204) and children exposed to TPM (N = 403) (Australian;
North American Register; see Analysis 45.1). This gave a non-
significant RD (RD 0.01, 95% CI −0.03 to 0.05; I2 = 0%).
45.2 Neural tube malformations
We could not estimate pooled results from two studies due to
there being no reported neural tube malformations in children
exposed to PB (N = 204) and children exposed to TPM (N = 403)
(Australian; North American Register; see Analysis 45.2). This
gave a non-significant RD (RD 0.00, 95% CI −0.01 to 0.01; I2
= 0%).
45.3 Cardiac malformations
Pooled results from two studies showed a significant outcome (RR
9.02, 95% CI 1.06 to 76.67; I2 = NA), with children exposed
to PB (N = 204) experiencing more cardiac malformations than
children exposed to TPM (N = 403) (Australian; North American
Register; see Analysis 45.3). This gave a non-significant RD (RD
0.02, 95% CI −0.00 to 0.05; I2 = 0%).
45.4 Oro-facial cleft/craniofacial malformations
Pooled results from two studies showed a non-significant outcome
(RR1.44, 95%CI 0.39 to 5.31; I2 =NA), with no difference in the
number of oro-facial cleft/craniofacial malformations in children
exposed to PB (N = 204) and children exposed to TPM (N = 403)
(Australian; North American Register; see Analysis 45.4). This
gave a non-significant RD (RD 0.01, 95% CI −0.02 to 0.03; I2
= 0%).
45.5 Skeletal/limb malformations
Pooled results from two studies showed a non-significant outcome
(RR 0.36, 95% CI 0.04 to 3.07; I2 = NA), with no difference in
the number of skeletal/limbmalformations in children exposed to
PB (N=204) and children exposed toTPM(N= 403) (Australian;
North American Register; see Analysis 45.5). This gave a non-
significant RD (RD −0.01, 95% CI −0.03 to 0.01; I2 = 0%).
46 VPA versus GBP
46.1 All major malformations
Pooled results from three studies showed a significant outcome
(RR 6.21, 95% CI 1.91 to 20.23; I2 = 0%), with children exposed
to VPA (N = 1814) experiencing more major malformations than
children exposed to GBP (N = 190) (Australian; North American
Register; UK Register; see Analysis 46.1). This gave a significant
RD (RD 0.08, 95% CI 0.05 to 0.11; I2 = 39%).
46.2 Neural tube malformations
Data from one study showed a non-significant outcome (RR 0.83,
95%CI 0.05 to 13.81; I2 =NA), with no difference in the number
of neural tube malformations in children exposed to VPA (N =
271) and children exposed to GBP (N = 14) (Australian; see
Analysis 46.2). This gave a non-significant RD (RD 0.03, 95%
CI −0.07 to 0.12; I2 = NA).
46.3 Cardiac malformations
Results from one study showed a non-significant outcome (RR
1.16, 95% CI 0.07 to 18.84; I2 = NA), with no difference in the
number of cardiac malformations in children exposed to VPA (N
= 271) and children exposed to GBP (N = 14) (Australian; see
Analysis 46.3). This gave a non-significant RD (RD 0.04, 95%
CI −0.06 to 0.13; I2 = NA).
46.4 Oro-facial cleft/craniofacial malformations
Data from one study showed a non-significant outcome (RR 1.38,
95% CI 0.09 to 22.19; I2 = NA), with no difference in the num-
ber of oro-facial cleft/craniofacial malformations in children ex-
posed to VPA (N = 271) and children exposed to GBP (N = 14)
(Australian; see Analysis 46.4). This gave a non-significant RD
(RD 0.04, 95% CI −0.05 to 0.14; I2 = NA).
46.5 Skeletal/limb malformations
One study reported a non-significant outcome (RR 0.72, 95%
CI 0.04 to 12.14; I2 = NA), with no difference in the number
of skeletal/limb malformations in children exposed to VPA (N
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= 271) and children exposed to GBP (N = 14) (Australian; see
Analysis 46.5). This gave a non-significant RD (RD 0.02, 95%
CI −0.07 to 0.11; I2 = NA).
47 VPA versus LEV
47.1 All major malformations
Pooled results from three studies showed a significant outcome
(RR5.82, 95%CI 3.13 to 10.81; I2 = 13%), with children exposed
to VPA (N = 1814) experiencing more major malformations than
children exposed to LEV (N = 817) (Australian; North American
Register; UK Register; see Analysis 47.1). This gave a significant
RD (RD 0.07, 95% CI 0.05 to 0.09; I2 = 60%). Due to high het-
erogeneity, we undertook a random-effects analysis, which upheld
the significant result (RD (RE) 0.08, 95% CI 0.05 to 0.10; I2 =
60%).
47.2 Neural tube malformations
Pooled results from three studies showed a significant outcome
(RR 5.28, 95% CI 1.17 to 23.83; I2 = 0%), with children exposed
to VPA (N = 1814) experiencing more neural tube malforma-
tions than children exposed to LEV (N = 817) (Australian; North
American Register; UK Register; see Analysis 47.2). This gave a
significant RD (RD 0.01, 95% CI 0.01 to 0.02; I2 = 0%).
47.3 Cardiac malformations
Pooled results from three studies showed a significant outcome
(RR 5.79, 95% CI 1.67 to 20.16; I2 = 0%), with children exposed
to VPA (N= 1814) experiencingmore cardiacmalformations than
children exposed to LEV (N = 817) (Australian; North American
Register; UK Register; see Analysis 47.3). This gave a significant
RD (RD 0.02, 95% CI 0.01 to 0.03; I2 = 15%).
47.4 Oro-facial cleft/craniofacial malformations
Pooled results from three studies showed a significant outcome
(RR 5.34, 95% CI 1.33 to 21.39; I2 = 0%), with children ex-
posed to VPA (N = 1814) experiencing more oro-facial cleft/cran-
iofacial malformations than children exposed to LEV (N = 817)
(Australian; North American Register; UK Register; see Analysis
47.4). This gave a significant RD (RD 0.01, 95% CI 0.01 to 0.02;
I2 = 0%).
47.5 Skeletal/limb malformations
Pooled results from three studies showed a significant outcome
(RR 6.45, 95% CI 1.33 to 31.16; I2 = 0%), with children exposed
to VPA (N = 1814) experiencing more skeletal/limb malforma-
tions than children exposed to LEV (N = 817) (Australian; North
American Register; UK Register; see Analysis 47.5). This gave a
significant RD (RD 0.01, 95% CI 0.01 to 0.02; I2 = 6%).
48 VPA versus LTG
48.1 All major malformations
Pooled results from seven studies showed a significant outcome
(RR 3.56, 95% CI 2.77 to 4.58; I2 = 0%), with children ex-
posed toVPA (N=2021) experiencingmoremajormalformations
than children exposed to LTG (N = 4164) (Australian; Cassina
2013; Martinez Ferri 2009; Mawer 2010; Meador 2006; North
American Register; UK Register; see Analysis 48.1). This gave a
significant RD (RD 0.06, 95% CI 0.05 to 0.07; I2 = 57%). Due
to high heterogeneity, we undertook a random-effects analysis,
which upheld the significant result (RD (RE) 0.08, 95% CI 0.05
to 0.11; I2 = 57%).
In the EURAP data, rates of MCM for children exposed to VPA
were: 24/431 (5.6%) for exposures < 700 mg/d, 50/480 (10.4%)
for exposures of 700 to < 1500 mg/d and 24/99 (24.2%) for
exposures > 1500 mg/d. In comparison, the rates of MCM for
children exposed to LTG were: 17/836 (2.0%) for exposures <
300 mg/d and 20/444 (4.5%) for exposures > 300 mg/d. Children
exposed to < 700 mg/d (P = 0.0019), 700 to < 1500 mg/d (P <
0.0001) and those at doses > 1500 mg/d all were at an increased
risk of having a MCM compared with children exposed to < 300
mg of LTG (P = 0.0012). There was no comparison to higher
doses of LTG.
48.2 Neural tube malformations
Pooled results from six studies showed a significant outcome (RR
9.09, 95% CI 3.56 to 23.22; I2 = 0%), with children exposed to
VPA (N = 1996) experiencing more neural tube malformations
than children exposed to LTG (N = 4155) (Australian; Cassina
2013; Martinez Ferri 2009; Meador 2006; North American
Register; UK Register; see Analysis 48.2). This gave a significant
RD (RD 0.01, 95% CI 0.01 to 0.02; I2 = 0%).
In the EURAP data, the prevalence of neural tube malformations
in those exposed to VPA and LTG was: VPA < 700 mg/d, 2/431
(1%); VPA 700 to < 1500 mg/d, 7/480 (2%) and VPA > 1500
mg/d, 2/99 (2%); LTG < 300, 0/836 (0%); LTG > 300 mg/d, 0/
444 (0%).
48.3 Cardiac malformations
Pooled results from six studies showed a significant outcome (RR
4.07, 95% CI 2.33 to 7.09; I2 = 0%), with children exposed to
VPA (N = 1996) experiencing more cardiac malformations than
children exposed to LTG (N = 4155) (Australian; Cassina 2013;
Martinez Ferri 2009;Meador 2006;NorthAmericanRegister; UK
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Register; see Analysis 48.3). This gave a significant RD (RD 0.02,
95% CI 0.01 to 0.02; I2 = 46%).
In the EURAP data, the prevalence of cardiac malformations in
those exposed to VPA and LTG was: VPA < 700 mg/d, 5/431
(1%); VPA 700 to < 1500 mg/d, 10/480 (2%) and VPA > 1500
mg/d, 7/99 (7%); LTG < 300, 3/836 (0%); LTG > 300 mg/d, 5/
444 (1%).
48.4 Oro-facial cleft/craniofacial malformations
Pooled results from six studies showed a significant outcome (RR
4.13, 95% CI 2.16 to 7.91; I2 = 0%), with children exposed
to VPA (N = 1996) experiencing more oro-facial cleft/craniofa-
cial malformations than children exposed to LTG (N = 4155)
(Australian; Cassina 2013; Martinez Ferri 2009; Meador 2006;
North American Register; UK Register; see Analysis 48.4). This
gave a significant RD (RD 0.01, 95% CI 0.01 to 0.02; I2 = 0%).
In the EURAP data, the prevalence of oro-facial cleft malforma-
tions in those exposed to VPA and LTG was: VPA < 700 mg/d,
3/431 (1%); VPA 700 to < 1500 mg/d, 1/480 (0%) and VPA >
1500 mg/d, 0/99 (0%); LTG < 300, 0/836 (0%); LTG > 300 mg/
d, 2/444 (1%).
48.5 Skeletal/limb malformations
Pooled results from six studies showed a significant outcome (RR
7.17, 95% CI 2.99 to 17.18; I2 = 0%), with children exposed to
VPA (N = 1996) experiencing more skeletal/limb malformations
than children exposed to LTG (N = 4155) (Australian; Cassina
2013; Martinez Ferri 2009; Meador 2006; North American
Register; UK Register; see Analysis 48.5). This gave a significant
RD (RD 0.01, 95% CI 0.01 to 0.02; I2 = 0%).
49 VPA versus TPM
49.1 All major malformations
Pooled results from three studies showed a significant outcome
(RR 2.35, 95% CI 1.40 to 3.95; I2 = 0%), with children exposed
to VPA (N = 1814) experiencing more major malformations than
children exposed to TPM (N = 473) (Australian; North American
Register; UK Register; see Analysis 49.1). This gave a significant
RD (RD 0.05, 95% CI 0.03 to 0.08; I2 = 62%). Due to high het-
erogeneity, we undertook a random-effects analysis, which upheld
the significant result (RD (RE) 0.06, 95% CI 0.01 to 0.10; I2 =
62%).
49.2 Neural tube malformations
Pooled results from three studies showed a non-significant out-
come (RR 3.67, 95% CI 0.79 to 17.08; I2 = 0%), with no dif-
ference in the number of neural tube malformations in children
exposed to VPA (N = 1814) and children exposed to TPM (N
= 473) (Australian; North American Register; UK Register; see
Analysis 49.2). However, this gave a significant RD (RD 0.01,
95% CI 0.00* to 0.02; I2 = 0%).
49.3 Cardiac malformations
Pooled results from three studies showed a significant outcome
(RR 4.73, 95% CI 1.21 to 18.49; I2 = 0%), with children exposed
to VPA (N= 1814) experiencingmore cardiac malformations than
children exposed to TPM (N = 473) (Australian; North American
Register; UK Register; see Analysis 49.3). This gave a significant
RD (RD 0.02, 95% CI 0.01 to 0.03; I2 = 0%).
49.4 Oro-facial cleft/craniofacial malformations
Pooled results from three studies showed a non-significant out-
come (RR 0.98, 95% CI 0.40 to 2.40; I2 = 26%), with no dif-
ference in the number of oro-facial cleft/craniofacial malforma-
tions in children exposed to VPA (N = 1814) and children ex-
posed to TPM (N = 473) (Australian; North American Register;
UK Register; see Analysis 49.4). This gave a non-significant RD
(RD 0.00, 95% CI −0.01 to 0.02; I2 = 64%). Due to high het-
erogeneity, we undertook a random-effects analysis, which upheld
the non-significant result (RD (RE) 0.01, 95% CI−0.02 to 0.04)
49.5 Skeletal/limb malformations
Pooled results from three studies showed a non-significant out-
come (RR 1.26, 95%CI 0.44 to 3.61; I2 = 0%), with no difference
in the number of skeletal/limbmalformations in children exposed
to VPA (N = 1814) and children exposed to TPM (N = 473)
(Australian; North American Register; UK Register; see Analysis
49.5). This gave a non-significant RD (RD 0.01, 95% CI −0.01
to 0.02; I2 = 0%).
50 VPA versus OXC
50.1 All major malformations
Pooled results from four studies showed a significant outcome
(RR 3.71, 95% CI 1.65 to 8.33; I2 = 18%), with children ex-
posed to VPA (N = 676) experiencing more major malforma-
tions than children exposed to OXC (N = 238) (Australian;
Kaaja 2003; Meischenguiser 2004; North American Register; see
Analysis 50.1). This gave a significant RD (RD 0.08, 95%CI 0.04
to 0.11; I2 = 3%).
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50.2 Neural tube malformations
Pooled results from four studies showed a non-significant outcome
(RR1.89, 95%CI 0.39 to 9.07; I2 = 0%), with no difference in the
number of neural tube malformations in children exposed to VPA
(N = 676) and children exposed to OXC (N = 238) (Australian;
Kaaja 2003; Meischenguiser 2004; North American Register; see
Analysis 50.2). This gave a non-significant RD (RD 0.01, 95%
CI −0.00 to 0.03; I2 = 0%).
50.3 Cardiac malformations
Pooled results from four studies showed a non-significant outcome
(RR 3.41, 95% CI 0.87 to 13.37; I2 = 0%), with no difference in
the number of cardiac malformations in children exposed to VPA
(N = 676) and children exposed to OXC (N = 238) (Australian;
Kaaja 2003; Meischenguiser 2004; North American Register; see
Analysis 50.3). However, this gave a significant RD (RD 0.03,
95% CI 0.01 to 0.05; I2 = 0%).
50.4 Oro-facial cleft/craniofacial malformations
Pooled results from four studies showed a non-significant outcome
(RR 2.17, 95% CI 0.63 to 7.47; I2 = 0%), with no difference
in the number of oro-facial cleft/craniofacial malformations in
children exposed to VPA (N = 676) and children exposed to OXC
(N = 238) (Australian; Kaaja 2003; Meischenguiser 2004; North
American Register; see Analysis 50.4). This gave a non-significant
RD (RD 0.02, 95% CI −0.00 to 0.04; I2 = 8%).
50.5 Skeletal/limb malformations
Pooled results from four studies showed a non-significant outcome
(RR 1.49, 95% CI 0.36 to 6.22; I2 = 0%), with no difference in
the number of skeletal/limb malformations in children exposed
to VPA (N = 676) and children exposed to OXC (N = 238) (
Australian; Kaaja 2003; Meischenguiser 2004; North American
Register; see Analysis 50.5). This gave a non-significant RD (RD
0.01, 95% CI −0.01 to 0.03; I2 = 0%).
51 VPA versus PB
51.1 All major malformations
Pooled results from 20 studies showed a significant outcome (RR
1.59, 95% CI 1.11 to 2.29; I2 = 0%), with children exposed to
VPA (N = 1137) experiencing more major malformations than
children exposed to PB (N = 626) (Al Bunyan 1999; Australian;
Canger 1999; Cassina 2013; Eroglu 2008; Froscher 1991; Kaaja
2003; Kaneko 1999; Kelly 1984; Kerala Pregnancy Registry; Koch
1992; Lindhout 1992;Martinez Ferri 2009;Meischenguiser 2004;
Montreal Series; North American Register; Omtzigt 1992; Pardi
1982; Steegers-Theunissen 1994; Tanganelli 1992; see Analysis
51.1). This gave a significant RD (RD 0.04, 95% CI 0.01 to 0.08;
I2 = 0%).
In the EURAP data, the prevalence of major malformation be-
tween these two groups for children exposed to VPA were: 24/431
(5.6%) for exposures < 700 mg/d, 50/480 (10.4%) for exposures
of 700 to <1500 mg/d and 24/99 (24.2%) for exposures > 1500
mg/d. In comparison, the rates for children exposed to PB were:
9/166 (5.4%) for exposures < 150 mg/d and 7/51 (13.7%) for
exposures > 150 mg/d. Samren 1997 reported six cases of major
malformation out of 184 (9%) VPA-exposed children and five
cases from 48 (10%) PB exposed children.
51.2 Neural tube malformations
Pooled results from 11 studies showed a significant outcome
(RR 4.56, 95% CI 1.69 to 12.33; I2 = 0%), with children ex-
posed to VPA (N = 813) experiencing more neural tube mal-
formations than children exposed to PB (N = 412) (Australian;
Canger 1999; Cassina 2013; Eroglu 2008; Froscher 1991; Kerala
Pregnancy Registry; Koch 1992; Meischenguiser 2004; North
American Register; Omtzigt 1992; Pardi 1982; see Analysis 51.2).
This gave a significant RD (RD 0.04, 95% CI 0.01 to 0.06; I2 =
47%).
In the EURAP data, the prevalence of neural tube malformations
in those exposed to VPA and PB were: VPA < 700 mg/d, 2/431
(1%); VPA 700 to < 1500 mg/d, 7/480 (2%) and VPA > 1500
mg/d, 2/99 (2%); PB < 150 mg/d, 1/166 (1%); PB > 150 mg/d,
0/51 (0%).
51.3 Cardiac malformations
Pooled results from 11 studies showed a non-significant outcome
(RR 0.76, 95% CI 0.42 to 1.38; I2 = 0%), with no difference in
the number of cardiac malformations in children exposed to VPA
(N = 878) and children exposed to PB (N = 446) (Australian;
Canger 1999; Cassina 2013; Eroglu 2008; Froscher 1991; Kerala
Pregnancy Registry; Koch 1992; Meischenguiser 2004; North
American Register; Omtzigt 1992; Pardi 1982; see Analysis 51.3).
This gave a non-significant RD (RD −0.01, 95% CI −0.03 to
0.02; I2 = 0%).
In the EURAP data, the prevalence of cardiac malformations in
those exposed to VPA and PBwere: VPA < 700mg/d, 5/431 (1%);
VPA 700 to < 1500 mg/d, 10/480 (2%) and VPA > 1500 mg/d,
7/99 (7%); PB < 150 mg/d, 2/166 (1%); PB > 150 mg/d, 4/51
(8%).
51.4 Oro-facial cleft/craniofacial malformations
Pooled results from 11 studies showed a non-significant outcome
(RR0.54, 95%CI 0.22 to 1.33; I2 = 0%), with no difference in the
number of oro-facial cleft/craniofacial malformations in children
exposed to VPA (N = 813) and children exposed to PB (N = 412)
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(Australian; Canger 1999; Cassina 2013; Eroglu 2008; Froscher
1991; Kerala Pregnancy Registry; Koch 1992; Meischenguiser
2004; North American Register; Omtzigt 1992; Pardi 1982; see
Analysis 51.4). This gave a non-significant RD (RD −0.03, 95%
CI −0.03 to 0.02; I2 = 0%).
In the EURAP data, the prevalence of oro-facial cleft malforma-
tions in those exposed to VPA and PB was: VPA < 700 mg/d, 3/
431 (1%); VPA 700 to <1500 mg/d, 1/480 (0%) and VPA > 1500
mg/d, 0/99 (0%); PB < 150 mg/d, 0/166 (0%); PB > 150 mg/d,
1/51 (2%).
51.5 Skeletal/limb malformations
Pooled results from 11 studies showed a non-significant outcome
(RR 1.98, 95% CI 0.79 to 4.98; I2 = 0%), with no difference in
the number of skeletal/limbmalformations in children exposed to
VPA (N = 813) and children exposed to PB (N = 412) (Australian;
Canger 1999; Cassina 2013; Eroglu 2008; Froscher 1991; Kerala
Pregnancy Registry; Koch 1992; Meischenguiser 2004; North
American Register; Omtzigt 1992; Pardi 1982; see Analysis 51.5).
This gave a non-significant RD (RD 0.02, 95%CI−0.00 to 0.04;
I2 = 0%).
52 VPA versus PHT
52.1 All major malformations
Pooled results from 21 studies showed a significant outcome (RR
2.00, 95%CI1.48 to 2.71; I2 =0%),with children exposed toVPA
(N = 2319) experiencingmoremajor malformations than children
exposed to PHT (N = 1137) (Al Bunyan 1999; Arulmozhi 2006;
Australian; Canger 1999; Eroglu 2008; Fairgrieve 2000; Froscher
1991; Garza-Morales 1996; Kaaja 2003; Kaneko 1999; Kelly
1984; Kerala Pregnancy Registry; Koch 1992; Lindhout 1992;
Mawer 2010; Meador 2006; Montreal Series; North American
Register; Omtzigt 1992; Pardi 1982; Steegers-Theunissen 1994;
UK Register; see Analysis 52.1). This gave a significant RD (RD
0.05, 95% CI 0.03 to 0.08; I2 = 0%).
Samren 1997 reported six cases of major malformation in 184
(9%) children exposed toVPA andnine in 141 (6%)PHT-exposed
children.
52.2 Neural tube malformations
Pooled results from 13 studies showed a significant outcome
(RR 4.47, 95% CI 1.79 to 11.17; I2 = 0%), with children ex-
posed to VPA (N = 2102) experiencing more neural tube mal-
formations than children exposed to PHT (N = 859) (Australian;
Canger 1999; Eroglu 2008; Froscher 1991; Garza-Morales 1996;
Kaaja 2003; Kerala Pregnancy Registry; Koch 1992; Meador
2006; North American Register; Omtzigt 1992; Pardi 1982; UK
Register; see Analysis 52.2). This gave a significant RD (RD 0.02,
95% CI 0.01 to 0.04; I2 = 24%).
52.3 Cardiac malformations
Pooled results from 13 studies showed a significant outcome (RR
2.93, 95% CI 1.50 to 5.72; I2 = 0%), with children exposed to
VPA (N = 2167) experiencing more cardiac malformations than
children exposed to PHT (N = 954) (Australian; Canger 1999;
Eroglu 2008; Froscher 1991; Garza-Morales 1996; Kaaja 2003;
Kerala Pregnancy Registry; Koch 1992; Meador 2006; North
American Register; Omtzigt 1992; Pardi 1982; UK Register; see
Analysis 52.3). This gave a significant RD (RD 0.02, 95%CI 0.01
to 0.04; I2 = 1%).
52.4 Oro-facial cleft/craniofacial malformations
Pooled results from 13 studies showed a non-significant outcome
(RR2.37, 95%CI 0.95 to 5.96; I2 = 0%), with no difference in the
number of oro-facial cleft/craniofacial malformations in children
exposed to VPA (N = 2102) and children exposed to PHT (N
= 859) (Australian; Canger 1999; Eroglu 2008; Froscher 1991;
Garza-Morales 1996; Kaaja 2003; Kerala Pregnancy Registry;
Koch 1992; Meador 2006; North American Register; Omtzigt
1992; Pardi 1982; UK Register; see Analysis 52.4). This gave a
non-significant RD (RD 0.01, 95% CI −0.00 to 0.02; I2 = 0%).
52.5 Skeletal/limb malformations
Pooled results from 13 studies showed a non-significant outcome
(RR 1.98, 95% CI 0.93 to 4.21; I2 = 0%), with no difference in
the number of skeletal/limb malformations in children exposed
to VPA (N = 2102) and children exposed to PHT (N = 859)
(Australian; Canger 1999; Eroglu 2008; Froscher 1991; Garza-
Morales 1996;Kaaja 2003;KeralaPregnancyRegistry; Koch1992;
Meador 2006; North American Register; Omtzigt 1992; Pardi
1982; UK Register; see Analysis 52.5). This gave a significant RD
(RD 0.01, 95% CI 0.00* to 0.03; I2 = 0%).
53 LTG versus PRM
53.1 All major malformations
No included studies reported data on this outcome.
53.2 Neural tube malformations
No included studies reported data on this outcome.
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53.3 Cardiac malformations
No included studies reported data on this outcome.
53.4 Oro-facial cleft/craniofacial malformations
No included studies reported data on this outcome.
53.5 Skeletal/limb malformations
No included studies reported data on this outcome.
54 PHT versus PRM
54.1 All major malformations
Pooled results from five studies showed a non-significant outcome
(RR 0.82, 95% CI 0.40 to 1.68; I2 = 29%), with no difference in
the number of major malformations in children exposed to PHT
(N = 316) and children exposed to PRM (N = 101) (Canger 1999;
Kaaja 2003; Kaneko 1999; Koch 1992; Pardi 1982; see Analysis
54.1). This gave a non-significant RD (RD−0.02, 95%CI−0.09
to 0.06; I2 = 0%).
Samren 1997 showed nine cases of major malformation in 141
PHT (6%) exposed children and four cases in 43 (9%) PRM-
exposed children.
54.2 Neural tube malformations
We could not estimate pooled results from two studies due to there
being no reported neural tube malformations in children exposed
to PHT (N = 36) or children exposed to PRM (N = 39) (Canger
1999; Pardi 1982; see Analysis 54.2). RD was calculable, and this
gave a non-significant result (RD 0.00, 95% CI −0.07 to 0.07; I
2 = 0%).
54.3 Cardiac malformations
Pooled results from two studies showed a non-significant outcome
(RR 0.38, 95% CI 0.02 to 8.88; I2 = NA), with no difference in
the number of cardiac malformations in children exposed to PHT
(N = 36) and children exposed to PRM (N = 39) (Canger 1999;
Pardi 1982; see Analysis 54.3). This gave a non-significant RD
(RD −0.03, 95% CI −0.11 to 0.06; I2 = 0%).
54.4 Oro-facial cleft/craniofacial malformations
We could not estimate pooled results from two studies due to there
being no reported oro-facial cleft/craniofacial malformations in
children exposed to PHT (N = 36) or children exposed to PRM
(N = 39) (Canger 1999; Pardi 1982; see Analysis 54.4). RD was
calculable, and this gave a non-significant result (RD 0.00, 95%
CI −0.07 to 0.07; I2 = 0%).
54.5 Skeletal/limb malformations
Pooled results from two studies showed a non-significant outcome
(RR 3.38, 95% CI 0.14 to 79.95; I2 = NA), with no difference in
the number of skeletal/limbmalformations in children exposed to
PHT (N = 36) and children exposed to PRM (N = 39) (Canger
1999; Pardi 1982; see Analysis 54.5). This gave a non-significant
RD (RD 0.03, 95% CI −0.06 to 0.12; I2 = 0%).
55 PB versus PRM
55.1 All major malformations
Pooled results from six studies showed a non-significant outcome
(RR 0.50, 95% CI 0.21 to 1.16; I2 = 0%), with no difference in
the number of major malformations in children exposed to PB (N
= 241) and children exposed to PRM (N = 110) (Canger 1999;
Delmiš 1991; Kaaja 2003; Kaneko 1999; Koch 1992; Pardi 1982;
see Analysis 55.1). This gave a non-significant RD (RD −0.05,
95% CI −0.12 to 0.02; I2 = 0%).
55.2 Neural tube malformations
We could not estimate pooled results from two studies due to there
being no reported neural tube malformations in children exposed
to PB (N = 95) or children exposed to PRM (N = 39) (Canger
1999; Pardi 1982; see Analysis 55.2). RD was calculable, and this
gave a non-significant result (RD 0.00, 95% CI −0.05 to 0.05; I
2 = 0%).
55.3 Cardiac malformations
Pooled results from two studies showed a non-significant outcome
(RR 0.42, 95% CI 0.03 to 6.55; I2 = NA), with no difference in
the number of cardiac malformations in children exposed to PB
(N = 95) and children exposed to PRM (N = 39) (Canger 1999;
Pardi 1982; see Analysis 55.3). This gave a non-significant RD
(RD −0.01, 95% CI −0.08 to 0.05; I2 = 0%).
55.4 Oro-facial cleft/craniofacial malformations
We could not estimate pooled results from two studies due to there
being no reported oro-facial cleft/craniofacial malformations in
children exposed to PB (N = 95) or children exposed to PRM
(N = 39) (Canger 1999; Pardi 1982; see Analysis 55.4). RD was
calculable, and this gave a non-significant result (RD 0.00, 95%
CI −0.05 to 0.05; I2 = 0%).
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55.5 Skeletal/limb malformations
Pooled results from two studies showed a non-significant outcome
(RR 1.29, 95% CI 0.05 to 30.82; I2 = NA), with no difference in
the number of cardiac malformations in children exposed to PB
(N = 95) and children exposed to PRM (N = 39) (Canger 1999;
Pardi 1982; see Analysis 55.5). This gave a non-significant RD
(RD 0.01, 95% CI −0.05 to 0.07; I2 = 0%).
56 LTG versus ZNS
56.1 All major malformations
Data from one study showed a non-significant outcome (RR 3.67,
95%CI 0.23 to 59.46; I2 =NA), with no difference in the number
of major malformations in children exposed to LTG (N = 1562)
and children exposed to ZNS (N = 90) (North American Register;
see Analysis 56.1). This gave a significant RD (RD 0.02, 95% CI
0.00* to 0.04; I2 = NA).
56.2 Neural tube malformations
No included studies reported data on this outcome.
56.3 Cardiac malformations
No included studies reported data on this outcome.
56.4 Oro-facial cleft/craniofacial malformations
No included studies reported data on this outcome.
56.5 Skeletal/limb malformations
No included studies reported data on this outcome.
57 OXC versus PRM
57.1 All major malformations
One study reported a non-significant outcome (RR 0.67, 95% CI
0.05 to 8.73; I2 = NA), with no difference in the number of major
malformations in children exposed to OXC (N = 9) and children
exposed to PRM (N = 6) (Kaaja 2003; see Analysis 57.1). This
gave a non-significant RD (RD −0.06, 95% CI −0.42 to 0.31; I
2 = NA).
57.2 Neural tube malformations
No included studies reported data on this outcome.
57.3 Cardiac malformations
No included studies reported data on this outcome.
57.4 Oro-facial cleft/craniofacial malformations
No included studies reported data on this outcome.
57.5 Skeletal/limb malformations
No included studies reported data on this outcome.
58 OXC versus TPM
58.1 All major malformations
Pooled results from two studies showed a non-significant outcome
(RR 0.57, 95% CI 0.20 to 1.57; I2 = 0%), with no difference in
the number of major malformations in children exposed to OXC
(N = 194) and children exposed to TPM (N = 403) (Australian;
North American Register; see Analysis 58.1). This gave a non-
significant RD (RD −0.02, 95% CI −0.05 to 0.01; I2 = 0%).
58.2 Neural tube malformations
We could not estimate pooled results from two studies due to
there being no reported neural tube malformations in children
exposed toOXC (N= 194) or children exposed to TPM (N = 403)
(Australian; North American Register; see Analysis 58.2). RD was
calculable, and this gave a non-significant result (RD 0.00, 95%
CI −0.01 to 0.01; I2 = 0%).
58.3 Cardiac malformations
Pooled results from two studies showed a non-significant outcome
(RR 0.66, 95% CI 0.03 to 16.02; I2 = NA), with no difference in
the number of cardiac malformations in children exposed to OXC
(N = 194) and children exposed to TPM (N = 403) (Australian;
North American Register; see Analysis 58.3). This gave a non-
significant RD (RD −0.00, 95% CI −0.02 to 0.01; I2 = 0%).
58.4 Oro-facial cleft/craniofacial malformations
Pooled results from two studies showed a non-significant outcome
(RR0.39, 95%CI 0.05 to 3.35, I2 =NA), with no difference in the
number of oro-facial cleft/craniofacial malformations in children
exposed to OXC (N = 194) and children exposed to TPM (N
= 403) (Australian; North American Register; see Analysis 58.4).
This gave a non-significant RD (RD −0.01, 95% CI −0.03 to
0.01; I2 = 0%).
49Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
58.5 Skeletal/limb malformations
Pooled results from two studies (Australian; North American
Register) showed a non-significant outcome (RR 0.39, 95% CI
0.05 to 3.35; I2 = NA), with no difference in the number of skele-
tal/limbmalformations in children exposed toOXC (N=194) and
children exposed to TPM (N = 403) (Australian; North American
Register; see Analysis 58.5). This gave a non-significant RD (RD
−0.01, 95% CI −0.03 to 0.01; I2 = 0%).
59 OXC versus ZNS
59.1 All major malformations
Data from one study showed a non-significant outcome (RR 4.48,
95%CI 0.24 to 82.23; I2 =NA), with no difference in the number
of major malformations in children exposed to OXC (N = 182)
and children exposed to ZNS (N = 90) (North American Register;
see Analysis 59.1). This gave a non-significant RD (RD 0.02, 95%
CI −0.01 to 0.05; I2 = NA).
59.2 Neural tube malformations
No included studies reported data on this outcome.
59.3 Cardiac malformations
No included studies reported data on this outcome.
59.4 Oro-facial cleft/craniofacial malformations
No included studies reported data on this outcome.
59.5 Skeletal/limb malformations
No included studies reported data on this outcome.
60 PB versus ZNS
60.1 All major malformations
Data from one study showed a non-significant outcome (RR
10.46, 95% CI 0.62 to 175.67; I2 = NA), with no difference in
the number of major malformations in children exposed to PB (N
= 199) and children exposed to ZNS (N = 90) (North American
Register; see Analysis 60.1). This gave a significant RD (RD 0.06,
95% CI 0.02 to 0.09; I2 = NA).
60.2 Neural tube malformations
No included studies reported data on this outcome.
60.3 Cardiac malformations
No included studies reported data on this outcome.
60.4 Oro-facial cleft/craniofacial malformations
No included studies reported data on this outcome.
60.5 Skeletal/limb malformations
No included studies reported data on this outcome.
61 PHT versus ZNS
61.1 All major malformations
Data from one study showed a non-significant outcome (RR 5.46,
95%CI 0.33 to 91.31; I2 =NA), with no difference in the number
of major malformations in children exposed to PHT (N = 416)
and children exposed to ZNS (N = 90) (North American Register;
see Analysis 61.1). However, this gave a significant RD (RD 0.03,
95% CI 0.01 to 0.05; I2 = NA).
61.2 Neural tube malformations
No included studies reported data on this outcome.
61.3 Cardiac malformations
No included studies reported data on this outcome.
61.4 Oro-facial cleft/craniofacial malformations
No included studies reported data on this outcome.
61.5 Skeletal/limb malformations
No included studies reported data on this outcome.
62 PRM versus TPM
62.1 All major malformations
No included studies reported data on this outcome.
62.2 Neural tube malformations
No included studies reported data on this outcome.
50Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
62.3 Cardiac malformations
No included studies reported data on this outcome.
62.4 Oro-facial cleft/craniofacial malformations
No included studies reported data on this outcome.
62.5 Skeletal/limb malformations
No included studies reported data on this outcome.
63 PRM versus VPA
63.1 All major malformations
Pooled results from five studies showed a non-significant outcome
(RR 0.72, 95% CI 0.37 to 1.40; I2 = 40%), with no difference in
the number of major malformations in children exposed to PRM
(N = 101) and children exposed to VPA (N = 201) (Canger 1999;
Kaaja 2003; Kaneko 1999; Koch 1992; Pardi 1982; see Analysis
63.1). This gave a non-significant RD (RD−0.04, 95%CI−0.13
to 0.05; I2 = 17%).
63.2 Neural tube malformations
Pooled results from two studies showed a non-significant outcome
(RR 0.11, 95% CI 0.01 to 1.99; I2 = NA), with no difference in
the number of neural tube malformations in children exposed to
PRM (N = 39) and children exposed to VPA (N = 45) (Canger
1999; Pardi 1982; see Analysis 63.2). This gave a non-significant
RD (RD −0.11, 95% CI −0.22 to 0.00; I2 = 0%).
63.3 Cardiac malformations
Pooled results from two studies showed a non-significant outcome
(RR 3.75, 95% CI 0.16 to 89.32; I2 = NA), with no difference
in the number of cardiac malformations in children exposed to
PRM (N = 39) and children exposed to VPA (N = 45) (Canger
1999; Pardi 1982; see Analysis 63.3). This gave a non-significant
RD (RD 0.03, 95% CI −0.06 to 0.11; I2 = 0%).
63.4 Oro-facial cleft/craniofacial malformations
We could not estimate pooled results from two studies due to there
being no reported oro-facial cleft/craniofacial malformations in
children exposed to PRM (N = 39) or children exposed to VPA
(N = 45) (Canger 1999; Pardi 1982; see Analysis 63.4). RD was
calculable, and this gave a non-significant result (RD 0.00, 95%
CI −0.07 to 0.07; I2 = 0%).
63.5 Skeletal/limb malformations
Pooled results from two studies showed a non-significant outcome
(RR 0.42, 95% CI 0.02 to 9.92; I2 = NA), with no difference in
the number of skeletal/limbmalformations in children exposed to
PRM (N = 39) and children exposed to VPA (N = 45) (Canger
1999; Pardi 1982; see Analysis 63.5). This gave a non-significant
RD (RD −0.02, 95% CI −0.10 to 0.06; I2 = 0%).
64 PRM versus ZNS
64.1 All major malformations
No included studies reported data on this outcome.
64.2 Neural tube malformations
No included studies reported data on this outcome.
64.3 Cardiac malformations
No included studies reported data on this outcome.
64.4 Oro-facial cleft/craniofacial malformations
No included studies reported data on this outcome.
64.5 Skeletal/limb malformations
No included studies reported data on this outcome.
65 TPM versus ZNS
65.1 All major malformations
Data from one study showed a non-significant outcome (RR 7.84,
95% CI 0.47 to 129.74; I2 = NA), with no difference in the
number of major malformations in children exposed to TPM (N
= 359) and children exposed to ZNS (N = 90) (North American
Register; see Analysis 65.1). However, this gave a non-significant
RD (RD 0.04, 95% CI 0.02 to 0.07; I2 = NA).
65.2 Neural tube malformations
No included studies reported data on this outcome.
65.3 Cardiac malformations
No included studies reported data on this outcome.
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65.4 Oro-facial cleft/craniofacial malformations
No included studies reported data on this outcome.
65.5 Skeletal/limb malformations
No included studies reported data on this outcome.
66 VPA versus ZNS
66.1 All major malformations
Data from one study showed a significant outcome (RR 17.13,
95% CI 1.06 to 277.48; I2 = NA), with children exposed to VPA
(N = 323) experiencing more major malformations than children
exposed to ZNS (N = 90) (North American Register; see Analysis
66.1). This gave a significant RD (RD 0.09, 95% CI 0.06 to 0.13;
I2 = NA).
66.2 Neural tube malformations
No included studies reported data on this outcome.
66.3 Cardiac malformationsCardiac malformations
No included studies reported data on this outcome.
66.4 Oro-facial cleft/craniofacial malformations
No included studies reported data on this outcome.
66.5 Skeletal/limb malformations
No included studies reported data on this outcome.
Random effects meta-analysis
In the protocol we planned to undertake a random-effects meta-
analysis when there was evidence of heterogeneity.However,many
of the studies had zero events in one or both arms or had low
event rates, and they were often substantially imbalanced. In such
cases, it is best to avoid theDerSimonian and Laird random-effects
meta-analysis (Higgins 2011). Nevertheless, there were only three
comparisons where there was evidence of heterogeneity in the
meta-analysis of risk ratios for which a corresponding random-
effects meta-analysis suggested a change in conclusion to a more
conservative estimate of effect. These were:
• PRM versus no medication (in women with epilepsy), all
major malformations: fixed-effect (FE): 2.81 (95% CI 1.13 to
7.02, P = 0.03); random-effects (RE): 3.92 (95% CI 0.76 to
20.14, P = 0.10);
• LEV versus PHT, all major malformations: FE: 0.49 (95%
CI 0.26 to 0.92, P = 0.03; RE: 0.34 (95% CI 0.08 to 1.50, P =
0.16);
• LTG versus TPM, facial cleft/craniofacial malformations:
FE: 0.32 (95% CI 0.13 to 0.76, P = 0.010); RE: 0.22 (95% CI
0.03 to 1.56, P = 0.13).
There were only two comparisons where there was evidence of
heterogeneity in the meta-analysis of risk differences for which a
corresponding random-effects meta-analysis suggested a change in
conclusion, with a more conservative estimate of effect under a
random effects model. These were:
• LEV versus PHT, all major malformations: FE: −0.02
(95% CI −0.04 to −0.00, P = 0.05); RE: −0.03 (95% CI
−0.06 to 0.01, P = 0.18) - also for risk ratio shown above;
• VPA versus PB, neural tube malformations: FE: 0.04 (95%
CI 0.01 to 0.06, P = 0.001); RE: 0.05 (95% CI −0.00 to 0.10),
P = 0.07).
Studies not included in the meta-analysis and not
narratively reported
The publications of the Bozhinova 2009, Diaz-Romero 1990,
Dravet 1992, Gaily 1988, Goujard 1974; Hill 1974, Jones 1989,
Laskowska 2002, Richmond 2004, Shapiro 1976, Sabers 2004,
Torres 1995 andWide 2000 did not report either the total number
of exposed cases separating out monotherapy or polytherapy use
for a particular AED, they did not provide a malformation rate
for monotherapy treatments in isolation, or the number of chil-
dren with malformations by AED monotherapy group was un-
clear. Therefore we could not include these studies in meta-anal-
ysis, and they could not be reliably reported in a narrative format
either. Israeli Teratogen Service showed variability in its reporting.
Its paper on CBZ could be included in the meta-analysis as the
number of monotherapy cases in women with epilepsy were re-
ported, whilst in this group’s reports on valproate and topiramate,
authors did not give details as to the number of monotherapy ex-
posures to women with epilepsy and therefore required narrative
reporting.
Minor congenital malformations
Thirteen studies collected data on minor anomalies (Hill 1974,
Jones 1989, Steegers-Theunissen 1994, Koch 1992, Garza-
Morales 1996, Froscher 1991, D’Souza 1990, Delmiš 1991, Yerby
1992, Gaily 1988, Diaz-Romero 1990, Wide 2000, Barqawi
2005). However, in the publications of Hill 1974, Jones 1989,
Steegers-Theunissen 1994, Garza-Morales 1996, D’Souza 1990,
Delmiš 1991,Yerby 1992, Gaily 1988, Diaz-Romero 1990, au-
thors either did not report the monotherapy and polytherapy re-
sults separately, or the prevalence of minor malformations in iso-
lation was unclear.
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We report the limited available information pertaining to minor
malformations below.
CBZ versus controls
Wide 2000 reported minor anomalies in 15/39 (38%) CBZ-
exposed infants, with the rate within the general population of
control infants being 5/32 (16%), giving a significant OR of
11.0 (95% CI 1.42 to 85.2, P value not reported). Frequent mi-
nor anomalies within the CBZ-exposed group included oro-facial
anomalies, digital anomalies, genital anomalies and skin anoma-
lies. Barqawi 2005 reported a 25% prevalence of minor anomalies
in their cohort exposed to CBZ (N = 16) compared with 0% in the
control group (N = 18), with common anomalies including distal
digital hypoplasia and ear flap abnormalities. Koch 1992 reported
a mean rate of minor anomalies in the CBZ group (N = 9) to be
3.0 compared with 2.0 for the control group (N = 116).
PHT versus controls
Wide 2000 reported minor anomalies in 5/21 (24%) PHT ex-
posed infants compared with 6/13 (46%) in controls, giving a
non-significant OR of 0.80 (95% CI 0.22 to 2.98, P value not
reported). Koch 1992 reported a mean of 3.6 minor anomalies for
the PHT exposed infants (N = 24) compared with control children
(mean 1.91, N = 116).
VPA versus controls
Koch 1992 reported a higher mean number of minor anomalies
(8.0) in the VPA exposed children (N = 14) compared with the
control children (N = 116), whose mean was 2. Koch 1992 noted
a pattern of minor anomalies in the VPA group, which included
minor craniofacial, skeletal and genital anomalies.
CBZ versus PHT
Although not directly compared, the rates of minor anomalies in
the study by Wide 2000 were 15/39 (38%) for children exposed
to CBZ and 5/21 (24%) in PHT-exposed children. Froscher 1991
reported a 12% prevalence rate of minor anomalies for children
exposed to CBZ (N = 31) compared with 0% in five children
exposed to PHT. Similarmeans forminor anomalies were reported
by Koch 1992 for the children exposed to CBZ (N = 9) and those
exposed to PHT (N = 24): 3.0 and 3.6, respectively.
CBZ versus VPA
Froscher 1991 reported a 12% prevalence of minor anomalies in
children exposed toCBZ (N=31) comparedwith 25%of children
exposed to VPA (N = 12). Although investigators did not report
the statistical significance, Koch 1992 reported a higher mean rate
of minor malformations (8%) for the children exposed to VPA
(N=14) compared with those exposed to CBZ (N = 9), where the
rate was 3%.
D I S C U S S I O N
Summary of main results
Table 2 provides a summary of the meta-analysis for all compar-
isons for risk of major congenital malformation.
Carbamazepine
CBZ was the most frequently investigated AED both in terms of
the number of publications and the number of included pregnan-
cies. The pooledmajor malformation prevalence was 4.93%, once
variation between the studies had been taken into consideration.
In comparison to both children born to women without epilepsy
and children born to women with untreated epilepsy, children ex-
posed to CBZ in utero had an increased risk of having a major
malformation, with the difference in risk ranging from 1% to 2%.
The level of increased risk compared with control children is con-
sistent with the findings of a case-control study that reported a
similar increase in risk of major malformation following exposure
to CBZ in utero (Jentink 2010b), but it is inconsistent with the
result of another linking electronic healthcare datasets (Artama
2005). however, there were only 805 carbamazepine monother-
apy-exposed participants in the Artama study, and this could ac-
count for the difference in findings.
Data were limited in terms of the specific malformation risk in
comparison to control children, mainly due to the absence of
control data from some of the large registry studies (e.g. North
American Register; UK Register). This limitation likely con-
tributed to the non-significant outcomes across the specific mal-
formation types of neural tube, cardiac and skeletal/limb. There
was a significant association between CBZ and oro-facial mal-
formations when compared to children born to women without
epilepsy, but this finding did not hold when we calculated the RD.
Reports have associated CBZ with an increased risk of neural tube
malformations (Jentink 2010b), but analysis here is too limited to
support or refute this compared with control children.
In comparison to the other AEDs, CBZ led to a 1% higher rate
of major malformation in exposed children than LEV or LTG.
No significant levels of difference were found in terms of the risk
estimates compared with OXC, PB , GBP, PRM, TPM, PHT or
ZNS for overall malformation risk. Finally, children exposed to
CBZ had a significantly lower risk of overall malformation than
the children exposed to VPA, with the risk being 5% lower if
exposed to CBZ rather than VPA.
In terms of specific malformation risk, we did not find any dif-
ference between the children exposed to CBZ and those exposed
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to LEV or LTG, despite the increased overall major malforma-
tion rate. This may be due to the limited amount of data avail-
able currently pertaining to specific malformation types. Children
exposed to CBZ had a 2% lower risk for cardiac malformations
than the children exposed to PB, but there was no difference in
risk for other types of malformation. Children exposed to CBZ
had a lower risk of oro-facial cleft and craniofacial malformation
compared with the children exposed to TPM, but this finding
did not hold when we analysed data as an RD, which takes into
account data with no reported events. In comparison to children
exposed to VPA, the children exposed to CBZ were at a lower risk
of neural tube malformations. Interestingly, both of these medica-
tions have been associated with an increased prevalence of neural
tube malformations (Jentink 2010; Jentink 2010b); however, data
here highlight that the risk with VPA is 2% higher than it is with
CBZ. Children exposed to CBZ also had a 1% a lower risk of car-
diac malformations, oro-facial cleft and craniofacial and skeletal
or limb malformations in comparison to VPA-exposed children.
Finally, we found no difference in terms of specific malformation
rate between children exposed to GBP, PRM,OXC, PHT or ZNS,
but caution is warranted due to the small numbers in these com-
parisons.
A large number of included studies did not investigate dose ofCBZ
and its relationship with malformation prevalence, despite dose
being a key feature of a teratogen (Brent 2004).Data fromEURAP
and the UK Register reported an association between CBZ and
malformation risk with the prevalence increasing from 1.9% up
to 8.7% at doses greater than 1000 mg daily. Other studies failed
to find an association with dose (e.g. Australian, North American
Register as well as a number of smaller studies); however, it is worth
noting that EURAP and the UK Register both scored relatively
well on the ’Risk of bias’ assessment and included larger numbers
of CBZ-exposed pregnancies than other studies.
Gabapentin
Experience with GBP exposure in pregnancy was limited to fewer
than 200 reported pregnancies. The pooled prevalence of major
malformation was 1.47%. We found no difference between the
children exposed to GBP compared with either type of control
group, but caution is warranted to due to limited numbers. There
were no data available in terms of specific malformation risk com-
pared with either control group.
We found no difference in overall malformation rate or in the spe-
cific malformations investigated for the children exposed to GBP
compared to CBZ, LTG, LEV, OXC, PHT, TPM and ZNS, but
there were very limited data. In comparison to the older medica-
tions such as PB, data were limited to a single study; it found that
children exposed to GBP had a lower risk of overall malformation
compared with the children exposed to PB. Data were too limited
to investigate specific malformation type between these two med-
ications. In comparison to the children exposed to VPA, children
exposed to GBP in utero had a significant, six-fold lower risk of
having a malformation than children exposed to VPA, with the
risk difference of 8%. No differences were found between these
two medications in terms of specific malformation type; however,
only one study contributed data.
Only North American Register investigated a possible association
between dose of GBP and malformation rate, and the study failed
to find an association. Numbers were small, however, so it is un-
clear whether increasing doses of GBP are associated with an in-
creased rate of malformations.
Lamotrigine
Use of LTG has increased over the last decade in women of child-
bearing age (Ackers 2009; Man 2012; Meador 2009; Wen 2015).
The majority of evidence indicated no difference in the overall
malformation rate between the children exposed to LTG and ei-
ther type of control group, with the majority of evidence coming
from pregnancy registries. A finding of no association is consis-
tent with other studies using population-based electronic health
records (Mølgaard-Nielsen 2011). Further, we found no increase
in any of the specific malformation types investigated in the LTG-
exposed groups; however, data were limited within the specific
malformation analyses. North American Register had reported an
association between LTG and oro-facial clefts, but updated data
from that register and pooled data here do not support this asso-
ciation in comparison to control children.
In comparison to LEV, which has also seen a significant increase in
use inwomenof childbearing age (Meador 2009;Wen2015), there
were no significant differences for either overall malformation rate
or the specific malformation types investigated. Children exposed
to LTG also did not differ either in terms of overall malformation
rate or in terms of specific malformations compared with children
exposed to OXC, GBP and ZNS, although data were limited for
all of these AEDs.
The children exposed to LTG were at a significantly lower risk of
overall malformation compared with children exposed to CBZ,
with a significant risk difference of 1%. Analyses at the specific
malformation level, however, revealed no significant differences
between the children exposed to LTG andCBZ for each of the spe-
cific malformations investigated. This is possibly due to reduced
sensitivity to detect such rare outcomes, as numbers of included
children were relatively small. In comparison to TPM, the chil-
dren exposed to LTG were at a lower risk of overall malformation
and specifically skeletal and limbmalformations; however, the risk
difference was not significant and further data is needed to con-
firm this possible association. Data were limited compared with
children exposed to PB, but the children exposed to LTG were at a
significantly lower risk for overall malformation risk; with the risk
being 4% lower. Children exposed to LTG had a 2% lower risk of
cardiac malformations compared with the children exposed to PB.
Children exposed to LTG were also at a significantly lower risk
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of oro-facial cleft or craniofacial malformations compared with
children exposed to PB, but the risk differences were not signifi-
cant. The prevalence of malformations of any type was lower for
the children exposed to LTG compared with children exposed to
PHT, with the risk being 2% lower. Cardiac malformations and
skeletal or limb malformations were also significantly less likely
in the children exposed to LTG compared with those exposed to
PHT; however, the risk differences were not significant for these
comparisons. Finally, children exposed to LTG had a three-fold
lower risk of overall malformation when compared to the children
exposed to VPA, with a risk difference showing that the significant
reduction in risk was 6% for children exposed to LTG. Neural
tube, cardiac, oro-facial cleft and craniofacial and skeletal and limb
malformations were all significantly lower for the LTG-exposed
children, with the reduction in risk ranging from 1% to 2%.
The large, well-designed EURAP study has demonstrated a dose
relationship between LTG treatment and malformation risk, with
exposures to LTG under 300 mg/d associated with a malformation
prevalence of 2.0%, whilst daily doses above this level were associ-
ated with a prevalence of 4.5%. Other studies did not find a dose
relationship, however (Australian; North American Register; UK
Register), and therefore further work is required before drawing
conclusions regarding an association with dose.
Levetriacetam
Despite the now widespread use of LEV in women of childbearing
age (Meador 2009; Wen 2015), the frequency of data and the
number of included pregnancies exposed to LEV were limited.
This delay is likely due in part to the time it takes for adequate
numbers of women taking newer AEDs to accumulate, and it is
of note that all the data on LEV comes from the national and
international registries; indicating that collection on a national or
international scale may speed up the availability of information on
newer AEDs. The limited experience with this drug in pregnancies
is also seen in the large population-based electronic health record
studies (Mølgaard-Nielsen 2011).
The pooled prevalence for malformations following LEV exposure
was 1.77%. There was no significant difference between the chil-
dren exposed to LEV and control children in the meta-analysis for
overall malformation rate, which is consistent with the findings of
others (Mølgaard-Nielsen 2011). Data pertaining to specific mal-
formation types in comparison to control children were extremely
limited, and it is not possible to draw conclusions until more data
is available.
In comparison to other AED treatments, children exposed to LEV
were not significantly different from children exposed to LTG in
terms of overall malformation prevalence or the specific malfor-
mation types investigated. In addition, we found no significant
difference between children exposed to LEV compared with those
exposed to GBP, OXC, PHT or ZNS, although data within these
comparisons were limited. Children exposed to LEV had a lower
overall malformation rate than the children exposed to CBZ, but
there was no difference in terms of the specific malformation types
investigated. There was also a significantly lower malformation
risk in comparison to children exposed to TPM; however, the risk
difference for this overall comparison was not significant. Chil-
dren exposed to LEV had around a 1% lower risk, however, of
having an oro-facial cleft or craniofacial malformation in compar-
ison to the TPM-exposed children. Children exposed to LEV had
a significant, four-fold lower risk of overall malformation than the
children exposed to PB, but the risk difference was not significant.
Finally, children exposed to LEV had a 7% lower risk of overall
malformations compared with the children exposed to VPA.
Investigation between dose of LEV and malformation outcome
was limited by numbers included within the individual studies
(i.e. North American Register; UK Register); to date no study has
reported evidence of a dose effect for LEV, but further data is
required before drawing conclusions.
Oxcarbazepine
Data for pregnancy outcomes following exposure to OXC were
limited to just over 200 pregnancies; we calculated the prevalence
of major malformation to be 2.39%. There was no significant
difference in malformation risk compared with control children;
however, outcomedatawere limited, andno informationwas avail-
able about the risk of specific malformations. Mølgaard-Nielsen
2011 also failed to find a significant association between OXC
exposure (N = 393) and increased malformation rate in compari-
son to controls using a population-based electronic health record
study design.
In limited comparisons to other AEDs, there was no significant
difference or no available data between the overall malformation
rate or the specificmalformations investigated comparedwith chil-
dren exposed to CBZ, LEV, LTG, PHT, PRM, TPM, and ZNS.
Children exposed to OXCwere at a significantly lower risk of hav-
ing a major congenital malformation of any type compared with
children exposed to VPA, with the risk difference being 8%.
There were very limited data pertaining to specific malformation
types, and caution is required. Children exposed to OXC had a
significantly lower rate of cardiac malformation compared with
the children exposed to PB, with the risk difference indicating
that risk was 3% lower for the children exposed to OXC. Limited
data pertaining to specific malformation types did not show a
significant difference, however, between the children exposed to
OXC and those exposed to VPA.
None of the included studies investigated dose ofOXCandmalfor-
mation rate; therefore it remains unknown whether higher doses
of OXC are associated with an increased rate of malformation.
Phenobarbital
Despite years of PBuse, data fromprospective studies investigating
PB as monotherapy were surprisingly limited. Data pooled from
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included studies generated a major malformation prevalence of
7.10%. We found a significantly increased risk of overall malfor-
mation compared with children born to women without epilepsy,
with a risk difference of 4%. We found no significant difference
compared with children born to women without epilepsy. Data
pertaining to specific malformations were extremely limited or
missing and likely contributed to the non-significant differences
found. This is certainly the case for cardiac malformations where,
as noted below, rates compared with other AEDs indicate a spe-
cific increased risk of cardiac malformations in PB-exposed chil-
dren across comparisons, which was not documented within the
limited data compared with control children.
In comparison to other AEDs, children exposed to PB were not
at a significantly increased rate of overall malformation compared
with children exposed toCBZ, PHT,OXC,TPM,PRMandZNS.
There was a significant increase in the prevalence ofmalformations
between the children exposed to PB and the children exposed to
LEV and GBP; however, the risk differences were not significant,
and further investigation is required. Finally, a significantly in-
creased risk of malformations was found for the PB-exposed chil-
dren compared with the children exposed to LTG, with the level of
risk being increased by 4%. In contrast, the rate of malformations
was significantly lower for the children exposed to PB compared
with the children exposed to VPA, with the risk being 4% lower.
PB was associated with an increased risk of cardiac malformations
compared to CBZ, LTG, PHT and OXC, with the increase in risk
falling between 2% and 3%. There was also an increased risk in
comparison to children exposed to LEV or TPM, but the RDs
were not significant, and further data are required. PB was also
significantly associated with an increased risk of oro-facial clefts
and craniofacial malformations when compared to LEV or PHT,
but again, the RDanalyses were not significant and further data are
required to draw conclusions. Finally, children exposed to PB were
at a significantly lower risk of neural tubemalformations compared
with children exposed to VPA, with the risk being reduced by
4%. There was no difference in terms of cardiac malformations in
comparison to VPA, a drug also associated with an increased risk
of cardiac malformations.
The majority of studies did not investigate or report on a poten-
tial relationship between dose to PB and malformation risk. How-
ever, EURAP found an increased rate of overall malformations in
children exposed to PB (5.4% for exposures < 150 mg/d versus
13.7% for exposures > 150 mg/d). A dose-mediated risk was also
apparent for cardiac malformations, with the prevalence increas-
ing from 1% to 8% for doses < 150 mg/d and those > 150 mg/d,
respectively. Kaneko 1999 also found a dose effect for PB; how-
ever, North American Register and Samren 1997 did not. Dose is
a key principle of teratogenic risk (Brent 2004), and although a
dose effect is unclear, it should be considered a possible factor to
PB-associated malformations.
Phenytoin
The pooled prevalence of major malformation in the PHT-ex-
posed children was 6.26% once variation between the studies had
been taken into consideration, which is consistent with that re-
ported by other studies (Wide 2004). The children exposed to
PHTwere at a significantly increased risk in comparison with both
types of control group, with the difference in risk ranging from2%
to 4% depending on the nature of the control group. However,
we found no association between PHT and specific malformation
types, although data were limited in these comparisons due to the
limited control data.
In comparison to other AEDs, children exposed to PHT were not
at an increased risk of overall malformation or the specific mal-
formation types investigated compared with children exposed to
CBZ, GBP, OXC, TPM, PRM, PB or ZNS; however, data com-
paring PHT with the ’newer’ AEDs were limited. Children ex-
posed to PHT were at an increased risk of overall malformation
compared with children exposed to LTG, with the risk difference
indicating a 2% increase in malformation. The children exposed
to PHT were at a greater risk of malformation in comparison to
children exposed to LEV; however, there were high levels of het-
erogeneity between the included studies, and the random-effects
modelling failed to uphold the significance of this result. In con-
trast, the children exposed to PHT were half as likely to have a
malformation than the children exposed to VPA, with the differ-
ence in risk being 5%.
In terms of specific malformations, children exposed to PHTwere
less likely than those exposed to PB to be born with a cardiac
malformation, with risk differences indicating that the riskwas 3%
lower.We found a significant RR favouring PHTwhen comparing
PHT and PB in terms of oro-facial malformations; however, the
RD was not significant and more data are required. There was no
difference between these two medications in terms of skeletal or
limb malformations or neural tube malformations. There was a
noted increase in cardiac and skeletal and limb malformations for
the PHT exposed children compared with those exposed to LTG
when measured as an RR; however, the RD was not significant.
Rates of neural tube and cardiac malformations were significantly
lower for the children exposed to PHT in comparison the to VPA-
exposed children, with the risk found to be 2% lower for the PHT
exposed children.
The majority of studies did not report on whether the risk of
being born with a major malformation was associated with dose
of PHT; however, those that did investigate such an association do
not show a consistent pattern. Kaaja 2003,Motherisk Registry and
North American Register all failed to find an association between
dose and outcome; however, Kaneko 1999 and Samren 1997 did,
therefore the conclusion around dose effects is uncertain.
Primidone
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Evidence pertaining to PRM was extremely limited to under 200
pregnancies and caution is warranted when interpreting results.
Pooled data from included studies gave a malformation prevalence
of 8.49%. There was no difference in the malformation rate com-
pared with either control group once the significant levels of het-
erogeneity had been taken into account.
Therewere nodata comparingmalformationoutcomes in children
exposed to PRM compared with GBP, LEV, LTG, TPM, OXC
and ZNS. In comparison to the children exposed to CBZ, PHT,
PB or VPA, there was no difference in overall malformation rate
or in terms of specific malformations, but data were limited.
Only the study of Kaneko 1999 investigated dose of PRM and
outcome, and it only included 19 PRM cases. Therefore it remains
unknown as to whether there is an association between PRM dose
and increased malformation risk.
Topiramate
Experience with TPM was limited to fewer than 500 pregnancies,
therefore caution is required when considering our results. The
prevalence of malformation within included studies was 4.28%.
In comparison to children born to women without epilepsy, chil-
dren exposed to TPM had a three-fold higher rate of being born
with a malformation with the risk difference being 3%. We found
no significant difference compared with the no medication con-
trol group, but this comparison had even fewer TPM cases (N =
115). The Mølgaard-Nielsen 2011 database study failed to find
a significant difference in the malformation rate of 108 TPM ex-
posed infants in comparison to control children. Data were too
limited here to allow for the investigation of specific malformation
outcomes in comparison to control children, mainly due to a lack
of data pertaining to controls from two of the main pregnancy
registers (North American Register; UK Register).
We found no significant level of difference in rate of malformation
compared with children exposed to CBZ, GBP, PHT, PB, PRM,
OXC and ZNS. We found a significant increase in the rate of
malformation for the children exposed to TPM compared with
the children exposed to LTG or LEV; however, the risk differences
failed to reach significance, so caution is required. The children
exposed toTPMwere less likely to have amalformation of any type
compared with the children exposed to VPA, with the difference
in risk being 5%.
In terms of specific malformation types, children exposed to TPM
were at a significantly increased risk for an oro-facial cleft or cran-
iofacial malformation compared with children exposed to CBZ or
LEV; however, only the comparison to LEV yielded a significant
risk difference of 1%, and data were limited. There is evidence of
an association between topiramate and oral clefts from insurance
database studies (Mines 2014), in a case-control study (Margulis
2012), and in a previous meta-analysis (Alsaad 2015), so the fail-
ure to obtain a consistent finding here may be due to the limited
data currently available from prospective observational studies in
isolation. In comparison to children exposed to LTG, those ex-
posed to TPM were at an increased risk of skeletal and limb mal-
formations, although the risk difference was not significant, and
further data are required. In contrast, children exposed to TPM
had a significantly lower risk of cardiac malformations than the
children exposed to PB, although again the risk difference was
not significant. Consistently, the risk of cardiacmalformations was
also significantly lower in the TPM-exposed children compared
with the children exposed to VPA, with a difference in risk of 2%.
No evidence of a dose association was found; however, date were
limited and further experience with TPM exposure in utero is
required.
Valproate
In utero exposure to VPA and its possible association with an in-
creased teratological risk has been discussed in the literature since
the 1980s, when the first case reports emerged documenting chil-
dren with a specific constellation of malformations following ex-
posure to VPA (Ardinger 1988; DiLiberti 1983). Larger cohorts
such as EURAP and data frompopulation-based electronic health-
care records (e.g. Artama 2005; Wide 2004) as well as the preg-
nancy registries and observational studies included here, have all
provided evidence to confirm that VPA is a human teratogen.
In the meta-analyses reported here a consistent pattern emerged:
children exposed to VPA were at an increased risk of both a higher
overall malformation risk and risk of a specific malformations in-
cluding neural tube, cardiac, oro-facial cleft and craniofacial and
skeletal and limb malformations. The prevalence of major mal-
formation following exposure to VPA in the womb was 10.93%,
once variation between the studies had been taken into consider-
ation. Children exposed to VPA were at an increased risk of be-
ing born with a malformation compared with both the children
of women without epilepsy and the children of women with un-
treated epilepsy, with the risk difference being 8% and 6% com-
pared with the respective control groups. Analysis of the risks as-
sociated with VPA treatment at the specific malformation level
was limited by a lack of control data; however, children exposed to
VPA remained at a significantly increased risk for neural tube, car-
diac and skeletal malformations compared with control children.
In comparison to other AEDs in the meta-analyses reported here,
children exposed toVPAwere at an increased risk ofmalformations
compared with children exposed to CBZ, GBP, LEV, LTG, TPM,
OXC, PB and PHT, with risk estimates ranging from a two-fold
to six-fold increase. The risk differences ranged from 4% to 8%
depending on the comparator AED.
At the specific malformation level, children exposed to VPA were
at an increased risk of neural tube malformation compared with
the children exposed to CBZ, LEV, LTG, PB and PHT, with the
increases in risk ranging from 1% to 4%. We did not note any
increase compared to children exposed to GBP,OXC or TPM, but
this could be due to limited data. Similarly, we found an increased
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rate of cardiac malformation compared to CBZ, LEV, LTG, TPM,
PHT, with the risk difference ranging from 1% to 2% depend-
ing on the comparator AED. We found no difference in the risk
of cardiac malformations for VPA compared to PB; however, as
noted above, this AED also appears to be associated with an in-
creased risk of cardiac malformations. Oro-facial cleft and cran-
iofacial malformations were also significantly more common in
the children exposed to VPA compared with children exposed to
CBZ, LEV and LTG, with risk differences being 1%. There was
no difference in the rate of oro-facial cleft or craniofacial malfor-
mations compared with TPM, PB or PHT. Finally, skeletal or limb
malformations in children exposed to VPA compared with chil-
dren exposed to CBZ, LEV or LTG were significantly higher. All
specific malformation comparisons the data compared with GBP,
ZNS and OXC were too limited for conclusions to be made.
Data reported in themeta-analysis were consistent with the reports
reviewed narratively and the findings of studies not eligible for
inclusion in the review due to their design (Artama 2005; Jentink
2010; Wide 2004). We therefore conclude that prenatal exposure
to VPA is associated with a significant increase in risk for a wide
range of malformations. Further, when weighing up the risks and
benefits of VPA treatment, the effects of VPA on the developing
brain should also be considered, as VPA is now also recognised
as a neurobehavioural teratogen, with implications for the future
cognitive functioning of the exposed child (Bromley 2014).
More than any other AED, studies have reported dose asso-
ciations with level of risk for VPA (Australian; Canger 1999;
Fairgrieve 2000; Israeli Teratogen Service; Kaneko 1999; Lindhout
1992; Mawer 2010; North American Register; Samren 1997; UK
Register). The largest data set with clear dose comparisons is the
EURAP collaboration, which finds that the prevalence of major
congenital malformations increases from 5.6% at doses < 700 mg
daily to 24.2% for doses > 1500 mg daily. Interestingly, Australian
reports a decrease in the mean dose for new registrations and have
noted that this is associated with a reduction in the number of
observed cases of neural tube malformations.
Zonisamide
Expereince with ZNS exposure was limited to 90 cases described
in a single publication (North American Register), therefore it is
not possible to draw conclusions at this time. Further efforts are
needed to develop experience with this medication in pregnancy.
Other antiepileptic drugs
No data were found pertaining to AEDs such as ethosuximide,
sulthiame, lacosamide or vigabatrin.
Overall completeness and applicability of
evidence
Data were limited for the risk of specific types of malformations,
due in a large part to the failure of included studies to publish
specific malformation outcomes. Whilst this is undoubtedly due
to publication space, providing such information is critical for un-
derstanding the risks associated with specific malformation types.
As demonstrated in the case of PB, an AED may be associated
with a constellation of specific malformations, so reporting only
an overall malformation figure may mask important associations.
The completeness of data was further challenged due to authors
not reporting data for rarermalformation types, for less commonly
used AEDs and by the larger registers not reporting specific mal-
formation data for control children (North American Register;
UK Register); these factors limited the analysis that we could un-
dertake. Further, unclear reporting also meant that we could not
investigate hypospadias, which has been linked to certain AED
exposures (Wide 2004), as it was unclear if the included studies
had limited their data specifically to males.
A few points of heterogeneity were found between included stud-
ies, which may limit the completeness of the evidence. Studies
varied in how they dealt with the inclusion of foetal deaths (with
and without malformations) and in whether they counted genetic
causes of malformation in their overall prevalence. At the outset
of this review, we decided to use the author-defined malformation
rate, as the review authors would be unlikely to have all the data
required to determine information about reported malformations.
Considering this however, we cannot confirm that all the studies
applied the same criteria for classifying a major congential mal-
formation. Further, there were differences between studies in the
time at which the outcome was reported. For example, the UK
Register has a malformation reporting time before three months
of age, whilst others included malformation presence at birth (e.g.
Bozhinova 2009). Data from the EURAP collaboration demon-
strates that the reviewing of malformation outcome at 12 months
of age leads to an increased detection and therefore higher preva-
lence. Thus data reported from some studies may in fact be an
underestimation of the prevalence of major malformations if the
assessment of the child occurs prior to 12 months of age. A fur-
ther challenge to the completeness of the evidence was that the
use of data in meta-analysis was limited in a number of cases by
reporting issues. One of themost common limitations came in the
form of studies not reporting specific monotherapy outcomes or
reporting monotherapy and polytherapy outcomes for a particular
AED together (e.g. Sabers 2004). In certain cases, we were able to
extrapolate prevalence of malformations for specific monotherapy
treatments, but in others this was not possible.
The way in which some ongoing pregnancy registries update their
results meant that we often had to take outcomes for different
AEDs from a number of different papers, or that authors inves-
tigated malformation types separately over different papers. For
example, Kerala Pregnancy Registry had published more recently
on cardiac malformations in isolation and therefore substantially
larger numbers were available for investigations into cardiac mal-
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formations than for overall malformation rates or rates of other
specific malformation types. Similarly, UK Register recently pub-
lished outcomes pertaining to LTG, VPA, CBZ and in a separate
publication LEV, without updating malformation prevalences for
other AEDs such as PHT or TPM.
The completeness of data is also limited by the significant lack
of data pertaining to the secondary outcome of minor malforma-
tions. Few included studies reported such outcomes, and the ma-
jor pregnancy registries in particular limit their outcomes to ma-
jor malformations only. Minor malformations are an important
part of the diagnostic criteria for teratogens generally and foetal
anticonvulsant syndromes in particular (Dean 2000). A constella-
tion of minor anomalies associated with specific exposures provide
clinicians with key diagnostic markers, and their presence may
lead to a more detailed physical examination to check for more
severe physical symptoms of exposure or neurodevelopmental im-
pairment.
In addition to the limitations with the data, this review has a
number of limitations itself. One important limitation is the ex-
clusion of studies using large population-based electronic health-
care datasets (e.g. the Swedish Birth Register) and the exclusion
of malformation registers (e.g.Artama 2005; Wide 2004). We de-
cided to exclude these study designs from our review due to the
potential difficulties in combining the data from these methods
with those from the observational studies included. In particular,
there are problems ascertaining timing of exposure and dose with
these studies (Charlton 2014; Wide 2004), and there is a sugges-
tion that they may be at risk of underreporting the malformation
rate (Charlton 2008).We also excluded case-controlmalformation
registers that record children with and without malformations . In
these registers, children are enrolled once the outcome when the
presence or absence of a malformation is known, and therefore we
classified recruitment as retrospective (e.g. Jentink 2010; Jentink
2010b). Further, the nature of this data meant that it could not
be directly combined into meta-analysis with the data from the
prospective observational studies.
Strengths of this review include, the creation and advance publi-
cation of the review protocol, the clear inclusion criteria, exten-
sive searches, the acquisition of unpublished data, the inclusion of
articles not written in English, meta-analysis for all possible com-
parisons, the consideration of specific as well as overall malforma-
tion risk, the balance of both systematic reviewing and content
expertise and the assessment of risk of bias and quality in the non-
randomised evidence. Under the Cochrane guidelines this review
will be updated every two years, or following the publication of
a significant amount of new data, to ensure it remains up to date
which adds further strength.
Quality of the evidence
Randomised controlled trials are thought to be unethical in this
area due to the permanence of potential adverse effects for the
foetus. Gold standard evidence for this area would therefore com-
prise of data coming from a prospective, blinded cohort studies
using statistical methods to limit the influence of confounding
variables. The methodological quality for each study is displayed
in the Characteristics of included studies tables. Only one study
was an RCT, which contained no information on the randomi-
sation process. All other included studies were non-randomised
observational studies, and hence were rated as high risk on the ran-
domisation sequence and allocation concealment domains. The
included studies varied in their approach to controlling confound-
ing variables, a key issue in non- randomised studies. Blinding
rarely occurred in the larger register based studies due to their re-
liance on family doctors to report the outcomes over large pop-
ulations. Whilst the size of the populations which registers can
recruit should be considered their strength the failure to blind
should be considered a potential source of bias. Concerningly, a
larger number of the included studies did not mention whether
or not outcome assessors were blinded. The majority of studies
scored low risk in terms of selective reporting but few were able
to provide protocols to the review team to ensure this. Attrition
was rated as low risk for the majority of studies. The majority of
studies were found to have one or more aspects of additional bias.
For example, many of the studies did not indicate the upper level
of gestational age for recruitment or whether children with genetic
syndromes had been excluded from the malformation prevalence;
things which may have been deduced if protocols had been made
available. A comprehensive understanding of how the majority of
studies were designed and undertaken was not possible due to the
limited number of protocols received. This undoubtedly impacted
on the risk of bias judgements.
In conclusion, our risk of bias review indicates that across the
included studies there are number of important biases assessed as
high risk which should be taken into account when interpreting
the results. The biases however, were balanced across the AEDs
investigated and therefore it is not felt that the finding that VPA
is associated with a higher risk of major congenital malformation
in comparison to other AEDs is due to these biases.
Potential biases in the review process
Review authors RB and JCS were authors on two included studies
(Mawer 2010; Meador 2006). This potential bias was reduced by
delegating data extraction and risk of bias assessments to two other
review authors.
Agreements and disagreements with other
studies or reviews
Despite a large number of review articles in this area there are few
systematic reviews where meta-analysis has been conducted and,
where they have been completed, the inclusion criteria have var-
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ied, particularly with respect to study methodology. The review by
Meador 2008 for example, included both prospective and retro-
spective studies, studies using population-based electronic health-
care records as well as data from case-control studies. Whilst this
lead to increased numbers of included pregnancies within themeta
analysis, the comparability of data from these different method-
ological types is unclear and caution is warranted over including
data from such diverse methodologies as Charlton 2008 found
lower rates of malformation reporting from the UK Clinical Prac-
tice Research Database in comparison to the UK Epilepsy and
Pregnancy Register. In total the Meador 2008 review included 59
studies involving 65,533 pregnancies to women with epilepsy.De-
spite differences in methodologies the findings of the review here
are consistent with this previous review in that VPA was associ-
ated with the largest risk for major congenital malformation with
the prevalence being 10.7% (95% CI 8.16 to 13.29). Consistent
with data here, the prevalence for malformation following expo-
sure to CBZ was lower (4.62%, 95% CI 3.48 to 5.76), as was
that for PHT (7.36%, 95% CI 3.60 to 11.11), PB (4.91%, 95%
CI 3.22 to 6.59) and finally for LTG (2.91%, 95% CI 2.00 to
3.82). Further consistent findings were reported by Jentink 2010b
who found the prevalence of malformation following CBZ to be
3.3% based on 2680 CBZ children from eight studies. In contrast
to the review here, Jentink 2010b found a significant associated
between CBZ exposure and spina bifida, however this is not repli-
cated here compared with control children or children exposed to
other AEDs, with current available data. Similarly, Jentink 2010
found, based on eight studies and 1565 VPA exposed pregnancies,
the prevalence to be 7.5% (95% CI 6.3 to 9.0) for pregnancies
exposed to VPA and noted an increase in terms of specific malfor-
mations which is also found here.
The data reported here pertaining to LEV is consistent with a pre-
vious systematic review (Chaudhry 2014) who included the three
prospective studies reported here (Australian; North American
Register; UK Register) as well as studies utilising other method-
ologies and reported a prevalence rate of 2.2% (27/1213, 95% CI
1.53 to 3.22).
Analysis here did not however consistently replicate the reported
association between TPM exposure and oral clefts. In a previously
completed meta-analysis Alsaad 2015 had a wider inclusion cri-
teria which included 3420 patients taking TPM (mixed etiolo-
gies) and 1,204,981 controls and reported a significant odds ra-
tio (OR 6.26, 95% confidence interval: 3.13 to 12.51). As noted
throughout this discussion, data were limited pertaining to the
newer AEDs and by the reporting of specific malformations in
included studies and therefore it is possible that limited data con-
tributed to this meta-analysis not consistently upholding this as-
sociation across all comparisons.
Finally, it is now also known that VPA exposure is associated with
neurodevelopmental delays which may have lifelong implications
for the exposed child; a topic covered in a linked Cochrane review
(Bromley 2014). The findings of this review in partnership with
theBromley2014 reviewhighlight thewide range of risk associated
with exposure to VPA in the womb.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is consistent evidence that prenatal exposure to VPA in-
creases the risk of having a child with a major congenital mal-
formation with the increase in risk covering neural tube, cardiac,
skeletal and limb and oro-facial cleft and craniofacial malforma-
tions.
Exposure to CBZ is associated with an increased risk of malfor-
mations but to a lesser extent than VPA. The risk with PB appears
to be related specifically to cardiac malformations in comparison
to other AEDs. Finally, no increase risk of malformation is found
for LTG or LEV compared with controls and more favourable
outcomes are found for the child compared with VPA and other
AEDs. Whilst the RDs for comparisons not including VPA may
appear relatively small at around1-2%, the importance of a cardiac
or neural tube defect on the individual child and family should be
considered. Also, at a societal level a 1% increase in malformation
rate will result in significantly more affected children born each
year which represents a significant cost to health and educational
services.
Given the variance in outcome data pertaining to the malforma-
tion risk associated with a individual treatment the primary impli-
cation for practice is that counselling should be tailored to the in-
dividual treatment and its dose. Although traditional counselling
has been that 90% of children born to women with epilepsy have
healthy children, this simplifies a complex set of data. The dose
of AED and considerations regarding specific malformation types
should also be central to counselling. It is also important to high-
light that whilst major malformations are likely to represent the
more severe end of a continuum of effect, minor malformations
can still result in health problems and impact on quality of life. Fi-
nally, the limited data about the newer AEDs should be discussed
with women planning a pregnancy or who are in the childbearing
years. Absence of risk data should not imply lack of risk.
Implications for research
The role of the clinician and women with epilepsy working to-
gether to improve the evidence base should be considered and the
collection of data should be embedded in routine practice enabling
pregnancy registers and other study designs.
Whilst research methodologies have become more refined over
the years there are still a number of limitations in the data which
could be addressed in future research. Firstly, the reporting of an
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overall malformation figure is, as demonstrated above for PB, un-
likely to be the most reliable measure of risk and where data is
large enough to allow, prevalences pertaining to specific malfor-
mation types should be investigated and reported. To facilitate
this, all studies however large or small should provide informa-
tion on specific malformation types to aid future meta-analyses
and generation of risk estimates. Secondly, registries and report-
ing clinicians should be encouraged to use the standardised phe-
notypic terms which are now used in recognised phenotype on-
tologies such as the Human Phenotype Ontology (HPO) (http://
human-phenotype-ontology.github.io/about.html). This will not
only allowmore accurate comparison across studies but analysis of
the computational codes attached to HPO terms can also indicate
similarities in underlying genomic pathways involved in aetiology
and direct further investigation. Thirdly, treatment dose should
also be considered a central aspect of reporting given its key fea-
ture of human teratogens (Brent 2004) and as highlighted by the
dose mediated risk documented for VPA. The advice which may
be given to an individual female on VPA would likely be very
different depending on her dose. The studies which did investi-
gate the relationship between dose and outcome used varying cut
offs and therefore comparisons across studies was difficult. In the
future research groups should look to standardise dose categories
to enable uniform reporting. Fourthly, all data should be reported
for the control groups, even if just in tabular format to aid future
meta-analysis.
The fifth recommendation would be that observations have shown
that some women who take AEDs, even at a very low dose, appear
to be at higher risk of having a child with an AED-associated mal-
formation. Further research focusing on identification of genomic
variants which might modify how different women metabolise
AEDs is crucial so that those who may be at higher risk of having
a child with a malformation, even taking a lower dose of a specific
AED, can be identified. Whilst this has proven difficult in the
past, whole exome/genome sequencing, with careful selection of
individuals for testing is likely to make this more achievable (Ku
2011).
Finally, there is a clear trend that data for newer drugs is coming
from the large national registers. This is not surprising given the
time it can take for cases in individual hospitals to accumulate. The
continued existence of these registers are of central importance
to the generation of information to inform preconceptual coun-
selling and efforts to increase reporting to such registers should be
undertaken at a clinician and regulatory level.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Al Bunyan 1999
Methods A single-centre prospective registry study (Saudi Arabia)
Participants 79 children enrolled, all were analysed.
Interventions Intervention group (monotherapy):
1) CBZ (N = 31)
2) PHT (N = 9)
3) VPA (N = 5)
4) PB (N = 2)
Control group:
1) Women with epilepsy not taking any AEDs (N = 10)
Outcomes 1) Apgar score
2) Birth weight
3) Birth length
4) Head circumference
5) Congenital malformations
6) Pregnancy outcome
AEDs were analysed together.
Notes Protocol requested - no response received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk High in bias due to non-randomised design
Allocation concealment (selection bias) Unclear risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as some confounders were consid-
ered but not adjusted for
Blinding High risk Rated 5 as no methods of blinding em-
ployed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 1 as no missing data
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective report-
ing, no protocol available
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Al Bunyan 1999 (Continued)
Other bias High risk Rated 5 as dose not investigated, unclear
gestational age at enrolment, unclear if chil-
drenwith genetic syndromeswere excluded
Arulmozhi 2006
Methods A prospective study (India)
Participants 63 children enrolled in the study. 60 children reviewed and analysed:
1) Offspring of women taking AEDs- 30 children
2) Offspring of women without epilepsy
Interventions Intervention group:
1) CBZ (N = 7)
2) PHT (N = 18)
3) VPA (N = 3)
Control group:
1) no medication (in women without epilepsy) (N = 30)
Outcomes 1) Physical growth
2) Psychomotor development
3) Congenital malformations
AEDs were analysed together.
Notes Of the 3 children not analysed, 2 were lost to follow-up after delivery and 1 was aborted
Protocol requested - no response received.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as some confounders were considered but not
adjusted for
Blinding Unclear risk No details of blinding in text
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data, unlikely to affect
outcome
Selective reporting (reporting bias) Unclear risk Rated 3 as malformation data reported in narrative form,
it was not stipulated in the methods section that the out-
comes would be reported, only birthweight and head cir-
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Arulmozhi 2006 (Continued)
cumference etc
Other bias High risk Rated 5 as AEDs not analysed separately, no consideration
of dose of AED, unclear if childrenwith genetic syndromes
were excluded
Australian
Methods A prospective study (Australia)
Participants 1317 pregnancies were examined including:-
1) Women with epilepsy treated with AED
2) Women in whom AED was prescribed for other non-epilepsy indications
3) Women untreated at least in the first half of their pregnancy
Interventions Intervention groups (monotherapy):
1) CBZ (N = 361)
2) VPA (N = 271)
3) LTG (N = 315)
4) TPM (N = 44)
5) PHT (N = 44)
6) LEV (N = 63)
7) OXC (N = 12)
8) PB (N = 5)
9) GBP (N = 14)
Control group:
1) Women with epilepsy not taking any AEDs (N = 147)
Outcomes 1) Incidence of malformations- AEDs were analysed separately
Notes Protocol received. Personal communication received regarding number of specific mal-
formation by monotherapy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Low risk Rated 2 as most important confounders considers and
adjusted for appropriately in analyses
Blinding High risk Rated 5 as outcome assessors unblinded as assessments
completed by family physician
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Australian (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data reported over
3 key papers
Selective reporting (reporting bias) Low risk Rated 1 as no evidence of selective reporting, protocol
available
Other bias High risk Rated 5 as some cases enrolled following a scan (out-
come maybe known) and no information reported as
to whether they exclude children with genetic syn-
dromes
Bag 1989
Methods A prospective study (India)
Participants 30 pregnant epileptic patients were enrolled. All 30 were taking AED treatment, and all
were analysed
Interventions Intervention group (monotherapy):
1) PHT (N = 20)
2) CBZ (N = 4)
Outcomes 1) Seizure frequency
2) Serum drug and hormone (oestrogen and progesterone) levels
3) Congenital abnormalities
4) Pregnancy outcome
AEDs were analysed separately.
Notes There were 2 spontaneous abortions.
Study authors’ contact details could not be found
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as some confounders were considered but not
adjusted for
Blinding Unclear risk No details of blinding in text
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as only small amount of missing data, unlikely to
affect outcome
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Bag 1989 (Continued)
Selective reporting (reporting bias) Unclear risk Rated as 3 Limited information regarding a priori out-
comes and protocol not available
Other bias High risk Rated 5 unclear of gestational age at enrolment, unclear
if children with genetic syndromes were excluded
Barqawi 2005
Methods A prospective study (Jordan)
Participants 50 women with epilepsy were enrolled. All were receiving various drug therapies for
epilepsy management. The offspring of all women were analysed
Interventions Intervention group (monotherapy):
1) Carbamazepine (N = 16)
Control group:
1) Women with epilepsy not taking any AEDs (N = 18)
Outcomes 1) Seizure frequency
2) Pregnancy outcome
3) Minor congenital abnormalities
4) Major congenital abnormalities
AEDs were analysed separately.
Notes Control group were not randomised but intervention group were
Protocol requested - no response received.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details in text regarding randomisation method
Allocation concealment (selection bias) Unclear risk No details in text regarding methods of allocation con-
cealment
Confounding variables Unclear risk Rated Unclear as intervention group were randomised
but control group were not
Blinding Unclear risk Rated unclear no details in text
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 1 as no missing data
Selective reporting (reporting bias) High risk Rated 3 limited information regarding a priori outcomes.
No protocol available
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Barqawi 2005 (Continued)
Other bias High risk Rated 5 as dose not investigated, unclear gestational age
at enrolment, unclearwhether childrenwith genetic con-
ditions were excluded
Bozhinova 2009
Methods A prospective study (Bulgaria)
Participants Pregnancies and deliveries of 107 women with epilepsy were monitored between 1996
and 2007; 5 women reported malformations of the foetus and baby
Interventions Intervention group (monotherapy):
1) VPA (N = 2)
2) CBZ (N = 1)
Control Group:
3) Women with epilepsy not taking AED
Outcomes 1) Major malformations
2) Death
Notes Study authors’ contact details could not be found. Reported in narrative form only as
details of outcome by individual AED are not given
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 5 as no confounding variables considered or ad-
justed for
Blinding Unclear risk Rated unclear no details in text
Incomplete outcome data (attrition bias)
All outcomes
High risk Rated 5 as no information provided regarding missing
data
Selective reporting (reporting bias) Unclear risk Rated 3 as limited information regarding a priori out-
comes, no protocol available
Other bias High risk Rated 5 as AEDs not reported separately, no figures
reported for individual drug groups, no investigation
of dose, unclear gestational age at enrolment, unclear
if children with genetic conditions were excluded
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Canger 1999
Methods A prospective study (Italy)
Participants 517 women were enrolled, totaling an overall 628 pregnancies. Only the first pregnancies
of each of the 517 women were included in analysis
Interventions Intervention group (monotherapy):
1) PB (N = 83)
2) CBZ (N = 113)
3) PRM (N = 35)
4) PHT (N = 31)
5) VPA (N = 44)
Control group:
1) Women with epilepsy not taking any AEDs (N = 25)
Outcomes 1) Pregnancy outcome
2) Birth weight
3) Head circumference
4) Severe malformations
5) Mild malformations
6) Deformities
7) Malformations specific to a) Cardiac, b) Gastrointestinal, c) Neural tube defects
8) Perinatal deaths
AEDs were analysed separately
Notes 58 pregnancies that had ended with early spontaneous (N = 38) or early voluntary (N =
20) abortions were excluded from the analysis
Linked to Battino 1992 and Battino 1999
Study authors’ contact details count not be found
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as many important confounding variables were
considered however none were adjusted for in analysis
Blinding Unclear risk Rated unclear no details in text
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount ofmissing datawith reasons given,
unlikely to affect outcome
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective reporting, no protocol
available but clear outcomes outlined in methods
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Canger 1999 (Continued)
Other bias Low risk Rated 1 as no other bias identified
Cassina 2013
Methods A prospective study (Italy)
Participants 1562 pregnant women were recruited to the study:-
1) Pregnant women with epilepsy taking AEDs (N = 385)
2) Pregnant no medication (in women without epilepsy) taking AEDs therapy (310)
3) no medication (in women without epilepsy) (N = 867)
Interventions Intervention group (monotherapy, with known malformation outcomes, limited to
women with epilepsy):
1) VPA (N = 45)
2) CBZ (N = 88)
3) PB (N = 67)
4) LTG (N = 26)
Control group:
1) no medication (in women without epilepsy) (N = 803)
Outcomes 1) Major congenital malformation
2) Twin gestation
3) Foetus born with chromosomal abnormalities
4) Spontaneous abortion
5) Elective termination of pregnancy
7) Foetal death or still birth
AEDs were analysed separately
Notes Protocol requested - protocol received.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as some confounders considered and adjusted for
appropriately in analyses
Blinding High risk Rated 5 as outcome assessors unblinded as assessments
completed by family physician
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data with reasons given
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Cassina 2013 (Continued)
Selective reporting (reporting bias) Low risk Rated 1 as no evidence of selective reporting, protocol avail-
able
Other bias High risk Rated 5 unclear gestational age at enrolment, unclear if
children with genetic conditions were excluded
D’Souza 1990
Methods A prospective study (UK).
Participants 61 infants born tomotherswith epilepsy.Non-epilepticmotherswere selected asmatched
controls (N = 62):-
1) Offspring of women with epilepsy exposed to AEDs throughout pregnancy (N = 49)
2) Offspring of women with epilepsy exposed to AEDs only in first trimester (N = 4)
3) Offspring of women with epilepsy not exposed to AEDs (N = 8)
4) Offspring of no medication (in women without epilepsy) (N = 62)
Interventions Intervention group (monotherapy):
1) PHT (N = 22)
2) CBZ (N = 3)
3) PB (N = 4)
Control group:
1) Women with epilepsy not taking any AEDs (N = 8)
2) no medication (in women without epilepsy) (N = 62)
Outcomes 1) Congenital abnormalities
2) Incidence of hypoplastic nails
3) Neonatal conditions (specifically “jitteriness”)
AEDs were analysed separately.
Notes Protocol requested - authors unable to provide protocol but description of study plan
given
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as some confounders considered but several im-
portant confounders not considered and adjusted for
Blinding Low risk Rated 2 as outcome assessor blinded
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D’Souza 1990 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 1 as no missing data
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective reporting, no protocol
available
Other bias High risk Rated 5 did not investigate dose, unclear if child with ge-
netic syndrome was excluded
Delmiš 1991
Methods A prospective study (Croatia)
Participants 134 infants born to women with epilepsy (N = 132). Although 7 women with epilepsy
were excluded from this review as they were receiving polytherapy. Therefore 127 infants
born to pregnant women with epilepsy
503 infants born to no medication (in women without epilepsy) (N = 499)
Interventions Intervention group (monotherapy):
1) PB (N = 58)
2) CBZ (N = 18)
3) PRM (N = 9)
Control group:
1) Women with epilepsy not taking any AEDs (N = 10)
Outcomes 1) Major congenital malformation
2) Specific malformations (heart, skeletal, urogenital, cleft lip and palate and cleft spine)
2) Neonatal complications
3) Complication during pregnancy and delivery
AEDs were analysed separately.
Notes Study authors’ contact details could not be found.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as some confounders considered but no adjust-
ment employed
Blinding Unclear risk Rated unclear no details in text
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Delmiš 1991 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 1 as no reported missing data
Selective reporting (reporting bias) Unclear risk Rated 3 as limited information regarding a priori out-
comes, protocol not available
Other bias High risk Rated 5 as no investigation of dose, gestational age at
enrolment is unclear, unclear if excluded genetic syn-
dromes
Diaz-Romero 1990
Methods A prospective study (Mexico)
Participants 72 full-term newborns of epileptic mothers were studied. These were compared with a
control group of offspring of mothers without epilepsy
Interventions Intervention group (monotherapy):
1) CBZ (N = 26)
2) PHT (N = 21)
3) VPA (N = 10)
4) PHT (N = 2)
Control group:
1) Women with epilepsy not taking any AEDs (N = 8)
Outcomes 1) Facial anthropometric measurements
AEDs were analysed separately.
Notes All newborns in the intensive care unit, and those with congenital malformations with
a different specific recognisable aetiology were excluded
Study authors’ contact details could not be found.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as limited confounding variables adjusted for
Blinding Unclear risk Rated unclear as no details of blinding in text
Incomplete outcome data (attrition bias)
All outcomes
High risk Rated 5 as no details given regarding the number re-
cruited
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Diaz-Romero 1990 (Continued)
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective reporting, no proto-
col available
Other bias High risk Rated 5 as dose not investigated, unclear gestational age
at enrolment, unclear if childrenwith genetic syndromes
were excluded
Dravet 1992
Methods A prospective study (France).
Participants 281 pregnant women with epilepsy treated or not treated with AEDs were included in
the study. Out of these, some were lost to follow-up (N = 35), some miscarried (N = 12)
, and some terminated pregnancy (N = 7). 227 outcomes of pregnancy were evaluated
overall (229 infants)
Interventions Intervention groups (monotherapy):
1) 1 AED (N = 128)
Control group:
3) No AED (N = 14)
Outcomes 1) Malformations (broken down into specific malformations)
2) Change in seizure frequency during first trimester (in 50 women)
3) Relationship between type of epilepsy and malformations
4) Relationship between treatment and malformations
Notes Protocol requested - author unable to provide protocol. Not included in meta-analysis
or narrative reporting as numbers of individual AEDs not available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as several considered and adjusted for appropri-
ately
Blinding Unclear risk Rated unclear as no details of blinding in text
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as only small amount of missing data, unlikely
to affect outcome
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective reporting, noprotocol
available
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Dravet 1992 (Continued)
Other bias High risk Rated 5 as drug data were separated but not clear on
numbers, no examination of dose, unclear gestational
age at enrolment, unclear whether children with genetic
syndromes were excluded
Eroglu 2008
Methods A prospective study (Turkey)
Participants 84 pregnant women with epilepsy were enrolled; the 80 pregnancies that were full-term
were all analysed
Interventions Intervention group (monotherapy):
1) CBZ (N = 46)
2) PHT (N = 14)
3) VPA (N = 15)
4) PB (N = 5)
Outcomes 1) Seizure frequency
2) Congenital malformations
AEDs were analysed separately.
Notes Protocol requested - no response received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 5 as no confounding variables adjusted for in anal-
ysis
Blinding Unclear risk Rated unclear as no details of blinding in text
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as only small amount of missing data, unlikely
to affect outcome
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective reporting, no protocol
available
Other bias High risk Rated 5 as unclear gestational age at enrolment, unclear
as to whether children with genetic syndromes were ex-
cluded
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EURAP
Methods A prospective registry study (42 countries)
Participants 4540 pregnant women with epilepsy were included in this study
Interventions The pregnant women with epilepsy were taking:-
1) CBZ (N = 1402)
2) LTG (N = 1280)
3) PB (N = 217)
4) VPA (N = 1010)
Outcomes 1) Congenital malformations
Notes Protocol requested - no response received. Not included in meta-analysis due to overlap
with other studies (e.g. UK Epilepsy and Pregnancy Register)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Low risk Rated 2 as most important confounders
considered and adjusted for appropriately
in analyses
Blinding High risk Rated 5 as outcome assessors unblinded as
assessments completed by family physician
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data
with reasons given
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective report-
ing, no protocol available
Other bias Low risk Rated 1 as no further bias identified
Fairgrieve 2000
Methods A prospective study (UK)
Participants 400 pregnant women with epilepsy were identified, 300 of which took part in the study
Interventions Intervention group (monotherapy):
1) CBZ (N = 109)
2) VPA (N = 74)
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Fairgrieve 2000 (Continued)
Control group:
1) Women with epilepsy not taking any AEDs (N = 48)
Outcomes 1) Major malformations
2) Still births
3) Miscarriages
4) Medical terminations
5) Terminations
Notes Protocol requested - protocol unavailable.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk High in bias due to non-randomised design
Allocation concealment (selection bias) Unclear risk High in bias due to non-randomised design
Confounding variables High risk Rated 5 as no important confounders considered and no
adjustment employed
Blinding Unclear risk Rated unclear as no details in text
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data
Selective reporting (reporting bias) Unclear risk Rated 3 as limited information regarding a priori outcomes,
protocol not available
Other bias High risk Rated 5 as unclear gestational age at enrolment, unclear as
to whether children with genetic syndromes were excluded
Froscher 1991
Methods A prospective study (Gemany)
Participants 66 pregnant women with epilepsy were included in this study; there were 79 pregnancies
in total
Interventions Intervention group (monotherapy):
1) CBZ (N = 31)
2) VPA (N = 12)
3) PB (N = 5)
4) PHT (N = 3)
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Froscher 1991 (Continued)
Outcomes 1) Seizure frequency
2) Miscarriage and perinatal mortality
3) Major congenital malformations
4) Minor congenital malformations
Notes Protocol requested - author could not provide protocol but summarised the aims of the
study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 5 as no confounders considered or adjusted for
Blinding Unclear risk No details on text regarding methods of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data
Selective reporting (reporting bias) Unclear risk Rated 3 as limited information regarding outcomes in
methods section, no protocol available
Other bias High risk Rated 5 as dose not investigated, unclear gestational age
at enrolment, unclear whether children with genetic
syndromes were excluded
Fujji 2013
Methods A prospective study (several countries including Canada, France, England, Italy and
Korea)
Participants 446 pregnant women with epilepsy were included in this study
Interventions Intervention group (monotherapy)
GBP (N = 223)
Control group:
Women with epilepsy not exposed to GBP (N = 223)
Outcomes 1) Major malformations
2) Live births
3) Spontaneous abortions
4) Therapeutic abortions
85Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fujji 2013 (Continued)
5) Still births
6) Preterm births
7) Neonatal intensive care unit (NICU)/ special care nursery (SCN)
8) Low birth weight
9) Intrauterine growth retardation
10) Mean birth weight
11) Mean gestational age at birth
Notes Protocol requested - protocol received. Not included in meta-analysis due to inclusion
of non-epilepsy cases >10%. This study was reviewed narratively
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as some confounders considered
and partial adjustments made
Blinding High risk Rated 5 as outcome assessors unblinded as
assessments completed by family physician
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Rated unclear as only report numbers with
complete data
Selective reporting (reporting bias) Low risk Rated 1 as no evidence of selective report-
ing, protocol available
Other bias High risk Rated 5 unclear gestational age at enrol-
ment, unclear as to whether children with
genetic syndromes were excluded
Gaily 1988
Methods A prospective cohort-controlled study. Duration: 4 years. Follow-up: 5.5 years
Participants 153 children of epileptic mothers were enrolled in the study, but 5 died in the perinatal
period. 120 of the surviving 148 were seen at 5.5 ± 0.25 years, and 1 at 8 years
Interventions Intervention group (monotherapy):
1) PHT (N = 46)
Control group:
1) Children born to women with untreated epilepsy (N = 15)
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Gaily 1988 (Continued)
2) Children born to no medication (in women without epilepsy) (N = 105)
Outcomes 1) Minor physical anomalies
Notes Protocol requested - no response received.Out of the AEDs, only phenytoin was analysed
separately
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as some confounders were consid-
ered
Blinding Low risk Rated 2 as outcome assessor blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data
with reasons given
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective report-
ing, no protocol available
Other bias High risk Rated 5 as control group recruited at a later
time point, unclear whether children with
genetic conditions were excluded, unclear
gestational age at enrolment
Garza-Morales 1996
Methods Prospective observational study (Spain)
Participants 61 pregnant women with epilepsy
Interventions Intervention group (monotherapy):
1) PHT (N = 27)
2) CBZ (N = 24)
3) VPA (N = 5)
Control group
1) Women with epilepsy not taking any AEDs (N = 18)
Outcomes 1) Major malformations
2) Minor malformations
3) Complications during pregnancy
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Garza-Morales 1996 (Continued)
Notes Study authors’ contact details could not be found.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 5 as consideration or adjustment for
confounders
Blinding Unclear risk Rated unclear as no details in text
Incomplete outcome data (attrition bias)
All outcomes
High risk Rated 5 as no information given about attri-
tion
Selective reporting (reporting bias) Unclear risk Rated 3 as limited information regarding a
priori outcomes, protocol not available
Other bias High risk Rated 5 as unclear gestational age at en-
rolment, no investigation of dose, unclear
whether children with genetic syndromes
were excluded
Goujard 1974
Methods A prospective study (France).
Participants 42 pregnant women with epilepsy were included in this study.
Interventions Intervention group (monotherapy):
1) AEDs (N = 39)
Control group:
1) Women with epilepsy not taking any AEDs (N = 3)
Outcomes 1) Major malformations
2) Minor malformations
Notes Study authors’ contact details could not be found. Not included in meta-analysis due to
unclear numbers of malformations for specific monotherapy groups
Risk of bias
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Goujard 1974 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 5 as no consideration of adjustment undertaken
Blinding Unclear risk Rated unclear as no details in text
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Rated unclear as no details in text
Selective reporting (reporting bias) Unclear risk Rated 3 as limited information regarding a priori out-
comes, protocol not available
Other bias High risk Rated 5 no investigation of dose, unclear whether chil-
dren with genetic syndromes were excluded, no clear
information given about monotherapy cases given
Hill 1974
Methods A prospective, cohort-controlled, multicentre study (USA). Duration: 4 years (plus 3
years follow-up)
Participants 28 newly born infants were recruited between January 1969 and November 1972 and
examined. All infants were the offspring of women who had required AED treatment
during their pregnancy
The control group was made up of 165 infants not exposed to AEDs
Interventions Intervention group (monotherapy):
1) PHT (N = 9)
2) PB (N = 1)
Control group:
1) Women who were not taking any AEDs (N = 165)
Outcomes 1) Minor malformations
2) Major malformations
3) Apgar score
4) Birth weight and length of infant
5) Gross motor index
6) Fine motor index
7) Adaptive index
8) Language index
9) Personal-social index
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Hill 1974 (Continued)
Notes Study authors’ contact details could not be found. Not included in meta-analysis due to
unclear numbers of malformations for specific monotherapy groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as many variables where data has
been collected but not adjusted for
Blinding Low risk Rated 2 as outcome assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as only small amount of missing
data, unlikely to affect outcome
Selective reporting (reporting bias) Low risk Rated 2 as data presented in tables shows
overall AED group versus controls however
in the text many the cases of malformations
are described and drug exposure is stated
Other bias High risk Rated 5 as AEDs not analysed separately,
unclear gestational age at enrolment, un-
clear as to whether children with genetic
syndromes were excluded
Israeli Teratogen Service
Methods A prospective study (Israel)
Participants Data reported across four papers.
Interventions Intervention group (monotherapy):
1) VPA (N = 89)
2) CBZ (N = 108)
3) TPM (N = 57)
Control group:
1) Pregnant women not exposed to teratogenic substances (N = 1315)
Outcomes 1) Rate of major congenital anomalies
2) Pregnancy outcome
3) Gestational age at delivery
4) Rate of preterm deliveries
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Israeli Teratogen Service (Continued)
5) Birth weight
Notes Protocol requested - protocol received. Data could not be included in the meta-analysis
for VPA and TPM as number of women taking these AED for non-epilepsy conditions
was >10%. In the paper on CBZ data were specifically reported for the women with
epilepsy on CBZ and therefore this data could contribute to the meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as some confounders considered and adjusted for
Blinding High risk Rated 5 as outcome assessors unblinded as assessments
completed by family physician
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Rated 3 as larger amount of missing data with reasons
given, possible implication on outcome
Selective reporting (reporting bias) Low risk Rated 1 as no evidence of selective reporting, protocol
available
Other bias High risk Rated 5 as reported monotherapy and polytherapy cases
together in some papers, unclear gestational age at enrol-
ment, unclear whether children with genetic conditions
were excluded
Jones 1989
Methods A prospective and retrospective study (USA). Only participants who were prospectively
recruited were included in this review
Participants The offspring of 145 women were enrolled:-
1) Offspring of women, taking some combination of AEDs including carbamazepine
(all but 1 woman were taking for seizure control) (N = 54)
2) Offspring of women not taking any AEDs, or any other drug known or suspected to
be a teratogen (N = 70)
Interventions Intervention group (monotherapy):
1) Carbamazepine alone (N = 50)
Control group:
1) Women with epilepsy not taking any AEDs (N = 73)
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Jones 1989 (Continued)
Outcomes 1) Incidence of major malformations
2) Incidence of minor malformations
3) Birth weight
4) Birth length
5) Head circumference at birth
Notes Protocol requested - no response received. Data was not included in meta-analysis as
outcomes pertaining to specific monotherapy exposures were not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as some confounders considered
andpartially adjusted for but several impor-
tant confounders not considered and ad-
justed for
Blinding Low risk Rated 2 as outcome assessor blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Rated 4 as 33% missing data from original
recruitment, unclear about the balance of
dropouts
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective report-
ing, no protocol available
Other bias High risk Rated 5 as monotherapy and polytherapy
reported together, dose not investigated,
unclear if children with genetic syndromes
were excluded
Kaaja 2003
Methods A prospective study (Finland)
Participants The 970 pregnancies of the 641 epileptic women enrolled, resulted in 979 offspring
which were included in the study:-
1) Offspring of women with epilepsy, taking 1 or more AED during the first trimester
(N = 733)
2) Offspring of women with epilepsy, not exposed to AEDs (N = 237)
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Kaaja 2003 (Continued)
Interventions Intervention group (monotherapy):
1) CBZ (N = 363)
2) PHT (N = 124)
3) VPA (N = 61)
4) PB (N = 5)
5) PRM (N = 6)
6) OXC (N = 9)
Control group:
1) Women with epilepsy who were not taking any AEDs (N = 237)
Outcomes 1) Major malformations
2) Birth weight
3) Apgar score
4) Pregnancy outcome
AEDs were analysed separately.
Notes Study authors’ contact details could not be found
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as some confounders considered and adjusted
for
Blinding Unclear risk Rated unclear as no details in text regarding methods
of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data with reasons
given
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective reporting, no proto-
col available
Other bias High risk Rated 5 as no investigation of dose, unclear as to
whether children with genetic syndromes were ex-
cluded, unclear gestational age at enrolment
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Kaneko 1999
Methods A prospective study (Japan, Italy, Canada)
Participants 145 infants born to AED-treated mothers between 1985-1989, and a previous group
of 172 infants of AED-treated mothers and 20 infants of non-AED-treated mothers
selected between 1978-1984, were included in the study group
Interventions Intervention group (monotherapy):
1) VPA (N = 81)
2) CBZ (N = 158)
3) PRM (N = 35)
4) PB (N = 79)
5) PHT (N = 132)
Control group:
1) Women with epilepsy who were not taking any AEDs (N = 98)
Outcomes 1) Incidence of congenital malformations
AEDs were analysed separately.
Notes Study authors’ contact details could not be found.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 5 as no confounders considered or
adjusted for
Blinding Unclear risk Rated unclear as not details in text regard-
ing methods of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data
with reasons given
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective report-
ing, no protocol available
Other bias High risk Rated 5 as no investigation of dose, un-
clear gestational age at enrolment, unclear
whether children with genetic conditions
were excluded
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Kelly 1984
Methods A prospective study (USA).
Participants 171 children were evaluated from 468 women with epilepsy enrolled
Interventions Intervention group (monotherapy):
1) PHT (N = 24)
2) PB (N = 6)
3) VPA (N = 4)
Control group:
1) Women with untreated epilepsy (N = 23)
Outcomes 1) Major abnormality
2) Microcephaly
3) Distal digital hypoplasia
4) Craniofacial abnormality
5) Delayed development
Notes Study authors’ contact details could not be found.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 5 as no confounding variables considered or ad-
justed for in analysis
Blinding Unclear risk Rated unclear as no details of blinding in text
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data with reasons
given
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective reporting, no protocol
available
Other bias High risk Rated 5 as dose not investigated, unclear as to whether
children with genetic conditions were excluded, unclear
gestational age at enrolment
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Kerala Pregnancy Registry
Methods A prospective registry study (India). Data reported across two papers
Participants 85 women with epilepsy were enrolled, but only 32 had completed their current preg-
nancy. Only these 32 are analysed and included in the review:-
1) Women taking AED/s (N = 23)
2) Women not taking any AEDs (N = 9)
Interventions Study 1. Overall malformation risk
Interevntion group (monotherapy):
1) PB (N = 9)
2) CBZ (N = 7)
3) VPA (N = 6)
4) PHT (N = 5)
Control group:
1) Women with epilepsy not taking any AEDs (N = 9).
Study 2. Heart defects risk
Interevntion group (monotherapy):
1) PB (N = 43)
2) CBZ (N = 112)
3) VPA (N = 71)
4) PHT (N = 100)
Control group:
1) Women with epilepsy not taking any AEDs (N = 10).
Outcomes 1) Pregnancy outcome
2) Seizure frequency
3) Congenital malformations
4) Infant head circumference
5) Birth weight
Notes Protocol requested - no response received. Data reported across two papers. The more re-
cent paper reported outcomes pertaining to heart defects only and therefore the numbers
available for meta-analysis for heart defects is substantially higher than that for overall
malformation risk and other specific malformation types
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as many variables where data has
been collected but not adjusted for in the
analysis
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Kerala Pregnancy Registry (Continued)
Blinding High risk Rated 4 as partial or no blinding involved
in study.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as smaller amount of missing data,
unlikely to affect outcome
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective report-
ing, no protocol available
Other bias High risk Rated 5 as no investigation of dose, unclear
whether children with genetic conditions
were excluded, recruitment into the third
trimester
Koch 1992
Methods A prospective study (Germany).
Participants 1) Women with epilepsy treated with AEDs (N = 116)
2) Women with epilepsy without AED treatment (N = 25)
Each of these study groups had a corresponding matched control group with an identical
number of mother-child pairs. Total number of control pairs (N = 163)
Interventions Intervention group (monotherapy):
1) PB (N = 4)
2) PRM (N = 21)
3) PHT (N = 24)
4) CBZ (N = 9)
5) VPA (N = 14)
Control group:
1) no medication (in women without epilepsy) (N = 116)
Outcomes 1) Major malformations
2) Minor anomalies
Notes Study authors’ contact details could not be found.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
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Koch 1992 (Continued)
Confounding variables Unclear risk Rated 3 as some confounders considered and partial
adjustment employed
Blinding High risk Rated 5 as no methods of blinding were employed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Rated unclear as no details of numbers recruited ver-
sus those analysed
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective reporting, no pro-
tocol available
Other bias High risk Rated 5 as dose not investigated, unclear gestational
age at enrolment, unclear whether children with ge-
netic syndromes were excluded
Laskowska 2002
Methods A prospective study (Poland)
Participants 53 pregnant women with epilepsy and 53 pregnant no medication (in women without
epilepsy) were involved in this study
Interventions Intervention group (monotherapy):
1) AED (N = 39)
Control group:
1) Women with epilepsy not taking any AEDs (N = 5)
2) no medication (in women without epilepsy) (N = 53)
Outcomes 1) Seizure frequency
2) Complications during pregnancy
3) Congenital malformations
4) Birth weight/height
Notes Protocol requested - no response received. Study was not included in meta-analysis as
outcomes for specific monotherapy groups were not clear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 5 as no confounders considered or adjusted for
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Laskowska 2002 (Continued)
Blinding Unclear risk Rated unclear as no details in text
Incomplete outcome data (attrition bias)
All outcomes
High risk Rated 5 as no information given
Selective reporting (reporting bias) Unclear risk Rated 3 as limited information regarding a priori out-
comes
Other bias High risk Rated 5 as did not analysis AEDs separately, unclear
gestational age at enrolment, unclear if excluded children
with genetic syndromes
Lindhout 1992
Methods A prospective study (Germany)
Participants 172 live infants born to women taking AEDs
Interventions Intervention group (monotherapy):
1) VPA (N = 66)
2) PB (N = 26)
3) CBZ (N = 50)
4) PHT (N = 17)
Control group:
1) Women with epilepsy who were not taking any AEDs (N = 28)
Outcomes 1) Congenital malformations
Notes Study authors’ details could not be found.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as some variables where data has been col-
lected but not adjusted for in the analysis
Blinding Unclear risk Rated unclear as no details of blinding methods em-
ployed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data, unlikely to
affect outcome
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Lindhout 1992 (Continued)
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective reporting, no pro-
tocol available
Other bias High risk Rated 5 unclear gestational age at enrolment, individ-
ual malformation data unclearly reported across num-
ber of data tables
Martinez Ferri 2009
Methods A prospective study (Spain)
Participants 269 women with epilepsy being treated with monotherapy were included in this study
Interventions Intervention group (monotherapy):
1) CBZ (N = 105)
2) VPA (N = 68)
3) LTG (N = 56)
4) PB (N = 11)
Outcomes 1) Major malformations
2) Perinatal death
Notes Protocol requested - no response received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as some confounders considered and full or partial
adjustment employed
Blinding Unclear risk Rated unclear as details not given in text
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data, reasons given
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective reporting, protocol not
available
Other bias High risk Rated 5 as dose not investigated, unclear if children with
genetic syndromes were excluded
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Mawer 2010
Methods A prospective study (UK)
Participants 277 women with epilepsy were recruited but three were excluded and 315 nomedication
(in women without epilepsy) were recruited as control participants
Interventions Intervention group (monotherapy):
1) CBZ (N = 74)
2) VPA (N = 57)
3) LTG (N = 40)
4) PHT (N = 7)
Control group:
1) no medication (in women without epilepsy) (N = 315)
2) Women with untreated epilepsy (N = 40)
Outcomes 1) Major congenital malformations
2) Birth weight
Notes Protocol requested - protocol received. Overlap in data with NEAD study. Data com-
bined in meta-analysis along with NEAD data were non-NEAD data from this study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Low risk Rated 2 as the majority of important confounders consid-
ered and appropriately adjusted for
Blinding High risk Rated 5 as no methods of blinding were employed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as smaller amount of missing data with reasons
given, balanced across groups
Selective reporting (reporting bias) Low risk Rated 1 as no evidence of selective reporting, protocol avail-
able
Other bias High risk Rated 5 as recruitment continued into the third trimester.
Dose not investigated
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Meador 2006
Methods A prospective study (USA and UK)
Participants 354 mother/child pairs were enrolled. 323 mothers and 333 children were included in
the analysis. All mothers were being treated for epilepsy with AED monotherapy
Interventions Intervention group (monotherapy):
1) CBZ (N = 110)
2) LTG (N = 98)
3) PHT (N = 56)
4) VPA (N = 69)
Outcomes 1) Major congenital malformations
2) Fetal death
Notes Protocol requested - protocol received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Low risk Rated 2 as themajority of important confounders
considered and appropriately adjusted for
Blinding Low risk Rated 2 as some methods of blinding were em-
ployed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as smaller amount of missing data with
reasons given, balanced across groups
Selective reporting (reporting bias) Low risk Rated 1 as no evidence of selective reporting, pro-
tocol available
Other bias High risk Rated 5 as no investigation of dose of individual
AED, unclear gestational age at recruitment
Meischenguiser 2004
Methods A prospective registry study (Argentina).
Participants 114 women being treated with AEDs for epilepsy, who were pregnant or intending to
become pregnant
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Meischenguiser 2004 (Continued)
Interventions Intervention group (monotherapy):
1) OXC (N = 35)
2) VPA (N = 21)
3) CBZ (N = 16)
4) PB (N = 5)
Outcomes 1) Major malformations
2) Minor malformations
3) Pregnancy and delivery complications
AEDs were analysed separately.
Notes Protocol requested - no response received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as some confounders collected but
no adjustment in the analysis
Blinding Unclear risk Rated unclear as no details of blinding in
text
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data,
unlikely to affect outcome
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective reporting,
no protocol available
Other bias High risk Rated 5 as dose not investigated, unclear ges-
tational age at enrolment, unclear whether
children with genetic syndromes excluded
Montreal Series
Methods A prospective study (Canada)
Participants 82173 births were analysed between 1978 and 2000 of:-
1) Women with epilepsy receiving AEDs (N = 335)
2) Women with epilepsy not receiving AEDs (N = 66)
3) no medication (in women without epilepsy) (N = 81759)
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Montreal Series (Continued)
Interventions Intervention group (monotherapy):
1) CBZ (N = 32)
2) PHT (N = 44)
3) VPA (N = 15)
4) PB (N = 10)
Control group:
1) Women with epilepsy not taking any AEDs (N = 8)
Outcomes 1) Neonatal outcome (including Stillbirths, Apgar score, birth weight)
2) Congenital malformations
AEDs were analysed together
Notes Protocol requested - no response received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as some confounders considered and full or
partial adjustment employed
Blinding Unclear risk Rated unclear as no details in text
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data, unlikely to
affect outcome
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective reporting, no proto-
col available
Other bias High risk Rated 5 as dose not investigated, unclear whether chil-
dren with genetic syndromes, unclear gestational age at
recruitment
Motherisk Registry
Methods A prospective study (Canada)
Participants 118 women were enrolled between 1987 and 1992, and 70 mother-child pairs analysed.
(+9 non-medicated)
Interventions Intervention group (monotherapy):
1) PHT (N = 34)
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Motherisk Registry (Continued)
2) CBZ (N = 36)
Control group:
1) Women with epilepsy not taking any AEDs (N = 9)
2) no medication (in women without epilepsy) (N = 79)
Outcomes 1) Major malformations
2) Minor anomalies
Notes Protocol requested - no response received. Data not included in meta-analysis as non-
epilepsy cases >10%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as some confounders considered and no adjust-
ment employed
Blinding Unclear risk Rated 3 as partial blinding involved in study as some
outcomes were blindly assessed, others were not
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data pertaining to
minor anomalies
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective reporting, no proto-
col available
Other bias High risk Rated 5 as dose not investigated, unclear of gestational
age at enrolment, unclear if children with genetic con-
ditions were included
North American Register
Methods A prospective, cohort-controlled study (USA). Duration: 14 years. Follow-up: Up to 12
weeks
Participants 5265 women were enrolled and analysed in the study:-
Interventions Intervention group (monotherapy):
1) CBZ (N = 1033)
2) LTG (N = 1562)
3) PHT (N = 416)
4) LEV (N = 450)
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North American Register (Continued)
5) TPM (N = 359)
6) VPA (N = 323)
7) PB (N = 199)
8) OXC (N = 182)
9) GBP (N = 145)
10) ZNS (N = 90)
Control group:
1) no medication (in women without epilepsy) (N = 442)
Outcomes 1) Major congenital malformations, most commonly: hypospadias, neural tube defects,
cardiovascular anomalies and oral clefts
Notes Protocol requested - no response received. Data not available for specific malformations
for GBP or ZNS
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Low risk Rated 2 as most important confounders
considered and suitable method of adjust-
ment employed
Blinding High risk Rated 5 as no methods of blinding were
employed, reviewed by family physician
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data,
unlikely to affect outcome
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective report-
ing, no protocol available
Other bias High risk Rated 5 as women recruited at any stage of
pregnancy
Omtzigt 1992
Methods A prospective study (Netherlands)
Participants 261 women enrolled, 297 children of women with epilepsy examined
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Omtzigt 1992 (Continued)
Interventions Intervention group (monotherapy):
1) VPA (N = 60)
2) CBZ (114)
3) PHT (N = 28)
4) PB (N = 18)
Outcomes 1) Levels of maternal serum alpha fetoprotein
2) Foetus death
3) Malformations
Notes Study authors’ contact details could not be found.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as some confounders considered and no
adjustment employed
Blinding High risk Rated 5 as no methods of blinding were employed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Rated 2 as small amount of missing data, unlikely
to affect outcome
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective reporting, no
protocol available
Other bias Low risk Rated 1 as no other bias identified
Pardi 1982
Methods A prospective study (Italy)
Participants 59 pregnant women with epilepsy were included in this study.
Interventions Intervention group (monotherapy):
1) CBZ (N = 2)
2) PB (N = 12)
3) PHT (N = 5)
4) PRM (N = 4)
5) VPA (N = 1)
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Pardi 1982 (Continued)
Outcomes 1) Seizure frequency
2) Major malformations
3) Minor malformations
Notes Study authors’ contact details could not be found.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 5 as no confounding variables considered or adjusted
for in analysis
Blinding Unclear risk Rated unclear as no details on methods of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data, unlikely to affect
outcome
Selective reporting (reporting bias) Unclear risk Rated 3 as limited information regarding a priori outcomes
and measures
Other bias High risk Rated 5 as AEDs not reported separately, unclear whether
children with genetic syndromes were excluded, no inves-
tigation of dose, unclear gestational age at enrolment
Richmond 2004
Methods A prospective study (Canada)
Participants 82173 foetuses were evaluated in this study; 414 births were to 313 women with epilepsy.
Therefore 414 foetuses were included in the intervention group and 81759were included
in the control group
Interventions The women were taking:-
1) PB
2) VPA
3) CBZ
4) PHT
The number of pregnant women with epilepsy taking each AED was unclear
Outcomes 1) Congenital malformations
2) Neonatal deaths
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Richmond 2004 (Continued)
3) Still births
4) Mean Apgar at 1 minute
5) Mean Apgar at 2 minutes
6) Mean birth weight
Notes The number of pregnant women with epilepsy taking each AED was unclear
Protocol requested - no response received.Data not included inmeta-analysis as outcomes
by specific AED group were not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as some confounders considered and no adjust-
ment employed
Blinding Unclear risk Rated unclear as no details on methods of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 1 as no missing data
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective reporting, no proto-
col available
Other bias High risk Rated 5 as AEDs not analysed separately, no investiga-
tion of dose, unclear whether children with genetic syn-
dromes excluded, unclear gestational age at enrolment/
recording
Sabers 2004
Methods A prospective study (Denmark)
Participants 151 women were enrolled in the study. Of these, 147 pregnancies were analysed (includ-
ing 137 living newborns). All women involved had epilepsy. Monotherapy and Poly-
therapy outcomes were not reported separately
Interventions The women were taking either:-
1) LTG
2) OXC
3) VPA
4) CBZ
5) GBP
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Sabers 2004 (Continued)
6) PRM
7) TPM
8) PB
9) PHT
Monotherapy numbers were unclear.
Control group:
1) Women with epilepsy who were not taking any AEDs (N = 9)
Outcomes 1) Neonatal outcome
2) Congenital malformations
3) Birth weight
Notes The number of pregnant women with epilepsy taking each AED in monotherapy was
unclear
Protocol requested - no response received. Data was not included in meta-analysis as
outcomes pertaining to specific monotherapy groups was not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 5 as no important confounders considered and
no adjustment employed
Blinding Unclear risk Rated unclear as no details on methods of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data, unlikely to
affect outcome
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective reporting, no pro-
tocol available
Other bias High risk Rated 5 as monotherapy and polytherapy reported
together, unclear whether children with genetic syn-
dromes were excluded, unclear gestational age at en-
rolment
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Samren 1997
Methods A prospective study (Finland, Germany, Netherlands)
Participants 1221pregnantwomenwith epilepsy and158nomedication (inwomenwithout epilepsy)
were included in this study
Interventions Intervention group (monotherapy):
1) CBZ (N = 280)
2) PB (N = 48)
3) PHT (N = 141)
4) PRM (N = 43)
5) VPA (N = 184)
Control group:
1) no medication (in women without epilepsy) (N = 158)‘
Outcomes 1) Major malformations
Notes Study authors’ contact details could not be found.
Not included in meta analysis due to overlap with other included studies; reviewed
narratively
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) Unclear risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as some confounders considered
and full or partial adjustment employed
Blinding High risk Rated 5 as no blinding employed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Rated unclear as no information provided
Selective reporting (reporting bias) Unclear risk Rated 2 as no evidence of selective report-
ing, protocol not available
Other bias High risk Rated 5 as unclear gestational age at recruit-
ment, unclear is genetic syndromes were
excluded
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Shapiro 1976
Methods Twoprospective registry studies (Finland andUSA).Only theUSA studymeets inclusion
criteria
Participants 305 women with epilepsy in USA study.
Interventions Intervention group:
1) PHT (N = 102)
Unclear if this is monotherapy in isolation.
Outcomes 1) Major and minor malformations
Notes Protocol requested - Study author declined request. Limited data available on method-
ology. Not included in meta-analysis due to it being unclear if cases were exposed to
monotherapy PHT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 5 as no important confounders con-
sidered and no adjustment employed
Blinding Unclear risk Rated as unclear as no details in text
Incomplete outcome data (attrition bias)
All outcomes
High risk Rated 5 as no information provided regard-
ing missing data
Selective reporting (reporting bias) Unclear risk Rated 3 as limited information regarding a
priori outcomes; protocol not available
Other bias High risk Rated 5 as no investigation of dose, unclear
gestational age at recruitment, inclusion of
malformations linked to genetic syndrome
Steegers-Theunissen 1994
Methods A prospective study (Netherlands).
Participants 119 pregnant women with epilepsy and 106 pregnant women were included in this study
Interventions Intervention group (monotherapy):
1) CBZ (N = 39)
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Steegers-Theunissen 1994 (Continued)
2) VPA (N = 19)
3) PB (N = 12)
4) PHT (N = 8)
Control group:
1) Women with epilepsy not taking any AEDs (N = 126)
2) no medication (in women without epilepsy) (N = 106)
Outcomes 1) Major congenital malformations
2) Minor congenital malformations
3) Ectopic pregnancies
4) Abortions
5) Neonatal head circumference
6) Birth weight
7) Birth length
AEDs analysed together.
Notes Protocol requested - no response received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Low risk Rated 2 as most important confounders consid-
ered and suitable method of adjustment employed
Blinding Unclear risk Rated unclear as no details onmethods of blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Rated unclear as no details of numbers recruited
versus those analysed
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective reporting, no
protocol available
Other bias High risk Rated 5 as no investigation of dose, unclear
whether children with genetic syndromes ex-
cluded, unclear gestational age at enrolment
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Tanganelli 1992
Methods A prospective study (Italy)
Participants 97 women with epilepsy (138 pregnancies) and 88 no medication (in women without
epilepsy) (140 pregnancies) were included in this study. 278 pregnancies were analysed
Interventions Intervention group (monotherapy):
1) PB (N = 63)
2) CBZ (N = 9)
3) VPA (N = 6)
Control group
1) no medication (in women without epilepsy) (N = 124).
Outcomes 1) Seizure frequency
2) Pregnancy outcome
3) Presence of major congenital malformations
AEDs were analysed together.
Notes Study authors’ contact details could not be found
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 5 as no important confounders considered and no
adjustment employed
Blinding Unclear risk Rated unclear as no details on methods of blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Rated unclear as no details of numbers recruited versus
those analysed
Selective reporting (reporting bias) Unclear risk Rated 3 as limited information regarding a priori outcomes
and measures
Other bias High risk Rated 5 as no investigation of dose, unclear gestational age
at enrolment, unclear if children with genetic syndromes
excluded
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Torres 1995
Methods A prospective study (Spain)
Participants 61 pregnant women with epilepsy were included in this study.
Interventions Intervention group (monotherapy):
CBZ
PHT
VPA
PRM
CLO
Number of participants in each monotherapy group are unclear
Outcomes 1) Complications during pregnancy
2) Congenital malformations
Notes Study authors contact details could not be found. Not included in meta-analysis due
to outcomes not being reported for specific monotherapy groups. Numbers in each
monotherapy group are unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 5 as no consideration or adjustment for con-
founders
Blinding Unclear risk Rated unclear as no details in text
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data, reasons given
Selective reporting (reporting bias) Unclear risk Rated as 3 as limited information regarding a priori out-
comes; protocol not available
Other bias High risk Rated 5 numbers of monotherapy unclear, no investiga-
tion of dose, unclear gestational age at enrolment, unclear
if children with genetic syndromes were excluded
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UK Register
Methods A prospective registry study (UK).
Participants 4414pregnancies ofwomenwith epilepsywere included in this study, 3607were analysed
Interventions Intervention group (monotherapy):
1) CBZ (N = 1657)
2) VPZ (N = 1220)
3) LTG (N = 2098)
4) PHT (N = 106)
5) GBP (N = 31)
6) TPM (N = 70)
7) LEV (N = 304)
Control group:
1) Women with epilepsy who were not taking any AEDs (N = 541)
Outcomes 1) Congenital malformations
2) Pregnancy outcome
Notes Personal communication from the authors provided up to date figures for PHT and
controls
Protocol requested - protocol received.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as some confounders considered and fully
adjusted for
Blinding High risk Rated 5 as no methods of blinding were employed,
reviewed by family physician
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 a small amount of missing data, unlikely
to affect outcome
Selective reporting (reporting bias) Low risk Rated 1 as no evidence of selective reporting, pro-
tocol provided
Other bias High risk Rated 5 as unclear gestational age at enrolment,
unclear whether children with genetic syndromes
were excluded
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Waters 1994
Methods A prospective study (USA)
Participants Of the 211 women with epilepsy enrolled, data from 174 pregnancies was available for
analysis
Interventions Intervention group (monotherapy):
1) CBZ (N = 33)
2) PHT (N = 28)
3) PB (N = 21)
Control group:
1) Women with epilepsy who were not taking any AEDS (N = 15)
Outcomes 1) Major malformations
2) Fetal death
Notes Protocol requested - author unable to provide protocol.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as some confounders considered but several im-
portant confounders not considered and adjusted for
Blinding Unclear risk Rated unclear as no details on methods of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as only small amount of missing data, unlikely to
affect outcome
Selective reporting (reporting bias) Unclear risk Rated 3 as limited information regarding a priori outcomes
and measures
Other bias High risk Rated 5 as AEDs were reported together, no investigation
of dose, unclear gestational age at enrolment, unclear if
children with genetic syndromes were excluded
Wide 2000
Methods A prospective, controlled study (Sweden). Duration: 10 years. Follow-up: 9 months
Participants 167 infants born towomenwith epilepsy andnomedication (inwomenwithout epilepsy)
between 1985 and 1995 were included in this study
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Wide 2000 (Continued)
Interventions Intervention group (monotherapy):
1) CBZ (N = 39)
2) PHT (N = 22)
Control group:
1) Women with epilepsy who were not taking any AEDs (N = 8).
2) no medication (in women without epilepsy) (N = 83)
Outcomes 1) Griffiths test results (psychomotor development)
2) Minor anomalies
Some AEDs were analysed separately.
Notes Protocol requested - protocol received.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as some confounders were consid-
ered but not adjusted for
Blinding Low risk Rated 2 as assessors blinded to participants
drug regimen
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data,
unlikely to affect outcome
Selective reporting (reporting bias) Low risk Rated 1 as no evidence of selective report-
ing, protocol available
Other bias High risk Rated 5 as unclear whether children with
genetic syndromeswere excluded, no inves-
tigation of dose
Yerby 1992
Methods A prospective study (USA)
Participants 145 women were enrolled in the study. 64 children born to women with epilepsy and
46 children born to no medication (in women without epilepsy) were included in this
study
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Yerby 1992 (Continued)
Interventions Intervention group (monotherapy):
1) CBZ (N = 20)
2) PB (N = 8)
3) PHT (N = 12)
4) PRM (N = 1)
5) VPA (N = 3)
Control group:
1) Women with epilepsy who were not taking AEDs
2) no medication (in women without epilepsy) (N = 46)
Outcomes 1) Birth weight
2) Birth length
3) Gestational age
4) Head circumference
5) Apgar score
6) Feeding difficulties
7) Neonatal irritability
8) Major malformations
9) Congenital anomalies
Notes Protocol requested - no response received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as some confounders were considered but not
adjusted for
Blinding Low risk Rated 2 as assessors blinded to participants drug regimen
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data, unlikely to affect
outcome
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective reporting, no protocol
available
Other bias High risk Rated 5 as women recruited up to 26 weeks therefore pres-
encemalformations may already be known, unclear if chil-
dren with genetic syndromes were excluded, no investiga-
tion of dose
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Annegers 1974 Retrospective methodology
Artama 2013 Record linkage study
Arteaga-Vazques 2012 Case control study
Baermig 1973 Retrospective methodology
Canun-Serrano 1986 Retrospective methodology
Castilla-Puentes 2014 Pharmaceutical post-marketing report with no control group
Dobos 1985 Retrospective methodology
Elshove 1971 Mixed prospective and retrospective methodology
Holmes 1994 Retrospective methodology
Jacobsen 2014 Record linkage study
Knight 1975 No control group
Lamotrigine Pregnancy Register No control group
Miskov 2009 No control group
Monson 1973 Record linkage study
Montouris 2003 Mixed prospective and retrospective methodology
Mostacci 2014 Record linkage study
Nakane 1980 Mixed prospective and retrospective methodology
Pearse 1992 No control group
Robert 1983 Case control study
Starveld-Zimmerman 1975 Retrospective methodology
Veiby 2014 Record linkage
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Characteristics of studies awaiting assessment [ordered by study ID]
Babic 2014
Methods Prospective, observational, single-centre study (Serbia)
Participants 21 women with juvenile myoclonic epilepsy (25 pregnancies, mean age 26.4, ranged 22-34 years)
Interventions 1) Valproate (N = 6)
2) Lamotrigine (N = 8)
3) Topiramate (N = 2)
4) Levetiracetam (N = 4)
5) Polytherapy (N = 5)
Outcomes 1) Congenital malformations
2) Miscarriage
3) Mode of delivery
4) APGAR score
Notes
Idriz-Oglu 2014
Methods Prospective cohort study (Turkey)
Participants 35 pregnant women with epilepsy being treated with either monotherapy or polytherapy
Interventions 1) Lamotrigine (N = 12)
2) Carbamazepine (N = 11)
3) Valproic Acid (N = 9)
4) Other (N = 3)
Outcomes 1) Spontaneous abortion
2) Medical termination
3) Birthweight
4) Respiratory distress
5) Intensive care
Notes
Jones 1992
Methods
Participants
Interventions
Outcomes
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Jones 1992 (Continued)
Notes
Kaabi 2013
Methods Retrospective cohort study (Tunisia)
Participants 19 women exposed to AEDs during pregnancy were involved in the study
Interventions 1) Valproic acid (N = 7)
2) Carbamazepine (N = 5)
3) Phenobarbital (N = 2)
4) Phenytoin (N = 1)
Outcomes 1) Birthweight
2) Malformations
Notes
Kutlu 2013
Methods Prospective cohort study (Canada). Duration: 10 years
Participants 87 pregnancies from 83 women with epilepsy:
1) focal onset with secondary generalised seizures (N = 52)
2) generalised seizures (N = 31)
Interventions AEDs
Outcomes 1) Spontaneous abortions
2) Major malformations
Notes
Lazzaroni Fossati 1986
Methods Cohort study (Italy)
Participants 36 women with epilepsy
Interventions 1) Phenobarbital
2) Benzodiazepines
3) Diphenylhydantoin
4) Sodium valproate
5) Primidone
6) Carbamazepine
7) Sultiame
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Lazzaroni Fossati 1986 (Continued)
Outcomes 1) Congenital malformations
Notes
Midi 2014
Methods Prospective cohort study (Canada). Duration: 1 year
Participants 43 pregnant women with epilepsy
Interventions 1) Lamotrigine
2) Carbamazepine
Outcomes 1) Malformations
2) Spontaneous abortion
Notes
Shvartzman 1986
Methods Cohort study (Hebrew paper)
Participants 14 women with epilepsy
Interventions 1) Hydantoin + Phenobarbitone
2) Phenobarbitone
3) Hydantoin
4) Primidone
5) Methosuximide
6) Carbamazepine
7) Diazepam
8) No treatment
Outcomes 1) Congenital malformations
2) Development
Notes
Vlasov 2014
Methods Cohort study (Russia)
Participants 162 pregnant women (49 in 1998 and 113 in 2013) with:
1) Focal epilepsy (N = 124; 38 in 1998 and 86 in 2013)
2) Ideopathic generalised epilepsy (N = 31; 6 in 1998 and 25 in 2013)
3) Undetermined epilepsy (N = 7; 5 in 1998 and 2 in 2013)
123Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Vlasov 2014 (Continued)
Interventions 1) Carbamazepine (N = 48)
2) Valproate (N = 26)
3) Barbiturates (N = 8)
4) Levetiracetam (N = 13)
5) Other drugs (N = 34)
Outcomes 1) Mode of delivery
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. CBZ vs Controls
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 23 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 CBZ vs Women Without
Epilepsy
8 3513 Risk Ratio (M-H, Fixed, 95% CI) 2.01 [1.20, 3.36]
1.2 CBZ vs WWE - No
Medication
17 4345 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [1.03, 2.19]
2 Neural Tube Malformations 8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 CBZ vs Women Without
Epilepsy
3 832 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.06, 34.14]
2.2 CBZ vs WWE - No
Medication
7 1026 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.15, 5.61]
3 Cardiac Malformations 8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 CBZ vs Women Without
Epilepsy
3 832 Risk Ratio (M-H, Fixed, 95% CI) 1.41 [0.28, 7.02]
3.2 CBZ vs WWE - No
Medication
7 1026 Risk Ratio (M-H, Fixed, 95% CI) 1.84 [0.32, 10.71]
4 Oro-Facial Cleft / Craniofacial
Malformations
8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 CBZ vs Women Without
Epilepsy
3 832 Risk Ratio (M-H, Fixed, 95% CI) 6.13 [1.19, 31.49]
4.2 CBZ vs WWE - No
Medication
7 1026 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.27, 5.00]
5 Skeletal / Limb Malformations 8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 CBZ vs Woment Without
Epilepsy
3 832 Risk Ratio (M-H, Fixed, 95% CI) 3.9 [0.17, 89.64]
5.2 CBZ vs WWE - No
Medication
7 1026 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.18, 3.01]
Comparison 2. GBP vs Controls
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 GBP vs Women Without
Epilepsy
1 587 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.07, 5.18]
1.2 GBP vs WWE - No
Medication
2 733 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.23, 5.93]
2 Neural Tube Malformations 0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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2.1 GBP vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 GBP vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 GBP vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 GBP vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 GBP vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 GBP vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 GBP vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 GBP vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. LEV vs Controls
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 LEV vs Women Without
Epilepsy
1 892 Risk Ratio (M-H, Fixed, 95% CI) 2.16 [0.76, 6.17]
1.2 LEV vs WWE - No
Medication
2 1055 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.10, 1.07]
2 Neural Tube Malformations 0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 LEV vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 LEV vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 LEV vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 LEV vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 LEV vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 LEV vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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5.1 LEV vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 LEV vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. LTG vs Controls
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 LTG vs Women Without
Epilepsy
3 3188 Risk Ratio (M-H, Fixed, 95% CI) 1.68 [0.78, 3.65]
1.2 LTG vs WWE - No
Medication
3 3181 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.64, 1.77]
2 Neural Tube Malformations 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 LTG vs Women Without
Epilepsy
1 355 Risk Ratio (M-H, Fixed, 95% CI) 2.57 [0.11, 62.03]
2.2 LTG vs WWE - No
Medication
2 542 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 LTG vs Women Without
Epilepsy
1 355 Risk Ratio (M-H, Fixed, 95% CI) 2.57 [0.11, 62.03]
3.2 LTG vs WWE - No
Medication
2 542 Risk Ratio (M-H, Fixed, 95% CI) 1.4 [0.15, 13.35]
4 Oro-Facial Cleft / Crainofacial
Malformations
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 LTG vs Women Without
Epilepsy
1 355 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 LTG vs WWE - No
Medication
2 542 Risk Ratio (M-H, Fixed, 95% CI) 5.15 [0.29, 92.56]
5 Skeletal / Limb Malformations 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 LTG vs Women Without
Epilepsy
1 355 Risk Ratio (M-H, Fixed, 95% CI) 23.12 [0.96, 558.25]
5.2 LTG vs WWE - No
Medication
2 542 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.12, 4.12]
Comparison 5. OXC vs Controls
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 OXC vs Women Without
Epilepsy
1 624 Risk Ratio (M-H, Fixed, 95% CI) 1.94 [0.53, 7.15]
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1.2 OXC vs WWE - No
Medication
2 407 Risk Ratio (M-H, Fixed, 95% CI) 2.75 [0.53, 14.43]
2 Neural Tube Malformations 0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 OXC vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 OXC vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 OXC vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 OXC vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 OXC vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 OXC vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 OXC vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 OXC vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. PB vs Controls
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 17 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 PB vs Women Without
Epilepsy
5 1936 Risk Ratio (M-H, Fixed, 95% CI) 2.84 [1.57, 5.13]
1.2 PB vs WWE - No
Medication
13 1030 Risk Ratio (M-H, Fixed, 95% CI) 1.95 [0.97, 3.93]
2 Neural Tube Malformations 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 PB vs Women Without
Epilepsy
1 120 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 PB vs WWE - No
Medication
2 181 Risk Ratio (M-H, Fixed, 95% CI) 1.73 [0.08, 36.75]
3 Cardiac Malformations 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 PB vs Women Without
Epilepsy
1 120 Risk Ratio (M-H, Fixed, 95% CI) 7.8 [0.36, 168.52]
3.2 PB vs WWE - No
Medication
2 181 Risk Ratio (M-H, Fixed, 95% CI) 8.22 [0.37, 181.57]
4 Oro-Facial Cleft / Craniofacial
Malformations
2 Risk Difference (M-H, Fixed, 95% CI) Subtotals only
4.1 PB vs Women Without
Epilepsy
1 120 Risk Difference (M-H, Fixed, 95% CI) -0.03 [-0.29, 0.24]
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4.2 PB vs WWE - No
Medication
2 181 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.21, 0.21]
5 Skeletal / Limb Malformations 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 PB vs Women Without
Epilepsy
1 120 Risk Ratio (M-H, Fixed, 95% CI) 7.8 [0.36, 168.52]
5.2 PB vs WWE - No
Medication
2 181 Risk Ratio (M-H, Fixed, 95% CI) 8.22 [0.37, 181.57]
Comparison 7. PHT vs Controls
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 18 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 PHT vs Women Without
Epilepsy
5 1464 Risk Ratio (M-H, Fixed, 95% CI) 2.38 [1.12, 5.03]
1.2 PHT vs WWE - No
Medication
15 1896 Risk Ratio (M-H, Fixed, 95% CI) 2.40 [1.42, 4.08]
2 Neural Tube Malformations 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 PHT vs Women Without
Epilepsy
2 462 Risk Ratio (M-H, Fixed, 95% CI) 13.17 [0.58, 299.00]
2.2 PHT vs WWE - No
Medication
5 388 Risk Ratio (M-H, Fixed, 95% CI) 1.65 [0.32, 8.51]
3 Cardiac Malformations 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 PHT vs Women Without
Epilepsy
2 462 Risk Ratio (M-H, Fixed, 95% CI) 6.31 [0.75, 52.91]
3.2 PHT vs WWE - No
Medication
5 388 Risk Ratio (M-H, Fixed, 95% CI) 3.23 [0.40, 26.25]
4 Oro-Facial Cleft / Craniofacial
Malformations
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 PHT vs Women Without
Epilepsy
2 462 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.04, 12.54]
4.2 PHT vs WWE - No
Medication
5 663 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 PHT vs Women Without
Epilepsy
2 462 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.07, 37.19]
5.2 PHT vs WWE - No
Medication
5 388 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [0.19, 15.30]
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Comparison 8. PRM vs Controls
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 PRM vs Women Without
Epilepsy
1 137 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.03, 8.43]
1.2 PRM vs WWE - No
Medication
5 503 Risk Ratio (M-H, Random, 95% CI) 3.92 [0.76, 20.14]
2 Neural Tube Malformations 0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 PRM vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 PRM vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 PRM vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 PRM vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 PRM vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 PRM vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 PRM vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 PRM vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 9. TPM vs Controls
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 TPM vs Women Without
Epilepsy
1 801 Risk Ratio (M-H, Fixed, 95% CI) 3.69 [1.36, 10.07]
1.2 TPM vs WWE - No
Medication
2 802 Risk Ratio (M-H, Fixed, 95% CI) 1.99 [0.65, 6.08]
2 Neural Tube Malformations 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 TPM vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 TPM vs WWE - No
Medication
1 191 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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3.1 TPM vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 TPM vs WWE - No
Medication
1 191 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.05, 26.45]
4 Oro-Facial Cleft / Craniofacial
Malformations
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 TPM vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 TPM vs WWE - No
Medication
1 191 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 TPM vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 TPM vs WWE - No
Medication
1 191 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.05, 26.45]
Comparison 10. VPA vs Controls
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 19 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 VPA vs Women Without
Epilepsy
7 2403 Risk Ratio (M-H, Fixed, 95% CI) 5.69 [3.33, 9.73]
1.2 VPA vs WWE - No Med
Controls
14 3182 Risk Ratio (M-H, Fixed, 95% CI) 3.13 [2.16, 4.54]
2 Neural Tube Malformations 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 VPA vs Women Without
Epilepsy
2 502 Risk Ratio (M-H, Fixed, 95% CI) 6.05 [0.94, 38.81]
2.2 VPA vs WWE - No
Medication
6 768 Risk Ratio (M-H, Fixed, 95% CI) 5.30 [1.05, 26.70]
3 Cardiac Malformations 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 VPA vs Women without
Medication
2 502 Risk Ratio (M-H, Fixed, 95% CI) 16.40 [3.05, 88.19]
3.2 VPA vs WWE - No
Medication
6 768 Risk Ratio (M-H, Fixed, 95% CI) 4.85 [1.28, 18.47]
4 Oro-Facial Cleft / Craniofacial
Malformations
6 Risk Difference (M-H, Fixed, 95% CI) Subtotals only
4.1 VPA vs Women Without
Epilepsy
2 502 Risk Difference (M-H, Fixed, 95% CI) 0.01 [-0.03, 0.04]
4.2 VPA vs WWE - No
Medication
6 768 Risk Difference (M-H, Fixed, 95% CI) 0.03 [0.01, 0.05]
5 Skeletal / Limb Malformations 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 VPA vs Women Without
Epilepsy
2 502 Risk Ratio (M-H, Fixed, 95% CI) 16.48 [2.46, 110.49]
5.2 VPA vs WWE - No
Medication
6 768 Risk Ratio (M-H, Fixed, 95% CI) 2.57 [0.82, 8.04]
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Comparison 11. ZNS vs Controls
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 ZNS vs Women Without
Epilepsy
1 532 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.02, 7.93]
1.2 ZNS vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Neural Tube Malformations 0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 ZNS vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 ZNS vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 ZNS vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 ZNS vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 ZNS vs Women Without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 ZNS vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 ZNS vs Women without
Epilepsy
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 ZNS vs WWE - No
Medication
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 12. CBZ vs GBP
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 3 3241 Risk Ratio (M-H, Fixed, 95% CI) 2.28 [0.67, 7.79]
2 Neural Tube Malformations 1 375 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.01, 2.93]
3 Cardiac Malformations 1 375 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.02, 5.37]
4 Oro-Facial Cleft / Craniofacial
Malformations
1 375 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.02, 6.62]
5 Skeletal / Limb Malformations 1 375 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.13]
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Comparison 13. CBZ vs LEV
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 3 3868 Risk Ratio (M-H, Fixed, 95% CI) 1.84 [1.03, 3.29]
2 Neural Tube Malformations 3 3868 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.25, 5.55]
3 Cardiac Malformations 3 3868 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [0.48, 6.97]
4 Oro-Facial Cleft / Craniofacial
Malformations
3 3868 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [0.44, 7.61]
5 Skeletal / Limb Malformations 3 3868 Risk Ratio (M-H, Fixed, 95% CI) 2.30 [0.44, 11.86]
Comparison 14. CBZ vs LTG
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 7 7549 Risk Ratio (M-H, Fixed, 95% CI) 1.34 [1.01, 1.76]
2 Neural Tube Malformations 6 7509 Risk Ratio (M-H, Fixed, 95% CI) 2.32 [0.79, 6.82]
3 Cardiac Malformations 6 7509 Risk Ratio (M-H, Fixed, 95% CI) 1.57 [0.85, 2.89]
4 Oro-Facial Cleft / Crainofacial
Malformations
6 7509 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.53, 2.37]
5 Skeletal / Limb Malformations 6 7509 Risk Ratio (M-H, Fixed, 95% CI) 2.56 [0.97, 6.73]
Comparison 15. CBZ vs OXC
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 4 2011 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [0.66, 3.16]
2 Neural Tube Malformations 4 2011 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.09, 2.54]
3 Cardiac Malformations 4 2011 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.69]
4 Oro-Facial Cleft / Craniofacial
Malformations
4 2011 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.12, 2.33]
5 Skeletal / Limb Malformations 4 2011 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.11, 2.11]
133Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 16. CBZ vs PB
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 22 3368 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.60, 1.16]
2 Neural Tube Malformations 12 2246 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.19, 5.39]
3 Cardiac Malformations 12 2385 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.18, 0.62]
4 Oro-Facial Cleft / Craniofacial
Malformations
12 2246 Risk Ratio (M-H, Fixed, 95% CI) 0.18 [0.07, 0.48]
5 Skeletal / Limb Malformation 12 2246 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.45, 3.21]
Comparison 17. CBZ vs PHT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 23 5445 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.61, 1.11]
2 Neural Tube Malformations 14 4734 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.31, 3.37]
3 Cardiac Malformations 14 4934 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.47, 1.78]
4 Oro-Facial Cleft / Craniofacial
Malformations
14 4734 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.31, 2.05]
5 Skeletal / Limb Malformation 14 4734 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.35, 1.75]
Comparison 18. CBZ vs PRM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 6 777 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.21, 2.01]
2 Neural Tube Malformations 2 158 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.04, 22.75]
3 Cardiac Malformations 2 158 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.00, 2.53]
4 Oro-Facial Cleft / Craniofacial
Malformations
2 158 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 2 158 Risk Ratio (M-H, Fixed, 95% CI) 2.84 [0.16, 51.53]
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Comparison 19. CBZ vs TPM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 3 3524 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.47, 1.31]
2 Neural Tube Malformations 3 3524 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.19, 5.06]
3 Cardiac Malformations 3 3524 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.23, 4.78]
4 Oro-Facial Cleft / Craniofacial
Malformations
3 3524 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.13, 0.81]
5 Skeletal / Limb Malformations 3 3524 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.13, 1.09]
Comparison 20. CBZ vs VPA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 25 7078 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.34, 0.50]
2 Neural Tube Malformations 16 6476 Risk Ratio (M-H, Fixed, 95% CI) 0.17 [0.09, 0.31]
3 Cardiac Malformations 16 6646 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.31, 0.68]
4 Oro-Facial Cleft / Craniofacial
Malformations
16 6476 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.16, 0.49]
5 Skeletal / Limb Malformations 16 6476 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.19, 0.57]
Comparison 21. CBZ vs ZNS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 1 1123 Risk Ratio (M-H, Fixed, 95% CI) 5.54 [0.34, 89.86]
2 Neural Tube Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 22. GBP vs LTG
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 3 4165 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.17, 2.07]
2 Neural Tube Malformations 1 329 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 1 329 Risk Ratio (M-H, Fixed, 95% CI) 3.01 [0.16, 55.67]
4 Oro-Facial Cleft / Craniofacial
Malformations
1 329 Risk Ratio (M-H, Fixed, 95% CI) 1.92 [0.11, 33.05]
5 Skeletal / Limb Malformations 1 329 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 23. GBP vs OXC
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 2 353 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.04, 2.78]
2 Neural Tube Malformations 1 26 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 1 26 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
1 26 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 1 26 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 24. GBP vs PB
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 2 363 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.02, 0.96]
2 Neural Tube Malformations 1 19 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 1 19 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
1 19 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 1 19 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 25. GBP vs PRM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Neural Tube Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 26. GBP vs TPM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 3 663 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.09, 1.17]
2 Neural Tube Malformations 1 58 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 1 58 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
1 58 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 1 58 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 27. GBP vs ZNS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 1 235 Risk Ratio (M-H, Fixed, 95% CI) 1.87 [0.08, 45.41]
2 Neural Tube Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 28. LEV vs GBP
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 3 1007 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [0.43, 5.42]
2 Neural Tube Malformations 1 77 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 1 77 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.03, 16.42]
4 Oro-Facial Cleft / Craniofacial
Malformations
1 77 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.03, 16.42]
5 Skeletal / Limb Malformation 1 77 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 29. LEV vs LTG
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 3 4792 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.20, 1.88]
2 Neural Tude Malformations 3 4792 Risk Ratio (M-H, Fixed, 95% CI) 1.59 [0.24, 10.38]
3 Cardiac Malformations 3 4792 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.22, 3.36]
4 Oro-Facial Cleft / Craniofacial
Malformations
3 4792 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.14, 2.48]
5 Skeletal / Limb Malformation 3 4792 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.10, 6.80]
Comparison 30. LEV vs OXC
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 2 707 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.36, 3.03]
2 Neural Tube Malformations 2 707 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.05, 29.74]
3 Cardiac Malformations 2 707 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.10, 8.21]
4 Oro-Facial Cleft / Craniofacial
Malformations
2 707 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.03, 2.20]
5 Skeletal / Limb Malformations 2 707 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 3.30]
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Comparison 31. LEV vs PB
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 2 717 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.20, 0.96]
2 Neural Tube Malformations 2 717 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.05, 32.52]
3 Cardiac Malformations 2 717 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.02, 0.66]
4 Oro-Facial Cleft / Craniofacial
Malformations
2 717 Risk Ratio (M-H, Fixed, 95% CI) 0.08 [0.01, 0.67]
5 Skeletal / Limb Malformation 2 717 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.01, 3.61]
Comparison 32. LEV vs PHT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 3 1383 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.26, 0.92]
2 Neural Tube Malformations 3 1359 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.12, 5.34]
3 Cardiac Malformations 3 1359 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.06, 1.09]
4 Oro-Facial Cleft / Craniofacial
Malformations
3 1359 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.08, 1.56]
5 Skeletal / Limb Malformations 3 1359 Risk Ratio (M-H, Fixed, 95% CI) 0.10 [0.01, 1.90]
Comparison 33. LEV vs PRM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Neural Tube Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 34. LEV vs TPM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 3 1290 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.26, 0.97]
2 Neural Tube Malformations 3 1290 Risk Ratio (M-H, Fixed, 95% CI) 2.39 [0.10, 58.61]
3 Cardiac Malformations 3 1290 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.16, 9.54]
4 Oro-Facial Cleft / Craniofacial
Malformations
3 1290 Risk Ratio (M-H, Fixed, 95% CI) 0.17 [0.04, 0.68]
5 Skeletal / Limb Malformations 3 1290 Risk Ratio (M-H, Fixed, 95% CI) 0.07 [0.00, 1.31]
Comparison 35. LEV vs ZNS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 1 540 Risk Ratio (M-H, Fixed, 95% CI) 4.64 [0.28, 78.05]
2 Neural Tube Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 36. LTG vs OXC
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 2 2071 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.35, 2.43]
2 Neural Tube Malformations 2 2071 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.03, 12.15]
3 Cardiac Malformation 2 2071 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.07, 4.30]
4 Oro-Facial Cleft / Craniofacial
Malformations
2 2071 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.13, 3.71]
5 Skeletal / Limb Malformation 2 2071 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.02, 2.56]
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Comparison 37. LTG vs PB
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 4 2241 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.17, 0.61]
2 Neural Tube Malformations 3 2174 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.03, 13.28]
3 Cardiac Malformations 3 2174 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.04, 0.42]
4 Oro-Facial Cleft / Craniofacial
Malformations
3 2174 Risk Ratio (M-H, Fixed, 95% CI) 0.22 [0.07, 0.68]
5 Skeletal / Limb Malformations 3 2174 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.02, 2.80]
Comparison 38. LTG vs PHT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 5 4706 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.34, 0.84]
2 Neural Tube Malformations 4 4671 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.07, 1.34]
3 Cardiac Malformations 4 4671 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.14, 0.92]
4 Oro-Facial Cleft / Craniofacial
Malformations
4 4671 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.24, 2.34]
5 Skeletal / Limb Malformations 4 4671 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.03, 0.66]
Comparison 39. LTG vs TPM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 3 4448 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.34, 0.94]
2 Neural Tube Malformations 3 4448 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.08, 4.94]
3 Cardiac Malformations 3 4448 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.17, 3.42]
4 Oro-Facial Cleft / Craniofacial
Malformations
3 4448 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.03, 1.56]
5 Skeletal / Limb Malformations 3 4448 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.03, 0.45]
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Comparison 40. PHT vs GBP
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 3 756 Risk Ratio (M-H, Fixed, 95% CI) 2.81 [0.77, 10.23]
2 Neural Tube Malformations 1 58 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.04, 23.26]
3 Cardiac Malformations 1 58 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.04, 23.26]
4 Oro-Facial Cleft / Craniofacial
Malformations
1 58 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 1 58 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 41. PHT vs OXC
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 3 787 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.43, 2.71]
2 Neural Tube Malformations 3 787 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.04, 20.03]
3 Cardiac Malformations 3 787 Risk Ratio (M-H, Fixed, 95% CI) 2.32 [0.30, 18.27]
4 Oro-Facial Cleft / Craniofacial
Malformations
3 787 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.10, 4.05]
5 Skeletal / Limb Malformations 3 787 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [0.20, 15.55]
Comparison 42. PHT vs PB
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 18 1483 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.53, 1.21]
2 Neural Tube Malformations 10 936 Risk Ratio (M-H, Fixed, 95% CI) 0.4 [0.02, 8.75]
3 Cardiac Malformations 10 1065 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.16, 0.71]
4 Oro-Facial Cleft / Craniofacial
Malformations
10 936 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.07, 0.82]
5 Skeletal / Limb Malformations 10 936 Risk Ratio (M-H, Fixed, 95% CI) 1.45 [0.40, 5.22]
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Comparison 43. PHT vs TPM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 3 1039 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.49, 1.67]
2 Neural Tube Malformations 3 1015 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 71.70]
3 Cardiac Malformations 3 1015 Risk Ratio (M-H, Fixed, 95% CI) 3.12 [0.65, 14.93]
4 Oro-Facial Cleft / Craniofacial
Malformations
3 1015 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.10, 1.42]
5 Skeletal / Limb Malformations 3 1015 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.19, 2.55]
Comparison 44. PB vs OXC
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 4 452 Risk Ratio (M-H, Fixed, 95% CI) 2.52 [0.98, 6.43]
2 Neural Tube Malformations 3 438 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 3 438 Risk Ratio (M-H, Fixed, 95% CI) 11.77 [1.24, 111.80]
4 Oro-Facial Cleft / Craniofacial
Malformations
3 438 Risk Ratio (M-H, Fixed, 95% CI) 3.66 [0.41, 32.43]
5 Skeletal / Limb Malformations 3 438 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.06, 14.52]
Comparison 45. PB vs TPM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 2 607 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [0.65, 2.84]
2 Neural Tube Malformations 2 607 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 2 607 Risk Ratio (M-H, Fixed, 95% CI) 9.02 [1.06, 76.67]
4 Oro-Facial Cleft / Craniofacial
Malformations
2 607 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [0.39, 5.31]
5 Skeletal / Limb Malformations 2 607 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.04, 3.07]
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Comparison 46. VPA vs GBP
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 3 2004 Risk Ratio (M-H, Fixed, 95% CI) 6.21 [1.91, 20.23]
2 Neural Tube Malformations 1 285 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.05, 13.81]
3 Cardiac Malformations 1 285 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.07, 18.84]
4 Oro-Facial Cleft / Craniofacial
Malformations
1 285 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [0.09, 22.19]
5 Skeletal / Limb Malformations 1 285 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.04, 12.14]
Comparison 47. VPA vs LEV
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 3 2631 Risk Ratio (M-H, Fixed, 95% CI) 5.82 [3.13, 10.81]
2 Neural Tube Malformations 3 2631 Risk Ratio (M-H, Fixed, 95% CI) 5.28 [1.17, 23.83]
3 Cardiac Malformations 3 2631 Risk Ratio (M-H, Fixed, 95% CI) 5.79 [1.67, 20.16]
4 Oro-Facial Cleft / Craniofacial
Malformations
3 2631 Risk Ratio (M-H, Fixed, 95% CI) 5.34 [1.33, 21.39]
5 Skeletal / Limb Malformations 3 2631 Risk Ratio (M-H, Fixed, 95% CI) 6.45 [1.33, 31.16]
Comparison 48. VPA vs LTG
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 7 6185 Risk Ratio (M-H, Fixed, 95% CI) 3.56 [2.77, 4.58]
2 Neural Tube Malformations 6 6151 Risk Ratio (M-H, Fixed, 95% CI) 9.09 [3.56, 23.22]
3 Cardiac Malformations 6 6151 Risk Ratio (M-H, Fixed, 95% CI) 4.07 [2.33, 7.09]
4 Oro-Facial Cleft / Craniofacial
Malformations
6 6151 Risk Difference (M-H, Fixed, 95% CI) 0.01 [0.01, 0.02]
5 Skeletal / Limb Malformations 6 6151 Risk Ratio (M-H, Fixed, 95% CI) 7.17 [2.99, 17.18]
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Comparison 49. VPA vs TPM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 3 2287 Risk Ratio (M-H, Fixed, 95% CI) 2.35 [1.40, 3.95]
2 Neural Tube Malformations 3 2287 Risk Ratio (M-H, Fixed, 95% CI) 3.67 [0.79, 17.08]
3 Cardiac Malformations 3 2287 Risk Ratio (M-H, Fixed, 95% CI) 4.73 [1.21, 18.49]
4 Oro-Facial Cleft / Craniofacial
Malformations
3 2287 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.40, 2.40]
5 Skeletal / Limb Malformation 3 2287 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.44, 3.61]
Comparison 50. VPA vs OXC
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 4 914 Risk Ratio (M-H, Fixed, 95% CI) 3.71 [1.65, 8.33]
2 Neural Tube Malformations 4 914 Risk Ratio (M-H, Fixed, 95% CI) 1.89 [0.39, 9.07]
3 Cardiac Malformations 4 914 Risk Ratio (M-H, Fixed, 95% CI) 3.41 [0.87, 13.37]
4 Oro-Facial Cleft / Craniofacial
Malformations
4 914 Risk Ratio (M-H, Fixed, 95% CI) 2.17 [0.63, 7.47]
5 Skeletal / Limb Malformations 4 914 Risk Ratio (M-H, Fixed, 95% CI) 1.49 [0.36, 6.22]
Comparison 51. VPA vs PB
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 20 1763 Risk Ratio (M-H, Fixed, 95% CI) 1.59 [1.11, 2.29]
2 Neural Tube Malformations 11 1225 Risk Difference (M-H, Random, 95% CI) 0.05 [-0.00, 0.10]
3 Cardiac Malformations 11 1324 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.42, 1.38]
4 Oro-Facial Cleft / Craniofacial
Malformations
11 1225 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.22, 1.33]
5 Skeletal / Limb Malformations 11 1225 Risk Ratio (M-H, Fixed, 95% CI) 1.98 [0.79, 4.98]
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Comparison 52. VPA vs PHT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 21 3456 Risk Ratio (M-H, Fixed, 95% CI) 2.00 [1.48, 2.71]
2 Neural Tube Malformations 13 2961 Risk Ratio (M-H, Fixed, 95% CI) 4.47 [1.79, 11.17]
3 Cardiac Malformations 13 3121 Risk Ratio (M-H, Fixed, 95% CI) 2.93 [1.50, 5.72]
4 Oro-Facial Cleft / Craniofacial
Malformations
13 2961 Risk Ratio (M-H, Fixed, 95% CI) 2.37 [0.95, 5.96]
5 Skeletal / Limb Malformations 13 2961 Risk Ratio (M-H, Fixed, 95% CI) 1.98 [0.93, 4.21]
Comparison 53. LTG vs PRM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Neural Tube Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 54. PHT vs PRM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 5 417 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.40, 1.68]
2 Neural Tube Malformations 2 75 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 2 75 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.02, 8.88]
4 Oro-Facial Cleft / Craniofacial
Malformations
2 75 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 2 75 Risk Ratio (M-H, Fixed, 95% CI) 3.38 [0.14, 79.95]
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Comparison 55. PB vs PRM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 6 351 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.21, 1.16]
2 Neural Tube Malformations 2 134 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 2 134 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.03, 6.55]
4 Oro-Facial Cleft / Craniofacial
Malformations
2 134 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 2 134 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.05, 30.82]
Comparison 56. LTG vs ZNS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 1 1652 Risk Ratio (M-H, Fixed, 95% CI) 3.67 [0.23, 59.46]
2 Neural Tube Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 57. OXC vs PRM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 1 15 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.05, 8.73]
2 Neural Tube Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 58. OXC vs TPM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 2 597 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.20, 1.57]
2 Neural Tube Malformations 2 597 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 2 597 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.03, 16.02]
4 Oro-Facial Cleft / Craniofacial
Malformations
2 597 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.05, 3.35]
5 Skeletal / Limb Malformations 2 597 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.05, 3.35]
Comparison 59. OXC vs ZNS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 1 272 Risk Ratio (M-H, Fixed, 95% CI) 4.48 [0.24, 82.23]
2 Neural Tube Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 60. PB vs ZNS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 1 289 Risk Ratio (M-H, Fixed, 95% CI) 10.47 [0.62, 175.67]
2 Neural Tube Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 61. PHT vs ZNS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 1 506 Risk Ratio (M-H, Fixed, 95% CI) 5.46 [0.33, 91.31]
2 Neural Tube Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 62. PRM vs TPM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Neural Tube Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 63. PRM vs VPA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 5 302 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.37, 1.40]
2 Neural Tube Malformations 2 84 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 1.99]
3 Cardiac Malformations 2 84 Risk Ratio (M-H, Fixed, 95% CI) 3.75 [0.16, 89.32]
4 Oro-Facial Cleft / Craniofacial
Malformations
2 84 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 2 84 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.02, 9.92]
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Comparison 64. PRM vs ZNS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Neural Tube Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 65. TPM vs ZNS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 1 449 Risk Ratio (M-H, Fixed, 95% CI) 7.84 [0.47, 129.74]
2 Neural Tube Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 66. VPA vs ZNS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Major Malformations 1 413 Risk Ratio (M-H, Fixed, 95% CI) 17.13 [1.06, 277.48]
2 Neural Tube Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Cardiac Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Oro-Facial Cleft / Craniofacial
Malformations
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Skeletal / Limb Malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 CBZ vs Controls, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 1 CBZ vs Controls
Outcome: 1 All Major Malformations
Study or subgroup CBZ Controls Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CBZ vs Women Without Epilepsy
Arulmozhi 2006 0/7 0/30 Not estimable
Cassina 2013 5/88 25/803 23.6 % 1.83 [ 0.72, 4.65 ]
Israeli Teratogen Service 6/108 6/210 19.5 % 1.94 [ 0.64, 5.89 ]
Koch 1992 0/9 5/116 4.1 % 1.06 [ 0.06, 17.88 ]
Mawer 2010 2/74 6/315 10.9 % 1.42 [ 0.29, 6.89 ]
North American Register 31/1033 5/442 33.5 % 2.65 [ 1.04, 6.78 ]
Steegers-Theunissen 1994 1/39 2/106 5.1 % 1.36 [ 0.13, 14.57 ]
Tanganelli 1992 0/9 4/124 3.2 % 1.39 [ 0.08, 24.01 ]
Subtotal (95% CI) 1367 2146 100.0 % 2.01 [ 1.20, 3.36 ]
Total events: 45 (CBZ), 53 (Controls)
Heterogeneity: Chi2 = 0.93, df = 6 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 2.67 (P = 0.0076)
2 CBZ vs WWE - No Medication
Al Bunyan 1999 1/31 0/10 1.6 % 1.03 [ 0.05, 23.50 ]
Australian 18/361 5/147 15.3 % 1.47 [ 0.55, 3.88 ]
Barqawi 2005 0/16 0/18 Not estimable
Canger 1999 12/113 0/25 1.8 % 5.70 [ 0.35, 93.24 ]
D’Souza 1990 1/3 1/8 1.2 % 2.67 [ 0.23, 30.40 ]
Delmi 1991 4/18 0/10 1.4 % 5.21 [ 0.31, 87.93 ]
Fairgrieve 2000 4/109 3/48 9.0 % 0.59 [ 0.14, 2.52 ]
Garza-Morales 1996 0/24 0/18 Not estimable
Kaaja 2003 10/363 2/239 5.2 % 3.29 [ 0.73, 14.89 ]
Kaneko 1999 9/158 3/98 8.0 % 1.86 [ 0.52, 6.71 ]
Kerala Pregnancy Registry 1/7 0/9 1.0 % 3.75 [ 0.18, 80.19 ]
Koch 1992 0/9 1/25 1.8 % 0.87 [ 0.04, 19.56 ]
Lindhout 1992 5/50 2/28 5.5 % 1.40 [ 0.29, 6.75 ]
0.01 0.1 1 10 100
Favours CBZ Favours Controls
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(. . . Continued)
Study or subgroup CBZ Controls Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mawer 2010 2/74 1/40 2.8 % 1.08 [ 0.10, 11.56 ]
Montreal Series 5/32 0/8 1.7 % 3.00 [ 0.18, 49.32 ]
UK Register 43/1657 13/541 42.3 % 1.08 [ 0.59, 1.99 ]
Waters 1994 1/33 0/15 1.5 % 1.41 [ 0.06, 32.78 ]
Subtotal (95% CI) 3058 1287 100.0 % 1.50 [ 1.03, 2.19 ]
Total events: 116 (CBZ), 31 (Controls)
Heterogeneity: Chi2 = 6.53, df = 14 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 2.13 (P = 0.033)
Test for subgroup differences: Chi2 = 0.80, df = 1 (P = 0.37), I2 =0.0%
0.01 0.1 1 10 100
Favours CBZ Favours Controls
Analysis 1.2. Comparison 1 CBZ vs Controls, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 1 CBZ vs Controls
Outcome: 2 Neural Tube Malformations
Study or subgroup CBZ Controls Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CBZ vs Women Without Epilepsy
Israeli Teratogen Service 0/108 0/210 Not estimable
Koch 1992 0/9 0/116 Not estimable
Mawer 2010 0/74 1/315 100.0 % 1.40 [ 0.06, 34.14 ]
Subtotal (95% CI) 191 641 100.0 % 1.40 [ 0.06, 34.14 ]
Total events: 0 (CBZ), 1 (Controls)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
2 CBZ vs WWE - No Medication
Al Bunyan 1999 0/31 0/10 Not estimable
0.01 0.1 1 10 100
Favours CBZ Favours Controls
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(. . . Continued)
Study or subgroup CBZ Controls Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/361 0/147 30.1 % 1.23 [ 0.05, 29.94 ]
Barqawi 2005 0/16 0/18 Not estimable
Canger 1999 1/113 0/25 34.5 % 0.68 [ 0.03, 16.32 ]
Fairgrieve 2000 0/109 0/48 Not estimable
Koch 1992 0/9 1/25 35.3 % 0.87 [ 0.04, 19.56 ]
Mawer 2010 0/74 0/40 Not estimable
Subtotal (95% CI) 713 313 100.0 % 0.91 [ 0.15, 5.61 ]
Total events: 2 (CBZ), 1 (Controls)
Heterogeneity: Chi2 = 0.07, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 1.3. Comparison 1 CBZ vs Controls, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 1 CBZ vs Controls
Outcome: 3 Cardiac Malformations
Study or subgroup CBZ Controls Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CBZ vs Women Without Epilepsy
Israeli Teratogen Service 1/108 2/210 62.6 % 0.97 [ 0.09, 10.60 ]
Koch 1992 0/9 1/116 10.9 % 3.90 [ 0.17, 89.64 ]
Mawer 2010 0/74 1/315 26.5 % 1.40 [ 0.06, 34.14 ]
Subtotal (95% CI) 191 641 100.0 % 1.41 [ 0.28, 7.02 ]
Total events: 1 (CBZ), 4 (Controls)
Heterogeneity: Chi2 = 0.50, df = 2 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
2 CBZ vs WWE - No Medication
Al Bunyan 1999 0/31 0/10 Not estimable
Australian 3/361 1/147 67.3 % 1.22 [ 0.13, 11.65 ]
Barqawi 2005 0/16 0/18 Not estimable
Canger 1999 0/113 0/25 Not estimable
Fairgrieve 2000 3/109 0/48 32.7 % 3.12 [ 0.16, 59.22 ]
Koch 1992 0/9 0/25 Not estimable
Mawer 2010 0/74 0/40 Not estimable
Subtotal (95% CI) 713 313 100.0 % 1.84 [ 0.32, 10.71 ]
Total events: 6 (CBZ), 1 (Controls)
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 1.4. Comparison 1 CBZ vs Controls, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 1 CBZ vs Controls
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup CBZ Controls Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CBZ vs Women Without Epilepsy
Israeli Teratogen Service 2/108 0/210 31.4 % 9.68 [ 0.47, 199.84 ]
Koch 1992 0/9 3/116 50.9 % 1.67 [ 0.09, 30.13 ]
Mawer 2010 1/74 0/315 17.7 % 12.64 [ 0.52, 307.22 ]
Subtotal (95% CI) 191 641 100.0 % 6.13 [ 1.19, 31.49 ]
Total events: 3 (CBZ), 3 (Controls)
Heterogeneity: Chi2 = 1.06, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.17 (P = 0.030)
2 CBZ vs WWE - No Medication
Al Bunyan 1999 0/31 0/10 Not estimable
Australian 4/361 0/147 20.7 % 3.68 [ 0.20, 67.92 ]
Barqawi 2005 0/16 0/18 Not estimable
Canger 1999 0/113 0/25 Not estimable
Fairgrieve 2000 0/109 1/48 60.5 % 0.15 [ 0.01, 3.58 ]
Koch 1992 0/9 0/25 Not estimable
Mawer 2010 1/74 0/40 18.8 % 1.64 [ 0.07, 39.35 ]
Subtotal (95% CI) 713 313 100.0 % 1.16 [ 0.27, 5.00 ]
Total events: 5 (CBZ), 1 (Controls)
Heterogeneity: Chi2 = 2.25, df = 2 (P = 0.32); I2 =11%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Chi2 = 2.21, df = 1 (P = 0.14), I2 =55%
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Analysis 1.5. Comparison 1 CBZ vs Controls, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 1 CBZ vs Controls
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup CBZ Controls Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CBZ vs Woment Without Epilepsy
Israeli Teratogen Service 0/108 0/210 Not estimable
Koch 1992 0/9 1/116 100.0 % 3.90 [ 0.17, 89.64 ]
Mawer 2010 0/74 0/315 Not estimable
Subtotal (95% CI) 191 641 100.0 % 3.90 [ 0.17, 89.64 ]
Total events: 0 (CBZ), 1 (Controls)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
2 CBZ vs WWE - No Medication
Al Bunyan 1999 0/31 0/10 Not estimable
Australian 2/361 1/147 33.0 % 0.81 [ 0.07, 8.91 ]
Barqawi 2005 0/16 0/18 Not estimable
Canger 1999 4/113 0/25 18.9 % 2.05 [ 0.11, 36.95 ]
Fairgrieve 2000 0/109 1/48 48.1 % 0.15 [ 0.01, 3.58 ]
Koch 1992 0/9 0/25 Not estimable
Mawer 2010 0/74 0/40 Not estimable
Subtotal (95% CI) 713 313 100.0 % 0.73 [ 0.18, 3.01 ]
Total events: 6 (CBZ), 2 (Controls)
Heterogeneity: Chi2 = 1.46, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Chi2 = 0.91, df = 1 (P = 0.34), I2 =0.0%
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Analysis 2.1. Comparison 2 GBP vs Controls, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 2 GBP vs Controls
Outcome: 1 All Major Malformations
Study or subgroup GBP Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 GBP vs Women Without Epilepsy
North American Register 1/145 5/442 100.0 % 0.61 [ 0.07, 5.18 ]
Subtotal (95% CI) 145 442 100.0 % 0.61 [ 0.07, 5.18 ]
Total events: 1 (GBP), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
2 GBP vs WWE - No Medication
Australian 0/14 5/147 41.8 % 0.90 [ 0.05, 15.44 ]
UK Register 1/31 13/541 58.2 % 1.34 [ 0.18, 9.93 ]
Subtotal (95% CI) 45 688 100.0 % 1.16 [ 0.23, 5.93 ]
Total events: 1 (GBP), 18 (Control)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Chi2 = 0.22, df = 1 (P = 0.64), I2 =0.0%
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Analysis 3.1. Comparison 3 LEV vs Controls, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 3 LEV vs Controls
Outcome: 1 All Major Malformations
Study or subgroup LEV Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LEV vs Women Without Epilepsy
North American Register 11/450 5/442 100.0 % 2.16 [ 0.76, 6.17 ]
Subtotal (95% CI) 450 442 100.0 % 2.16 [ 0.76, 6.17 ]
Total events: 11 (LEV), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
2 LEV vs WWE - No Medication
Australian 1/63 5/147 24.3 % 0.47 [ 0.06, 3.91 ]
UK Register 2/304 13/541 75.7 % 0.27 [ 0.06, 1.21 ]
Subtotal (95% CI) 367 688 100.0 % 0.32 [ 0.10, 1.07 ]
Total events: 3 (LEV), 18 (Control)
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.065)
Test for subgroup differences: Chi2 = 5.45, df = 1 (P = 0.02), I2 =82%
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Analysis 4.1. Comparison 4 LTG vs Controls, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 4 LTG vs Controls
Outcome: 1 All Major Malformations
Study or subgroup LTG Controls Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LTG vs Women Without Epilepsy
Cassina 2013 0/26 25/803 15.3 % 0.58 [ 0.04, 9.34 ]
Mawer 2010 2/40 6/315 12.5 % 2.63 [ 0.55, 12.57 ]
North American Register 31/1562 5/442 72.1 % 1.75 [ 0.69, 4.49 ]
Subtotal (95% CI) 1628 1560 100.0 % 1.68 [ 0.78, 3.65 ]
Total events: 33 (LTG), 36 (Controls)
Heterogeneity: Chi2 = 0.88, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
2 LTG vs WWE - No Medication
Australian 13/315 5/147 23.9 % 1.21 [ 0.44, 3.34 ]
Mawer 2010 2/40 1/40 3.5 % 2.00 [ 0.19, 21.18 ]
UK Register 49/2098 13/541 72.6 % 0.97 [ 0.53, 1.78 ]
Subtotal (95% CI) 2453 728 100.0 % 1.07 [ 0.64, 1.77 ]
Total events: 64 (LTG), 19 (Controls)
Heterogeneity: Chi2 = 0.43, df = 2 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Chi2 = 0.94, df = 1 (P = 0.33), I2 =0.0%
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Analysis 4.2. Comparison 4 LTG vs Controls, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 4 LTG vs Controls
Outcome: 2 Neural Tube Malformations
Study or subgroup LTG Controls Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LTG vs Women Without Epilepsy
Mawer 2010 0/40 1/315 100.0 % 2.57 [ 0.11, 62.03 ]
Subtotal (95% CI) 40 315 100.0 % 2.57 [ 0.11, 62.03 ]
Total events: 0 (LTG), 1 (Controls)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
2 LTG vs WWE - No Medication
Australian 0/315 0/147 Not estimable
Mawer 2010 0/40 0/40 Not estimable
Subtotal (95% CI) 355 187 Not estimable
Total events: 0 (LTG), 0 (Controls)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 LTG vs Controls, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 4 LTG vs Controls
Outcome: 3 Cardiac Malformations
Study or subgroup LTG Controls Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LTG vs Women Without Epilepsy
Mawer 2010 0/40 1/315 100.0 % 2.57 [ 0.11, 62.03 ]
Subtotal (95% CI) 40 315 100.0 % 2.57 [ 0.11, 62.03 ]
Total events: 0 (LTG), 1 (Controls)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
2 LTG vs WWE - No Medication
Australian 3/315 1/147 100.0 % 1.40 [ 0.15, 13.35 ]
Mawer 2010 0/40 0/40 Not estimable
Subtotal (95% CI) 355 187 100.0 % 1.40 [ 0.15, 13.35 ]
Total events: 3 (LTG), 1 (Controls)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.76), I2 =0.0%
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Analysis 4.4. Comparison 4 LTG vs Controls, Outcome 4 Oro-Facial Cleft / Crainofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 4 LTG vs Controls
Outcome: 4 Oro-Facial Cleft / Crainofacial Malformations
Study or subgroup LTG Controls Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LTG vs Women Without Epilepsy
Mawer 2010 0/40 0/315 Not estimable
Subtotal (95% CI) 40 315 Not estimable
Total events: 0 (LTG), 0 (Controls)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 LTG vs WWE - No Medication
Australian 5/315 0/147 100.0 % 5.15 [ 0.29, 92.56 ]
Mawer 2010 0/40 0/40 Not estimable
Subtotal (95% CI) 355 187 100.0 % 5.15 [ 0.29, 92.56 ]
Total events: 5 (LTG), 0 (Controls)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 LTG vs Controls, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 4 LTG vs Controls
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup LTG Controls Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LTG vs Women Without Epilepsy
Mawer 2010 1/40 0/315 100.0 % 23.12 [ 0.96, 558.25 ]
Subtotal (95% CI) 40 315 100.0 % 23.12 [ 0.96, 558.25 ]
Total events: 1 (LTG), 0 (Controls)
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.053)
2 LTG vs WWE - No Medication
Australian 0/315 1/147 80.3 % 0.16 [ 0.01, 3.81 ]
Mawer 2010 1/40 0/40 19.7 % 3.00 [ 0.13, 71.51 ]
Subtotal (95% CI) 355 187 100.0 % 0.72 [ 0.12, 4.12 ]
Total events: 1 (LTG), 1 (Controls)
Heterogeneity: Chi2 = 1.66, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Chi2 = 3.51, df = 1 (P = 0.06), I2 =72%
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Analysis 5.1. Comparison 5 OXC vs Controls, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 5 OXC vs Controls
Outcome: 1 All Major Malformations
Study or subgroup OXC Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 OXC vs Women Without Epilepsy
North American Register 4/182 5/442 100.0 % 1.94 [ 0.53, 7.15 ]
Subtotal (95% CI) 182 442 100.0 % 1.94 [ 0.53, 7.15 ]
Total events: 4 (OXC), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
2 OXC vs WWE - No Medication
Australian 0/12 5/147 86.0 % 1.03 [ 0.06, 17.70 ]
Kaaja 2003 1/9 2/239 14.0 % 13.28 [ 1.32, 133.28 ]
Subtotal (95% CI) 21 386 100.0 % 2.75 [ 0.53, 14.43 ]
Total events: 1 (OXC), 7 (Control)
Heterogeneity: Chi2 = 2.24, df = 1 (P = 0.13); I2 =55%
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.75), I2 =0.0%
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Analysis 6.1. Comparison 6 PB vs Controls, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 6 PB vs Controls
Outcome: 1 All Major Malformations
Study or subgroup PB Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 PB vs Women Without Epilepsy
Cassina 2013 5/67 25/803 36.2 % 2.40 [ 0.95, 6.06 ]
Koch 1992 0/4 5/116 4.2 % 2.13 [ 0.14, 33.38 ]
North American Register 11/199 5/442 29.2 % 4.89 [ 1.72, 13.88 ]
Steegers-Theunissen 1994 0/12 2/106 5.1 % 1.65 [ 0.08, 32.45 ]
Tanganelli 1992 3/63 4/124 25.3 % 1.48 [ 0.34, 6.39 ]
Subtotal (95% CI) 345 1591 100.0 % 2.84 [ 1.57, 5.13 ]
Total events: 19 (PB), 41 (Control)
Heterogeneity: Chi2 = 2.10, df = 4 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 3.46 (P = 0.00054)
2 PB vs WWE - No Medication
Al Bunyan 1999 0/2 0/10 Not estimable
Australian 0/5 5/147 3.9 % 2.24 [ 0.14, 36.06 ]
Canger 1999 4/83 0/25 6.9 % 2.79 [ 0.16, 50.05 ]
D’Souza 1990 1/4 1/8 6.0 % 2.00 [ 0.16, 24.33 ]
Delmi 1991 4/58 0/10 7.6 % 1.68 [ 0.10, 29.01 ]
Kaaja 2003 0/5 2/239 1.1 % 8.00 [ 0.43, 149.27 ]
Kaneko 1999 4/79 3/98 24.1 % 1.65 [ 0.38, 7.17 ]
Kelly 1984 4/79 1/23 14.0 % 1.16 [ 0.14, 9.91 ]
Kerala Pregnancy Registry 1/9 0/9 4.5 % 3.00 [ 0.14, 65.16 ]
Koch 1992 0/4 1/25 4.4 % 1.73 [ 0.08, 36.75 ]
Lindhout 1992 1/26 2/28 17.4 % 0.54 [ 0.05, 5.59 ]
Montreal Series 2/10 0/8 5.0 % 4.09 [ 0.22, 74.78 ]
Waters 1994 3/21 0/15 5.2 % 5.09 [ 0.28, 91.82 ]
Subtotal (95% CI) 385 645 100.0 % 1.95 [ 0.97, 3.93 ]
Total events: 24 (PB), 15 (Control)
Heterogeneity: Chi2 = 3.16, df = 11 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.87 (P = 0.062)
Test for subgroup differences: Chi2 = 0.65, df = 1 (P = 0.42), I2 =0.0%
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Analysis 6.2. Comparison 6 PB vs Controls, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 6 PB vs Controls
Outcome: 2 Neural Tube Malformations
Study or subgroup PB Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 PB vs Women Without Epilepsy
Koch 1992 0/4 0/116 Not estimable
Subtotal (95% CI) 4 116 Not estimable
Total events: 0 (PB), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 PB vs WWE - No Medication
Australian 0/5 0/147 Not estimable
Koch 1992 0/4 1/25 100.0 % 1.73 [ 0.08, 36.75 ]
Subtotal (95% CI) 9 172 100.0 % 1.73 [ 0.08, 36.75 ]
Total events: 0 (PB), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 PB vs Controls, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 6 PB vs Controls
Outcome: 3 Cardiac Malformations
Study or subgroup PB Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 PB vs Women Without Epilepsy
Koch 1992 0/4 1/116 100.0 % 7.80 [ 0.36, 168.52 ]
Subtotal (95% CI) 4 116 100.0 % 7.80 [ 0.36, 168.52 ]
Total events: 0 (PB), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
2 PB vs WWE - No Medication
Australian 0/5 1/147 100.0 % 8.22 [ 0.37, 181.57 ]
Koch 1992 0/4 0/25 Not estimable
Subtotal (95% CI) 9 172 100.0 % 8.22 [ 0.37, 181.57 ]
Total events: 0 (PB), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
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Analysis 6.4. Comparison 6 PB vs Controls, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 6 PB vs Controls
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup PB Control
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 PB vs Women Without Epilepsy
Koch 1992 0/4 3/116 100.0 % -0.03 [ -0.29, 0.24 ]
Subtotal (95% CI) 4 116 100.0 % -0.03 [ -0.29, 0.24 ]
Total events: 0 (PB), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
2 PB vs WWE - No Medication
Australian 0/5 0/147 58.4 % 0.0 [ -0.22, 0.22 ]
Koch 1992 0/4 0/25 41.6 % 0.0 [ -0.27, 0.27 ]
Subtotal (95% CI) 9 172 100.0 % 0.0 [ -0.21, 0.21 ]
Total events: 0 (PB), 0 (Control)
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
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Analysis 6.5. Comparison 6 PB vs Controls, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 6 PB vs Controls
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup PB Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 PB vs Women Without Epilepsy
Koch 1992 0/4 1/116 100.0 % 7.80 [ 0.36, 168.52 ]
Subtotal (95% CI) 4 116 100.0 % 7.80 [ 0.36, 168.52 ]
Total events: 0 (PB), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
2 PB vs WWE - No Medication
Australian 0/5 1/147 100.0 % 8.22 [ 0.37, 181.57 ]
Koch 1992 0/4 0/25 Not estimable
Subtotal (95% CI) 9 172 100.0 % 8.22 [ 0.37, 181.57 ]
Total events: 0 (PB), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
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Analysis 7.1. Comparison 7 PHT vs Controls, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 7 PHT vs Controls
Outcome: 1 All Major Malformations
Study or subgroup PHT Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 PHT vs Women Without Epilepsy
D’Souza 1990 6/22 1/8 16.8 % 2.18 [ 0.31, 15.43 ]
Koch 1992 2/24 5/116 19.6 % 1.93 [ 0.40, 9.38 ]
Mawer 2010 0/7 6/315 3.7 % 3.04 [ 0.19, 49.45 ]
North American Register 12/416 5/442 55.5 % 2.55 [ 0.91, 7.18 ]
Steegers-Theunissen 1994 0/8 2/106 4.4 % 2.38 [ 0.12, 45.85 ]
Subtotal (95% CI) 477 987 100.0 % 2.38 [ 1.12, 5.03 ]
Total events: 20 (PHT), 19 (Control)
Heterogeneity: Chi2 = 0.12, df = 4 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 2.27 (P = 0.023)
2 PHT vs WWE - No Medication
Al Bunyan 1999 0/9 0/10 Not estimable
Arulmozhi 2006 0/18 0/30 Not estimable
Australian 2/44 5/147 13.2 % 1.34 [ 0.27, 6.65 ]
Canger 1999 3/31 0/25 3.2 % 5.69 [ 0.31, 105.21 ]
Garza-Morales 1996 0/27 0/18 Not estimable
Kaaja 2003 3/124 2/239 7.9 % 2.89 [ 0.49, 17.08 ]
Kaneko 1999 12/132 3/98 19.8 % 2.97 [ 0.86, 10.24 ]
Kelly 1984 1/24 1/23 5.9 % 0.96 [ 0.06, 14.43 ]
Kerala Pregnancy Registry 0/5 0/9 Not estimable
Koch 1992 2/24 1/25 5.6 % 2.08 [ 0.20, 21.50 ]
Lindhout 1992 1/17 2/28 8.7 % 0.82 [ 0.08, 8.41 ]
Mawer 2010 0/7 1/40 2.8 % 1.71 [ 0.08, 38.29 ]
Montreal Series 6/44 0/8 4.8 % 2.60 [ 0.16, 42.16 ]
UK Register 7/106 13/541 24.5 % 2.75 [ 1.12, 6.73 ]
Waters 1994 3/28 0/15 3.7 % 3.86 [ 0.21, 70.16 ]
Subtotal (95% CI) 640 1256 100.0 % 2.40 [ 1.42, 4.08 ]
Total events: 40 (PHT), 28 (Control)
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(. . . Continued)
Study or subgroup PHT Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 2.51, df = 10 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 3.25 (P = 0.0011)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
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Analysis 7.2. Comparison 7 PHT vs Controls, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 7 PHT vs Controls
Outcome: 2 Neural Tube Malformations
Study or subgroup PHT Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 PHT vs Women Without Epilepsy
Koch 1992 0/24 0/116 Not estimable
Mawer 2010 0/7 1/315 100.0 % 13.17 [ 0.58, 299.00 ]
Subtotal (95% CI) 31 431 100.0 % 13.17 [ 0.58, 299.00 ]
Total events: 0 (PHT), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
2 PHT vs WWE - No Medication
Australian 1/44 0/147 13.7 % 9.87 [ 0.41, 238.01 ]
Canger 1999 0/31 0/25 Not estimable
Garza-Morales 1996 0/27 0/18 Not estimable
Koch 1992 0/24 1/25 86.3 % 0.35 [ 0.01, 8.12 ]
Mawer 2010 0/7 0/40 Not estimable
Subtotal (95% CI) 133 255 100.0 % 1.65 [ 0.32, 8.51 ]
Total events: 1 (PHT), 1 (Control)
Heterogeneity: Chi2 = 2.15, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Chi2 = 1.33, df = 1 (P = 0.25), I2 =25%
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Analysis 7.3. Comparison 7 PHT vs Controls, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 7 PHT vs Controls
Outcome: 3 Cardiac Malformations
Study or subgroup PHT Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 PHT vs Women Without Epilepsy
Koch 1992 1/24 1/116 82.2 % 4.83 [ 0.31, 74.61 ]
Mawer 2010 0/7 1/315 17.8 % 13.17 [ 0.58, 299.00 ]
Subtotal (95% CI) 31 431 100.0 % 6.31 [ 0.75, 52.91 ]
Total events: 1 (PHT), 2 (Control)
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.089)
2 PHT vs WWE - No Medication
Australian 1/44 1/147 48.5 % 3.34 [ 0.21, 52.33 ]
Canger 1999 0/31 0/25 Not estimable
Garza-Morales 1996 0/27 0/18 Not estimable
Koch 1992 1/24 0/25 51.5 % 3.12 [ 0.13, 73.04 ]
Mawer 2010 0/7 0/40 Not estimable
Subtotal (95% CI) 133 255 100.0 % 3.23 [ 0.40, 26.25 ]
Total events: 2 (PHT), 1 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Chi2 = 0.19, df = 1 (P = 0.66), I2 =0.0%
0.01 0.1 1 10 100
Favours PHT Favours Controls
172Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.4. Comparison 7 PHT vs Controls, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 7 PHT vs Controls
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup PHT Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 PHT vs Women Without Epilepsy
Koch 1992 0/24 3/116 100.0 % 0.67 [ 0.04, 12.54 ]
Mawer 2010 0/7 0/315 Not estimable
Subtotal (95% CI) 31 431 100.0 % 0.67 [ 0.04, 12.54 ]
Total events: 0 (PHT), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
2 PHT vs WWE - No Medication
Australian 0/44 0/147 Not estimable
Canger 1999 0/31 0/25 Not estimable
Garza-Morales 1996 0/27 0/18 Not estimable
Koch 1992 0/24 0/25 Not estimable
Mawer 2010 0/7 0/315 Not estimable
Subtotal (95% CI) 133 530 Not estimable
Total events: 0 (PHT), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 7.5. Comparison 7 PHT vs Controls, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 7 PHT vs Controls
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup PHT Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 PHT vs Women Without Epilepsy
Koch 1992 0/24 1/116 100.0 % 1.56 [ 0.07, 37.19 ]
Mawer 2010 0/7 0/315 Not estimable
Subtotal (95% CI) 31 431 100.0 % 1.56 [ 0.07, 37.19 ]
Total events: 0 (PHT), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
2 PHT vs WWE - No Medication
Australian 0/44 1/147 55.9 % 1.10 [ 0.05, 26.45 ]
Canger 1999 1/31 0/25 44.1 % 2.44 [ 0.10, 57.37 ]
Garza-Morales 1996 0/27 0/18 Not estimable
Koch 1992 0/24 0/25 Not estimable
Mawer 2010 0/7 0/40 Not estimable
Subtotal (95% CI) 133 255 100.0 % 1.69 [ 0.19, 15.30 ]
Total events: 1 (PHT), 1 (Control)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
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Analysis 8.1. Comparison 8 PRM vs Controls, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 8 PRM vs Controls
Outcome: 1 All Major Malformations
Study or subgroup PRM Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 PRM vs Women Without Epilepsy
Koch 1992 0/21 5/116 100.0 % 0.48 [ 0.03, 8.43 ]
Subtotal (95% CI) 21 116 100.0 % 0.48 [ 0.03, 8.43 ]
Total events: 0 (PRM), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
2 PRM vs WWE - No Medication
Canger 1999 3/35 0/25 19.2 % 5.06 [ 0.27, 93.73 ]
Delmi 1991 0/9 0/10 Not estimable
Kaaja 2003 1/6 2/239 25.5 % 19.92 [ 2.08, 190.79 ]
Kaneko 1999 5/35 3/98 36.6 % 4.67 [ 1.18, 18.52 ]
Koch 1992 0/21 2/25 18.7 % 0.24 [ 0.01, 4.67 ]
Subtotal (95% CI) 106 397 100.0 % 3.92 [ 0.76, 20.14 ]
Total events: 9 (PRM), 7 (Control)
Heterogeneity: Tau2 = 1.41; Chi2 = 6.20, df = 3 (P = 0.10); I2 =52%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Chi2 = 1.55, df = 1 (P = 0.21), I2 =36%
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Analysis 9.1. Comparison 9 TPM vs Controls, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 9 TPM vs Controls
Outcome: 1 All Major Malformations
Study or subgroup TPM Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 TPM vs Women Without Epilepsy
North American Register 15/359 5/442 100.0 % 3.69 [ 1.36, 10.07 ]
Subtotal (95% CI) 359 442 100.0 % 3.69 [ 1.36, 10.07 ]
Total events: 15 (TPM), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.55 (P = 0.011)
2 TPM vs WWE - No Medication
Australian 1/44 1/147 13.4 % 3.34 [ 0.21, 52.33 ]
UK Register 3/70 13/541 86.6 % 1.78 [ 0.52, 6.10 ]
Subtotal (95% CI) 114 688 100.0 % 1.99 [ 0.65, 6.08 ]
Total events: 4 (TPM), 14 (Control)
Heterogeneity: Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Chi2 = 0.65, df = 1 (P = 0.42), I2 =0.0%
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Analysis 9.2. Comparison 9 TPM vs Controls, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 9 TPM vs Controls
Outcome: 2 Neural Tube Malformations
Study or subgroup TPM Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 TPM vs Women Without Epilepsy
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (TPM), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 TPM vs WWE - No Medication
Australian 0/44 0/147 Not estimable
Subtotal (95% CI) 44 147 Not estimable
Total events: 0 (TPM), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 9.3. Comparison 9 TPM vs Controls, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 9 TPM vs Controls
Outcome: 3 Cardiac Malformations
Study or subgroup TPM Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 TPM vs Women Without Epilepsy
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (TPM), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 TPM vs WWE - No Medication
Australian 0/44 1/147 100.0 % 1.10 [ 0.05, 26.45 ]
Subtotal (95% CI) 44 147 100.0 % 1.10 [ 0.05, 26.45 ]
Total events: 0 (TPM), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 9.4. Comparison 9 TPM vs Controls, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 9 TPM vs Controls
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup TPM Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 TPM vs Women Without Epilepsy
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (TPM), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 TPM vs WWE - No Medication
Australian 0/44 0/147 Not estimable
Subtotal (95% CI) 44 147 Not estimable
Total events: 0 (TPM), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 9.5. Comparison 9 TPM vs Controls, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 9 TPM vs Controls
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup TPM Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 TPM vs Women Without Epilepsy
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (TPM), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 TPM vs WWE - No Medication
Australian 0/44 1/147 100.0 % 1.10 [ 0.05, 26.45 ]
Subtotal (95% CI) 44 147 100.0 % 1.10 [ 0.05, 26.45 ]
Total events: 0 (TPM), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 VPA vs Controls, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 10 VPA vs Controls
Outcome: 1 All Major Malformations
Study or subgroup VPA WWE - No Meds Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 VPA vs Women Without Epilepsy
Arulmozhi 2006 0/3 0/30 Not estimable
Cassina 2013 3/45 25/803 24.4 % 2.14 [ 0.67, 6.83 ]
Koch 1992 3/14 5/116 9.9 % 4.97 [ 1.33, 18.60 ]
Mawer 2010 6/57 6/315 16.9 % 5.53 [ 1.85, 16.53 ]
North American Register 30/323 5/442 38.8 % 8.21 [ 3.22, 20.93 ]
Steegers-Theunissen 1994 3/19 2/106 5.6 % 8.37 [ 1.50, 46.79 ]
Tanganelli 1992 0/6 4/124 4.4 % 1.98 [ 0.12, 33.31 ]
Subtotal (95% CI) 467 1936 100.0 % 5.69 [ 3.33, 9.73 ]
Total events: 45 (VPA), 47 (WWE - No Meds)
Heterogeneity: Chi2 = 4.09, df = 5 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 6.35 (P < 0.00001)
2 VPA vs WWE - No Med Controls
Al Bunyan 1999 0/5 0/10 Not estimable
Australian 37/271 5/147 16.8 % 4.01 [ 1.61, 9.99 ]
Canger 1999 8/44 0/25 1.6 % 9.82 [ 0.59, 163.31 ]
Fairgrieve 2000 4/74 3/48 9.4 % 0.86 [ 0.20, 3.70 ]
Garza-Morales 1996 0/5 0/18 Not estimable
Kaaja 2003 4/61 2/239 2.1 % 7.84 [ 1.47, 41.79 ]
Kaneko 1999 9/81 3/98 7.0 % 3.63 [ 1.02, 12.96 ]
Kelly 1984 0/4 1/23 1.3 % 1.60 [ 0.08, 33.86 ]
Kerala Pregnancy Registry 2/6 0/9 1.1 % 7.14 [ 0.40, 127.07 ]
Koch 1992 3/14 1/25 1.9 % 5.36 [ 0.61, 46.76 ]
Lindhout 1992 5/66 2/28 7.3 % 1.06 [ 0.22, 5.14 ]
Mawer 2010 6/57 1/40 3.0 % 4.21 [ 0.53, 33.64 ]
Montreal Series 4/15 0/8 1.7 % 5.06 [ 0.31, 83.69 ]
UK Register 82/1220 13/541 46.7 % 2.80 [ 1.57, 4.98 ]
0.01 0.1 1 10 100
Favours VPA Favours Controls
(Continued . . . )
181Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup VPA WWE - No Meds Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 1923 1259 100.0 % 3.13 [ 2.16, 4.54 ]
Total events: 164 (VPA), 31 (WWE - No Meds)
Heterogeneity: Chi2 = 8.02, df = 11 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 6.02 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.22, df = 1 (P = 0.07), I2 =69%
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Analysis 10.2. Comparison 10 VPA vs Controls, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 10 VPA vs Controls
Outcome: 2 Neural Tube Malformations
Study or subgroup VPA WWE - No Meds Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 VPA vs Women Without Epilepsy
Koch 1992 1/14 0/116 19.6 % 23.40 [ 1.00, 548.88 ]
Mawer 2010 0/57 1/315 80.4 % 1.82 [ 0.07, 44.04 ]
Subtotal (95% CI) 71 431 100.0 % 6.05 [ 0.94, 38.81 ]
Total events: 1 (VPA), 1 (WWE - No Meds)
Heterogeneity: Chi2 = 1.25, df = 1 (P = 0.26); I2 =20%
Test for overall effect: Z = 1.90 (P = 0.058)
2 VPA vs WWE - No Medication
Australian 7/271 0/147 32.4 % 8.16 [ 0.47, 141.91 ]
Canger 1999 5/44 0/25 31.7 % 6.36 [ 0.37, 110.37 ]
Fairgrieve 2000 0/74 0/48 Not estimable
Garza-Morales 1996 0/5 0/18 Not estimable
Koch 1992 1/14 1/25 35.9 % 1.79 [ 0.12, 26.40 ]
Mawer 2010 0/57 0/40 Not estimable
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(. . . Continued)
Study or subgroup VPA WWE - No Meds Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 465 303 100.0 % 5.30 [ 1.05, 26.70 ]
Total events: 13 (VPA), 1 (WWE - No Meds)
Heterogeneity: Chi2 = 0.73, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.02 (P = 0.043)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.92), I2 =0.0%
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Analysis 10.3. Comparison 10 VPA vs Controls, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 10 VPA vs Controls
Outcome: 3 Cardiac Malformations
Study or subgroup VPA WWE - No Meds Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 VPA vs Women without Medication
Koch 1992 1/14 1/116 41.3 % 8.29 [ 0.55, 125.25 ]
Mawer 2010 4/57 1/315 58.7 % 22.11 [ 2.52, 194.20 ]
Subtotal (95% CI) 71 431 100.0 % 16.40 [ 3.05, 88.19 ]
Total events: 5 (VPA), 2 (WWE - No Meds)
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 3.26 (P = 0.0011)
2 VPA vs WWE - No Medication
Australian 10/271 1/147 45.4 % 5.42 [ 0.70, 41.96 ]
Canger 1999 0/44 0/25 Not estimable
Fairgrieve 2000 1/74 0/48 21.2 % 1.96 [ 0.08, 47.15 ]
Garza-Morales 1996 0/5 0/18 Not estimable
Koch 1992 1/14 0/25 12.8 % 5.20 [ 0.23, 119.77 ]
Mawer 2010 4/57 0/40 20.5 % 6.36 [ 0.35, 114.96 ]
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(. . . Continued)
Study or subgroup VPA WWE - No Meds Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 465 303 100.0 % 4.85 [ 1.28, 18.47 ]
Total events: 16 (VPA), 1 (WWE - No Meds)
Heterogeneity: Chi2 = 0.36, df = 3 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 2.32 (P = 0.021)
Test for subgroup differences: Chi2 = 1.23, df = 1 (P = 0.27), I2 =19%
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Analysis 10.4. Comparison 10 VPA vs Controls, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 10 VPA vs Controls
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup VPA WWE - No Meds
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 VPA vs Women Without Epilepsy
Koch 1992 1/14 3/116 20.6 % 0.05 [ -0.09, 0.18 ]
Mawer 2010 0/57 0/315 79.4 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 71 431 100.0 % 0.01 [ -0.03, 0.04 ]
Total events: 1 (VPA), 3 (WWE - No Meds)
Heterogeneity: Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.59)
2 VPA vs WWE - No Medication
Australian 12/271 0/147 53.9 % 0.04 [ 0.02, 0.07 ]
Canger 1999 0/44 0/25 9.0 % 0.0 [ -0.06, 0.06 ]
Fairgrieve 2000 1/74 1/48 16.5 % -0.01 [ -0.06, 0.04 ]
Garza-Morales 1996 0/5 0/18 2.2 % 0.0 [ -0.23, 0.23 ]
Koch 1992 1/14 0/25 5.1 % 0.07 [ -0.09, 0.23 ]
Mawer 2010 0/57 0/40 13.3 % 0.0 [ -0.04, 0.04 ]
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(. . . Continued)
Study or subgroup VPA WWE - No Meds
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 465 303 100.0 % 0.03 [ 0.01, 0.05 ]
Total events: 14 (VPA), 1 (WWE - No Meds)
Heterogeneity: Chi2 = 6.26, df = 5 (P = 0.28); I2 =20%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 0.68, df = 1 (P = 0.41), I2 =0.0%
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Analysis 10.5. Comparison 10 VPA vs Controls, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 10 VPA vs Controls
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup VPA Controls Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 VPA vs Women Without Epilepsy
Koch 1992 2/14 1/116 58.1 % 16.57 [ 1.60, 171.26 ]
Mawer 2010 1/57 0/315 41.9 % 16.34 [ 0.67, 396.33 ]
Subtotal (95% CI) 71 431 100.0 % 16.48 [ 2.46, 110.49 ]
Total events: 3 (VPA), 1 (Controls)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 2.89 (P = 0.0039)
2 VPA vs WWE - No Medication
Australian 6/271 1/147 31.7 % 3.25 [ 0.40, 26.78 ]
Canger 1999 1/44 0/25 15.5 % 1.73 [ 0.07, 41.02 ]
Fairgrieve 2000 1/74 1/48 29.6 % 0.65 [ 0.04, 10.13 ]
Garza-Morales 1996 0/5 0/18 Not estimable
Koch 1992 2/14 0/25 8.9 % 8.67 [ 0.45, 168.78 ]
Mawer 2010 1/57 0/40 14.3 % 2.12 [ 0.09, 50.77 ]
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(. . . Continued)
Study or subgroup VPA Controls Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 465 303 100.0 % 2.57 [ 0.82, 8.04 ]
Total events: 11 (VPA), 2 (Controls)
Heterogeneity: Chi2 = 1.73, df = 4 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.62 (P = 0.11)
Test for subgroup differences: Chi2 = 2.70, df = 1 (P = 0.10), I2 =63%
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Analysis 11.1. Comparison 11 ZNS vs Controls, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 11 ZNS vs Controls
Outcome: 1 All Major Malformations
Study or subgroup ZNS Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ZNS vs Women Without Epilepsy
North American Register 0/90 5/442 100.0 % 0.44 [ 0.02, 7.93 ]
Subtotal (95% CI) 90 442 100.0 % 0.44 [ 0.02, 7.93 ]
Total events: 0 (ZNS), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
2 ZNS vs WWE - No Medication
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (ZNS), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 12.1. Comparison 12 CBZ vs GBP, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 12 CBZ vs GBP
Outcome: 1 All Major Malformations
Study or subgroup CBZ GBP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 18/361 0/14 20.5 % 1.53 [ 0.10, 24.25 ]
North American Register 31/1033 1/145 37.5 % 4.35 [ 0.60, 31.63 ]
UK Register 43/1657 1/31 42.0 % 0.80 [ 0.11, 5.66 ]
Total (95% CI) 3051 190 100.0 % 2.28 [ 0.67, 7.79 ]
Total events: 92 (CBZ), 2 (GBP)
Heterogeneity: Chi2 = 1.59, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 12.2. Comparison 12 CBZ vs GBP, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 12 CBZ vs GBP
Outcome: 2 Neural Tube Malformations
Study or subgroup CBZ GBP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/361 0/14 100.0 % 0.12 [ 0.01, 2.93 ]
Total (95% CI) 361 14 100.0 % 0.12 [ 0.01, 2.93 ]
Total events: 1 (CBZ), 0 (GBP)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours CBZ Favours GBP
187Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 12.3. Comparison 12 CBZ vs GBP, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 12 CBZ vs GBP
Outcome: 3 Cardiac Malformations
Study or subgroup CBZ GBP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 3/361 0/14 100.0 % 0.29 [ 0.02, 5.37 ]
Total (95% CI) 361 14 100.0 % 0.29 [ 0.02, 5.37 ]
Total events: 3 (CBZ), 0 (GBP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 12.4. Comparison 12 CBZ vs GBP, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 12 CBZ vs GBP
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup CBZ GBP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 4/361 0/14 100.0 % 0.37 [ 0.02, 6.62 ]
Total (95% CI) 361 14 100.0 % 0.37 [ 0.02, 6.62 ]
Total events: 4 (CBZ), 0 (GBP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 12.5. Comparison 12 CBZ vs GBP, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 12 CBZ vs GBP
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup CBZ GBP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 2/361 0/14 100.0 % 0.21 [ 0.01, 4.13 ]
Total (95% CI) 361 14 100.0 % 0.21 [ 0.01, 4.13 ]
Total events: 2 (CBZ), 0 (GBP)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 13.1. Comparison 13 CBZ vs LEV, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 13 CBZ vs LEV
Outcome: 1 All Major Malformations
Study or subgroup CBZ LEV Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 18/361 1/63 8.3 % 3.14 [ 0.43, 23.11 ]
North American Register 31/1033 11/450 75.1 % 1.23 [ 0.62, 2.42 ]
UK Register 43/1657 2/304 16.6 % 3.94 [ 0.96, 16.20 ]
Total (95% CI) 3051 817 100.0 % 1.84 [ 1.03, 3.29 ]
Total events: 92 (CBZ), 14 (LEV)
Heterogeneity: Chi2 = 2.76, df = 2 (P = 0.25); I2 =27%
Test for overall effect: Z = 2.05 (P = 0.040)
Test for subgroup differences: Not applicable
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Analysis 13.2. Comparison 13 CBZ vs LEV, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 13 CBZ vs LEV
Outcome: 2 Neural Tube Malformations
Study or subgroup CBZ LEV Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/361 0/63 27.5 % 0.53 [ 0.02, 12.88 ]
North American Register 3/1033 1/450 45.1 % 1.31 [ 0.14, 12.53 ]
UK Register 4/1657 0/304 27.4 % 1.66 [ 0.09, 30.67 ]
Total (95% CI) 3051 817 100.0 % 1.19 [ 0.25, 5.55 ]
Total events: 8 (CBZ), 1 (LEV)
Heterogeneity: Chi2 = 0.30, df = 2 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 13.3. Comparison 13 CBZ vs LEV, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 13 CBZ vs LEV
Outcome: 3 Cardiac Malformations
Study or subgroup CBZ LEV Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 3/361 1/63 43.2 % 0.52 [ 0.06, 4.95 ]
North American Register 3/1033 1/450 35.4 % 1.31 [ 0.14, 12.53 ]
UK Register 14/1657 0/304 21.4 % 5.33 [ 0.32, 89.19 ]
Total (95% CI) 3051 817 100.0 % 1.83 [ 0.48, 6.97 ]
Total events: 20 (CBZ), 2 (LEV)
Heterogeneity: Chi2 = 1.83, df = 2 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 13.4. Comparison 13 CBZ vs LEV, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 13 CBZ vs LEV
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup CBZ LEV Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 4/361 1/63 52.5 % 0.70 [ 0.08, 6.14 ]
North American Register 5/1033 0/450 21.5 % 4.80 [ 0.27, 86.58 ]
UK Register 4/1657 0/304 26.0 % 1.66 [ 0.09, 30.67 ]
Total (95% CI) 3051 817 100.0 % 1.83 [ 0.44, 7.61 ]
Total events: 13 (CBZ), 1 (LEV)
Heterogeneity: Chi2 = 1.18, df = 2 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 13.5. Comparison 13 CBZ vs LEV, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 13 CBZ vs LEV
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup CBZ LEV Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 2/361 0/63 35.5 % 0.88 [ 0.04, 18.20 ]
North American Register 5/1033 0/450 29.1 % 4.80 [ 0.27, 86.58 ]
UK Register 4/1657 0/304 35.3 % 1.66 [ 0.09, 30.67 ]
Total (95% CI) 3051 817 100.0 % 2.30 [ 0.44, 11.86 ]
Total events: 11 (CBZ), 0 (LEV)
Heterogeneity: Chi2 = 0.68, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 14.1. Comparison 14 CBZ vs LTG, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 14 CBZ vs LTG
Outcome: 1 All Major Malformations
Study or subgroup CBZ LTG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 18/361 13/315 16.3 % 1.21 [ 0.60, 2.43 ]
Cassina 2013 5/88 0/26 0.9 % 3.34 [ 0.19, 58.44 ]
Martinez Ferri 2009 4/105 0/56 0.8 % 4.84 [ 0.27, 88.30 ]
Mawer 2010 2/31 0/9 0.9 % 1.56 [ 0.08, 29.92 ]
Meador 2006 5/110 1/98 1.2 % 4.45 [ 0.53, 37.47 ]
North American Register 31/1033 31/1562 29.0 % 1.51 [ 0.92, 2.47 ]
UK Register 43/1657 49/2098 50.8 % 1.11 [ 0.74, 1.66 ]
Total (95% CI) 3385 4164 100.0 % 1.34 [ 1.01, 1.76 ]
Total events: 108 (CBZ), 94 (LTG)
Heterogeneity: Chi2 = 3.51, df = 6 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.06 (P = 0.039)
Test for subgroup differences: Not applicable
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Analysis 14.2. Comparison 14 CBZ vs LTG, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 14 CBZ vs LTG
Outcome: 2 Neural Tube Malformations
Study or subgroup CBZ LTG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/361 0/315 11.8 % 2.62 [ 0.11, 64.06 ]
Cassina 2013 0/88 0/26 Not estimable
Martinez Ferri 2009 1/105 0/56 14.3 % 1.61 [ 0.07, 38.96 ]
Meador 2006 0/110 0/98 Not estimable
North American Register 3/1033 2/1562 35.1 % 2.27 [ 0.38, 13.55 ]
UK Register 4/1657 2/2098 38.9 % 2.53 [ 0.46, 13.81 ]
Total (95% CI) 3354 4155 100.0 % 2.32 [ 0.79, 6.82 ]
Total events: 9 (CBZ), 4 (LTG)
Heterogeneity: Chi2 = 0.07, df = 3 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 14.3. Comparison 14 CBZ vs LTG, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 14 CBZ vs LTG
Outcome: 3 Cardiac Malformations
Study or subgroup CBZ LTG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 3/361 3/315 19.4 % 0.87 [ 0.18, 4.29 ]
Cassina 2013 3/88 0/26 4.6 % 2.12 [ 0.11, 39.84 ]
Martinez Ferri 2009 2/105 0/56 3.9 % 2.69 [ 0.13, 55.05 ]
Meador 2006 0/110 1/98 9.6 % 0.30 [ 0.01, 7.21 ]
North American Register 3/1033 3/1562 14.4 % 1.51 [ 0.31, 7.48 ]
UK Register 14/1657 9/2098 48.0 % 1.97 [ 0.85, 4.54 ]
Total (95% CI) 3354 4155 100.0 % 1.57 [ 0.85, 2.89 ]
Total events: 25 (CBZ), 16 (LTG)
Heterogeneity: Chi2 = 2.02, df = 5 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 14.4. Comparison 14 CBZ vs LTG, Outcome 4 Oro-Facial Cleft / Crainofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 14 CBZ vs LTG
Outcome: 4 Oro-Facial Cleft / Crainofacial Malformations
Study or subgroup CBZ LTG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 4/361 5/315 42.1 % 0.70 [ 0.19, 2.58 ]
Cassina 2013 0/88 0/26 Not estimable
Martinez Ferri 2009 0/105 0/56 Not estimable
Meador 2006 0/110 0/98 Not estimable
North American Register 5/1033 7/1562 44.0 % 1.08 [ 0.34, 3.39 ]
UK Register 4/1657 2/2098 13.9 % 2.53 [ 0.46, 13.81 ]
Total (95% CI) 3354 4155 100.0 % 1.12 [ 0.53, 2.37 ]
Total events: 13 (CBZ), 14 (LTG)
Heterogeneity: Chi2 = 1.40, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 14.5. Comparison 14 CBZ vs LTG, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 14 CBZ vs LTG
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup CBZ LTG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 2/361 0/315 9.8 % 4.36 [ 0.21, 90.57 ]
Cassina 2013 0/88 0/26 Not estimable
Martinez Ferri 2009 1/105 0/56 12.0 % 1.61 [ 0.07, 38.96 ]
Meador 2006 0/110 0/98 Not estimable
North American Register 5/1033 2/1562 29.4 % 3.78 [ 0.73, 19.45 ]
UK Register 4/1657 3/2098 48.8 % 1.69 [ 0.38, 7.53 ]
Total (95% CI) 3354 4155 100.0 % 2.56 [ 0.97, 6.73 ]
Total events: 12 (CBZ), 5 (LTG)
Heterogeneity: Chi2 = 0.71, df = 3 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Not applicable
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Analysis 15.1. Comparison 15 CBZ vs OXC, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 15 CBZ vs OXC
Outcome: 1 All Major Malformations
Study or subgroup CBZ OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 18/361 0/12 9.6 % 1.33 [ 0.08, 20.87 ]
Kaaja 2003 10/363 1/9 19.4 % 0.25 [ 0.04, 1.74 ]
Meischenguiser 2004 2/16 0/35 3.2 % 10.59 [ 0.54, 208.68 ]
North American Register 31/1033 4/182 67.7 % 1.37 [ 0.49, 3.82 ]
Total (95% CI) 1773 238 100.0 % 1.44 [ 0.66, 3.16 ]
Total events: 61 (CBZ), 5 (OXC)
Heterogeneity: Chi2 = 4.87, df = 3 (P = 0.18); I2 =38%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 15.2. Comparison 15 CBZ vs OXC, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 15 CBZ vs OXC
Outcome: 2 Neural Tube Malformations
Study or subgroup CBZ OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/361 0/12 34.6 % 0.11 [ 0.00, 2.52 ]
Kaaja 2003 3/363 0/9 34.9 % 0.19 [ 0.01, 3.48 ]
Meischenguiser 2004 0/16 0/35 Not estimable
North American Register 3/1033 0/182 30.5 % 1.24 [ 0.06, 23.88 ]
Total (95% CI) 1773 238 100.0 % 0.48 [ 0.09, 2.54 ]
Total events: 7 (CBZ), 0 (OXC)
Heterogeneity: Chi2 = 1.65, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 15.3. Comparison 15 CBZ vs OXC, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 15 CBZ vs OXC
Outcome: 3 Cardiac Malformations
Study or subgroup CBZ OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 3/361 0/12 34.6 % 0.25 [ 0.01, 4.62 ]
Kaaja 2003 2/363 0/9 34.9 % 0.14 [ 0.01, 2.68 ]
Meischenguiser 2004 0/16 0/35 Not estimable
North American Register 3/1033 0/182 30.5 % 1.24 [ 0.06, 23.88 ]
Total (95% CI) 1773 238 100.0 % 0.51 [ 0.10, 2.69 ]
Total events: 8 (CBZ), 0 (OXC)
Heterogeneity: Chi2 = 1.33, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 15.4. Comparison 15 CBZ vs OXC, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 15 CBZ vs OXC
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup CBZ OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 4/361 0/12 26.5 % 0.32 [ 0.02, 5.69 ]
Kaaja 2003 2/363 0/9 26.7 % 0.14 [ 0.01, 2.68 ]
Meischenguiser 2004 0/16 0/35 Not estimable
North American Register 5/1033 1/182 46.7 % 0.88 [ 0.10, 7.50 ]
Total (95% CI) 1773 238 100.0 % 0.53 [ 0.12, 2.33 ]
Total events: 11 (CBZ), 1 (OXC)
Heterogeneity: Chi2 = 1.13, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
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Analysis 15.5. Comparison 15 CBZ vs OXC, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 15 CBZ vs OXC
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup CBZ OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 2/361 0/12 26.5 % 0.18 [ 0.01, 3.55 ]
Kaaja 2003 1/363 0/9 26.7 % 0.08 [ 0.00, 1.90 ]
Meischenguiser 2004 0/16 0/35 Not estimable
North American Register 5/1033 1/182 46.7 % 0.88 [ 0.10, 7.50 ]
Total (95% CI) 1773 238 100.0 % 0.48 [ 0.11, 2.11 ]
Total events: 8 (CBZ), 1 (OXC)
Heterogeneity: Chi2 = 1.94, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 16.1. Comparison 16 CBZ vs PB, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 16 CBZ vs PB
Outcome: 1 All Major Malformations
Study or subgroup CBZ PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Al Bunyan 1999 1/31 0/2 1.5 % 0.28 [ 0.01, 5.50 ]
Australian 18/361 0/5 1.6 % 0.61 [ 0.04, 9.04 ]
Canger 1999 12/113 4/83 7.4 % 2.20 [ 0.74, 6.59 ]
Cassina 2013 5/88 5/67 9.1 % 0.76 [ 0.23, 2.52 ]
D’Souza 1990 1/3 1/4 1.4 % 1.33 [ 0.13, 13.74 ]
Delmi 1991 4/18 4/58 3.0 % 3.22 [ 0.89, 11.60 ]
Eroglu 2008 3/46 1/5 2.9 % 0.33 [ 0.04, 2.57 ]
Froscher 1991 2/31 1/5 2.8 % 0.32 [ 0.04, 2.93 ]
Kaaja 2003 10/363 0/5 1.6 % 0.35 [ 0.02, 5.25 ]
Kaneko 1999 9/158 4/79 8.6 % 1.13 [ 0.36, 3.54 ]
Kerala Pregnancy Registry 1/7 1/9 1.4 % 1.29 [ 0.10, 17.14 ]
Koch 1992 0/9 0/4 Not estimable
Lindhout 1992 5/50 1/26 2.1 % 2.60 [ 0.32, 21.11 ]
Martinez Ferri 2009 4/105 1/11 2.9 % 0.42 [ 0.05, 3.43 ]
Meischenguiser 2004 2/16 1/5 2.4 % 0.63 [ 0.07, 5.53 ]
Montreal Series 5/32 2/10 4.9 % 0.78 [ 0.18, 3.43 ]
North American Register 31/1033 11/199 29.6 % 0.54 [ 0.28, 1.06 ]
Omtzigt 1992 4/114 3/18 8.3 % 0.21 [ 0.05, 0.86 ]
Pardi 1982 0/6 0/12 Not estimable
Steegers-Theunissen 1994 1/39 0/12 1.2 % 0.98 [ 0.04, 22.50 ]
Tanganelli 1992 0/9 3/63 1.5 % 0.91 [ 0.05, 16.41 ]
Waters 1994 1/33 3/21 5.9 % 0.21 [ 0.02, 1.91 ]
Total (95% CI) 2665 703 100.0 % 0.84 [ 0.60, 1.16 ]
Total events: 119 (CBZ), 46 (PB)
Heterogeneity: Chi2 = 18.68, df = 19 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 16.2. Comparison 16 CBZ vs PB, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 16 CBZ vs PB
Outcome: 2 Neural Tube Malformations
Study or subgroup CBZ PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/361 0/5 41.0 % 0.05 [ 0.00, 1.10 ]
Canger 1999 1/113 0/83 24.0 % 2.21 [ 0.09, 53.59 ]
Cassina 2013 0/88 0/67 Not estimable
D’Souza 1990 0/3 0/4 Not estimable
Eroglu 2008 0/49 0/5 Not estimable
Froscher 1991 0/31 0/5 Not estimable
Kerala Pregnancy Registry 0/7 0/9 Not estimable
Koch 1992 0/9 0/4 Not estimable
Meischenguiser 2004 0/16 0/5 Not estimable
North American Register 3/1033 0/199 35.0 % 1.35 [ 0.07, 26.11 ]
Omtzigt 1992 0/114 0/18 Not estimable
Pardi 1982 0/6 0/12 Not estimable
Total (95% CI) 1830 416 100.0 % 1.02 [ 0.19, 5.39 ]
Total events: 5 (CBZ), 0 (PB)
Heterogeneity: Chi2 = 3.92, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 16.3. Comparison 16 CBZ vs PB, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 16 CBZ vs PB
Outcome: 3 Cardiac Malformations
Study or subgroup CBZ PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 3/361 0/5 3.6 % 0.12 [ 0.01, 2.01 ]
Canger 1999 0/113 1/83 6.3 % 0.25 [ 0.01, 5.95 ]
Cassina 2013 3/88 2/67 8.3 % 1.14 [ 0.20, 6.64 ]
D’Souza 1990 0/3 1/4 4.9 % 0.42 [ 0.02, 7.71 ]
Eroglu 2008 0/49 0/5 Not estimable
Froscher 1991 1/31 1/5 6.3 % 0.16 [ 0.01, 2.18 ]
Kerala Pregnancy Registry 7/112 3/43 15.9 % 0.90 [ 0.24, 3.31 ]
Koch 1992 0/9 0/4 Not estimable
Meischenguiser 2004 0/16 1/5 8.1 % 0.12 [ 0.01, 2.51 ]
North American Register 3/1033 5/199 30.8 % 0.12 [ 0.03, 0.48 ]
Omtzigt 1992 0/114 2/18 15.7 % 0.03 [ 0.00, 0.66 ]
Pardi 1982 0/6 0/12 Not estimable
Total (95% CI) 1935 450 100.0 % 0.34 [ 0.18, 0.62 ]
Total events: 17 (CBZ), 16 (PB)
Heterogeneity: Chi2 = 9.84, df = 8 (P = 0.28); I2 =19%
Test for overall effect: Z = 3.51 (P = 0.00045)
Test for subgroup differences: Not applicable
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Analysis 16.4. Comparison 16 CBZ vs PB, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 16 CBZ vs PB
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup CBZ PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 4/361 0/5 8.1 % 0.15 [ 0.01, 2.47 ]
Canger 1999 0/113 0/83 Not estimable
Cassina 2013 0/88 0/67 Not estimable
D’Souza 1990 0/3 0/4 Not estimable
Eroglu 2008 0/49 1/5 22.1 % 0.04 [ 0.00, 0.88 ]
Froscher 1991 0/31 0/5 Not estimable
Kerala Pregnancy Registry 0/7 0/9 Not estimable
Koch 1992 0/9 0/4 Not estimable
Meischenguiser 2004 0/16 0/5 Not estimable
North American Register 5/1033 4/199 55.4 % 0.24 [ 0.07, 0.89 ]
Omtzigt 1992 1/114 1/18 14.3 % 0.16 [ 0.01, 2.41 ]
Pardi 1982 0/6 0/12 Not estimable
Total (95% CI) 1830 416 100.0 % 0.18 [ 0.07, 0.48 ]
Total events: 10 (CBZ), 6 (PB)
Heterogeneity: Chi2 = 1.13, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 3.40 (P = 0.00068)
Test for subgroup differences: Not applicable
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Analysis 16.5. Comparison 16 CBZ vs PB, Outcome 5 Skeletal / Limb Malformation.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 16 CBZ vs PB
Outcome: 5 Skeletal / Limb Malformation
Study or subgroup CBZ PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 2/361 0/5 15.3 % 0.08 [ 0.00, 1.55 ]
Canger 1999 4/113 1/83 17.9 % 2.94 [ 0.33, 25.81 ]
Cassina 2013 0/88 0/67 Not estimable
D’Souza 1990 1/3 0/4 6.9 % 3.75 [ 0.20, 69.40 ]
Eroglu 2008 0/49 0/5 Not estimable
Froscher 1991 0/31 0/5 Not estimable
Kerala Pregnancy Registry 0/7 1/9 20.7 % 0.42 [ 0.02, 8.91 ]
Koch 1992 0/9 0/4 Not estimable
Meischenguiser 2004 0/16 0/5 Not estimable
North American Register 5/1033 1/199 26.0 % 0.96 [ 0.11, 8.20 ]
Omtzigt 1992 1/114 0/18 13.3 % 0.50 [ 0.02, 11.72 ]
Pardi 1982 0/6 0/12 Not estimable
Total (95% CI) 1830 416 100.0 % 1.20 [ 0.45, 3.21 ]
Total events: 13 (CBZ), 3 (PB)
Heterogeneity: Chi2 = 5.24, df = 5 (P = 0.39); I2 =5%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 17.1. Comparison 17 CBZ vs PHT, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 17 CBZ vs PHT
Outcome: 1 All Major Malformations
Study or subgroup CBZ PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Al Bunyan 1999 1/31 0/9 0.9 % 0.94 [ 0.04, 21.25 ]
Arulmozhi 2006 0/7 0/18 Not estimable
Australian 18/361 2/44 4.4 % 1.10 [ 0.26, 4.57 ]
Bag 1989 0/4 0/20 Not estimable
Canger 1999 12/113 3/31 5.8 % 1.10 [ 0.33, 3.65 ]
D’Souza 1990 1/3 6/22 1.8 % 1.22 [ 0.21, 6.96 ]
Eroglu 2008 3/46 2/14 3.7 % 0.46 [ 0.08, 2.46 ]
Froscher 1991 2/31 0/3 1.1 % 0.63 [ 0.04, 10.84 ]
Garza-Morales 1996 0/24 0/27 Not estimable
Kaaja 2003 10/363 3/124 5.5 % 1.14 [ 0.32, 4.07 ]
Kaneko 1999 9/158 12/132 16.0 % 0.63 [ 0.27, 1.44 ]
Kerala Pregnancy Registry 1/7 0/5 0.7 % 2.25 [ 0.11, 46.13 ]
Koch 1992 0/9 2/24 1.7 % 0.50 [ 0.03, 9.52 ]
Lindhout 1992 5/50 1/17 1.8 % 1.70 [ 0.21, 13.54 ]
Mawer 2010 2/31 0/2 1.1 % 0.47 [ 0.03, 7.68 ]
Meador 2006 5/110 4/56 6.5 % 0.64 [ 0.18, 2.28 ]
Montreal Series 5/32 6/44 6.2 % 1.15 [ 0.38, 3.43 ]
North American Register 31/1033 12/416 20.9 % 1.04 [ 0.54, 2.01 ]
Omtzigt 1992 4/114 0/28 1.0 % 2.27 [ 0.13, 40.97 ]
Pardi 1982 0/6 0/5 Not estimable
Steegers-Theunissen 1994 1/39 0/8 1.0 % 0.68 [ 0.03, 15.25 ]
UK Register 43/1657 7/106 16.1 % 0.39 [ 0.18, 0.85 ]
Waters 1994 1/33 3/28 4.0 % 0.28 [ 0.03, 2.57 ]
Total (95% CI) 4262 1183 100.0 % 0.82 [ 0.61, 1.11 ]
Total events: 154 (CBZ), 63 (PHT)
Heterogeneity: Chi2 = 8.78, df = 18 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 17.2. Comparison 17 CBZ vs PHT, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 17 CBZ vs PHT
Outcome: 2 Neural Tube Malformations
Study or subgroup CBZ PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/361 1/44 35.8 % 0.12 [ 0.01, 1.91 ]
Bag 1989 0/4 0/20 Not estimable
Canger 1999 1/113 0/31 15.7 % 0.84 [ 0.04, 20.18 ]
D’Souza 1990 0/3 0/22 Not estimable
Eroglu 2008 0/49 0/14 Not estimable
Froscher 1991 0/31 0/3 Not estimable
Kaaja 2003 3/363 0/124 15.0 % 2.40 [ 0.13, 46.21 ]
Kerala Pregnancy Registry 0/7 0/5 Not estimable
Koch 1992 0/9 0/24 Not estimable
Meador 2006 0/110 0/56 Not estimable
North American Register 3/1033 0/416 14.3 % 2.82 [ 0.15, 54.53 ]
Omtzigt 1992 0/114 0/28 Not estimable
Pardi 1982 0/6 0/5 Not estimable
UK Register 4/1657 0/82 19.2 % 0.45 [ 0.02, 8.30 ]
Total (95% CI) 3860 874 100.0 % 1.03 [ 0.31, 3.37 ]
Total events: 12 (CBZ), 1 (PHT)
Heterogeneity: Chi2 = 3.39, df = 4 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 17.3. Comparison 17 CBZ vs PHT, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 17 CBZ vs PHT
Outcome: 3 Cardiac Malformations
Study or subgroup CBZ PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 3/361 1/44 11.5 % 0.37 [ 0.04, 3.44 ]
Bag 1989 0/4 0/20 Not estimable
Canger 1999 0/113 0/31 Not estimable
D’Souza 1990 0/3 2/22 4.8 % 1.15 [ 0.07, 19.78 ]
Eroglu 2008 0/49 1/14 14.9 % 0.10 [ 0.00, 2.33 ]
Froscher 1991 1/31 0/3 5.8 % 0.38 [ 0.02, 7.74 ]
Kaaja 2003 2/363 0/124 4.8 % 1.72 [ 0.08, 35.52 ]
Kerala Pregnancy Registry 7/112 0/100 3.4 % 13.41 [ 0.78, 231.80 ]
Koch 1992 0/9 1/24 5.5 % 0.83 [ 0.04, 18.79 ]
Meador 2006 0/110 0/56 Not estimable
North American Register 3/1033 4/416 36.9 % 0.30 [ 0.07, 1.34 ]
Omtzigt 1992 0/114 0/28 Not estimable
Pardi 1982 0/6 0/5 Not estimable
UK Register 14/1657 1/82 12.3 % 0.69 [ 0.09, 5.20 ]
Total (95% CI) 3965 969 100.0 % 0.92 [ 0.47, 1.78 ]
Total events: 30 (CBZ), 10 (PHT)
Heterogeneity: Chi2 = 8.68, df = 8 (P = 0.37); I2 =8%
Test for overall effect: Z = 0.26 (P = 0.80)
Test for subgroup differences: Not applicable
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Analysis 17.4. Comparison 17 CBZ vs PHT, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 17 CBZ vs PHT
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup CBZ PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 4/361 0/44 10.6 % 1.12 [ 0.06, 20.44 ]
Bag 1989 0/4 0/20 Not estimable
Canger 1999 0/113 0/31 Not estimable
D’Souza 1990 0/3 1/22 5.3 % 1.92 [ 0.09, 39.25 ]
Eroglu 2008 0/49 0/14 Not estimable
Froscher 1991 0/31 0/3 Not estimable
Kaaja 2003 2/363 1/124 17.8 % 0.68 [ 0.06, 7.47 ]
Kerala Pregnancy Registry 0/7 0/5 Not estimable
Koch 1992 0/9 0/24 Not estimable
Meador 2006 0/110 0/56 Not estimable
North American Register 5/1033 2/416 34.0 % 1.01 [ 0.20, 5.17 ]
Omtzigt 1992 1/114 0/28 9.5 % 0.76 [ 0.03, 18.09 ]
Pardi 1982 0/6 0/5 Not estimable
UK Register 4/1657 1/82 22.7 % 0.20 [ 0.02, 1.75 ]
Total (95% CI) 3860 874 100.0 % 0.80 [ 0.31, 2.05 ]
Total events: 16 (CBZ), 5 (PHT)
Heterogeneity: Chi2 = 2.04, df = 5 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 17.5. Comparison 17 CBZ vs PHT, Outcome 5 Skeletal / Limb Malformation.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 17 CBZ vs PHT
Outcome: 5 Skeletal / Limb Malformation
Study or subgroup CBZ PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 2/361 0/44 8.0 % 0.62 [ 0.03, 12.74 ]
Bag 1989 0/4 0/20 Not estimable
Canger 1999 4/113 1/31 14.1 % 1.10 [ 0.13, 9.47 ]
D’Souza 1990 1/3 2/22 4.3 % 3.67 [ 0.46, 29.21 ]
Eroglu 2008 0/49 0/14 Not estimable
Froscher 1991 0/31 0/3 Not estimable
Kaaja 2003 1/363 0/124 6.7 % 1.03 [ 0.04, 25.13 ]
Kerala Pregnancy Registry 0/7 0/5 Not estimable
Koch 1992 0/9 0/24 Not estimable
Meador 2006 0/110 0/56 Not estimable
North American Register 5/1033 4/416 51.2 % 0.50 [ 0.14, 1.87 ]
Omtzigt 1992 1/114 0/28 7.2 % 0.76 [ 0.03, 18.09 ]
Pardi 1982 0/6 0/5 Not estimable
UK Register 4/1657 0/82 8.6 % 0.45 [ 0.02, 8.30 ]
Total (95% CI) 3860 874 100.0 % 0.78 [ 0.35, 1.75 ]
Total events: 18 (CBZ), 7 (PHT)
Heterogeneity: Chi2 = 2.85, df = 6 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 18.1. Comparison 18 CBZ vs PRM, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 18 CBZ vs PRM
Outcome: 1 All Major Malformations
Study or subgroup CBZ PRM Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Canger 1999 12/113 3/35 31.7 % 1.24 [ 0.37, 4.14 ]
Delmi 1991 4/18 0/9 12.3 % 4.74 [ 0.28, 79.44 ]
Kaaja 2003 10/363 1/6 20.9 % 0.17 [ 0.02, 1.09 ]
Kaneko 1999 9/158 5/35 35.1 % 0.40 [ 0.14, 1.12 ]
Koch 1992 0/9 0/21 Not estimable
Pardi 1982 0/6 0/4 Not estimable
Total (95% CI) 667 110 100.0 % 0.64 [ 0.21, 2.01 ]
Total events: 35 (CBZ), 9 (PRM)
Heterogeneity: Tau2 = 0.69; Chi2 = 6.48, df = 3 (P = 0.09); I2 =54%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 18.2. Comparison 18 CBZ vs PRM, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 18 CBZ vs PRM
Outcome: 2 Neural Tube Malformations
Study or subgroup CBZ PRM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Canger 1999 1/113 0/35 100.0 % 0.95 [ 0.04, 22.75 ]
Pardi 1982 0/6 0/4 Not estimable
Total (95% CI) 119 39 100.0 % 0.95 [ 0.04, 22.75 ]
Total events: 1 (CBZ), 0 (PRM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 18.3. Comparison 18 CBZ vs PRM, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 18 CBZ vs PRM
Outcome: 3 Cardiac Malformations
Study or subgroup CBZ PRM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Canger 1999 0/113 1/35 100.0 % 0.11 [ 0.00, 2.53 ]
Pardi 1982 0/6 0/4 Not estimable
Total (95% CI) 119 39 100.0 % 0.11 [ 0.00, 2.53 ]
Total events: 0 (CBZ), 1 (PRM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours CBZ Favours PRM
214Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 18.4. Comparison 18 CBZ vs PRM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 18 CBZ vs PRM
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup CBZ PRM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Canger 1999 0/113 0/35 Not estimable
Pardi 1982 0/6 0/4 Not estimable
Total (95% CI) 119 39 Not estimable
Total events: 0 (CBZ), 0 (PRM)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours CBZ Favours PRM
Analysis 18.5. Comparison 18 CBZ vs PRM, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 18 CBZ vs PRM
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup CBZ PRM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Canger 1999 4/113 0/35 100.0 % 2.84 [ 0.16, 51.53 ]
Pardi 1982 0/6 0/4 Not estimable
Total (95% CI) 119 39 100.0 % 2.84 [ 0.16, 51.53 ]
Total events: 4 (CBZ), 0 (PRM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 19.1. Comparison 19 CBZ vs TPM, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 19 CBZ vs TPM
Outcome: 1 All Major Malformations
Study or subgroup CBZ TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 18/361 1/44 6.0 % 2.19 [ 0.30, 16.04 ]
North American Register 31/1033 15/359 74.7 % 0.72 [ 0.39, 1.31 ]
UK Register 43/1657 3/70 19.3 % 0.61 [ 0.19, 1.90 ]
Total (95% CI) 3051 473 100.0 % 0.78 [ 0.47, 1.31 ]
Total events: 92 (CBZ), 19 (TPM)
Heterogeneity: Chi2 = 1.31, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 19.2. Comparison 19 CBZ vs TPM, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 19 CBZ vs TPM
Outcome: 2 Neural Tube Malformations
Study or subgroup CBZ TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/361 0/44 34.3 % 0.37 [ 0.02, 9.02 ]
North American Register 3/1033 0/359 28.6 % 2.44 [ 0.13, 47.07 ]
UK Register 4/1657 0/70 37.0 % 0.39 [ 0.02, 7.09 ]
Total (95% CI) 3051 473 100.0 % 0.97 [ 0.19, 5.06 ]
Total events: 8 (CBZ), 0 (TPM)
Heterogeneity: Chi2 = 1.10, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 19.3. Comparison 19 CBZ vs TPM, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 19 CBZ vs TPM
Outcome: 3 Cardiac Malformations
Study or subgroup CBZ TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 3/361 0/44 26.7 % 0.87 [ 0.05, 16.57 ]
North American Register 3/1033 1/359 44.5 % 1.04 [ 0.11, 9.99 ]
UK Register 14/1657 0/70 28.8 % 1.24 [ 0.07, 20.61 ]
Total (95% CI) 3051 473 100.0 % 1.05 [ 0.23, 4.78 ]
Total events: 20 (CBZ), 1 (TPM)
Heterogeneity: Chi2 = 0.03, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 19.4. Comparison 19 CBZ vs TPM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 19 CBZ vs TPM
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup CBZ TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 4/361 0/44 7.3 % 1.12 [ 0.06, 20.44 ]
North American Register 5/1033 5/359 61.1 % 0.35 [ 0.10, 1.19 ]
UK Register 4/1657 2/70 31.6 % 0.08 [ 0.02, 0.45 ]
Total (95% CI) 3051 473 100.0 % 0.32 [ 0.13, 0.81 ]
Total events: 13 (CBZ), 7 (TPM)
Heterogeneity: Chi2 = 3.15, df = 2 (P = 0.21); I2 =36%
Test for overall effect: Z = 2.42 (P = 0.016)
Test for subgroup differences: Not applicable
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Analysis 19.5. Comparison 19 CBZ vs TPM, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 19 CBZ vs TPM
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup CBZ TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 2/361 0/44 9.6 % 0.62 [ 0.03, 12.74 ]
North American Register 5/1033 5/359 80.1 % 0.35 [ 0.10, 1.19 ]
UK Register 4/1657 0/70 10.3 % 0.39 [ 0.02, 7.09 ]
Total (95% CI) 3051 473 100.0 % 0.38 [ 0.13, 1.09 ]
Total events: 11 (CBZ), 5 (TPM)
Heterogeneity: Chi2 = 0.12, df = 2 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.80 (P = 0.072)
Test for subgroup differences: Not applicable
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Analysis 20.1. Comparison 20 CBZ vs VPA, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 20 CBZ vs VPA
Outcome: 1 All Major Malformations
Study or subgroup CBZ VPA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Al Bunyan 1999 1/31 0/5 0.3 % 0.56 [ 0.03, 12.23 ]
Arulmozhi 2006 0/7 0/3 Not estimable
Australian 18/361 37/271 14.9 % 0.37 [ 0.21, 0.63 ]
Canger 1999 12/113 8/44 4.1 % 0.58 [ 0.26, 1.33 ]
Cassina 2013 5/88 3/45 1.4 % 0.85 [ 0.21, 3.41 ]
Eroglu 2008 3/46 2/15 1.1 % 0.49 [ 0.09, 2.66 ]
Fairgrieve 2000 4/109 4/74 1.7 % 0.68 [ 0.18, 2.63 ]
Froscher 1991 2/31 1/12 0.5 % 0.77 [ 0.08, 7.77 ]
Garza-Morales 1996 0/24 0/5 Not estimable
Kaaja 2003 10/363 4/61 2.4 % 0.42 [ 0.14, 1.30 ]
Kaneko 1999 9/158 9/81 4.2 % 0.51 [ 0.21, 1.24 ]
Kerala Pregnancy Registry 1/7 2/6 0.8 % 0.43 [ 0.05, 3.64 ]
Koch 1992 0/9 3/14 1.0 % 0.21 [ 0.01, 3.72 ]
Lindhout 1992 5/50 5/66 1.5 % 1.32 [ 0.40, 4.31 ]
Martinez Ferri 2009 4/105 7/68 3.0 % 0.37 [ 0.11, 1.22 ]
Mawer 2010 2/31 3/25 1.2 % 0.54 [ 0.10, 2.97 ]
Meador 2006 5/110 12/69 5.2 % 0.26 [ 0.10, 0.71 ]
Meischenguiser 2004 2/16 3/21 0.9 % 0.88 [ 0.17, 4.63 ]
Montreal Series 5/32 4/15 1.9 % 0.59 [ 0.18, 1.87 ]
North American Register 31/1033 30/323 16.1 % 0.32 [ 0.20, 0.53 ]
Omtzigt 1992 4/114 7/60 3.2 % 0.30 [ 0.09, 0.99 ]
Pardi 1982 0/6 0/1 Not estimable
0.01 0.1 1 10 100
Favours CBZ Favours VPA
(Continued . . . )
219Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup CBZ VPA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Steegers-Theunissen 1994 1/39 3/19 1.4 % 0.16 [ 0.02, 1.46 ]
Tanganelli 1992 0/9 0/6 Not estimable
UK Register 43/1657 82/1220 33.3 % 0.39 [ 0.27, 0.55 ]
Total (95% CI) 4549 2529 100.0 % 0.41 [ 0.34, 0.50 ]
Total events: 167 (CBZ), 229 (VPA)
Heterogeneity: Chi2 = 11.08, df = 20 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 8.88 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 20.2. Comparison 20 CBZ vs VPA, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 20 CBZ vs VPA
Outcome: 2 Neural Tube Malformations
Study or subgroup CBZ VPA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/361 7/271 14.2 % 0.11 [ 0.01, 0.87 ]
Canger 1999 1/113 5/44 12.7 % 0.08 [ 0.01, 0.65 ]
Cassina 2013 0/88 1/45 3.5 % 0.17 [ 0.01, 4.15 ]
Eroglu 2008 0/49 0/16 Not estimable
Fairgrieve 2000 0/109 0/74 Not estimable
Froscher 1991 0/31 0/12 Not estimable
Kaaja 2003 3/363 2/61 6.1 % 0.25 [ 0.04, 1.48 ]
Kerala Pregnancy Registry 0/7 2/6 4.7 % 0.18 [ 0.01, 3.06 ]
Koch 1992 0/9 1/14 2.1 % 0.50 [ 0.02, 11.09 ]
Martinez Ferri 2009 1/105 2/68 4.3 % 0.32 [ 0.03, 3.50 ]
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(. . . Continued)
Study or subgroup CBZ VPA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Meador 2006 0/110 0/69 Not estimable
Meischenguiser 2004 0/16 0/21 Not estimable
North American Register 3/1033 4/323 10.8 % 0.23 [ 0.05, 1.04 ]
Omtzigt 1992 0/114 6/60 15.0 % 0.04 [ 0.00, 0.71 ]
Pardi 1982 0/6 0/1 Not estimable
UK Register 4/1657 13/1220 26.5 % 0.23 [ 0.07, 0.69 ]
Total (95% CI) 4171 2305 100.0 % 0.17 [ 0.09, 0.31 ]
Total events: 13 (CBZ), 43 (VPA)
Heterogeneity: Chi2 = 3.02, df = 9 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 5.73 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 20.3. Comparison 20 CBZ vs VPA, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 20 CBZ vs VPA
Outcome: 3 Cardiac Malformations
Study or subgroup CBZ VPA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 3/361 10/271 17.1 % 0.23 [ 0.06, 0.81 ]
Canger 1999 0/113 0/44 Not estimable
Cassina 2013 3/88 2/45 4.0 % 0.77 [ 0.13, 4.43 ]
Eroglu 2008 0/49 0/16 Not estimable
Fairgrieve 2000 3/109 1/74 1.8 % 2.04 [ 0.22, 19.20 ]
Froscher 1991 1/31 0/12 1.1 % 1.22 [ 0.05, 28.02 ]
Kaaja 2003 2/363 2/61 5.1 % 0.17 [ 0.02, 1.17 ]
Kerala Pregnancy Registry 7/112 7/71 12.8 % 0.63 [ 0.23, 1.73 ]
Koch 1992 0/9 1/14 1.8 % 0.50 [ 0.02, 11.09 ]
Martinez Ferri 2009 2/105 2/68 3.6 % 0.65 [ 0.09, 4.49 ]
Meador 2006 0/110 4/69 8.3 % 0.07 [ 0.00, 1.28 ]
Meischenguiser 2004 0/16 1/21 2.0 % 0.43 [ 0.02, 9.94 ]
North American Register 3/1033 8/323 18.3 % 0.12 [ 0.03, 0.44 ]
Omtzigt 1992 0/114 0/60 Not estimable
Pardi 1982 0/6 0/1 Not estimable
UK Register 14/1657 14/1220 24.2 % 0.74 [ 0.35, 1.54 ]
Total (95% CI) 4276 2370 100.0 % 0.45 [ 0.31, 0.68 ]
Total events: 38 (CBZ), 52 (VPA)
Heterogeneity: Chi2 = 12.43, df = 11 (P = 0.33); I2 =12%
Test for overall effect: Z = 3.88 (P = 0.00010)
Test for subgroup differences: Not applicable
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Analysis 20.4. Comparison 20 CBZ vs VPA, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 20 CBZ vs VPA
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup CBZ VPA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 4/361 12/271 28.4 % 0.25 [ 0.08, 0.77 ]
Canger 1999 0/113 0/44 Not estimable
Cassina 2013 0/88 0/45 Not estimable
Eroglu 2008 0/49 1/16 4.6 % 0.11 [ 0.00, 2.65 ]
Fairgrieve 2000 0/109 1/74 3.7 % 0.23 [ 0.01, 5.50 ]
Froscher 1991 0/31 0/12 Not estimable
Kaaja 2003 2/363 1/61 3.6 % 0.34 [ 0.03, 3.65 ]
Kerala Pregnancy Registry 0/7 0/6 Not estimable
Koch 1992 0/9 1/14 2.5 % 0.50 [ 0.02, 11.09 ]
Martinez Ferri 2009 0/105 1/68 3.8 % 0.22 [ 0.01, 5.25 ]
Meador 2006 0/110 1/69 3.8 % 0.21 [ 0.01, 5.09 ]
Meischenguiser 2004 0/16 2/21 4.5 % 0.26 [ 0.01, 5.04 ]
North American Register 5/1033 4/323 12.6 % 0.39 [ 0.11, 1.45 ]
Omtzigt 1992 1/114 0/60 1.4 % 1.59 [ 0.07, 38.48 ]
Pardi 1982 0/6 0/1 Not estimable
UK Register 4/1657 13/1220 31.1 % 0.23 [ 0.07, 0.69 ]
Total (95% CI) 4171 2305 100.0 % 0.28 [ 0.16, 0.49 ]
Total events: 16 (CBZ), 37 (VPA)
Heterogeneity: Chi2 = 2.12, df = 10 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 4.45 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 20.5. Comparison 20 CBZ vs VPA, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 20 CBZ vs VPA
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup CBZ VPA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 2/361 6/271 15.7 % 0.25 [ 0.05, 1.23 ]
Canger 1999 4/113 1/44 3.3 % 1.56 [ 0.18, 13.55 ]
Cassina 2013 0/88 2/45 7.5 % 0.10 [ 0.01, 2.11 ]
Eroglu 2008 0/49 0/16 Not estimable
Fairgrieve 2000 0/109 1/74 4.1 % 0.23 [ 0.01, 5.50 ]
Froscher 1991 0/31 1/12 4.9 % 0.14 [ 0.01, 3.11 ]
Kaaja 2003 1/363 1/61 3.9 % 0.17 [ 0.01, 2.65 ]
Kerala Pregnancy Registry 0/7 1/6 3.7 % 0.29 [ 0.01, 6.07 ]
Koch 1992 0/9 2/14 4.6 % 0.30 [ 0.02, 5.61 ]
Martinez Ferri 2009 1/105 0/68 1.4 % 1.95 [ 0.08, 47.25 ]
Meador 2006 0/110 1/69 4.2 % 0.21 [ 0.01, 5.09 ]
Meischenguiser 2004 0/16 0/21 Not estimable
North American Register 5/1033 5/323 17.4 % 0.31 [ 0.09, 1.07 ]
Omtzigt 1992 1/114 1/60 3.0 % 0.53 [ 0.03, 8.27 ]
Pardi 1982 0/6 0/1 Not estimable
UK Register 4/1657 10/1220 26.4 % 0.29 [ 0.09, 0.94 ]
Total (95% CI) 4171 2305 100.0 % 0.33 [ 0.19, 0.57 ]
Total events: 18 (CBZ), 32 (VPA)
Heterogeneity: Chi2 = 4.69, df = 12 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 3.96 (P = 0.000076)
Test for subgroup differences: Not applicable
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Analysis 21.1. Comparison 21 CBZ vs ZNS, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 21 CBZ vs ZNS
Outcome: 1 All Major Malformations
Study or subgroup CBZ ZNS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
North American Register 31/1033 0/90 100.0 % 5.54 [ 0.34, 89.86 ]
Total (95% CI) 1033 90 100.0 % 5.54 [ 0.34, 89.86 ]
Total events: 31 (CBZ), 0 (ZNS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 22.1. Comparison 22 GBP vs LTG, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 22 GBP vs LTG
Outcome: 1 All Major Malformations
Study or subgroup GBP LTG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/14 13/315 15.5 % 0.78 [ 0.05, 12.51 ]
North American Register 1/145 31/1562 66.5 % 0.35 [ 0.05, 2.53 ]
UK Register 1/31 49/2098 18.0 % 1.38 [ 0.20, 9.69 ]
Total (95% CI) 190 3975 100.0 % 0.60 [ 0.17, 2.07 ]
Total events: 2 (GBP), 93 (LTG)
Heterogeneity: Chi2 = 1.03, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 22.2. Comparison 22 GBP vs LTG, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 22 GBP vs LTG
Outcome: 2 Neural Tube Malformations
Study or subgroup GBP LTG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/14 0/315 Not estimable
Total (95% CI) 14 315 Not estimable
Total events: 0 (GBP), 0 (LTG)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 22.3. Comparison 22 GBP vs LTG, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 22 GBP vs LTG
Outcome: 3 Cardiac Malformations
Study or subgroup GBP LTG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/14 3/315 100.0 % 3.01 [ 0.16, 55.67 ]
Total (95% CI) 14 315 100.0 % 3.01 [ 0.16, 55.67 ]
Total events: 0 (GBP), 3 (LTG)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 22.4. Comparison 22 GBP vs LTG, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 22 GBP vs LTG
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup GBP LTG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/14 5/315 100.0 % 1.92 [ 0.11, 33.05 ]
Total (95% CI) 14 315 100.0 % 1.92 [ 0.11, 33.05 ]
Total events: 0 (GBP), 5 (LTG)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 22.5. Comparison 22 GBP vs LTG, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 22 GBP vs LTG
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup GBP LTG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/14 0/315 Not estimable
Total (95% CI) 14 315 Not estimable
Total events: 0 (GBP), 0 (LTG)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 23.1. Comparison 23 GBP vs OXC, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 23 GBP vs OXC
Outcome: 1 All Major Malformations
Study or subgroup GBP OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/14 0/12 Not estimable
North American Register 1/145 4/182 100.0 % 0.31 [ 0.04, 2.78 ]
Total (95% CI) 159 194 100.0 % 0.31 [ 0.04, 2.78 ]
Total events: 1 (GBP), 4 (OXC)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 23.2. Comparison 23 GBP vs OXC, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 23 GBP vs OXC
Outcome: 2 Neural Tube Malformations
Study or subgroup GBP OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/14 0/12 Not estimable
Total (95% CI) 14 12 Not estimable
Total events: 0 (GBP), 0 (OXC)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 23.3. Comparison 23 GBP vs OXC, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 23 GBP vs OXC
Outcome: 3 Cardiac Malformations
Study or subgroup GBP OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/14 0/12 Not estimable
Total (95% CI) 14 12 Not estimable
Total events: 0 (GBP), 0 (OXC)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 23.4. Comparison 23 GBP vs OXC, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 23 GBP vs OXC
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup GBP OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/14 0/12 Not estimable
Total (95% CI) 14 12 Not estimable
Total events: 0 (GBP), 0 (OXC)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 23.5. Comparison 23 GBP vs OXC, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 23 GBP vs OXC
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup GBP OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/14 0/12 Not estimable
Total (95% CI) 14 12 Not estimable
Total events: 0 (GBP), 0 (OXC)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 24.1. Comparison 24 GBP vs PB, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 24 GBP vs PB
Outcome: 1 All Major Malformations
Study or subgroup GBP PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/14 0/5 Not estimable
North American Register 1/145 11/199 100.0 % 0.12 [ 0.02, 0.96 ]
Total (95% CI) 159 204 100.0 % 0.12 [ 0.02, 0.96 ]
Total events: 1 (GBP), 11 (PB)
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.045)
Test for subgroup differences: Not applicable
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Analysis 24.2. Comparison 24 GBP vs PB, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 24 GBP vs PB
Outcome: 2 Neural Tube Malformations
Study or subgroup GBP PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/14 0/5 Not estimable
Total (95% CI) 14 5 Not estimable
Total events: 0 (GBP), 0 (PB)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 24.3. Comparison 24 GBP vs PB, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 24 GBP vs PB
Outcome: 3 Cardiac Malformations
Study or subgroup GBP PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/14 0/5 Not estimable
Total (95% CI) 14 5 Not estimable
Total events: 0 (GBP), 0 (PB)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours GBP Favours PB
231Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 24.4. Comparison 24 GBP vs PB, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 24 GBP vs PB
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup GBP PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/14 0/5 Not estimable
Total (95% CI) 14 5 Not estimable
Total events: 0 (GBP), 0 (PB)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 24.5. Comparison 24 GBP vs PB, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 24 GBP vs PB
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup GBP PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/14 0/5 Not estimable
Total (95% CI) 14 5 Not estimable
Total events: 0 (GBP), 0 (PB)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 26.1. Comparison 26 GBP vs TPM, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 26 GBP vs TPM
Outcome: 1 All Major Malformations
Study or subgroup GBP TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/14 1/44 6.7 % 1.00 [ 0.04, 23.26 ]
North American Register 1/145 15/359 76.9 % 0.17 [ 0.02, 1.24 ]
UK Register 1/31 3/70 16.4 % 0.75 [ 0.08, 6.95 ]
Total (95% CI) 190 473 100.0 % 0.32 [ 0.09, 1.17 ]
Total events: 2 (GBP), 19 (TPM)
Heterogeneity: Chi2 = 1.50, df = 2 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.085)
Test for subgroup differences: Not applicable
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Analysis 26.2. Comparison 26 GBP vs TPM, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 26 GBP vs TPM
Outcome: 2 Neural Tube Malformations
Study or subgroup GBP TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/14 0/44 Not estimable
Total (95% CI) 14 44 Not estimable
Total events: 0 (GBP), 0 (TPM)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 26.3. Comparison 26 GBP vs TPM, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 26 GBP vs TPM
Outcome: 3 Cardiac Malformations
Study or subgroup GBP TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/14 0/44 Not estimable
Total (95% CI) 14 44 Not estimable
Total events: 0 (GBP), 0 (TPM)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours GBP Favours TPM
Analysis 26.4. Comparison 26 GBP vs TPM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 26 GBP vs TPM
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup GBP TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/14 0/44 Not estimable
Total (95% CI) 14 44 Not estimable
Total events: 0 (GBP), 0 (TPM)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 26.5. Comparison 26 GBP vs TPM, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 26 GBP vs TPM
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup GBP TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/14 0/44 Not estimable
Total (95% CI) 14 44 Not estimable
Total events: 0 (GBP), 0 (TPM)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 27.1. Comparison 27 GBP vs ZNS, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 27 GBP vs ZNS
Outcome: 1 All Major Malformations
Study or subgroup GBP ZNS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
North American Register 1/145 0/90 100.0 % 1.87 [ 0.08, 45.41 ]
Total (95% CI) 145 90 100.0 % 1.87 [ 0.08, 45.41 ]
Total events: 1 (GBP), 0 (ZNS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 28.1. Comparison 28 LEV vs GBP, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 28 LEV vs GBP
Outcome: 1 All Major Malformations
Study or subgroup LEV GBP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/63 0/14 19.6 % 0.70 [ 0.03, 16.42 ]
North American Register 11/450 1/145 36.6 % 3.54 [ 0.46, 27.22 ]
UK Register 2/304 1/31 43.9 % 0.20 [ 0.02, 2.19 ]
Total (95% CI) 817 190 100.0 % 1.52 [ 0.43, 5.42 ]
Total events: 14 (LEV), 2 (GBP)
Heterogeneity: Chi2 = 3.65, df = 2 (P = 0.16); I2 =45%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 28.2. Comparison 28 LEV vs GBP, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 28 LEV vs GBP
Outcome: 2 Neural Tube Malformations
Study or subgroup LEV GBP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/63 0/14 Not estimable
Total (95% CI) 63 14 Not estimable
Total events: 0 (LEV), 0 (GBP)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 28.3. Comparison 28 LEV vs GBP, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 28 LEV vs GBP
Outcome: 3 Cardiac Malformations
Study or subgroup LEV GBP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/63 0/14 100.0 % 0.70 [ 0.03, 16.42 ]
Total (95% CI) 63 14 100.0 % 0.70 [ 0.03, 16.42 ]
Total events: 1 (LEV), 0 (GBP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 28.4. Comparison 28 LEV vs GBP, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 28 LEV vs GBP
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup LEV GBP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/63 0/14 100.0 % 0.70 [ 0.03, 16.42 ]
Total (95% CI) 63 14 100.0 % 0.70 [ 0.03, 16.42 ]
Total events: 1 (LEV), 0 (GBP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 28.5. Comparison 28 LEV vs GBP, Outcome 5 Skeletal / Limb Malformation.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 28 LEV vs GBP
Outcome: 5 Skeletal / Limb Malformation
Study or subgroup LEV GBP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/63 0/14 Not estimable
Total (95% CI) 63 14 Not estimable
Total events: 0 (LEV), 0 (GBP)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 29.1. Comparison 29 LEV vs LTG, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 29 LEV vs LTG
Outcome: 1 All Major Malformations
Study or subgroup LEV LTG Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Australian 1/63 13/315 20.2 % 0.38 [ 0.05, 2.89 ]
North American Register 11/450 31/1562 49.3 % 1.23 [ 0.62, 2.43 ]
UK Register 2/304 49/2098 30.6 % 0.28 [ 0.07, 1.15 ]
Total (95% CI) 817 3975 100.0 % 0.62 [ 0.20, 1.88 ]
Total events: 14 (LEV), 93 (LTG)
Heterogeneity: Tau2 = 0.53; Chi2 = 4.44, df = 2 (P = 0.11); I2 =55%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
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Analysis 29.2. Comparison 29 LEV vs LTG, Outcome 2 Neural Tude Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 29 LEV vs LTG
Outcome: 2 Neural Tude Malformations
Study or subgroup LEV LTG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/63 0/315 Not estimable
North American Register 1/450 2/1562 58.5 % 1.74 [ 0.16, 19.10 ]
UK Register 0/304 2/2098 41.5 % 1.38 [ 0.07, 28.60 ]
Total (95% CI) 817 3975 100.0 % 1.59 [ 0.24, 10.38 ]
Total events: 1 (LEV), 4 (LTG)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 29.3. Comparison 29 LEV vs LTG, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 29 LEV vs LTG
Outcome: 3 Cardiac Malformations
Study or subgroup LEV LTG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/63 3/315 21.0 % 1.67 [ 0.18, 15.76 ]
North American Register 1/450 3/1562 28.2 % 1.16 [ 0.12, 11.10 ]
UK Register 0/304 9/2098 50.7 % 0.36 [ 0.02, 6.21 ]
Total (95% CI) 817 3975 100.0 % 0.86 [ 0.22, 3.36 ]
Total events: 2 (LEV), 15 (LTG)
Heterogeneity: Chi2 = 0.75, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 29.4. Comparison 29 LEV vs LTG, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 29 LEV vs LTG
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup LEV LTG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/63 5/315 29.4 % 1.00 [ 0.12, 8.41 ]
North American Register 0/450 7/1562 59.3 % 0.23 [ 0.01, 4.04 ]
UK Register 0/304 2/2098 11.2 % 1.38 [ 0.07, 28.60 ]
Total (95% CI) 817 3975 100.0 % 0.59 [ 0.14, 2.48 ]
Total events: 1 (LEV), 14 (LTG)
Heterogeneity: Chi2 = 0.95, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 29.5. Comparison 29 LEV vs LTG, Outcome 5 Skeletal / Limb Malformation.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 29 LEV vs LTG
Outcome: 5 Skeletal / Limb Malformation
Study or subgroup LEV LTG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/63 0/315 Not estimable
North American Register 0/450 2/1562 55.8 % 0.69 [ 0.03, 14.41 ]
UK Register 0/304 3/2098 44.2 % 0.98 [ 0.05, 18.99 ]
Total (95% CI) 817 3975 100.0 % 0.82 [ 0.10, 6.80 ]
Total events: 0 (LEV), 5 (LTG)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LEV Favours LTG
Analysis 30.1. Comparison 30 LEV vs OXC, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 30 LEV vs OXC
Outcome: 1 All Major Malformations
Study or subgroup LEV OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/63 0/12 12.7 % 0.61 [ 0.03, 14.14 ]
North American Register 11/450 4/182 87.3 % 1.11 [ 0.36, 3.45 ]
Total (95% CI) 513 194 100.0 % 1.05 [ 0.36, 3.03 ]
Total events: 12 (LEV), 4 (OXC)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 30.2. Comparison 30 LEV vs OXC, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 30 LEV vs OXC
Outcome: 2 Neural Tube Malformations
Study or subgroup LEV OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/63 0/12 Not estimable
North American Register 1/450 0/182 100.0 % 1.22 [ 0.05, 29.74 ]
Total (95% CI) 513 194 100.0 % 1.22 [ 0.05, 29.74 ]
Total events: 1 (LEV), 0 (OXC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Not applicable
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Analysis 30.3. Comparison 30 LEV vs OXC, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 30 LEV vs OXC
Outcome: 3 Cardiac Malformations
Study or subgroup LEV OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/63 0/12 53.9 % 0.61 [ 0.03, 14.14 ]
North American Register 1/450 0/182 46.1 % 1.22 [ 0.05, 29.74 ]
Total (95% CI) 513 194 100.0 % 0.89 [ 0.10, 8.21 ]
Total events: 2 (LEV), 0 (OXC)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
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Analysis 30.4. Comparison 30 LEV vs OXC, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 30 LEV vs OXC
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup LEV OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/63 0/12 28.0 % 0.61 [ 0.03, 14.14 ]
North American Register 0/450 1/182 72.0 % 0.14 [ 0.01, 3.30 ]
Total (95% CI) 513 194 100.0 % 0.27 [ 0.03, 2.20 ]
Total events: 1 (LEV), 1 (OXC)
Heterogeneity: Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 30.5. Comparison 30 LEV vs OXC, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 30 LEV vs OXC
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup LEV OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/63 0/12 Not estimable
North American Register 0/450 1/182 100.0 % 0.14 [ 0.01, 3.30 ]
Total (95% CI) 513 194 100.0 % 0.14 [ 0.01, 3.30 ]
Total events: 0 (LEV), 1 (OXC)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 31.1. Comparison 31 LEV vs PB, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 31 LEV vs PB
Outcome: 1 All Major Malformations
Study or subgroup LEV PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/63 0/5 5.7 % 0.28 [ 0.01, 6.18 ]
North American Register 11/450 11/199 94.3 % 0.44 [ 0.19, 1.00 ]
Total (95% CI) 513 204 100.0 % 0.43 [ 0.20, 0.96 ]
Total events: 12 (LEV), 11 (PB)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 2.07 (P = 0.039)
Test for subgroup differences: Not applicable
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Analysis 31.2. Comparison 31 LEV vs PB, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 31 LEV vs PB
Outcome: 2 Neural Tube Malformations
Study or subgroup LEV PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/63 0/5 Not estimable
North American Register 1/450 0/199 100.0 % 1.33 [ 0.05, 32.52 ]
Total (95% CI) 513 204 100.0 % 1.33 [ 0.05, 32.52 ]
Total events: 1 (LEV), 0 (PB)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 31.3. Comparison 31 LEV vs PB, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 31 LEV vs PB
Outcome: 3 Cardiac Malformations
Study or subgroup LEV PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/63 0/5 11.6 % 0.28 [ 0.01, 6.18 ]
North American Register 1/450 5/199 88.4 % 0.09 [ 0.01, 0.75 ]
Total (95% CI) 513 204 100.0 % 0.11 [ 0.02, 0.66 ]
Total events: 2 (LEV), 5 (PB)
Heterogeneity: Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.42 (P = 0.016)
Test for subgroup differences: Not applicable
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Analysis 31.4. Comparison 31 LEV vs PB, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 31 LEV vs PB
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup LEV PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/63 0/5 12.8 % 0.28 [ 0.01, 6.18 ]
North American Register 0/450 4/199 87.2 % 0.05 [ 0.00, 0.91 ]
Total (95% CI) 513 204 100.0 % 0.08 [ 0.01, 0.67 ]
Total events: 1 (LEV), 4 (PB)
Heterogeneity: Chi2 = 0.75, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 2.32 (P = 0.020)
Test for subgroup differences: Not applicable
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Analysis 31.5. Comparison 31 LEV vs PB, Outcome 5 Skeletal / Limb Malformation.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 31 LEV vs PB
Outcome: 5 Skeletal / Limb Malformation
Study or subgroup LEV PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/63 0/5 Not estimable
North American Register 0/450 1/199 100.0 % 0.15 [ 0.01, 3.61 ]
Total (95% CI) 513 204 100.0 % 0.15 [ 0.01, 3.61 ]
Total events: 0 (LEV), 1 (PB)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 32.1. Comparison 32 LEV vs PHT, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 32 LEV vs PHT
Outcome: 1 All Major Malformations
Study or subgroup LEV PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/63 2/44 9.3 % 0.35 [ 0.03, 3.73 ]
North American Register 11/450 12/416 49.5 % 0.85 [ 0.38, 1.90 ]
UK Register 2/304 7/106 41.2 % 0.10 [ 0.02, 0.47 ]
Total (95% CI) 817 566 100.0 % 0.49 [ 0.26, 0.92 ]
Total events: 14 (LEV), 21 (PHT)
Heterogeneity: Chi2 = 5.87, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Not applicable
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Analysis 32.2. Comparison 32 LEV vs PHT, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 32 LEV vs PHT
Outcome: 2 Neural Tube Malformations
Study or subgroup LEV PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/63 1/44 77.2 % 0.23 [ 0.01, 5.62 ]
North American Register 1/450 0/416 22.8 % 2.77 [ 0.11, 67.90 ]
UK Register 0/304 0/82 Not estimable
Total (95% CI) 817 542 100.0 % 0.81 [ 0.12, 5.34 ]
Total events: 1 (LEV), 1 (PHT)
Heterogeneity: Chi2 = 1.15, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 32.3. Comparison 32 LEV vs PHT, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 32 LEV vs PHT
Outcome: 3 Cardiac Malformations
Study or subgroup LEV PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/63 1/44 15.3 % 0.70 [ 0.04, 10.87 ]
North American Register 1/450 4/416 54.0 % 0.23 [ 0.03, 2.06 ]
UK Register 0/304 1/82 30.7 % 0.09 [ 0.00, 2.21 ]
Total (95% CI) 817 542 100.0 % 0.26 [ 0.06, 1.09 ]
Total events: 2 (LEV), 6 (PHT)
Heterogeneity: Chi2 = 0.93, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.065)
Test for subgroup differences: Not applicable
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Analysis 32.4. Comparison 32 LEV vs PHT, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 32 LEV vs PHT
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup LEV PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/63 0/44 10.6 % 2.11 [ 0.09, 50.61 ]
North American Register 0/450 2/416 46.9 % 0.18 [ 0.01, 3.84 ]
UK Register 0/304 1/82 42.5 % 0.09 [ 0.00, 2.21 ]
Total (95% CI) 817 542 100.0 % 0.35 [ 0.08, 1.56 ]
Total events: 1 (LEV), 3 (PHT)
Heterogeneity: Chi2 = 2.08, df = 2 (P = 0.35); I2 =4%
Test for overall effect: Z = 1.38 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 32.5. Comparison 32 LEV vs PHT, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 32 LEV vs PHT
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup LEV PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/63 0/44 Not estimable
North American Register 0/450 4/416 100.0 % 0.10 [ 0.01, 1.90 ]
UK Register 0/304 0/82 Not estimable
Total (95% CI) 817 542 100.0 % 0.10 [ 0.01, 1.90 ]
Total events: 0 (LEV), 4 (PHT)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 34.1. Comparison 34 LEV vs TPM, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 34 LEV vs TPM
Outcome: 1 All Major Malformations
Study or subgroup LEV TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/63 1/44 5.2 % 0.70 [ 0.04, 10.87 ]
North American Register 11/450 15/359 73.4 % 0.59 [ 0.27, 1.26 ]
UK Register 2/304 3/70 21.4 % 0.15 [ 0.03, 0.90 ]
Total (95% CI) 817 473 100.0 % 0.50 [ 0.26, 0.97 ]
Total events: 14 (LEV), 19 (TPM)
Heterogeneity: Chi2 = 1.93, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.040)
Test for subgroup differences: Not applicable
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Analysis 34.2. Comparison 34 LEV vs TPM, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 34 LEV vs TPM
Outcome: 2 Neural Tube Malformations
Study or subgroup LEV TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/63 0/44 Not estimable
North American Register 1/450 0/359 100.0 % 2.39 [ 0.10, 58.61 ]
UK Register 0/304 0/70 Not estimable
Total (95% CI) 817 473 100.0 % 2.39 [ 0.10, 58.61 ]
Total events: 1 (LEV), 0 (TPM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 34.3. Comparison 34 LEV vs TPM, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 34 LEV vs TPM
Outcome: 3 Cardiac Malformations
Study or subgroup LEV TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/63 0/44 34.5 % 2.11 [ 0.09, 50.61 ]
North American Register 1/450 1/359 65.5 % 0.80 [ 0.05, 12.71 ]
UK Register 0/304 0/70 Not estimable
Total (95% CI) 817 473 100.0 % 1.25 [ 0.16, 9.54 ]
Total events: 2 (LEV), 1 (TPM)
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 34.4. Comparison 34 LEV vs TPM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 34 LEV vs TPM
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup LEV TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/63 0/44 5.5 % 2.11 [ 0.09, 50.61 ]
North American Register 0/450 5/359 56.8 % 0.07 [ 0.00, 1.31 ]
UK Register 0/304 2/70 37.7 % 0.05 [ 0.00, 0.96 ]
Total (95% CI) 817 473 100.0 % 0.17 [ 0.04, 0.68 ]
Total events: 1 (LEV), 7 (TPM)
Heterogeneity: Chi2 = 3.45, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 2.53 (P = 0.012)
Test for subgroup differences: Not applicable
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Analysis 34.5. Comparison 34 LEV vs TPM, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 34 LEV vs TPM
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup LEV TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/63 0/44 Not estimable
North American Register 0/450 5/359 100.0 % 0.07 [ 0.00, 1.31 ]
UK Register 0/304 0/70 Not estimable
Total (95% CI) 817 473 100.0 % 0.07 [ 0.00, 1.31 ]
Total events: 0 (LEV), 5 (TPM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.075)
Test for subgroup differences: Not applicable
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Analysis 35.1. Comparison 35 LEV vs ZNS, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 35 LEV vs ZNS
Outcome: 1 All Major Malformations
Study or subgroup LEV ZNS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
North American Register 11/450 0/90 100.0 % 4.64 [ 0.28, 78.05 ]
Total (95% CI) 450 90 100.0 % 4.64 [ 0.28, 78.05 ]
Total events: 11 (LEV), 0 (ZNS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 36.1. Comparison 36 LTG vs OXC, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 36 LTG vs OXC
Outcome: 1 All Major Malformations
Study or subgroup LTG OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 13/315 0/12 11.8 % 1.11 [ 0.07, 17.68 ]
North American Register 31/1562 4/182 88.2 % 0.90 [ 0.32, 2.53 ]
Total (95% CI) 1877 194 100.0 % 0.93 [ 0.35, 2.43 ]
Total events: 44 (LTG), 4 (OXC)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Not applicable
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Analysis 36.2. Comparison 36 LTG vs OXC, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 36 LTG vs OXC
Outcome: 2 Neural Tube Malformations
Study or subgroup LTG OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/315 0/12 Not estimable
North American Register 2/1562 0/182 100.0 % 0.59 [ 0.03, 12.15 ]
Total (95% CI) 1877 194 100.0 % 0.59 [ 0.03, 12.15 ]
Total events: 2 (LTG), 0 (OXC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 36.3. Comparison 36 LTG vs OXC, Outcome 3 Cardiac Malformation.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 36 LTG vs OXC
Outcome: 3 Cardiac Malformation
Study or subgroup LTG OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 3/315 0/12 51.8 % 0.29 [ 0.02, 5.29 ]
North American Register 3/1562 0/182 48.2 % 0.82 [ 0.04, 15.80 ]
Total (95% CI) 1877 194 100.0 % 0.54 [ 0.07, 4.30 ]
Total events: 6 (LTG), 0 (OXC)
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 36.4. Comparison 36 LTG vs OXC, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 36 LTG vs OXC
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup LTG OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 5/315 0/12 34.9 % 0.45 [ 0.03, 7.76 ]
North American Register 7/1562 1/182 65.1 % 0.82 [ 0.10, 6.59 ]
Total (95% CI) 1877 194 100.0 % 0.69 [ 0.13, 3.71 ]
Total events: 12 (LTG), 1 (OXC)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 36.5. Comparison 36 LTG vs OXC, Outcome 5 Skeletal / Limb Malformation.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 36 LTG vs OXC
Outcome: 5 Skeletal / Limb Malformation
Study or subgroup LTG OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/315 0/12 Not estimable
North American Register 2/1562 1/182 100.0 % 0.23 [ 0.02, 2.56 ]
Total (95% CI) 1877 194 100.0 % 0.23 [ 0.02, 2.56 ]
Total events: 2 (LTG), 1 (OXC)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 37.1. Comparison 37 LTG vs PB, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 37 LTG vs PB
Outcome: 1 All Major Malformations
Study or subgroup LTG PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 13/315 0/5 3.8 % 0.51 [ 0.03, 7.66 ]
Cassina 2013 0/26 5/67 12.0 % 0.23 [ 0.01, 4.00 ]
Martinez Ferri 2009 0/56 1/11 9.5 % 0.07 [ 0.00, 1.62 ]
North American Register 31/1562 11/199 74.8 % 0.36 [ 0.18, 0.70 ]
Total (95% CI) 1959 282 100.0 % 0.32 [ 0.17, 0.61 ]
Total events: 44 (LTG), 17 (PB)
Heterogeneity: Chi2 = 1.17, df = 3 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 3.51 (P = 0.00045)
Test for subgroup differences: Not applicable
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Analysis 37.2. Comparison 37 LTG vs PB, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 37 LTG vs PB
Outcome: 2 Neural Tube Malformations
Study or subgroup LTG PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/315 0/5 Not estimable
Cassina 2013 0/26 0/67 Not estimable
North American Register 2/1562 0/199 100.0 % 0.64 [ 0.03, 13.28 ]
Total (95% CI) 1903 271 100.0 % 0.64 [ 0.03, 13.28 ]
Total events: 2 (LTG), 0 (PB)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LTG Favours PB
257Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 37.3. Comparison 37 LTG vs PB, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 37 LTG vs PB
Outcome: 3 Cardiac Malformations
Study or subgroup LTG PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 3/315 0/5 8.7 % 0.13 [ 0.01, 2.30 ]
Cassina 2013 0/26 2/67 12.6 % 0.50 [ 0.02, 10.15 ]
North American Register 3/1562 5/199 78.7 % 0.08 [ 0.02, 0.32 ]
Total (95% CI) 1903 271 100.0 % 0.14 [ 0.04, 0.42 ]
Total events: 6 (LTG), 7 (PB)
Heterogeneity: Chi2 = 1.35, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 3.43 (P = 0.00059)
Test for subgroup differences: Not applicable
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Analysis 37.4. Comparison 37 LTG vs PB, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 37 LTG vs PB
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup LTG PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 5/315 0/5 12.1 % 0.21 [ 0.01, 3.37 ]
Cassina 2013 0/26 0/67 Not estimable
North American Register 7/1562 4/199 87.9 % 0.22 [ 0.07, 0.75 ]
Total (95% CI) 1903 271 100.0 % 0.22 [ 0.07, 0.68 ]
Total events: 12 (LTG), 4 (PB)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 2.63 (P = 0.0086)
Test for subgroup differences: Not applicable
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Analysis 37.5. Comparison 37 LTG vs PB, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 37 LTG vs PB
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup LTG PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/315 0/5 Not estimable
Cassina 2013 0/26 0/67 Not estimable
North American Register 2/1562 1/199 100.0 % 0.25 [ 0.02, 2.80 ]
Total (95% CI) 1903 271 100.0 % 0.25 [ 0.02, 2.80 ]
Total events: 2 (LTG), 1 (PB)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 38.1. Comparison 38 LTG vs PHT, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 38 LTG vs PHT
Outcome: 1 All Major Malformations
Study or subgroup LTG PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 13/315 2/44 8.6 % 0.91 [ 0.21, 3.89 ]
Mawer 2010 0/9 0/2 Not estimable
Meador 2006 1/98 4/56 12.5 % 0.14 [ 0.02, 1.25 ]
North American Register 31/1562 12/416 46.4 % 0.69 [ 0.36, 1.33 ]
UK Register 49/2098 7/106 32.6 % 0.35 [ 0.16, 0.76 ]
Total (95% CI) 4082 624 100.0 % 0.53 [ 0.34, 0.84 ]
Total events: 94 (LTG), 25 (PHT)
Heterogeneity: Chi2 = 3.60, df = 3 (P = 0.31); I2 =17%
Test for overall effect: Z = 2.72 (P = 0.0065)
Test for subgroup differences: Not applicable
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Analysis 38.2. Comparison 38 LTG vs PHT, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 38 LTG vs PHT
Outcome: 2 Neural Tube Malformations
Study or subgroup LTG PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/315 1/44 60.0 % 0.05 [ 0.00, 1.15 ]
Meador 2006 0/98 0/56 Not estimable
North American Register 2/1562 0/416 18.0 % 1.33 [ 0.06, 27.73 ]
UK Register 2/2098 0/82 22.0 % 0.20 [ 0.01, 4.09 ]
Total (95% CI) 4073 598 100.0 % 0.31 [ 0.07, 1.34 ]
Total events: 4 (LTG), 1 (PHT)
Heterogeneity: Chi2 = 2.31, df = 2 (P = 0.31); I2 =13%
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 38.3. Comparison 38 LTG vs PHT, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 38 LTG vs PHT
Outcome: 3 Cardiac Malformations
Study or subgroup LTG PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 3/315 1/44 16.5 % 0.42 [ 0.04, 3.94 ]
Meador 2006 1/98 0/56 6.0 % 1.73 [ 0.07, 41.70 ]
North American Register 3/1562 4/416 59.4 % 0.20 [ 0.04, 0.89 ]
UK Register 9/2098 1/82 18.1 % 0.35 [ 0.05, 2.74 ]
Total (95% CI) 4073 598 100.0 % 0.35 [ 0.14, 0.92 ]
Total events: 16 (LTG), 6 (PHT)
Heterogeneity: Chi2 = 1.54, df = 3 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Not applicable
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Analysis 38.4. Comparison 38 LTG vs PHT, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 38 LTG vs PHT
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup LTG PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 5/315 0/44 14.7 % 1.57 [ 0.09, 27.85 ]
Meador 2006 0/98 0/56 Not estimable
North American Register 7/1562 2/416 53.0 % 0.93 [ 0.19, 4.47 ]
UK Register 2/2098 1/82 32.3 % 0.08 [ 0.01, 0.85 ]
Total (95% CI) 4073 598 100.0 % 0.75 [ 0.24, 2.34 ]
Total events: 14 (LTG), 3 (PHT)
Heterogeneity: Chi2 = 3.76, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 38.5. Comparison 38 LTG vs PHT, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 38 LTG vs PHT
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup LTG PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/315 0/44 Not estimable
Meador 2006 0/98 0/56 Not estimable
North American Register 2/1562 4/416 86.8 % 0.13 [ 0.02, 0.72 ]
UK Register 3/2098 0/82 13.2 % 0.28 [ 0.01, 5.32 ]
Total (95% CI) 4073 598 100.0 % 0.15 [ 0.03, 0.66 ]
Total events: 5 (LTG), 4 (PHT)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 2.51 (P = 0.012)
Test for subgroup differences: Not applicable
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Analysis 39.1. Comparison 39 LTG vs TPM, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 39 LTG vs TPM
Outcome: 1 All Major Malformations
Study or subgroup LTG TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 13/315 1/44 5.5 % 1.82 [ 0.24, 13.54 ]
North American Register 31/1562 15/359 76.3 % 0.47 [ 0.26, 0.87 ]
UK Register 49/2098 3/70 18.2 % 0.54 [ 0.17, 1.71 ]
Total (95% CI) 3975 473 100.0 % 0.56 [ 0.34, 0.94 ]
Total events: 93 (LTG), 19 (TPM)
Heterogeneity: Chi2 = 1.61, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Not applicable
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Analysis 39.2. Comparison 39 LTG vs TPM, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 39 LTG vs TPM
Outcome: 2 Neural Tube Malformations
Study or subgroup LTG TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/315 0/44 Not estimable
North American Register 2/1562 0/359 45.7 % 1.15 [ 0.06, 23.94 ]
UK Register 2/2098 0/70 54.3 % 0.17 [ 0.01, 3.49 ]
Total (95% CI) 3975 473 100.0 % 0.62 [ 0.08, 4.94 ]
Total events: 4 (LTG), 0 (TPM)
Heterogeneity: Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 39.3. Comparison 39 LTG vs TPM, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 39 LTG vs TPM
Outcome: 3 Cardiac Malformations
Study or subgroup LTG TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 3/315 0/44 25.2 % 1.00 [ 0.05, 18.98 ]
North American Register 3/1562 1/359 46.9 % 0.69 [ 0.07, 6.61 ]
UK Register 9/2098 0/70 27.9 % 0.64 [ 0.04, 10.93 ]
Total (95% CI) 3975 473 100.0 % 0.75 [ 0.17, 3.42 ]
Total events: 15 (LTG), 1 (TPM)
Heterogeneity: Chi2 = 0.05, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 39.4. Comparison 39 LTG vs TPM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 39 LTG vs TPM
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup LTG TPM Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Australian 5/315 0/44 24.0 % 1.57 [ 0.09, 27.85 ]
North American Register 7/1562 5/359 42.6 % 0.32 [ 0.10, 1.01 ]
UK Register 2/2098 2/70 33.4 % 0.03 [ 0.00, 0.23 ]
Total (95% CI) 3975 473 100.0 % 0.22 [ 0.03, 1.56 ]
Total events: 14 (LTG), 7 (TPM)
Heterogeneity: Tau2 = 2.00; Chi2 = 6.35, df = 2 (P = 0.04); I2 =69%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 39.5. Comparison 39 LTG vs TPM, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 39 LTG vs TPM
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup LTG TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/315 0/44 Not estimable
North American Register 2/1562 5/359 89.4 % 0.09 [ 0.02, 0.47 ]
UK Register 3/2098 0/70 10.6 % 0.24 [ 0.01, 4.54 ]
Total (95% CI) 3975 473 100.0 % 0.11 [ 0.03, 0.45 ]
Total events: 5 (LTG), 5 (TPM)
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Not applicable
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Analysis 40.1. Comparison 40 PHT vs GBP, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 40 PHT vs GBP
Outcome: 1 All Major Malformations
Study or subgroup PHT GBP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 2/44 0/14 19.8 % 1.67 [ 0.08, 32.80 ]
North American Register 12/416 1/145 39.2 % 4.18 [ 0.55, 31.89 ]
UK Register 7/106 1/31 40.9 % 2.05 [ 0.26, 16.01 ]
Total (95% CI) 566 190 100.0 % 2.81 [ 0.77, 10.23 ]
Total events: 21 (PHT), 2 (GBP)
Heterogeneity: Chi2 = 0.36, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 40.2. Comparison 40 PHT vs GBP, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 40 PHT vs GBP
Outcome: 2 Neural Tube Malformations
Study or subgroup PHT GBP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/44 0/14 100.0 % 1.00 [ 0.04, 23.26 ]
Total (95% CI) 44 14 100.0 % 1.00 [ 0.04, 23.26 ]
Total events: 1 (PHT), 0 (GBP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 40.3. Comparison 40 PHT vs GBP, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 40 PHT vs GBP
Outcome: 3 Cardiac Malformations
Study or subgroup PHT GBP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/44 0/14 100.0 % 1.00 [ 0.04, 23.26 ]
Total (95% CI) 44 14 100.0 % 1.00 [ 0.04, 23.26 ]
Total events: 1 (PHT), 0 (GBP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 40.4. Comparison 40 PHT vs GBP, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 40 PHT vs GBP
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup PHT GBP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/44 0/14 Not estimable
Total (95% CI) 44 14 Not estimable
Total events: 0 (PHT), 0 (GBP)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 40.5. Comparison 40 PHT vs GBP, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 40 PHT vs GBP
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup PHT GBP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/44 0/14 Not estimable
Total (95% CI) 44 14 Not estimable
Total events: 0 (PHT), 0 (GBP)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 41.1. Comparison 41 PHT vs OXC, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 41 PHT vs OXC
Outcome: 1 All Major Malformations
Study or subgroup PHT OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 2/44 0/12 9.5 % 1.44 [ 0.07, 28.24 ]
Kaaja 2003 3/124 1/9 22.7 % 0.22 [ 0.03, 1.89 ]
North American Register 12/416 4/182 67.8 % 1.31 [ 0.43, 4.01 ]
Total (95% CI) 584 203 100.0 % 1.08 [ 0.43, 2.71 ]
Total events: 17 (PHT), 5 (OXC)
Heterogeneity: Chi2 = 2.26, df = 2 (P = 0.32); I2 =12%
Test for overall effect: Z = 0.16 (P = 0.88)
Test for subgroup differences: Not applicable
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Analysis 41.2. Comparison 41 PHT vs OXC, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 41 PHT vs OXC
Outcome: 2 Neural Tube Malformations
Study or subgroup PHT OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/44 0/12 100.0 % 0.87 [ 0.04, 20.03 ]
Kaaja 2003 0/124 0/9 Not estimable
North American Register 0/416 0/182 Not estimable
Total (95% CI) 584 203 100.0 % 0.87 [ 0.04, 20.03 ]
Total events: 1 (PHT), 0 (OXC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
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Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 41 PHT vs OXC
Outcome: 3 Cardiac Malformations
Study or subgroup PHT OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/44 0/12 52.7 % 0.87 [ 0.04, 20.03 ]
Kaaja 2003 0/124 0/9 Not estimable
North American Register 4/416 0/182 47.3 % 3.95 [ 0.21, 72.98 ]
Total (95% CI) 584 203 100.0 % 2.32 [ 0.30, 18.27 ]
Total events: 5 (PHT), 0 (OXC)
Heterogeneity: Chi2 = 0.51, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 41.4. Comparison 41 PHT vs OXC, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 41 PHT vs OXC
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup PHT OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/44 0/12 Not estimable
Kaaja 2003 1/124 0/9 40.0 % 0.24 [ 0.01, 5.52 ]
North American Register 2/416 1/182 60.0 % 0.88 [ 0.08, 9.59 ]
Total (95% CI) 584 203 100.0 % 0.62 [ 0.10, 4.05 ]
Total events: 3 (PHT), 1 (OXC)
Heterogeneity: Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 41.5. Comparison 41 PHT vs OXC, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 41 PHT vs OXC
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup PHT OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/44 0/12 Not estimable
Kaaja 2003 0/124 0/9 Not estimable
North American Register 4/416 1/182 100.0 % 1.75 [ 0.20, 15.55 ]
Total (95% CI) 584 203 100.0 % 1.75 [ 0.20, 15.55 ]
Total events: 4 (PHT), 1 (OXC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 42.1. Comparison 42 PHT vs PB, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 42 PHT vs PB
Outcome: 1 All Major Malformations
Study or subgroup PHT PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Al Bunyan 1999 0/9 0/2 Not estimable
Australian 2/44 0/5 2.1 % 0.67 [ 0.04, 12.29 ]
Canger 1999 3/31 4/83 5.1 % 2.01 [ 0.48, 8.47 ]
D’Souza 1990 6/22 1/4 4.0 % 1.09 [ 0.18, 6.80 ]
Eroglu 2008 2/14 1/5 3.5 % 0.71 [ 0.08, 6.27 ]
Froscher 1991 0/3 1/5 2.8 % 0.50 [ 0.03, 9.46 ]
Kaaja 2003 3/124 0/5 2.2 % 0.34 [ 0.02, 5.80 ]
Kaneko 1999 12/132 4/79 11.7 % 1.80 [ 0.60, 5.38 ]
Kelly 1984 1/24 0/6 1.8 % 0.84 [ 0.04, 18.44 ]
Kerala Pregnancy Registry 0/5 1/9 2.6 % 0.56 [ 0.03, 11.57 ]
Koch 1992 2/24 0/4 2.0 % 1.00 [ 0.06, 17.82 ]
Lindhout 1992 1/17 1/26 1.9 % 1.53 [ 0.10, 22.84 ]
Montreal Series 6/44 2/10 7.6 % 0.68 [ 0.16, 2.89 ]
North American Register 12/416 11/199 34.8 % 0.52 [ 0.23, 1.16 ]
Omtzigt 1992 0/28 3/18 9.9 % 0.09 [ 0.01, 1.71 ]
Pardi 1982 0/5 0/12 Not estimable
Steegers-Theunissen 1994 0/8 0/12 Not estimable
Waters 1994 3/28 3/21 8.0 % 0.75 [ 0.17, 3.35 ]
Total (95% CI) 978 505 100.0 % 0.80 [ 0.53, 1.21 ]
Total events: 53 (PHT), 32 (PB)
Heterogeneity: Chi2 = 7.79, df = 14 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 42.2. Comparison 42 PHT vs PB, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 42 PHT vs PB
Outcome: 2 Neural Tube Malformations
Study or subgroup PHT PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/44 0/5 100.0 % 0.40 [ 0.02, 8.75 ]
Canger 1999 0/31 0/83 Not estimable
D’Souza 1990 0/22 0/4 Not estimable
Eroglu 2008 0/14 0/5 Not estimable
Froscher 1991 0/3 0/5 Not estimable
Kerala Pregnancy Registry 0/5 0/9 Not estimable
Koch 1992 0/24 0/4 Not estimable
North American Register 0/416 0/199 Not estimable
Omtzigt 1992 0/28 0/18 Not estimable
Pardi 1982 0/5 0/12 Not estimable
Total (95% CI) 592 344 100.0 % 0.40 [ 0.02, 8.75 ]
Total events: 1 (PHT), 0 (PB)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PHT Favours PB
276Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 42.3. Comparison 42 PHT vs PB, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 42 PHT vs PB
Outcome: 3 Cardiac Malformations
Study or subgroup PHT PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/44 0/5 4.2 % 0.40 [ 0.02, 8.75 ]
Canger 1999 0/31 1/83 4.0 % 0.88 [ 0.04, 20.93 ]
D’Souza 1990 2/22 1/4 8.1 % 0.36 [ 0.04, 3.13 ]
Eroglu 2008 1/14 0/5 3.4 % 1.20 [ 0.06, 25.53 ]
Froscher 1991 0/3 1/5 5.8 % 0.50 [ 0.03, 9.46 ]
Kerala Pregnancy Registry 0/100 3/43 23.4 % 0.06 [ 0.00, 1.18 ]
Koch 1992 1/24 0/4 4.0 % 0.60 [ 0.03, 12.71 ]
North American Register 4/416 5/199 32.5 % 0.38 [ 0.10, 1.41 ]
Omtzigt 1992 0/28 2/18 14.5 % 0.13 [ 0.01, 2.58 ]
Pardi 1982 0/5 0/12 Not estimable
Total (95% CI) 687 378 100.0 % 0.33 [ 0.16, 0.71 ]
Total events: 9 (PHT), 13 (PB)
Heterogeneity: Chi2 = 2.93, df = 8 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 2.84 (P = 0.0045)
Test for subgroup differences: Not applicable
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Analysis 42.4. Comparison 42 PHT vs PB, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 42 PHT vs PB
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup PHT PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/44 0/5 Not estimable
Canger 1999 0/31 0/83 Not estimable
D’Souza 1990 1/22 0/4 8.1 % 0.65 [ 0.03, 13.78 ]
Eroglu 2008 0/14 1/5 21.0 % 0.13 [ 0.01, 2.84 ]
Froscher 1991 0/3 0/5 Not estimable
Kerala Pregnancy Registry 0/5 0/9 Not estimable
Koch 1992 0/24 0/4 Not estimable
North American Register 2/416 4/199 53.1 % 0.24 [ 0.04, 1.29 ]
Omtzigt 1992 0/28 1/18 17.8 % 0.22 [ 0.01, 5.09 ]
Pardi 1982 0/5 0/12 Not estimable
Total (95% CI) 592 344 100.0 % 0.25 [ 0.07, 0.82 ]
Total events: 3 (PHT), 6 (PB)
Heterogeneity: Chi2 = 0.55, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 2.29 (P = 0.022)
Test for subgroup differences: Not applicable
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Analysis 42.5. Comparison 42 PHT vs PB, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 42 PHT vs PB
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup PHT PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/44 0/5 Not estimable
Canger 1999 1/31 1/83 14.2 % 2.68 [ 0.17, 41.50 ]
D’Souza 1990 2/22 0/4 21.4 % 1.09 [ 0.06, 19.33 ]
Eroglu 2008 0/14 0/5 Not estimable
Froscher 1991 0/3 0/5 Not estimable
Kerala Pregnancy Registry 0/5 1/9 29.3 % 0.56 [ 0.03, 11.57 ]
Koch 1992 0/24 0/4 Not estimable
North American Register 4/416 1/199 35.2 % 1.91 [ 0.22, 17.01 ]
Omtzigt 1992 0/28 0/18 Not estimable
Pardi 1982 0/5 0/12 Not estimable
Total (95% CI) 592 344 100.0 % 1.45 [ 0.40, 5.22 ]
Total events: 7 (PHT), 3 (PB)
Heterogeneity: Chi2 = 0.68, df = 3 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 43.1. Comparison 43 PHT vs TPM, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 43 PHT vs TPM
Outcome: 1 All Major Malformations
Study or subgroup PHT TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 2/44 1/44 4.8 % 2.00 [ 0.19, 21.26 ]
North American Register 12/416 15/359 77.7 % 0.69 [ 0.33, 1.46 ]
UK Register 7/106 3/70 17.4 % 1.54 [ 0.41, 5.76 ]
Total (95% CI) 566 473 100.0 % 0.90 [ 0.49, 1.67 ]
Total events: 21 (PHT), 19 (TPM)
Heterogeneity: Chi2 = 1.56, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 43.2. Comparison 43 PHT vs TPM, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 43 PHT vs TPM
Outcome: 2 Neural Tube Malformations
Study or subgroup PHT TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/44 0/44 100.0 % 3.00 [ 0.13, 71.70 ]
North American Register 0/416 0/359 Not estimable
UK Register 0/82 0/70 Not estimable
Total (95% CI) 542 473 100.0 % 3.00 [ 0.13, 71.70 ]
Total events: 1 (PHT), 0 (TPM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 43.3. Comparison 43 PHT vs TPM, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 43 PHT vs TPM
Outcome: 3 Cardiac Malformations
Study or subgroup PHT TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 1/44 0/44 23.7 % 3.00 [ 0.13, 71.70 ]
North American Register 4/416 1/359 50.8 % 3.45 [ 0.39, 30.74 ]
UK Register 1/82 0/70 25.5 % 2.57 [ 0.11, 62.01 ]
Total (95% CI) 542 473 100.0 % 3.12 [ 0.65, 14.93 ]
Total events: 6 (PHT), 1 (TPM)
Heterogeneity: Chi2 = 0.02, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 43.4. Comparison 43 PHT vs TPM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 43 PHT vs TPM
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup PHT TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/44 0/44 Not estimable
North American Register 2/416 5/359 71.3 % 0.35 [ 0.07, 1.77 ]
UK Register 1/82 2/70 28.7 % 0.43 [ 0.04, 4.61 ]
Total (95% CI) 542 473 100.0 % 0.37 [ 0.10, 1.42 ]
Total events: 3 (PHT), 7 (TPM)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 43.5. Comparison 43 PHT vs TPM, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 43 PHT vs TPM
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup PHT TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/44 0/44 Not estimable
North American Register 4/416 5/359 100.0 % 0.69 [ 0.19, 2.55 ]
UK Register 0/82 0/70 Not estimable
Total (95% CI) 542 473 100.0 % 0.69 [ 0.19, 2.55 ]
Total events: 4 (PHT), 5 (TPM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Not applicable
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Analysis 44.1. Comparison 44 PB vs OXC, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 44 PB vs OXC
Outcome: 1 All Major Malformations
Study or subgroup PB OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/5 0/12 Not estimable
Kaaja 2003 0/5 1/9 20.7 % 0.56 [ 0.03, 11.57 ]
Meischenguiser 2004 1/5 0/35 2.6 % 18.00 [ 0.83, 392.32 ]
North American Register 11/199 4/182 76.7 % 2.52 [ 0.82, 7.76 ]
Total (95% CI) 214 238 100.0 % 2.52 [ 0.98, 6.43 ]
Total events: 12 (PB), 5 (OXC)
Heterogeneity: Chi2 = 2.52, df = 2 (P = 0.28); I2 =21%
Test for overall effect: Z = 1.93 (P = 0.054)
Test for subgroup differences: Not applicable
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Analysis 44.2. Comparison 44 PB vs OXC, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 44 PB vs OXC
Outcome: 2 Neural Tube Malformations
Study or subgroup PB OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/5 0/12 Not estimable
Meischenguiser 2004 0/5 0/35 Not estimable
North American Register 0/199 0/182 Not estimable
Total (95% CI) 209 229 Not estimable
Total events: 0 (PB), 0 (OXC)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 44.3. Comparison 44 PB vs OXC, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 44 PB vs OXC
Outcome: 3 Cardiac Malformations
Study or subgroup PB OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/5 0/12 Not estimable
Meischenguiser 2004 1/5 0/35 21.5 % 18.00 [ 0.83, 392.32 ]
North American Register 5/199 0/182 78.5 % 10.07 [ 0.56, 180.76 ]
Total (95% CI) 209 229 100.0 % 11.77 [ 1.24, 111.80 ]
Total events: 6 (PB), 0 (OXC)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 2.15 (P = 0.032)
Test for subgroup differences: Not applicable
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Analysis 44.4. Comparison 44 PB vs OXC, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 44 PB vs OXC
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup PB OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/5 0/12 Not estimable
Meischenguiser 2004 0/5 0/35 Not estimable
North American Register 4/199 1/182 100.0 % 3.66 [ 0.41, 32.43 ]
Total (95% CI) 209 229 100.0 % 3.66 [ 0.41, 32.43 ]
Total events: 4 (PB), 1 (OXC)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 44.5. Comparison 44 PB vs OXC, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 44 PB vs OXC
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup PB OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/5 0/12 Not estimable
Meischenguiser 2004 0/5 0/35 Not estimable
North American Register 1/199 1/182 100.0 % 0.91 [ 0.06, 14.52 ]
Total (95% CI) 209 229 100.0 % 0.91 [ 0.06, 14.52 ]
Total events: 1 (PB), 1 (OXC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 45.1. Comparison 45 PB vs TPM, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 45 PB vs TPM
Outcome: 1 All Major Malformations
Study or subgroup PB TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/5 1/44 3.2 % 2.50 [ 0.11, 54.68 ]
North American Register 11/199 15/359 96.8 % 1.32 [ 0.62, 2.82 ]
Total (95% CI) 204 403 100.0 % 1.36 [ 0.65, 2.84 ]
Total events: 11 (PB), 16 (TPM)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 45.2. Comparison 45 PB vs TPM, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 45 PB vs TPM
Outcome: 2 Neural Tube Malformations
Study or subgroup PB TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/5 0/44 Not estimable
North American Register 0/199 0/359 Not estimable
Total (95% CI) 204 403 Not estimable
Total events: 0 (PB), 0 (TPM)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 45.3. Comparison 45 PB vs TPM, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 45 PB vs TPM
Outcome: 3 Cardiac Malformations
Study or subgroup PB TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/5 0/44 Not estimable
North American Register 5/199 1/359 100.0 % 9.02 [ 1.06, 76.67 ]
Total (95% CI) 204 403 100.0 % 9.02 [ 1.06, 76.67 ]
Total events: 5 (PB), 1 (TPM)
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.044)
Test for subgroup differences: Not applicable
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Analysis 45.4. Comparison 45 PB vs TPM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 45 PB vs TPM
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup PB TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/5 0/44 Not estimable
North American Register 4/199 5/359 100.0 % 1.44 [ 0.39, 5.31 ]
Total (95% CI) 204 403 100.0 % 1.44 [ 0.39, 5.31 ]
Total events: 4 (PB), 5 (TPM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
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Analysis 45.5. Comparison 45 PB vs TPM, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 45 PB vs TPM
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup PB TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/5 0/44 Not estimable
North American Register 1/199 5/359 100.0 % 0.36 [ 0.04, 3.07 ]
Total (95% CI) 204 403 100.0 % 0.36 [ 0.04, 3.07 ]
Total events: 1 (PB), 5 (TPM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 46.1. Comparison 46 VPA vs GBP, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 46 VPA vs GBP
Outcome: 1 All Major Malformations
Study or subgroup VPA GBP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 37/271 0/14 22.2 % 4.14 [ 0.27, 64.14 ]
North American Register 30/323 1/145 32.3 % 13.47 [ 1.85, 97.81 ]
UK Register 82/1220 1/31 45.6 % 2.08 [ 0.30, 14.49 ]
Total (95% CI) 1814 190 100.0 % 6.21 [ 1.91, 20.23 ]
Total events: 149 (VPA), 2 (GBP)
Heterogeneity: Chi2 = 1.89, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 3.03 (P = 0.0024)
Test for subgroup differences: Not applicable
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Analysis 46.2. Comparison 46 VPA vs GBP, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 46 VPA vs GBP
Outcome: 2 Neural Tube Malformations
Study or subgroup VPA GBP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 7/271 0/14 100.0 % 0.83 [ 0.05, 13.81 ]
Total (95% CI) 271 14 100.0 % 0.83 [ 0.05, 13.81 ]
Total events: 7 (VPA), 0 (GBP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 46.3. Comparison 46 VPA vs GBP, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 46 VPA vs GBP
Outcome: 3 Cardiac Malformations
Study or subgroup VPA GBP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 10/271 0/14 100.0 % 1.16 [ 0.07, 18.84 ]
Total (95% CI) 271 14 100.0 % 1.16 [ 0.07, 18.84 ]
Total events: 10 (VPA), 0 (GBP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
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Analysis 46.4. Comparison 46 VPA vs GBP, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 46 VPA vs GBP
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup VPA GBP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 12/271 0/14 100.0 % 1.38 [ 0.09, 22.19 ]
Total (95% CI) 271 14 100.0 % 1.38 [ 0.09, 22.19 ]
Total events: 12 (VPA), 0 (GBP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
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Analysis 46.5. Comparison 46 VPA vs GBP, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 46 VPA vs GBP
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup VPA GBP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 6/271 0/14 100.0 % 0.72 [ 0.04, 12.14 ]
Total (95% CI) 271 14 100.0 % 0.72 [ 0.04, 12.14 ]
Total events: 6 (VPA), 0 (GBP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours VPA Favours GBP
Analysis 47.1. Comparison 47 VPA vs LEV, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 47 VPA vs LEV
Outcome: 1 All Major Malformations
Study or subgroup VPA LEV Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 37/271 1/63 11.6 % 8.60 [ 1.20, 61.51 ]
North American Register 30/323 11/450 65.6 % 3.80 [ 1.93, 7.47 ]
UK Register 82/1220 2/304 22.8 % 10.22 [ 2.53, 41.31 ]
Total (95% CI) 1814 817 100.0 % 5.82 [ 3.13, 10.81 ]
Total events: 149 (VPA), 14 (LEV)
Heterogeneity: Chi2 = 2.30, df = 2 (P = 0.32); I2 =13%
Test for overall effect: Z = 5.57 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 47.2. Comparison 47 VPA vs LEV, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 47 VPA vs LEV
Outcome: 2 Neural Tube Malformations
Study or subgroup VPA LEV Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 7/271 0/63 33.1 % 3.53 [ 0.20, 61.00 ]
North American Register 4/323 1/450 34.2 % 5.57 [ 0.63, 49.63 ]
UK Register 13/1220 0/304 32.7 % 6.74 [ 0.40, 113.14 ]
Total (95% CI) 1814 817 100.0 % 5.28 [ 1.17, 23.83 ]
Total events: 24 (VPA), 1 (LEV)
Heterogeneity: Chi2 = 0.11, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 2.16 (P = 0.030)
Test for subgroup differences: Not applicable
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Analysis 47.3. Comparison 47 VPA vs LEV, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 47 VPA vs LEV
Outcome: 3 Cardiac Malformations
Study or subgroup VPA LEV Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 10/271 1/63 49.8 % 2.32 [ 0.30, 17.83 ]
North American Register 8/323 1/450 25.6 % 11.15 [ 1.40, 88.67 ]
UK Register 14/1220 0/304 24.6 % 7.24 [ 0.43, 121.10 ]
Total (95% CI) 1814 817 100.0 % 5.79 [ 1.67, 20.16 ]
Total events: 32 (VPA), 2 (LEV)
Heterogeneity: Chi2 = 1.18, df = 2 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 2.76 (P = 0.0058)
Test for subgroup differences: Not applicable
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Analysis 47.4. Comparison 47 VPA vs LEV, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 47 VPA vs LEV
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup VPA LEV Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 12/271 1/63 57.1 % 2.79 [ 0.37, 21.06 ]
North American Register 4/323 0/450 14.7 % 12.53 [ 0.68, 231.88 ]
UK Register 13/1220 0/304 28.2 % 6.74 [ 0.40, 113.14 ]
Total (95% CI) 1814 817 100.0 % 5.34 [ 1.33, 21.39 ]
Total events: 29 (VPA), 1 (LEV)
Heterogeneity: Chi2 = 0.75, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.36 (P = 0.018)
Test for subgroup differences: Not applicable
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Analysis 47.5. Comparison 47 VPA vs LEV, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 47 VPA vs LEV
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup VPA LEV Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 6/271 0/63 39.9 % 3.06 [ 0.17, 53.60 ]
North American Register 5/323 0/450 20.6 % 15.31 [ 0.85, 275.93 ]
UK Register 10/1220 0/304 39.5 % 5.25 [ 0.31, 89.27 ]
Total (95% CI) 1814 817 100.0 % 6.45 [ 1.33, 31.16 ]
Total events: 21 (VPA), 0 (LEV)
Heterogeneity: Chi2 = 0.62, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 2.32 (P = 0.020)
Test for subgroup differences: Not applicable
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Analysis 48.1. Comparison 48 VPA vs LTG, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 48 VPA vs LTG
Outcome: 1 All Major Malformations
Study or subgroup VPA LTG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 37/271 13/315 19.6 % 3.31 [ 1.80, 6.09 ]
Cassina 2013 3/45 0/26 1.0 % 4.11 [ 0.22, 76.55 ]
Martinez Ferri 2009 7/68 0/56 0.9 % 12.39 [ 0.72, 212.33 ]
Mawer 2010 3/25 0/9 1.2 % 2.69 [ 0.15, 47.58 ]
Meador 2006 12/69 1/98 1.3 % 17.04 [ 2.27, 128.04 ]
North American Register 30/323 31/1562 17.3 % 4.68 [ 2.87, 7.62 ]
UK Register 82/1220 49/2098 58.7 % 2.88 [ 2.03, 4.07 ]
Total (95% CI) 2021 4164 100.0 % 3.56 [ 2.77, 4.58 ]
Total events: 174 (VPA), 94 (LTG)
Heterogeneity: Chi2 = 5.81, df = 6 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 9.85 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 48.2. Comparison 48 VPA vs LTG, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 48 VPA vs LTG
Outcome: 2 Neural Tube Malformations
Study or subgroup VPA LTG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 7/271 0/315 12.2 % 17.43 [ 1.00, 303.72 ]
Cassina 2013 1/45 0/26 16.6 % 1.76 [ 0.07, 41.72 ]
Martinez Ferri 2009 2/68 0/56 14.4 % 4.13 [ 0.20, 84.30 ]
Meador 2006 0/69 0/98 Not estimable
North American Register 4/323 2/1562 18.1 % 9.67 [ 1.78, 52.58 ]
UK Register 13/1220 2/2098 38.7 % 11.18 [ 2.53, 49.45 ]
Total (95% CI) 1996 4155 100.0 % 9.09 [ 3.56, 23.22 ]
Total events: 27 (VPA), 4 (LTG)
Heterogeneity: Chi2 = 1.57, df = 4 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 4.61 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 48.3. Comparison 48 VPA vs LTG, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 48 VPA vs LTG
Outcome: 3 Cardiac Malformations
Study or subgroup VPA LTG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 10/271 3/315 22.3 % 3.87 [ 1.08, 13.93 ]
Cassina 2013 2/45 0/26 5.1 % 2.93 [ 0.15, 58.88 ]
Martinez Ferri 2009 2/68 0/56 4.4 % 4.13 [ 0.20, 84.30 ]
Meador 2006 4/69 1/98 6.7 % 5.68 [ 0.65, 49.73 ]
North American Register 8/323 3/1562 8.3 % 12.90 [ 3.44, 48.35 ]
UK Register 14/1220 9/2098 53.3 % 2.68 [ 1.16, 6.16 ]
Total (95% CI) 1996 4155 100.0 % 4.07 [ 2.33, 7.09 ]
Total events: 40 (VPA), 16 (LTG)
Heterogeneity: Chi2 = 4.04, df = 5 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 4.94 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 48.4. Comparison 48 VPA vs LTG, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 48 VPA vs LTG
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup VPA LTG
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 12/271 5/315 11.4 % 0.03 [ 0.00, 0.06 ]
Cassina 2013 0/45 0/26 1.3 % 0.0 [ -0.06, 0.06 ]
Martinez Ferri 2009 1/68 0/56 2.4 % 0.01 [ -0.03, 0.06 ]
Meador 2006 1/69 0/98 3.2 % 0.01 [ -0.02, 0.05 ]
North American Register 4/323 7/1562 21.0 % 0.01 [ 0.00, 0.02 ]
UK Register 13/1220 2/2098 60.6 % 0.01 [ 0.00, 0.02 ]
Total (95% CI) 1996 4155 100.0 % 0.01 [ 0.01, 0.02 ]
Total events: 31 (VPA), 14 (LTG)
Heterogeneity: Chi2 = 2.30, df = 5 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 3.95 (P = 0.000078)
Test for subgroup differences: Not applicable
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Analysis 48.5. Comparison 48 VPA vs LTG, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 48 VPA vs LTG
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup VPA LTG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 6/271 0/315 10.5 % 15.10 [ 0.85, 266.87 ]
Cassina 2013 2/45 0/26 14.3 % 2.93 [ 0.15, 58.88 ]
Martinez Ferri 2009 0/68 0/56 Not estimable
Meador 2006 1/69 0/98 9.4 % 4.24 [ 0.18, 102.63 ]
North American Register 5/323 2/1562 15.6 % 12.09 [ 2.36, 62.04 ]
UK Register 10/1220 3/2098 50.2 % 5.73 [ 1.58, 20.79 ]
Total (95% CI) 1996 4155 100.0 % 7.17 [ 2.99, 17.18 ]
Total events: 24 (VPA), 5 (LTG)
Heterogeneity: Chi2 = 1.21, df = 4 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 4.41 (P = 0.000010)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours VPA Favours LTG
300Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 49.1. Comparison 49 VPA vs TPM, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 49 VPA vs TPM
Outcome: 1 All Major Malformations
Study or subgroup VPA TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 37/271 1/44 8.0 % 6.01 [ 0.85, 42.67 ]
North American Register 30/323 15/359 65.8 % 2.22 [ 1.22, 4.06 ]
UK Register 82/1220 3/70 26.3 % 1.57 [ 0.51, 4.84 ]
Total (95% CI) 1814 473 100.0 % 2.35 [ 1.40, 3.95 ]
Total events: 149 (VPA), 19 (TPM)
Heterogeneity: Chi2 = 1.41, df = 2 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 3.24 (P = 0.0012)
Test for subgroup differences: Not applicable
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Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 49 VPA vs TPM
Outcome: 2 Neural Tube Malformations
Study or subgroup VPA TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 7/271 0/44 37.7 % 2.48 [ 0.14, 42.70 ]
North American Register 4/323 0/359 20.8 % 10.00 [ 0.54, 185.02 ]
UK Register 13/1220 0/70 41.5 % 1.57 [ 0.09, 26.14 ]
Total (95% CI) 1814 473 100.0 % 3.67 [ 0.79, 17.08 ]
Total events: 24 (VPA), 0 (TPM)
Heterogeneity: Chi2 = 0.88, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.098)
Test for subgroup differences: Not applicable
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Analysis 49.3. Comparison 49 VPA vs TPM, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 49 VPA vs TPM
Outcome: 3 Cardiac Malformations
Study or subgroup VPA TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 10/271 0/44 31.2 % 3.47 [ 0.21, 58.26 ]
North American Register 8/323 1/359 34.4 % 8.89 [ 1.12, 70.71 ]
UK Register 14/1220 0/70 34.4 % 1.69 [ 0.10, 27.98 ]
Total (95% CI) 1814 473 100.0 % 4.73 [ 1.21, 18.49 ]
Total events: 32 (VPA), 1 (TPM)
Heterogeneity: Chi2 = 0.92, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.23 (P = 0.026)
Test for subgroup differences: Not applicable
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Analysis 49.4. Comparison 49 VPA vs TPM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 49 VPA vs TPM
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup VPA TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 12/271 0/44 9.2 % 4.14 [ 0.25, 68.63 ]
North American Register 4/323 5/359 50.5 % 0.89 [ 0.24, 3.28 ]
UK Register 13/1220 2/70 40.3 % 0.37 [ 0.09, 1.62 ]
Total (95% CI) 1814 473 100.0 % 0.98 [ 0.40, 2.40 ]
Total events: 29 (VPA), 7 (TPM)
Heterogeneity: Chi2 = 2.69, df = 2 (P = 0.26); I2 =26%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
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Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 49 VPA vs TPM
Outcome: 5 Skeletal / Limb Malformation
Study or subgroup VPA TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 6/271 0/44 13.1 % 2.15 [ 0.12, 37.52 ]
North American Register 5/323 5/359 72.4 % 1.11 [ 0.32, 3.80 ]
UK Register 10/1220 0/70 14.5 % 1.22 [ 0.07, 20.63 ]
Total (95% CI) 1814 473 100.0 % 1.26 [ 0.44, 3.61 ]
Total events: 21 (VPA), 5 (TPM)
Heterogeneity: Chi2 = 0.18, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 50.1. Comparison 50 VPA vs OXC, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 50 VPA vs OXC
Outcome: 1 All Major Malformations
Study or subgroup VPA OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 37/271 0/12 11.6 % 3.58 [ 0.23, 55.19 ]
Kaaja 2003 4/61 1/9 21.3 % 0.59 [ 0.07, 4.71 ]
Meischenguiser 2004 3/21 0/35 4.6 % 11.45 [ 0.62, 211.39 ]
North American Register 30/323 4/182 62.5 % 4.23 [ 1.51, 11.81 ]
Total (95% CI) 676 238 100.0 % 3.71 [ 1.65, 8.33 ]
Total events: 74 (VPA), 5 (OXC)
Heterogeneity: Chi2 = 3.65, df = 3 (P = 0.30); I2 =18%
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Not applicable
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Analysis 50.2. Comparison 50 VPA vs OXC, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 50 VPA vs OXC
Outcome: 2 Neural Tube Malformations
Study or subgroup VPA OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 7/271 0/12 38.9 % 0.72 [ 0.04, 11.89 ]
Kaaja 2003 2/61 0/9 35.1 % 0.81 [ 0.04, 15.59 ]
Meischenguiser 2004 0/21 0/35 Not estimable
North American Register 4/323 0/182 26.0 % 5.08 [ 0.28, 93.89 ]
Total (95% CI) 676 238 100.0 % 1.89 [ 0.39, 9.07 ]
Total events: 13 (VPA), 0 (OXC)
Heterogeneity: Chi2 = 1.22, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 50.3. Comparison 50 VPA vs OXC, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 50 VPA vs OXC
Outcome: 3 Cardiac Malformations
Study or subgroup VPA OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 10/271 0/12 33.7 % 1.00 [ 0.06, 16.21 ]
Kaaja 2003 2/61 0/9 30.4 % 0.81 [ 0.04, 15.59 ]
Meischenguiser 2004 1/21 0/35 13.4 % 4.91 [ 0.21, 115.29 ]
North American Register 8/323 0/182 22.6 % 9.60 [ 0.56, 165.40 ]
Total (95% CI) 676 238 100.0 % 3.41 [ 0.87, 13.37 ]
Total events: 21 (VPA), 0 (OXC)
Heterogeneity: Chi2 = 2.21, df = 3 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.079)
Test for subgroup differences: Not applicable
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Analysis 50.4. Comparison 50 VPA vs OXC, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 50 VPA vs OXC
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup VPA OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 12/271 0/12 27.5 % 1.19 [ 0.07, 19.09 ]
Kaaja 2003 1/61 0/9 24.8 % 0.48 [ 0.02, 11.07 ]
Meischenguiser 2004 2/21 0/35 10.9 % 8.18 [ 0.41, 162.65 ]
North American Register 4/323 1/182 36.8 % 2.25 [ 0.25, 20.01 ]
Total (95% CI) 676 238 100.0 % 2.17 [ 0.63, 7.47 ]
Total events: 19 (VPA), 1 (OXC)
Heterogeneity: Chi2 = 1.82, df = 3 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 50.5. Comparison 50 VPA vs OXC, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 50 VPA vs OXC
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup VPA OXC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 6/271 0/12 30.8 % 0.62 [ 0.04, 10.45 ]
Kaaja 2003 1/61 0/9 27.8 % 0.48 [ 0.02, 11.07 ]
Meischenguiser 2004 0/21 0/35 Not estimable
North American Register 5/323 1/182 41.3 % 2.82 [ 0.33, 23.93 ]
Total (95% CI) 676 238 100.0 % 1.49 [ 0.36, 6.22 ]
Total events: 12 (VPA), 1 (OXC)
Heterogeneity: Chi2 = 1.21, df = 2 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
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Analysis 51.1. Comparison 51 VPA vs PB, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 51 VPA vs PB
Outcome: 1 All Major Malformations
Study or subgroup VPA PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Al Bunyan 1999 0/5 0/2 Not estimable
Australian 37/271 0/5 2.2 % 1.65 [ 0.11, 23.90 ]
Canger 1999 8/44 4/83 6.3 % 3.77 [ 1.20, 11.83 ]
Cassina 2013 3/45 5/67 9.2 % 0.89 [ 0.22, 3.55 ]
Eroglu 2008 2/15 1/5 3.4 % 0.67 [ 0.08, 5.88 ]
Froscher 1991 1/12 1/5 3.2 % 0.42 [ 0.03, 5.43 ]
Kaaja 2003 4/61 0/5 2.1 % 0.87 [ 0.05, 14.31 ]
Kaneko 1999 9/81 4/79 9.2 % 2.19 [ 0.70, 6.84 ]
Kelly 1984 0/4 0/6 Not estimable
Kerala Pregnancy Registry 2/6 1/9 1.8 % 3.00 [ 0.34, 26.19 ]
Koch 1992 3/14 0/4 1.7 % 2.33 [ 0.14, 37.80 ]
Lindhout 1992 5/66 1/26 3.3 % 1.97 [ 0.24, 16.06 ]
Martinez Ferri 2009 7/68 1/11 3.9 % 1.13 [ 0.15, 8.33 ]
Meischenguiser 2004 3/21 1/5 3.7 % 0.71 [ 0.09, 5.51 ]
Montreal Series 4/15 2/10 5.5 % 1.33 [ 0.30, 5.96 ]
North American Register 30/323 11/199 31.0 % 1.68 [ 0.86, 3.28 ]
Omtzigt 1992 7/60 3/18 10.5 % 0.70 [ 0.20, 2.43 ]
Pardi 1982 0/1 0/12 Not estimable
Steegers-Theunissen 1994 3/19 0/12 1.4 % 4.55 [ 0.26, 81.03 ]
Tanganelli 1992 0/6 3/63 1.6 % 1.31 [ 0.07, 22.78 ]
Total (95% CI) 1137 626 100.0 % 1.59 [ 1.11, 2.29 ]
Total events: 128 (VPA), 38 (PB)
Heterogeneity: Chi2 = 8.43, df = 16 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 2.54 (P = 0.011)
Test for subgroup differences: Not applicable
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Analysis 51.2. Comparison 51 VPA vs PB, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 51 VPA vs PB
Outcome: 2 Neural Tube Malformations
Study or subgroup VPA PB
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Australian 7/271 0/5 4.3 % 0.03 [ -0.20, 0.25 ]
Canger 1999 5/44 0/83 14.1 % 0.11 [ 0.02, 0.21 ]
Cassina 2013 1/45 0/67 22.4 % 0.02 [ -0.03, 0.08 ]
Eroglu 2008 0/16 0/5 3.9 % 0.0 [ -0.24, 0.24 ]
Froscher 1991 0/12 0/5 3.6 % 0.0 [ -0.24, 0.24 ]
Kerala Pregnancy Registry 2/6 0/9 1.6 % 0.33 [ -0.05, 0.71 ]
Koch 1992 1/14 0/4 2.4 % 0.07 [ -0.23, 0.38 ]
Meischenguiser 2004 0/21 0/5 4.0 % 0.0 [ -0.23, 0.23 ]
North American Register 4/323 0/199 30.2 % 0.01 [ 0.00, 0.03 ]
Omtzigt 1992 6/60 0/18 12.8 % 0.10 [ -0.01, 0.21 ]
Pardi 1982 0/1 0/12 0.6 % 0.0 [ -0.61, 0.61 ]
Total (95% CI) 813 412 100.0 % 0.05 [ 0.00, 0.10 ]
Total events: 26 (VPA), 0 (PB)
Heterogeneity: Tau2 = 0.00; Chi2 = 19.03, df = 10 (P = 0.04); I2 =47%
Test for overall effect: Z = 1.81 (P = 0.070)
Test for subgroup differences: Not applicable
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Analysis 51.3. Comparison 51 VPA vs PB, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 51 VPA vs PB
Outcome: 3 Cardiac Malformations
Study or subgroup VPA PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 10/271 0/5 4.5 % 0.46 [ 0.03, 7.03 ]
Canger 1999 0/44 1/83 4.8 % 0.62 [ 0.03, 14.96 ]
Cassina 2013 2/45 2/67 7.4 % 1.49 [ 0.22, 10.19 ]
Eroglu 2008 0/16 0/5 Not estimable
Froscher 1991 0/12 1/5 9.4 % 0.15 [ 0.01, 3.25 ]
Kerala Pregnancy Registry 7/71 3/43 17.2 % 1.41 [ 0.39, 5.18 ]
Koch 1992 1/14 0/4 3.4 % 1.00 [ 0.05, 20.83 ]
Meischenguiser 2004 1/21 1/5 7.4 % 0.24 [ 0.02, 3.19 ]
North American Register 8/323 5/199 28.4 % 0.99 [ 0.33, 2.97 ]
Omtzigt 1992 0/60 2/18 17.5 % 0.06 [ 0.00, 1.24 ]
Pardi 1982 0/1 0/12 Not estimable
Total (95% CI) 878 446 100.0 % 0.76 [ 0.42, 1.38 ]
Total events: 29 (VPA), 15 (PB)
Heterogeneity: Chi2 = 6.24, df = 8 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 51.4. Comparison 51 VPA vs PB, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 51 VPA vs PB
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup VPA PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 12/271 0/5 8.7 % 0.55 [ 0.04, 8.28 ]
Canger 1999 0/44 0/83 Not estimable
Cassina 2013 0/45 0/67 Not estimable
Eroglu 2008 1/16 1/5 13.5 % 0.31 [ 0.02, 4.14 ]
Froscher 1991 0/12 0/5 Not estimable
Kerala Pregnancy Registry 0/6 0/9 Not estimable
Koch 1992 1/14 0/4 6.7 % 1.00 [ 0.05, 20.83 ]
Meischenguiser 2004 2/21 0/5 7.0 % 1.36 [ 0.08, 24.76 ]
North American Register 4/323 4/199 43.9 % 0.62 [ 0.16, 2.44 ]
Omtzigt 1992 0/60 1/18 20.3 % 0.10 [ 0.00, 2.44 ]
Pardi 1982 0/1 0/12 Not estimable
Total (95% CI) 813 412 100.0 % 0.54 [ 0.22, 1.33 ]
Total events: 20 (VPA), 6 (PB)
Heterogeneity: Chi2 = 1.80, df = 5 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 51.5. Comparison 51 VPA vs PB, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 51 VPA vs PB
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup VPA PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 6/271 0/5 15.5 % 0.29 [ 0.02, 4.53 ]
Canger 1999 1/44 1/83 11.0 % 1.89 [ 0.12, 29.44 ]
Cassina 2013 2/45 0/67 6.4 % 7.39 [ 0.36, 150.43 ]
Eroglu 2008 0/16 0/5 Not estimable
Froscher 1991 1/12 0/5 10.8 % 1.38 [ 0.07, 29.26 ]
Kerala Pregnancy Registry 1/6 1/9 12.7 % 1.50 [ 0.11, 19.64 ]
Koch 1992 2/14 0/4 11.9 % 1.67 [ 0.10, 29.18 ]
Meischenguiser 2004 0/21 0/5 Not estimable
North American Register 5/323 1/199 19.6 % 3.08 [ 0.36, 26.18 ]
Omtzigt 1992 1/60 0/18 12.1 % 0.93 [ 0.04, 22.00 ]
Pardi 1982 0/1 0/12 Not estimable
Total (95% CI) 813 412 100.0 % 1.98 [ 0.79, 4.98 ]
Total events: 19 (VPA), 3 (PB)
Heterogeneity: Chi2 = 3.11, df = 7 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
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Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 52 VPA vs PHT
Outcome: 1 All Major Malformations
Study or subgroup VPA PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Al Bunyan 1999 0/5 0/9 Not estimable
Arulmozhi 2006 0/3 0/18 Not estimable
Australian 37/271 2/44 5.9 % 3.00 [ 0.75, 12.02 ]
Canger 1999 8/44 3/31 6.1 % 1.88 [ 0.54, 6.52 ]
Eroglu 2008 2/15 2/14 3.6 % 0.93 [ 0.15, 5.76 ]
Froscher 1991 1/12 0/3 1.3 % 0.92 [ 0.05, 18.50 ]
Garza-Morales 1996 0/5 0/27 Not estimable
Kaaja 2003 4/61 3/124 3.4 % 2.71 [ 0.63, 11.73 ]
Kaneko 1999 9/81 12/132 15.7 % 1.22 [ 0.54, 2.77 ]
Kelly 1984 0/4 1/24 0.9 % 1.67 [ 0.08, 35.30 ]
Kerala Pregnancy Registry 2/6 0/5 0.9 % 4.29 [ 0.25, 72.90 ]
Koch 1992 3/14 2/24 2.5 % 2.57 [ 0.49, 13.57 ]
Lindhout 1992 5/66 1/17 2.7 % 1.29 [ 0.16, 10.31 ]
Mawer 2010 3/25 0/2 1.5 % 0.81 [ 0.05, 12.16 ]
Meador 2006 12/69 4/56 7.6 % 2.43 [ 0.83, 7.14 ]
Montreal Series 4/15 6/44 5.3 % 1.96 [ 0.64, 6.00 ]
North American Register 30/323 12/416 18.1 % 3.22 [ 1.68, 6.19 ]
Omtzigt 1992 7/60 0/28 1.2 % 7.13 [ 0.42, 120.64 ]
Pardi 1982 0/1 0/5 Not estimable
Steegers-Theunissen 1994 3/19 0/8 1.2 % 3.15 [ 0.18, 54.83 ]
UK Register 82/1220 7/106 22.2 % 1.02 [ 0.48, 2.15 ]
Total (95% CI) 2319 1137 100.0 % 2.00 [ 1.48, 2.71 ]
Total events: 212 (VPA), 55 (PHT)
Heterogeneity: Chi2 = 10.01, df = 16 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 4.49 (P < 0.00001)
Test for subgroup differences: Not applicable
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Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 52 VPA vs PHT
Outcome: 2 Neural Tube Malformations
Study or subgroup VPA PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 7/271 1/44 30.7 % 1.14 [ 0.14, 9.02 ]
Canger 1999 5/44 0/31 10.4 % 7.82 [ 0.45, 136.50 ]
Eroglu 2008 0/16 0/14 Not estimable
Froscher 1991 0/12 0/3 Not estimable
Garza-Morales 1996 0/5 0/27 Not estimable
Kaaja 2003 2/61 0/124 5.9 % 10.08 [ 0.49, 206.78 ]
Kerala Pregnancy Registry 2/6 0/5 9.6 % 4.29 [ 0.25, 72.90 ]
Koch 1992 1/14 0/24 6.7 % 5.00 [ 0.22, 115.05 ]
Meador 2006 0/69 0/56 Not estimable
North American Register 4/323 0/416 7.8 % 11.58 [ 0.63, 214.37 ]
Omtzigt 1992 6/60 0/28 12.1 % 6.18 [ 0.36, 106.02 ]
Pardi 1982 0/1 0/5 Not estimable
UK Register 13/1220 0/82 16.7 % 1.84 [ 0.11, 30.60 ]
Total (95% CI) 2102 859 100.0 % 4.47 [ 1.79, 11.17 ]
Total events: 40 (VPA), 1 (PHT)
Heterogeneity: Chi2 = 2.95, df = 7 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 3.20 (P = 0.0014)
Test for subgroup differences: Not applicable
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Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 52 VPA vs PHT
Outcome: 3 Cardiac Malformations
Study or subgroup VPA PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 10/271 1/44 16.0 % 1.62 [ 0.21, 12.37 ]
Canger 1999 0/44 0/31 Not estimable
Eroglu 2008 0/16 1/14 14.9 % 0.29 [ 0.01, 6.69 ]
Froscher 1991 0/12 0/3 Not estimable
Garza-Morales 1996 0/5 0/27 Not estimable
Kaaja 2003 2/61 0/124 3.1 % 10.08 [ 0.49, 206.78 ]
Kerala Pregnancy Registry 7/71 0/100 3.9 % 21.04 [ 1.22, 362.57 ]
Koch 1992 1/14 1/24 6.9 % 1.71 [ 0.12, 25.31 ]
Meador 2006 4/69 0/56 5.1 % 7.33 [ 0.40, 133.29 ]
North American Register 8/323 4/416 32.6 % 2.58 [ 0.78, 8.48 ]
Omtzigt 1992 0/60 0/28 Not estimable
Pardi 1982 0/1 0/5 Not estimable
UK Register 14/1220 1/82 17.5 % 0.94 [ 0.13, 7.07 ]
Total (95% CI) 2167 954 100.0 % 2.93 [ 1.50, 5.72 ]
Total events: 46 (VPA), 8 (PHT)
Heterogeneity: Chi2 = 6.69, df = 7 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 3.16 (P = 0.0016)
Test for subgroup differences: Not applicable
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Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 52 VPA vs PHT
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup VPA PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 12/271 0/44 13.0 % 4.14 [ 0.25, 68.63 ]
Canger 1999 0/44 0/31 Not estimable
Eroglu 2008 1/16 0/14 8.1 % 2.65 [ 0.12, 60.21 ]
Froscher 1991 0/12 0/3 Not estimable
Garza-Morales 1996 0/5 0/27 Not estimable
Kaaja 2003 1/61 1/124 10.0 % 2.03 [ 0.13, 31.95 ]
Kerala Pregnancy Registry 0/6 0/5 Not estimable
Koch 1992 1/14 0/24 5.7 % 5.00 [ 0.22, 115.05 ]
Meador 2006 1/69 0/56 8.4 % 2.44 [ 0.10, 58.83 ]
North American Register 4/323 2/416 26.5 % 2.58 [ 0.47, 13.98 ]
Omtzigt 1992 0/60 0/28 Not estimable
Pardi 1982 0/1 0/5 Not estimable
UK Register 13/1220 1/82 28.4 % 0.87 [ 0.12, 6.60 ]
Total (95% CI) 2102 859 100.0 % 2.37 [ 0.95, 5.96 ]
Total events: 33 (VPA), 4 (PHT)
Heterogeneity: Chi2 = 1.33, df = 6 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.066)
Test for subgroup differences: Not applicable
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Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 52 VPA vs PHT
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup VPA PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 6/271 0/44 8.8 % 2.15 [ 0.12, 37.52 ]
Canger 1999 1/44 1/31 12.1 % 0.70 [ 0.05, 10.84 ]
Eroglu 2008 0/16 0/14 Not estimable
Froscher 1991 1/12 0/3 7.9 % 0.92 [ 0.05, 18.50 ]
Garza-Morales 1996 0/5 0/27 Not estimable
Kaaja 2003 1/61 0/124 3.4 % 6.05 [ 0.25, 146.33 ]
Kerala Pregnancy Registry 1/6 0/5 5.5 % 2.57 [ 0.13, 52.12 ]
Koch 1992 2/14 0/24 3.9 % 8.33 [ 0.43, 162.13 ]
Meador 2006 1/69 0/56 5.7 % 2.44 [ 0.10, 58.83 ]
North American Register 5/323 4/416 36.0 % 1.61 [ 0.44, 5.95 ]
Omtzigt 1992 1/60 0/28 7.0 % 1.43 [ 0.06, 33.95 ]
Pardi 1982 0/1 0/5 Not estimable
UK Register 10/1220 0/82 9.7 % 1.43 [ 0.08, 24.15 ]
Total (95% CI) 2102 859 100.0 % 1.98 [ 0.93, 4.21 ]
Total events: 29 (VPA), 5 (PHT)
Heterogeneity: Chi2 = 2.41, df = 9 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.078)
Test for subgroup differences: Not applicable
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Analysis 54.1. Comparison 54 PHT vs PRM, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 54 PHT vs PRM
Outcome: 1 All Major Malformations
Study or subgroup PHT PRM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Canger 1999 3/31 3/35 21.4 % 1.13 [ 0.25, 5.19 ]
Kaaja 2003 3/124 1/6 14.5 % 0.15 [ 0.02, 1.20 ]
Kaneko 1999 12/132 5/35 60.1 % 0.64 [ 0.24, 1.69 ]
Koch 1992 2/24 0/21 4.0 % 4.40 [ 0.22, 86.78 ]
Pardi 1982 0/5 0/4 Not estimable
Total (95% CI) 316 101 100.0 % 0.82 [ 0.40, 1.68 ]
Total events: 20 (PHT), 9 (PRM)
Heterogeneity: Chi2 = 4.24, df = 3 (P = 0.24); I2 =29%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 54 PHT vs PRM
Outcome: 2 Neural Tube Malformations
Study or subgroup PHT PRM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Canger 1999 0/31 0/35 Not estimable
Pardi 1982 0/5 0/4 Not estimable
Total (95% CI) 36 39 Not estimable
Total events: 0 (PHT), 0 (PRM)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 54.3. Comparison 54 PHT vs PRM, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 54 PHT vs PRM
Outcome: 3 Cardiac Malformations
Study or subgroup PHT PRM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Canger 1999 0/31 1/35 100.0 % 0.38 [ 0.02, 8.88 ]
Pardi 1982 0/5 0/4 Not estimable
Total (95% CI) 36 39 100.0 % 0.38 [ 0.02, 8.88 ]
Total events: 0 (PHT), 1 (PRM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 54.4. Comparison 54 PHT vs PRM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 54 PHT vs PRM
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup PHT PRM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Canger 1999 0/31 0/35 Not estimable
Pardi 1982 0/5 0/4 Not estimable
Total (95% CI) 36 39 Not estimable
Total events: 0 (PHT), 0 (PRM)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 54 PHT vs PRM
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup PHT PRM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Canger 1999 1/31 0/35 100.0 % 3.38 [ 0.14, 79.95 ]
Pardi 1982 0/5 0/4 Not estimable
Total (95% CI) 36 39 100.0 % 3.38 [ 0.14, 79.95 ]
Total events: 1 (PHT), 0 (PRM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 55.1. Comparison 55 PB vs PRM, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 55 PB vs PRM
Outcome: 1 All Major Malformations
Study or subgroup PB PRM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Canger 1999 4/83 3/35 31.5 % 0.56 [ 0.13, 2.38 ]
Delmi 1991 4/58 0/9 6.4 % 1.53 [ 0.09, 26.21 ]
Kaaja 2003 0/5 1/6 10.3 % 0.39 [ 0.02, 7.88 ]
Kaneko 1999 4/79 5/35 51.8 % 0.35 [ 0.10, 1.24 ]
Koch 1992 0/4 0/21 Not estimable
Pardi 1982 0/12 0/4 Not estimable
Total (95% CI) 241 110 100.0 % 0.50 [ 0.21, 1.16 ]
Total events: 12 (PB), 9 (PRM)
Heterogeneity: Chi2 = 0.93, df = 3 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.62 (P = 0.11)
Test for subgroup differences: Not applicable
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Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 55 PB vs PRM
Outcome: 2 Neural Tube Malformations
Study or subgroup PB PRM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Canger 1999 0/83 0/35 Not estimable
Pardi 1982 0/12 0/4 Not estimable
Total (95% CI) 95 39 Not estimable
Total events: 0 (PB), 0 (PRM)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 55.3. Comparison 55 PB vs PRM, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 55 PB vs PRM
Outcome: 3 Cardiac Malformations
Study or subgroup PB PRM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Canger 1999 1/83 1/35 100.0 % 0.42 [ 0.03, 6.55 ]
Pardi 1982 0/12 0/4 Not estimable
Total (95% CI) 95 39 100.0 % 0.42 [ 0.03, 6.55 ]
Total events: 1 (PB), 1 (PRM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PB Favours PRM
323Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 55.4. Comparison 55 PB vs PRM, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 55 PB vs PRM
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup PB PRM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Canger 1999 0/83 0/35 Not estimable
Pardi 1982 0/12 0/4 Not estimable
Total (95% CI) 95 39 Not estimable
Total events: 0 (PB), 0 (PRM)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 55 PB vs PRM
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup PB PRM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Canger 1999 1/83 0/35 100.0 % 1.29 [ 0.05, 30.82 ]
Pardi 1982 0/12 0/4 Not estimable
Total (95% CI) 95 39 100.0 % 1.29 [ 0.05, 30.82 ]
Total events: 1 (PB), 0 (PRM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.88)
Test for subgroup differences: Not applicable
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Analysis 56.1. Comparison 56 LTG vs ZNS, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 56 LTG vs ZNS
Outcome: 1 All Major Malformations
Study or subgroup LTG ZNS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
North American Register 31/1562 0/90 100.0 % 3.67 [ 0.23, 59.46 ]
Total (95% CI) 1562 90 100.0 % 3.67 [ 0.23, 59.46 ]
Total events: 31 (LTG), 0 (ZNS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 57 OXC vs PRM
Outcome: 1 All Major Malformations
Study or subgroup OXC PRM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kaaja 2003 1/9 1/6 100.0 % 0.67 [ 0.05, 8.73 ]
Total (95% CI) 9 6 100.0 % 0.67 [ 0.05, 8.73 ]
Total events: 1 (OXC), 1 (PRM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 58.1. Comparison 58 OXC vs TPM, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 58 OXC vs TPM
Outcome: 1 All Major Malformations
Study or subgroup OXC TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/12 1/44 6.2 % 1.15 [ 0.05, 26.67 ]
North American Register 4/182 15/359 93.8 % 0.53 [ 0.18, 1.56 ]
Total (95% CI) 194 403 100.0 % 0.57 [ 0.20, 1.57 ]
Total events: 4 (OXC), 16 (TPM)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.27)
Test for subgroup differences: Not applicable
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Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 58 OXC vs TPM
Outcome: 2 Neural Tube Malformations
Study or subgroup OXC TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/12 0/44 Not estimable
North American Register 0/182 0/359 Not estimable
Total (95% CI) 194 403 Not estimable
Total events: 0 (OXC), 0 (TPM)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 58.3. Comparison 58 OXC vs TPM, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 58 OXC vs TPM
Outcome: 3 Cardiac Malformations
Study or subgroup OXC TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/12 0/44 Not estimable
North American Register 0/182 1/359 100.0 % 0.66 [ 0.03, 16.02 ]
Total (95% CI) 194 403 100.0 % 0.66 [ 0.03, 16.02 ]
Total events: 0 (OXC), 1 (TPM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
Test for subgroup differences: Not applicable
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Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 58 OXC vs TPM
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup OXC TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/12 0/44 Not estimable
North American Register 1/182 5/359 100.0 % 0.39 [ 0.05, 3.35 ]
Total (95% CI) 194 403 100.0 % 0.39 [ 0.05, 3.35 ]
Total events: 1 (OXC), 5 (TPM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 58.5. Comparison 58 OXC vs TPM, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 58 OXC vs TPM
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup OXC TPM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Australian 0/12 0/44 Not estimable
North American Register 1/182 5/359 100.0 % 0.39 [ 0.05, 3.35 ]
Total (95% CI) 194 403 100.0 % 0.39 [ 0.05, 3.35 ]
Total events: 1 (OXC), 5 (TPM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
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Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 59 OXC vs ZNS
Outcome: 1 All Major Malformations
Study or subgroup OXC ZNS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
North American Register 4/182 0/90 100.0 % 4.48 [ 0.24, 82.23 ]
Total (95% CI) 182 90 100.0 % 4.48 [ 0.24, 82.23 ]
Total events: 4 (OXC), 0 (ZNS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 60.1. Comparison 60 PB vs ZNS, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 60 PB vs ZNS
Outcome: 1 All Major Malformations
Study or subgroup PB ZNS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
North American Register 11/199 0/90 100.0 % 10.47 [ 0.62, 175.67 ]
Total (95% CI) 199 90 100.0 % 10.47 [ 0.62, 175.67 ]
Total events: 11 (PB), 0 (ZNS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Not applicable
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Analysis 61.1. Comparison 61 PHT vs ZNS, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 61 PHT vs ZNS
Outcome: 1 All Major Malformations
Study or subgroup PHT ZNS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
North American Register 12/416 0/90 100.0 % 5.46 [ 0.33, 91.31 ]
Total (95% CI) 416 90 100.0 % 5.46 [ 0.33, 91.31 ]
Total events: 12 (PHT), 0 (ZNS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PHT Favours ZNS
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Analysis 63.1. Comparison 63 PRM vs VPA, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 63 PRM vs VPA
Outcome: 1 All Major Malformations
Study or subgroup PRM VPA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Canger 1999 3/35 8/44 40.7 % 0.47 [ 0.14, 1.65 ]
Kaaja 2003 1/6 4/61 4.1 % 2.54 [ 0.34, 19.25 ]
Kaneko 1999 5/35 9/81 31.2 % 1.29 [ 0.46, 3.56 ]
Koch 1992 0/21 3/14 23.9 % 0.10 [ 0.01, 1.75 ]
Pardi 1982 0/4 0/1 Not estimable
Total (95% CI) 101 201 100.0 % 0.72 [ 0.37, 1.40 ]
Total events: 9 (PRM), 24 (VPA)
Heterogeneity: Chi2 = 5.01, df = 3 (P = 0.17); I2 =40%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PRM Favours VPA
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Analysis 63.2. Comparison 63 PRM vs VPA, Outcome 2 Neural Tube Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 63 PRM vs VPA
Outcome: 2 Neural Tube Malformations
Study or subgroup PRM VPA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Canger 1999 0/35 5/44 100.0 % 0.11 [ 0.01, 1.99 ]
Pardi 1982 0/4 0/1 Not estimable
Total (95% CI) 39 45 100.0 % 0.11 [ 0.01, 1.99 ]
Total events: 0 (PRM), 5 (VPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PRM Favours VPA
Analysis 63.3. Comparison 63 PRM vs VPA, Outcome 3 Cardiac Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 63 PRM vs VPA
Outcome: 3 Cardiac Malformations
Study or subgroup PRM VPA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Canger 1999 1/35 0/44 100.0 % 3.75 [ 0.16, 89.32 ]
Pardi 1982 0/4 0/1 Not estimable
Total (95% CI) 39 45 100.0 % 3.75 [ 0.16, 89.32 ]
Total events: 1 (PRM), 0 (VPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PRM Favours VPA
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Analysis 63.4. Comparison 63 PRM vs VPA, Outcome 4 Oro-Facial Cleft / Craniofacial Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 63 PRM vs VPA
Outcome: 4 Oro-Facial Cleft / Craniofacial Malformations
Study or subgroup PRM VPA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Canger 1999 0/35 0/44 Not estimable
Pardi 1982 0/4 0/1 Not estimable
Total (95% CI) 39 45 Not estimable
Total events: 0 (PRM), 0 (VPA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PRM Favours VPA
Analysis 63.5. Comparison 63 PRM vs VPA, Outcome 5 Skeletal / Limb Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 63 PRM vs VPA
Outcome: 5 Skeletal / Limb Malformations
Study or subgroup PRM VPA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Canger 1999 0/35 1/44 100.0 % 0.42 [ 0.02, 9.92 ]
Pardi 1982 0/4 0/1 Not estimable
Total (95% CI) 39 45 100.0 % 0.42 [ 0.02, 9.92 ]
Total events: 0 (PRM), 1 (VPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PRM Favours VPA
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Analysis 65.1. Comparison 65 TPM vs ZNS, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 65 TPM vs ZNS
Outcome: 1 All Major Malformations
Study or subgroup TPM ZNS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
North American Register 15/359 0/90 100.0 % 7.84 [ 0.47, 129.74 ]
Total (95% CI) 359 90 100.0 % 7.84 [ 0.47, 129.74 ]
Total events: 15 (TPM), 0 (ZNS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours TPM Favours ZNS
Analysis 66.1. Comparison 66 VPA vs ZNS, Outcome 1 All Major Malformations.
Review: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
Comparison: 66 VPA vs ZNS
Outcome: 1 All Major Malformations
Study or subgroup VPA ZNS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
North American Register 30/323 0/90 100.0 % 17.13 [ 1.06, 277.48 ]
Total (95% CI) 323 90 100.0 % 17.13 [ 1.06, 277.48 ]
Total events: 30 (VPA), 0 (ZNS)
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.046)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours VPA Favours ZNS
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A D D I T I O N A L T A B L E S
Table 1. Risk of bias scale parameters
1
Low risk
2 3 4 5
High risk
Confounding All important1 con-
founders considered
2
and suitablemethod
of adjustment3 em-
ployed. Out-
come unlikely to be
affected.
Most important
4 confounders con-
sidered and suit-
able method of ad-
justment employed.
Outcome unlikely
to be affected
Some confounders
5 considered and
full or partial ad-
justment employed
6. Possible implica-
tion on outcome.
Some con-
founders considered
and no adjustment
employed. Likely to
affect outcome
No important con-
founders considered
and no adjustment
employed. Likely to
affect outcome
Blinding Assessors blinded to
participant’s drug
regimen and par-
ticipants blinded to
drug regimen. Out-
come unlikely to be
affected
Assessors blinded to
participants
drug regimen. Out-
come unlikely to be
affected
Partial blinding7 in-
volved in study. Pos-
sible implication on
outcome.
Partial or no blind-
ing involved
in study. Outcome
likely to be affected
No blinding
involved in study.
Outcome likely to
be affected
Incomplete
outcome data
No missing data
and/or
appropriate analysis
8 used to deal with
missing data. Un-
likely to affect out-
come.
Smaller
amount (<25%) of
missing data with
reasons given, bal-
anced across groups.
Unlikely to affect
outcome
Larger amount of
miss-
ing data (>25%)
with or without rea-
sons given, balanced
across groups. Pos-
sible implication on
outcome.
Larger
amount (>25%) of
missing data, imbal-
ance across groups.
Outcome likely to
be affected
No information
provided regarding
missing data. Likely
to affect outcome.
Selective outcome
reporting
A pri-
ori outcomes mea-
sured, analysed and
reported in main re-
port. Protocol avail-
able. Unlikely to af-
fect outcome
A priori outcomes
measured, anal-
ysed and reported in
main report9. Pro-
tocol not available.
Unlikely to affect
outcomes.
Limited in-
formation regarding
a priori outcomes
and measures. Pos-
sible implication on
outcome
Outcomes mea-
sured but not anal-
ysed or reported.
Outcome likely to
be affected
Outcomes mea-
sured but not anal-
ysed or reported and
clinical judgement
infers the presence
of an unreported
measured outcome
10. Likely to affect
outcome.
Other bias No other bias iden-
tified.
Bias identified. Un-
likely to affect out-
come.
Bias identified. Pos-
sible implication on
outcome.
Bias
identified. Likely to
affect outcome.
Bias identified. Ex-
tremely likely to af-
fect outcome.
1 Important confounders include: maternal factors (socio-economic status, folate use, age, parity, epilepsy type, seizure exposure,
polytherapy, other concomitant disease, smoking, alcohol and child factors (family history of malformations, gestational age, birth
weight, sex and ethnicity).
2 Reported demographic information and other confounders.
3 Matching scores, multiple regression, analysis of co-variance, stratification.
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4 At least five out of eight of important confounders include: socio-economic status, folate use, gestational age, family history of
malformations.
5 At least two out of eight of important confounders.
6 Full adjustment of confounding variables e.g. see footnote 2 or partial adjustment e.g. researchers select limited number of variables
to adjust for.
7 Assessors of outcome are only blinded to certain groups e.g. blinded to intervention group but not controls.
8 Intention-to-treat analysis.
9 An a priori statement is made in methods section of main report regarding measurement and analysis of outcome.
10 For example, no data reported on number of deaths when obvious this outcome must have been recorded.
Table 2. Risk Ratios and Risk Differences- Overall Malformation Risk
Active CBZ GBP LEV LTG OXC PB PHT PRM TPM VPA ZNS
Com-
parator
Women
without
epilepsy
RR: 2.
01
(1.20, 3.
36)
RD:
0.02 (0.
00*, 0.
03)
RR: 0.
61
(0.07, 5.
18)
RD:−0.
00 (−0.
02, 0.
01)
RR: 2.
16
(0.76, 6.
17)
RD: 0.
01 (−0.
00, 0.
03)
RR: 1.
68
(0.78, 3.
65)
RD:
0.01
(−0.00,
0.02)
RR: 1.
94
(0.53, 7.
15)
RD: 0.
01 (−0.
01, 0.
03)
RR: 2.
84
(1.57, 5.
13)
RD: 0.
04
(0.01, 0.
06)
RD: 2.
38
(1.12, 5.
03)
RD: 0.
02 (−0.
00, 0.
04)
RR: 0.
48
(0.03, 8.
43)
RD:−0.
04 (−0.
12, 0.
03)
RR:
3.69 (1.
36, 10.
07)
RD: 0.
03
(0.01, 0.
05)
RR: 5.
69
(3.33, 9.
73)
RD: 0.
08
(0.05, 0.
11)
RR: 0.
44
(0.02, 7.
93)
RD:−0.
01 (−0.
03, 0.
01)
Women
with
epilepsy
un-
treated
RR: 1.
50
(1.03, 2.
19)
RD:
0.01 (0.
00*, 0.
03)
RR: 1.
16
(0.23, 5.
93)
RD:−0.
00 (−0.
06, 0.
05)
RR: 0.
32
(0.10, 1.
07)
RD:
−0.
02 (−0.
03, −0.
00)
RR: 1.
07
(0.64, 1.
77)
RD: 0.
00 (−0.
01, 0.
02)
RR:
2.75 (0.
53, 14.
43)
RD: 0.
03 (−0.
09, 0.
14)
RR: 1.
95
(0.97, 3.
93), P =
0.06
RD: 0.
03 (−0.
01, 0.
07)
RR: 2.
40
(1.42, 4.
08)
RD: 0.
03
(0.01, 0.
06)
RR(FE):
2.81
(1.13, 7.
02)
RR(RE)
: 3.92 (0.
76, 20.
14), P =
0.10
RD:
0.07
(−0.00,
0.14)
RR: 1.
99
(0.65, 6.
08)
RD: 0.
02 (−0.
02, 0.
05)
RR: 3.
13
(2.16, 4.
54),
p<0.
00001
RD: 0.
06
(0.04, 0.
08)
RR: No
studies
RD: No
studies
CBZ RR: 0.
44
(0.13, 1.
49)
RD:
−0.
02 (−0.
04, −0.
00)
RR: 0.
54
(0.30, 0.
97)
RD:
−0.
01 (−0.
02, −0.
00)
RR: 0.
75
(0.57, 0.
990)
RD:
−0.
01 (−0.
02, −0.
00)
RR: 0.
69
(0.32, 1.
52)
RD: 0.
01 (−0.
01, 0.
04),
RR: 1.
19
(0.86, 1.
67)
RD: 0.
01 (−0.
02, 0.
03)
RR: 1.
22
(0.90, 1.
64)
RD: 0.
01 (−0.
01, 0.
02)
RR(FE):
1.25
(0.64, 2.
44)
RR(RE):
1.56
(0.50, 4.
76)
RD: 0.
RR: 1.
28
(0.76, 2.
13)
RD: 0.
01 (−0.
01, 0.
03)
RR: 2.
44
(2.00, 2.
94)
RD: 0.
05
(0.04, 0.
07)
RR: 0.
18
(0.01, 2.
94),
RD:
−0.03
(−0.05,
−0.01)
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Table 2. Risk Ratios and Risk Differences- Overall Malformation Risk (Continued)
02 (−0.
05, 0.
09)
GBP RR: 2.
28
(0.67, 7.
79)
RD:
0.02 (0.
00*, 0.
04)
RR: 1.
52
(0.43, 5.
42)
RD: 0.
01 (−0.
01, 0.
03)
RR:
1.67 (0.
48,5.88)
RD: 0.
01 (−0.
01, 0.
03)
RR:
3.23 (0.
36, 25.
00)
RD: 0.
01 (−0.
01, 0.
04)
RR:
8.33 (1.
04, 50.
00)
RD: 0.
05
(0.01, 0.
08)
RR:
2.81 (0.
77, 10.
23)
RD:
0.03 (0.
00*, 0.
05)
RR: No
studies
RD: No
studies
RR:
3.13 (0.
85, 11.
11)
RD: 0.
03
(0.01, 0.
05)
RR:
6.21 (1.
91, 20.
23)
RD: 0.
08
(0.05, 0.
11)
RR:
0.53 (0.
02, 12.
50)
RD:−0.
01 (−0.
03, 0.
02)
LEV RR: 1.
84
(1.03, 3.
29)
RD:
0.01 (0.
00*, 0.
02)
RR: 0.
66
(0.18, 2.
33)
RD:−0.
01 (−0.
03, 0.
01)
RR(FE):
1.37
(0.78, 2.
44)
RR(RE):
1.61
(0.53, 5.
00)
RD: 0.
01 (−0.
00, 0.
02)
RR: 0.
95
(0.33, 2.
78)
RD:−0.
00 (−0.
03, 0.
02)
RR: 2.
33
(1.04, 5.
00)
RD: 0.
03 (−0.
01, 0.
06)
RR(FE):
2.04
(1.09, 3.
85)
RR(RE)
: 2.94 (0.
67, 12.
50)
RD(FE)
:
0.02 (0.
00*, 0.
04)
RD
(RE): 0.
03 (−0.
01, 0.
06)
RR: No
studies
RD: No
studies
RR: 2.
00
(1.03, 3.
85)
RD: 0.
02 (−0.
00, 0.
04)
RR:
5.82 (3.
13, 10.
81)
RD(FE)
: 0.07
(0.05, 0.
09)
RD(RE)
: 0.08
(0.05, 0.
10)
RR: 0.
22
(0.01, 3.
57)
RD:
−0.
02 (−0.
05, −0.
00)
LTG RR: 1.
34
(1.01, 1.
76)
RD:
0.01 (0.
00*, 0.
02)
RR: 0.
60
(0.17, 2.
07)
RD:−0.
01 (−0.
03, 0.
01)
RR(FE):
0.73
(0.41, 1.
29)
RR(RE):
0.62
(0.20, 1.
88)
RD:−0.
01 (−0.
02, 0.
00)
RR: 1.
08
(0.41, 2.
86)
RD:−0.
00 (−0.
02, 0.
02)
RR: 3.
13
(1.64, 5.
88)
RD: 0.
04
(0.01, 0.
07)
RR: 1.
89
(1.19, 2.
94)
RD:
0.02 (0.
00*, 0.
04)
RR: No
studies
RD: No
studies
RR: 1.
79
(1.06, 2.
94)
RD: 0.
02 (−0.
00, 0.
04)
RR: 3.
56
(2.77, 4.
58)
RD
(FE): 0.
06
(0.05, 0.
07)
RD
(RE): 0.
08
(0.05, 0.
11)
RR: 0.
27
(0.02, 4.
35)
RD:
−0.
02 (−0.
04, −0.
00)
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Table 2. Risk Ratios and Risk Differences- Overall Malformation Risk (Continued)
OXC RR: 1.
44
(0.66, 3.
16)
RD: 0.
01 (−0.
01, 0.
04)
RR: 0.
31
(0.04, 2.
78)
RD:−0.
01 (−0.
04, 0.
01)
RR: 1.
05
(0.36, 3.
03)
RD: 0.
00 (−0.
02, 0.
03)
RR: 0.
93
(0.35, 2.
43)
RD: 0.
00 (−0.
02, 0.
02)
RR: 2.
52
(0.98, 6.
43)
RD: 0.
03 (−0.
01, 0.
08)
RR: 1.
08
(0.43, 2.
71)
RD: 0.
00 (−0.
02, 0.
03)
RR:
1.49 (0.
11, 20.
00)
RD: 0.
06 (−0.
31, 0.
42)
RR: 1.
75
(0.64, 5.
00)
RD: 0.
02 (−0.
01, 0.
05)
RR: 3.
71
(1.65, 8.
33)
RD: 0.
08
(0.04, 0.
11)
RR: 0.
22
(0.01, 4.
17)
RD:−0.
02 (−0.
05, 0.
01)
PB RR: 0.
84
(0.60, 1.
16)
RD:−0.
01 (−0.
03, 0.
02)
RR: 0.
12
(0.02, 0.
96)
RD:
−0.
05 (−0.
08, −0.
01)
RR: 0.
43
(0.20, 0.
96)
RD:−0.
03 (−0.
06, 0.
01)
RR: 0.
32
(0.17, 0.
61)
RD:
−0.
04 (−0.
07, −0.
01)
RR: 0.
40
(0.16, 1.
02)
RD:−0.
03 (−0.
08, 0.
01)
RR: 0.
80
(0.53, 1.
21)
RD:−0.
01 (−0.
04, 0.
02)
RR: 2.
00
(0.86, 4.
76)
RD: 0.
05 (−0.
02, 0.
12)
RR: 0.
74
(0.35, 1.
54)
RD:−0.
01 (−0.
05, 0.
03)
RR: 1.
59
(1.11, 2.
29)
RD: 0.
04
(0.01, 0.
08)
RR: 0.
10
(0.01, 1.
61)
RD:
−0.
06 (−0.
09, −0.
02)
PHT RR: 0.
82
(0.61, 1.
11)
RD:−0.
01 (−0.
02, 0.
01)
RR: 0.
36
(0.10, 1.
30)
RD:
−0.
03 (−0.
05, −0.
00)
RR(FE):
0.49
(0.26, 0.
92)
RR(RE):
0.34
(0.08, 1.
50)
RD(FE)
: −0.02
(−0.04,
−0.00)
RD(RE)
: −0.03
(−0.06,
0.01)
RR: 0.
53
(0.34, 0.
84)
RD:
−0.
02 (−0.
04, −0.
00)
RR: 0.
93
(0.37, 2.
33)
RD:−0.
00 (−0.
03, 0.
02)
RR: 1.
25
(0.83, 1.
89)
RD: 0.
01 (−0.
02, 0.
04)
RR: 1.
22
(0.60, 2.
50)
RD: 0.
02 (−0.
06, 0.
09)
RR: 1.
11
(0.60, 2.
04)
RD: 0.
00 (−0.
02, 0.
03)
RR:
2.00
(1.48, 2.
71)
RD:
0.05
(0.03, 0.
08)
RR: 0.
18
(0.01, 3.
03)
RD:
−0.
03 (−0.
05, −0.
01)
PRM RR(FE):
0.80
(0.41, 1.
57)
RR(RE):
0.64
(0.21, 2.
01)
RD:−0.
02 (−0.
09, 0.
05)
RR: No
studies
RD: No
studies
RR: No
studies
RD: No
studies
RR: No
studies
RD: No
studies
RR: 0.
67
(0.05, 8.
73)
RD:−0.
06 (−0.
42, 0.
31)
RR: 0.
50
(0.21, 1.
16)
RD:−0.
05 (−0.
12, 0.
02)
RR: 0.
82
(0.40, 1.
68)
RD:−0.
02 (−0.
09, 0.
06)
RR: No
studies
RD: No
studies
RR: 1.
39
(0.71, 2.
70)
RD: 0.
04 (−0.
05, 0.
13)
RR: No
studies
RD: No
studies
337Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Risk Ratios and Risk Differences- Overall Malformation Risk (Continued)
TPM RR: 0.
78
(0.47, 1.
31)
RD:−0.
01 (−0.
03, 0.
01)
RR: 0.
32
(0.09, 1.
17)
RD:
−0.
03 (−0.
05, −0.
01)
RR: 0.
50
(0.26, 0.
97)
RD:−0.
02 (−0.
04, 0.
00)
RR: 0.
56
(0.34, 0.
94)
RD:−0.
02 (−0.
04, 0.
00)
RR: 0.
57
(0.20, 1.
57)
RD:−0.
02 (−0.
05, 0.
01)
RR: 1.
36
(0.65, 2.
84)
RD: 0.
01 (−0.
03, 0.
05)
RR: 0.
90
(0.49, 1.
67)
RD:−0.
00 (−0.
03, 0.
02)
RR: No
studies
RD: No
studies
RR: 2.
35
(1.40, 3.
95)
RD(FE)
: 0.05
(0.03, 0.
08)
RD(RE)
: 0.06
(0.01, 0.
10)
RR: 0.
13
(0.01, 2.
13)
RD:
−0.
04 (−0.
07, −0.
02)
VPA RR: 0.
41
(0.34, 0.
50)
RD:
−0.
05 (−0.
07, −0.
04)
RR: 0.
16
(0.05, 0.
52)
RD:
−0.
08 (−0.
11, −0.
05)
RR: 0.
17
(0.09, 0.
32)
RD(FE)
: −0.07
(−0.09,
−0.05)
RD(RE)
: −0.08
(−0.10,
−0.05)
RR: 0.
28
(0.22, 0.
36)
RD(FE)
: −0.06
(−0.07,
−0.05)
RD(RE)
: −0.08
(−0.11,
−0.05)
RR: 0.
27
(0.12, 0.
61)
RD:
−0.
08 (−0.
11, −0.
04)
RR: 0.
63
(0.44, 0.
90)
RD:
−0.
04 (−0.
08, −0.
01)
RR: 0.
50
(0.37, 0.
68)
RD:
−0.
05 (−0.
08, −0.
03)
RR: 0.
72
(0.37, 1.
40)
RD:−0.
04 (−0.
13, 0.
05)
RR: 0.
43
(0.25, 0.
71)
RD(FE)
: −0.05
(−0.08,
−0.03)
RD(RE)
: −0.06
(−0.10,
−0.01)
RR:
0.06 (0.
004, 0.
94)
RD:
−0.
09 (−0.
13, −0.
06)
ZNS RR:
5.54 (0.
34, 89.
86)
RD: 0.
03
(0.01, 0.
05)
RR:
1.87 (0.
08, 45.
41)
RD: 0.
01 (−0.
02, 0.
03)
RR:
4.64 (0.
28, 78.
05)
RD:
0.02 (0.
00*, 0.
05)
RR:
3.67 (0.
23, 59.
46)
RD:
0.02 (0.
00*, 0.
04)
RR:
4.48 (0.
24, 82.
23)
RD: 0.
02 (−0.
01, 0.
05)
RR: 10.
46 (0.
62, 175.
67)
RD: 0.
06
(0.02, 0.
09)
RR:
5.46 (0.
33, 91.
31)
RD: 0.
03
(0.01, 0.
05)
RR: No
studies
RD: No
studies
RR:
7.84 (0.
47, 129.
74)
RD: 0.
04
(0.02, 0.
07)
RR: 17.
13 (1.
06, 277.
48)
RD: 0.
09
(0.06, 0.
13)
Results highlighted bold were statistically significant
*Confidence limit rounded to be on boundary of significance.
Table 3. Comparison Matrix
Active CBZ GBP LEV LTG OXC PB PHT PRM TPM VPA ZNS
Con-
trols
Analy-
sis
1.1
Analy-
sis
2.1
Analy-
sis
3.1
Analy-
sis
4.1
Analy-
sis
5.1
Analy-
sis
6.1
Analy-
sis
7.1
Analy-
sis
8.1
Analy-
sis
9.1
Analy-
sis
10.1
Analy-
sis
11.1
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Table 3. Comparison Matrix (Continued)
CBZ Analy-
sis
1.1
Analy-
sis
12.1
Analy-
sis
13.1
Analy-
sis
14.1
Analy-
sis
15.1
Analy-
sis
16.1
Analy-
sis
17.1
Analy-
sis
18.1
Analy-
sis
19.1
Analy-
sis
20.1
Analy-
sis
21.1
GBP Analy-
sis
2.1
Analy-
sis
12.1
Analy-
sis
28.1
Analy-
sis
22.1
Analy-
sis
23.1
Analy-
sis
24.1
Analy-
sis
40.1
Analy-
sis 25.1
Analy-
sis
26.1
Analy-
sis
46.1
Analy-
sis
27.1
LEV Analy-
sis
3.1
Analy-
sis
13.1
Analy-
sis
28.1
Analy-
sis
29.1
Analy-
sis
30.1
Analy-
sis
31.1
Analy-
sis
32.1
Analy-
sis 33.1
Analy-
sis
34.1
Analy-
sis
47.1
Analy-
sis
35.1
LTG Analy-
sis
4.1
Analy-
sis
14.1
Analy-
sis
22.1
Analy-
sis
29.1
Analy-
sis
36.1
Analy-
sis
37.1
Analy-
sis
38.1
Analy-
sis 53.1
Analy-
sis
39.1
Analy-
sis
48.1
Analy-
sis
56.1
OXC Analy-
sis
5.1
Analy-
sis
15.1
Analy-
sis
23.1
Analy-
sis
30.1
Analy-
sis
36.1
Analy-
sis
44.1
Analy-
sis
41.1
Analy-
sis
57.1
Analy-
sis
58.1
Analy-
sis
50.1
Analy-
sis
59.1
PB Analy-
sis
6.1
Analy-
sis
16.1
Analy-
sis
24.1
Analy-
sis
31.1
Analy-
sis
37.1
Analy-
sis
44.1
Analy-
sis
42.1
Analy-
sis
55.1
Analy-
sis
45.1
Analy-
sis
51.1
Analy-
sis
60.1
PHT Analy-
sis
7.1
Analy-
sis
17.1
Analy-
sis
40.1
Analy-
sis
32.1
Analy-
sis
38.1
Analy-
sis
41.1
Analy-
sis
42.1
Analy-
sis
54.1
Analy-
sis
43.1
Analy-
sis
52.1
Analy-
sis
61.1
PRM Analy-
sis
8.1
Analy-
sis
18.1
Analy-
sis 25.1
Analy-
sis 33.1
Analy-
sis 53.1
Analy-
sis
57.1
Analy-
sis
55.1
Analy-
sis
54.1
Analy-
sis 62.1
Analy-
sis
63.1
Analy-
sis 64.1
TPM Analy-
sis
9.1
Analy-
sis
19.1
Analy-
sis
26.1
Analy-
sis
34.1
Analy-
sis
39.1
Analy-
sis
58.1
Analy-
sis
45.1
Analy-
sis
43.1
Analy-
sis 62.1
Analy-
sis
49.1
Analy-
sis
65.1
VPA Analy-
sis
10.1
Analy-
sis
20.1
Analy-
sis
46.1
Analy-
sis
47.1
Analy-
sis
48.1
Analy-
sis
50.1
Analy-
sis
51.1
Analy-
sis
52.1
Analy-
sis
63.1
Analy-
sis
49.1
Analy-
sis
66.1
ZNS Analy-
sis
11.1
Analy-
sis
21.1
Analy-
sis
27.1
Analy-
sis
35.1
Analy-
sis
56.1
Analy-
sis
59.1
Analy-
sis
60.1
Analy-
sis
61.1
Analy-
sis 64.1
Analy-
sis
65.1
Analy-
sis
66.1
Table displays links to specific analyses to assist with navigation around the review.
339Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A P P E N D I C E S
Appendix 1. Search strategy for Cochrane Epilepsy Group’s Specialized Register
#1 MeSH DESCRIPTOR Pregnancy Explode All
#2 MeSH DESCRIPTOR Pregnancy Complications Explode All
#3 MeSH DESCRIPTOR Prenatal Exposure Delayed Effects Explode All
#4 fetal or foetal or fetus or foetus or prenatal or pregnant or pregnanc*
#5 newborn or infant
#6 MeSH DESCRIPTOR Teratogens Explode All
#7 teratogen*
#8 in NEXT utero
#9 “intra uterine” or intrauterine
#10 MeSH DESCRIPTOR Fetal Development Explode All
#11 MeSH DESCRIPTOR Infant, Newborn Explode All
#12 birth maternal
#13 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12
Appendix 2. Search strategy for CENTRAL (The Cochrane Library)
#1 MeSH descriptor Pregnancy explode all trees
#2 MeSH descriptor Pregnancy Complications explode all trees
#3 MeSH descriptor Prenatal Exposure Delayed Effects explode all trees
#4 (fetal OR foetal OR fetus OR foetus OR prenatal)
#5 (newborn OR infant)
#6 MeSH descriptor Teratogens explode all trees
#7 (teratogen*)
#8 (in NEXT utero)
#9 (intra uterine) or (intrauterine)
#10 MeSH descriptor Fetal Development explode all trees
#11 MeSH descriptor Infant, Newborn explode all trees
#12 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11)
#13 MeSH descriptor Fetal Diseases explode all trees
#14 MeSH descriptor Fetal Death explode all trees
#15 MeSH descriptor Infant Mortality explode all trees
#16 MeSH descriptor Birth Weight explode all trees
#17 MeSH descriptor Abnormalities, Drug-Induced explode all trees
#18 MeSH descriptor Congenital Abnormalities explode all trees
#19 (congenital NEXT defec*)
#20 (congenital NEXT malformation*)
#21 (congenital NEXT anomal*)
#22 (birth NEXT defec*)
#23 (minor NEXT anomal*)
#24 (dysmorph*)
#25 (maternal NEXT mortality)
#26 MeSH descriptor Intellectual Disability explode all trees
#27 (intellectual* NEXT impair*)
#28 (IQ)
#29 (intellectual NEXT ability)
#30 neurodevelopment
#31 (mental* NEXT retard*)
#32 “educational needs”
#33 “longer term outcome”
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#34 MeSH descriptor Child Development explode all trees
#35 “child development”
#36 MeSH descriptor Autistic Disorder explode all trees
#37 (autism OR autistic)
#38 MeSH descriptor Attention Deficit Disorder with Hyperactivity explode all trees
#39 “attention deficit”
#40 MeSH descriptor Apraxias explode all trees
#41 dyspraxia
#42 MeSH descriptor Memory explode all trees
#43 (memory)
#44 MeSH descriptor Language Disorders explode all trees
#45 language
#46 MeSH descriptor Executive Function explode all trees
#47 (executive NEXT function*)
#48 cognitive
#49 MeSH descriptor Neuropsychology explode all trees
#50 neuropsycholog*
#51 (#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR
#27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR
#42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50)
#52 MeSH descriptor Phenytoin explode all trees
#53 MeSH descriptor Carbamazepine explode all trees
#54 MeSH descriptor Valproic Acid explode all trees
#55 MeSH descriptor Phenobarbital explode all trees
#56 MeSH descriptor Ethosuximide explode all trees
#57 MeSH descriptor Clonazepam explode all trees
#58 MeSH descriptor Anticonvulsants explode all trees
#59 (phenytoin) or (carbamazepine) or (valproate) or (valproic) or (phenobarb*)
#60 (lamotrigine) or (gabapentin) or (vigabatrin) or (levetiracetam) or (topiramate)
#61 (tiagabine) or (zonisamide) or (pregabalin) or (lacosamide) or (rufinamide)
#62 (retigabine) or (ezogabine) or (oxcarbazepine) or (ethosuximide) or (sulthiame)
#63 (clonazepam) or (clobazam) or (anti-epilep*) or (antiepilep*)
#64 MeSH descriptor Epilepsy explode all trees
#65 MeSH descriptor Seizures explode all trees
#66 (seizure*) or (epilep*) or (convuls*)
#67 (#52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR
#66)
#68 (#12 AND #51 AND #67) in Trials
Appendix 3. Search strategy for MEDLINE (Ovid)
1. exp Pregnancy/
2. exp Pregnancy Complications/
3. exp Prenatal Exposure Delayed Effects/
4. (fetal or foetal or fetus or foetus or prenatal).tw.
5. (newborn or infant).tw.
6. exp Teratogens/
7. teratogen$.tw.
8. (in adj utero).tw.
9. (intra uterine or intrauterine).tw.
10. exp Fetal Development/
11. exp Infant, Newborn/
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12. or/1-11
13. exp Fetal Diseases/
14. exp Fetal Death/
15. exp Infant Mortality/
16. exp Birth Weight/
17. exp Abnormalities, Drug-Induced/ or exp Congenital Abnormalities/
18. (congenital adj defec$).tw.
19. (congenital adj malformation$).tw.
20. (congenital adj anomal$).tw.
21. (birth adj defec$).tw.
22. (minor adj anomal$).tw.
23. dysmorph$.tw.
24. (maternal adj mortality).tw.
25. exp Intellectual Disability/
26. (intellectual$ adj impair$).tw.
27. IQ.tw.
28. (intellectual adj ability).tw.
29. neurodevelopment.tw.
30. (mental$ adj retard$).tw.
31. educational needs.tw.
32. longer term outcome.tw.
33. exp Child Development/
34. child development.tw.
35. exp Autistic Disorder/
36. (autism or autistic).tw.
37. exp Attention Deficit Disorder with Hyperactivity/
38. attention deficit.tw.
39. exp Apraxias/
40. dyspraxia.tw.
41. exp Memory/
42. memory.tw.
43. exp Language Disorders/
44. language.tw.
45. exp Executive Function/
46. executive function$.tw.
47. cognitive.tw.
48. exp Neuropsychology/
49. neuropsycholog$.tw.
50. or/13-49
51. phenytoin.tw.
52. exp Carbamazepine/
53. carbamazepine.tw.
54. exp Valproic Acid/
55. (valproic or valproate).tw.
56. exp Phenobarbital/
57. phenobarb$.tw.
58. lamotrigine.tw.
59. gabapentin.tw.
60. vigabatrin.tw.
61. levetiracetam.tw.
62. topiramate.tw.
63. tiagabine.tw.
64. zonisamide.tw.
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65. pregabalin.tw.
66. lacosamide.tw.
67. (retigabine or ezogabine).tw.
68. rufinamide.tw.
69. oxcarbazepine.tw.
70. exp Ethosuximide/
71. ethosuximide.tw.
72. sulthiame.tw.
73. exp Clonazepam/
74. clonazepam.tw.
75. clobazam.tw.
76. antiepilep$.tw.
77. anti-epilep$.tw.
78. exp Anticonvulsants/
79. exp Epilepsy/
80. exp Seizures/
81. (seizure$ or epilep$ or convuls$).tw.
82. or/51-81
83. 12 and 50 and 82
84. exp animals/ not humans.sh.
85. 83 not 84
Appendix 4. Extended risk of bias tool for non-randomised studies
Studies for which the risk of bias tool is intended
Only suitable for ’cohort-like’ studies, individually or cluster-allocated. This can include secondary analyses of clinical databases
providing the analysis is clearly structured as a comparison of control and intervention participants (Higgins 2011):
Individually allocated study designs
• Randomised controlled trial
• Quasi randomised controlled trial
• Non-randomised controlled trial
• Controlled before and after study (not common use of this label, see controlled cohort before and after study below)
• Prospective cohort study
• Retrospective cohort study
Cluster allocated study designs
• Cluster randomised controlled trial
• Cluster quasi randomised controlled trial
• Cluster non-randomised controlled trial
• Controlled interrupted time series
• Controlled cohort before and after study
Assessment of risk of bias
Issues when using modified risk of bias tool to assess cohort-like non-randomised studies:
• follow principle for existing Cochrane Collaboration’s tool for assessing risk of bias: score judgement and provide information
(preferably direct quote) to support judgement
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• modified risk of bias tool include an additional item on confounding.
• five-point scale for some items (distinguish “unclear” from intermediate risk of bias).
• keep in mind the general philosophy-assessment is not about whether researchers could have done better but about risk of bias;
the assessment tool must be used in a standard way whatever the difficulty / circumstances of investigating the research question of
interest and whatever study design features were used.
• use of a five-point scale is uncharted territory; very interested to know whether this makes things easier or more difficult for
reviewers.
• anchors for five-point scale: “1/No/low risk’ of bias should correspond to a high quality RCT. ”5/high risk“ of bias should
correspond to a risk of bias that means the findings should not be considered (too risky, too much bias, more likely to mislead than
inform).
Sequence generation
• Low/high/unclear risk of bias item
• Always high risk of bias (not random) for a non-randomised study
• Might argue that this item redundant for non-randomised studies since always high risk of bias - but important to include in risk
of bias table (’level playing field’ argument)
Allocation concealment
• Low/high/unclear risk of bias item
• Potentially low risk of bias for a non-randomised study, e.g. quasi-randomised (high risk of bias to sequence generation) but
concealed (reviewer judges that the people making decisions about including participants didn’t know how allocation was being done,
e.g. odd/even date of birth/hospital number)
Risk of bias from confounding (additional item for non-randomised studies; assess for each outcome)
• Assumes a prespecified list of potential confounders defined in the protocol for the systematic review
• Low(1) / 2 / 3 / 4 / high(5) / unclear risk of bias item
• Judgement needs to factor in (see ’worksheet’):
◦ proportion of confounders (from prespecified list) that were considered;
◦ whether most important confounders (from prespecified list) were considered;
◦ resolution / precision with which confounders were measured;
◦ extent of imbalance between groups at baseline;
◦ care with which adjustment was done (typically a judgement about the statistical modelling carried out by authors).
• Low risk of bias requires that all important confounders are balanced at baseline, i.e.
◦ not primarily/not only a statistical judgement; or
◦ measured ’well’ and ’carefully’ controlled for in the analysis.
We have provided an optional ’worksheet’ to help reviewers to focus on the task (rows = confounders and columns = factors to consider).
Reviewers should make a risk of bias judgement about each factor first and then combine these (by eyeballing rather than quantitatively)
to make the judgement in the main risk of bias table.
Risk of bias from lack of blinding (assess for each outcome, as per existing risk of bias tool)
• Low(1) / 2 / 3 / 4 / high(5) / unclear risk of bias item
• Judgement needs to factor in:
◦ nature of outcome (subjective/objective; source of information);
◦ who was / was not blinded and the risk that those who were not blinded could introduce performance or detection bias.
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Risk of bias from incomplete outcome data (assess for each outcome, as per existing risk of bias tool)
• Low(1) / 2 / 3 / 4 / high(5) / unclear risk of bias item
• Judgement needs to factor in:
◦ reasons for missing data;
◦ whether amount of missing data balanced across groups, with similar reasons;
◦ whether group comparison appropriate (e.g. ’analysed in allocated group’ issue).
Risk of bias from selective reporting (assess for each outcome)
• More wide ranging than existing recommendation; key issue is whether outcomes were clearly defined, and methods of analysis
were pre-specified and adhered to
• Low(1) / 2 / 3 / 4 / high(5) /unclear risk of bias item
• Judgement needs to factor in:
◦ existing risk of bias guidance on selective outcome reporting;
◦ also, extent to which analyses (and potentially other choices) could have been manipulated to bias the findings reported,
e.g. choice of method of model fitting, potential confounders considered/included;
◦ look for evidence that there was a protocol in advance of doing any analysis or obtaining the data (difficult unless explicitly
reported); non-randomised studies very different from RCTs. RCTs must have a protocol in advance of starting to recruit (for research
ethics committee/institutional review board/other regulatory approval); non-randomised studies need not (especially older studies);
◦ Hence, separate yes/no items asking reviewers whether they think the researchers had a prespecified protocol and analysis
plan.
Appendix 5. Assessment of confounding variables
Assessment of how researchers dealt with confounding
Method for identifying relevant confounders described by researchers: Yes/No
If yes, describe the method used:
Relevant confounders described: Yes/No
List confounders described below
Method used for controlling for confounding
At design stage: matching by characteristics of subjects (see below for matching by propensity score)
Variables on which subjects matched: ………………………………….
…………………………………
...............................................
At analysis stage: stratification
multivariable regression
propensity scores (matching)
propensity scores (multivariable regression)
Describe confounders controlled for below
Confounders described by researchers
Enter / preprint prespecified list of confounders (rank order in importance? Important in bold?)
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(Continued)
Tick (yes/no judgement) if confounder considered by the researchers [Cons’d?]
Score (1 to 5) precision with which confounder measured
Score (1 to 5) imbalance between groups
Score (1 to 5) care with which adjustment for confounder was carried out
Confounder Considered Precision Imbalance Adjustment
o o o o
o o o o
o o o o
C O N T R I B U T I O N S O F A U T H O R S
JW and RB wrote this review with input from CJ, NA, JG, AJM, CT, JCS and AM. Data extraction and risk of bias assessments were
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D E C L A R A T I O N S O F I N T E R E S T
RB and JCS have provided expert testimony regarding child outcomes following prenatal exposure to AEDs and has worked on
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and Boehringer Ingelheim, and has participated in regional advisory Board meetings for Eisai on their product Eslicarbazepine and
Zonisamide.
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companies (GSK, EISAI, UCB Pharma) funded the National Audit of Seizure Management in Hospitals (NASH) through grants paid
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol it stated that, where possible, we would conduct meta-analysis at the monotherapy and polytherapy group level.
However, given the bias likely to be included in any analysis including polytherapy combinations and on recommendation of one of
the peer reviewers we have not included these comparisons. The authors feel that given the heterogenous nature of the results across
the included medications that this was the best course of action to ensure reliable results.
In the protocol it was stated that we would look at the specific malformations of genitourinary and gastrointestinal nature, however at
the point of data extraction it became apparent that there was too little data reported from the included studies to be able to do this.
Therefore the included studies were consulted and the four most commonly reported specific malformation types were selected and
reported on.
Due to the small amount of data pertaining to minor malformations meta-analysis was not possible and therefore outcomes pertaining
to this secondary outcome are reviewed narratively.
Within the protocol it was stated that, if appropriate, summary of findings tables using the GRADE approach would be presented.
However, due to the inclusion of more than one AED across a number of outcomes, the creating and presenting of all data would be
difficult to produce in a manner that could be understood and used appropriately.
In the protocol it was also stated that both fixed-effect and random-effects model analyses would be implemented, however the authors
did not state exactly how these would be utilised and therefore we have elaborated on the methods here to clarify the situation. It was
always the intention that fixed-effect models would be carried out primarily, with random-effects model analysis to explore potential
heterogeneity. In addition, due to data being sparse in some comparisons, and with some studies reporting zero events in one or both
groups, the risk difference (RD) was calculated and this was not stipulated within the protocol as we were not expecting to find such
sparse data.
I N D E X T E R M S
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Medical Subject Headings (MeSH)
∗Abnormalities, Drug-Induced [classification]; Anticonvulsants [∗adverse effects]; Cardiovascular Abnormalities; Craniofacial Abnor-
malities; Epilepsy [∗drug therapy]; Musculoskeletal Abnormalities; Neural Tube Defects; Pregnancy Complications [∗drug therapy]
MeSH check words
Female; Humans; Infant, Newborn; Pregnancy
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